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Much research has focused on the inhibition of the cyclooxygenase (COX) enzyme as this 
protein is responsible for the first step in the pain pathway in the conversion of arachidonic acid 
into prostaglandins and thromboxanes. The binding of curcumin and celecoxib, a known 
cyclooxygenase-2 (COX-2) selective inhibitor, was investigated computationally in order to 
identify important ligand-protein interactions which would need to be mimicked by a novel 
COX-2 selective compound. Initial investigations into the binding of curcumin identified the 
lesser diketone tautomer as having potential COX-2 selective activity.  
 
Two novel COX-2 selective compounds were designed using moieties common amongst known 
COX-2 selective compounds and moieties found in curcumin. Initial docking and binding scores 
showed that these compounds interacted in a similar manner with the protein as did celecoxib. 
Modifications to these initial compounds yielded two classes of compounds which explored the 
impact of the substitutions on the docking and binding scores, the poses and the ligand-protein 
interactions. All modifications made resulted in enhanced binding towards COX-2, and in a 
number of cases a reduction in the binding scores for COX-1. Thirty of the 166 compounds 
designed were selected for synthesis and biological screening as these compounds exemplified 
the range of changes observed in the full complement of compounds.  
 
Retrosynthesis yielded two potential synthetic pathways, and while the first path proved 
unsuccessful, the second route, which makes use of convenient reaction conditions, afforded 
the compounds in modest to good yields. Complete NMR spectroscopic analysis was carried out 
on all compounds, with Diffusion Ordered Spectroscopy used to determine the diffusion 
coefficients and hydrodynamic radii of two compounds and illustrated the dependence of these 
measurements on the properties of the medium. NMR Analysis of Molecular Flexibility In 
Solution (NAMFIS) analysis of one of the final compounds identified six conformers as existing 
in solution, based on the comparison of experimentally derived Nuclear Overhauser 




Four of the six poses are responsible for >95% of the solution population, with one pose 
comprising almost 50%. All but one of the poses show Root Mean Squared Deviation (RMSD) 
values of less than 2 Å when compared to the predicted pose, indicating that any of these poses 
could bind into the protein.  
 
Initial inhibition screening results of the unsubstituted parent benzenesulfonate compound 
appeared to show three-fold selectivity of COX-2 over COX-1 at 100 nM. Testing of the 
substituted compounds revealed that these compounds are not COX-2 selective as desired, 
rather a number show promise as COX-1 selective compounds, with inhibition scores of over 
40%, and several other compounds show potential as non-selective COX inhibitors. There is no 
obvious correlation between the inhibition results and either the Glide XP docking scores or the 
Prime binding scores, and as such, additional computational analysis as well as experimental 
testing is required to identify a correlation between the theoretical results and the 
experimental data, and illustrates that computational results cannot be the sole criterion on 
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1.1. The History of Medicine: From Antiquity to Modern Times.  
 “Study the past if you would define the future.” 
Confucius  
In the history of mankind, there have only been two reasons for man to explore and exploit nature: as a 
source of food, and as a source of medicines. Many ancient civilizations had comprehensive works on 
herbs or mixtures of them and how they could be used to treat various diseases. One of the earliest 
records of the use of natural products was found on cuneiform-covered clay tablets from Mesopotamia 
(Figure 1.1) dated to 2500 B.C.E (Before Common Era). These tablets document the use of oils from 
cypress (Cupressus sempervirens) trees, licorice (Glycyrrhiza glabra) root,  poppy (Papaver somniferum) 
flowers and the resin from various myrrh (Commiphora) species  as treatments for coughs, colds and 
inflammation, treatments which are still used today.1-2  
 
Figure 1.1. Mesopotamian clay tablet, circa 2500 B.C.E 3 
The Mesopotamians were not the only ancient culture to record medical information. Written around 
1550 B.C.E., the Ebers Papyrus (Figure 1.2) is a record of over 700 plant-based prescriptions used in 
Ancient Egypt, ranging from ointments and pills to gargles and infusions.4 The Chinese Materia Medica 
(Wu Shi Er Bing Fang) from 1100 B.C.E, contains 52 prescriptions of natural products, the Shennong 
Herbal (~100 B.C.E) contains 365 drugs, and the Tang Herbal from 659 C.E contains 850.2 The first 
written book on medical matters, Shen Nong Ben Cao Jing, describes the characteristics, processing and 
prescription of 250 plant-derived drugs, as well as 60 from animals and 50 related to minerals. 
Appearing in the first centuries B.C.E. and C.E, this is the earliest Chinese pharmacopoeia known and has 
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been extensively studied over the years.4 Chinese medicine reached its peak during the Ming dynasty 
(1368-1644), with the writing of Pen Ts’ao Kang Mu (The Great Herbal) by Li Shih Chen (1518-1593). The 
best known of the Chinese herbal texts, it encompasses 520 volumes and upwards of 11,000 
prescriptions.4-5  
 
Figure 1.2. A section of the Ebers papyrus, written around 1550 B.C.E. 6 
Another source of ancient prescriptions is the Indian Ayurveda, dating back to 900 B.C.E. Literally 
translating as “the science and knowledge of life”, Ayurveda is based primarily on three texts – the 
Sushruta Samhita, the Charaka Samhita and the medical portions of the Bower Manuscript, also known 
as the Bheda Samhita. The Sushruta Samhita contains 184 chapters and the descriptions of 1,120 
illnesses, 700 medicinal plants, 57 preparations from animal sources, and 64 mineral preparations.7 The 
Ayurvedic system formed the basis for the primary text of Tibetan medicine, Gyu-Zhi (Four Tantras),8 
and is believed to be the basis for much of the North American Indian medicinal traditions as well. The 
similarities in the medicinal plants used by the North American Indians and the East Indian practitioners 
of Ayurveda is thought to be due to the migration of Asian Indians across the Beiring Strait to Alaska and 
then south into the Americas, as the knowledge would have been carried along the journey.4  
 
With regards to Western Medicine, the Greeks, greatly influenced by the Egyptians, contributed 
considerably to the development of the use of herbal drugs.4 Temples in ancient Greece were dedicated 
to Asklepios, the god of healing, and these temples became schools for physicians, such as the temple 
on the island of Kos. Under the leadership of Hippocrates, it is perhaps the most famous of medical 
schools in classical Greece, and it became a considerable influence on later medical schools, with the 
writings of the school, known as the Hippocratic Corpus, collected in the library of Alexandria around 
280 B.C.E. The modern Hippocratic Oath is a compendium of medical and pharmaceutical ethics from 
this original body of work. In his Historia Plantum (Figure 1.3), Theophrastus (370-287 B.C.E) 
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documented the medicinal qualities of over 500 herbs, and noted that some characteristics could be 
changed due to cultivation.1-2 Friend and disciple of Aristotle, Theophrastus classified plants into trees, 
shrubs, subshrubs and herbs, a simple classification, but nonetheless the most rational until the 
Linnaean system was adopted in the 18th century. Even the words pharmacy and pharmacology have 
Greek origins – in the Odyssey, written in the 8th or 9th century B.C.E, Homer uses the word “pharmakon” 
to refer to a drug.  
 
Figure 1.3. Cover plate of a Historia Plantarum edition dated 1644.9 
 
1.1.1. Witchcraft and Wizardry: The Joys of the Dark Ages. 
 “Half of writing history is hiding the truth.” 
Capt. Malcolm Reynolds, Serenity 
With the decline and fall of the Roman Empire in the fourth century, Europe was plunged into the 
depths of the Dark Age, where the use of plants and plant-based treatments were viewed as witchcraft 
and sorcery.2 Monasteries in European countries such as England, Ireland, Germany and France 
preserved what was left of this expertise, but it is the Arabs who are responsible for the conservation of 
the Greco-Roman knowledge, and for augmenting this knowledge base with their own traditions and 
those of the Chinese and Indian healers, knowledge which previously was unknown to the Greeks and 
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Romans.1-2,4 The Arabs were the first to establish privately owned drug stores,2 and the Persian 
pharmacist, physician, philosopher and poet Ibn-Sina (Avicenna) influenced the sciences of pharmacy 
and medicine well into the 17th century as his work Canon Medicinae (Figure 1.4) was the standard 
medical text at medieval universities, and was recommended as a textbook in the universities of 
Montpellier and Leuven as late as 1650.10-11 Completed in 1025, it is a clear, concise summary of all the 
medical knowledge of the time,12 consisting of 5 volumes as compared to Galen’s twenty.10 Ibn-Sina 
drew on many sources during the writing of his Canon, including the extensive pathology text, Zhubing 
Yuanhuo Lun, from the Chinese physician Chao Yuan-fang, which was written around 610 C.E, and the 
Maijing, a classic Chinese pulse diagnosis text by Wang Shu-hu, written ca. 310 C.E. Canon Medicinae is 
considered “the final codification of all Greco-Roman medicine.”2 Another important contributor to the 
field of medicine is the Arabic scientist Abulcasis, who wrote the medical encyclopedia al-Tasrif. A 
common text in European medical schools during the High Middle Ages, one part is devoted to surgery, 
with another section devoted to pharmaceutical practices. The 28th volume, Liber Servitoris de 
Praeparatione Medicinarum Simplicum, describes over 1,500 drugs, of which 400 are purely Arabic 
contributions.4 
 
Figure 1.4. A copy of Ibn Sina’s Canon Medicinae from 1597. 13 
 
A number of new drugs were introduced into what was then mainstream medicine with the discovery of 
America by the Spanish in 1492. Initial work on the medicinal plants of the Americas was not carried out 
by doctors or scientists, rather it was by monks, politicians and military men such as Fray Bernardino de 
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Sahagun, the Viceroy Fernandez de Oviedo and Pedro Cieza de Leon that much of the information on 
these plants was transmitted to Europe.4 Such was the flow of information that the physician Nicholas 
Monardes published a highly detailed book, “Medicinal de las cosas que se traen de nuestras Indias 
Occidentales” or “A book on the things brought from our West Indies that are used in medicine” without 
ever actually visiting the New World.14 The Historia de las Cosas de la Nueva Espana, written by Frey 
Bernardino de Sahagun and based on many years of anthropological, ethnological and ecological data 
collected from over 100 races and cultures, has been described as a magnificent work covering all 
aspects of pre-Columbian civilizations, including medicinal plants (Figure 1.5), and Pedro Cieza de Leon’s 
La Cronica del Peru, published in 1533, is portrayed as a masterful account of the lifestyles and costumes 
of the Incas and other native Indians.4 The first scientific expedition of the modern era was carried out 
by the royal doctor Francisco Hernandez, on a commission from King Philip II of Spain. Sent to Mexico on 
a royal commission from 1571 to 1577, Hernandez devoted the time to a thorough study and 
description of over 4,000 medicinal plants found in New Spain’s territory. While Hernandez died without 
seeing his work published, Nardo Antonio Rechi (Reccho) summarized the work and published it as 
Rerum Medicarum Novae Hispaniae Thesaurus, which only mentions 412 plants. Partially destroyed by a 
fire at the El Escorial Monastery library in 1671, the unaffected portion of Hernandez’ work was 
published in 1790 as Historia Plantarum Novae Hispaniae and covered 2,900 plants.15  
 
Figure 1.5. A page of de Sahagun’s Historia de las Cosas de la Nueva Espana detailing customs, dress and 
medical practices of pre-Colombian tribes.16 
During the height of the Renaissance, figures such as Vesalio and Copernicus arose and began to 
question thoughts, beliefs and teachings which had previously been accepted as truth. Vesalio, as chair 
of Surgery and Anatomy at Padua, used dissections as the primary teaching tool and carried out the 
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dissections himself, believing that hands-on experience was the only reliable source of information, 
rather than the classical texts of Galen, which at that point were over 1,000 years old.17 The field of 
toxicology was established by Paracelsus, who developed the concept of dose dependency for drug 
action and toxicity stating “sola dosis facit venenum” or “only the dose makes the poison.”18 Paracelsus 
is also credited for using laudanum, an analgesic preparation of opium containing morphine and 
codeine, as a painkiller, making him the first doctor to use a pharmacological agent against pain, 
however this remains speculation.19 A potent narcotic, laudanum was almost unknown until the 1670’s 
when Thomas Sydenham published Medical Observations Concerning the History and Cure of Acute 
Diseases in 1676, in which he promoted his own brand of laudanum, the contents of which differed 
greatly from the one encountered by Paracelsus.20 By the 18th century, the properties of laudanum and 
opium were well-known (Figure 1.6) and used for almost every ailment until the early 20th century.21  
 









1.1.2. The Modern Era: The Government Gets Involved.  
“Bureaucracy is the art of making the possible impossible.” 
Javier Pascual Salcedo 
The early 20th century brought greater understanding of the nature of the addictive properties of 
narcotics, including opium, and thus increased regulations were imposed on these substances. In the 
United States, the Food and Drug Act of 1906 required that certain drugs, including heroin, morphine, 
cocaine, cannabis and alcohol, be accurately labeled with contents and dosage, and many patent 
medications were affected as they had previously been sold with secret ingredients or with ambiguous 
labels. Britain passed similar laws limiting the narcotic content of medicines and revelation of these 
ingredients in 1906, as did Canada in 1908.23 Despite the fact that drugs such as cocaine, cannabis and 
heroin could still be legally sold without prescriptions as long as they were labeled (Figure 1.7), it is 
estimated that the sale of opium-containing patent medications decreased by 33% after labeling 
became mandatory.24  
 
Figure 1.7. Victorian era preparations of heroin,25 cocaine26 and cannabis.27 
Prior to the 20th century, there were very few federal laws which regulated the sale and contents of food 
and pharmaceuticals. Due to journalists like Upton Sinclair in the United States, the public became 
interested in the potential hazards of food and pharmaceutical goods, and this lead to more federal 
regulations for matters of public safety.28 Prior to the 1906 Food and Drug Act which essentially 
established the Food and Drug Administration (F.D.A.), a Biologics Control Act was passed in 1902 after a 
tetanus-contaminated diphtheria antitoxin lead to the deaths of thirteen children in St. Louis, Missouri.28 
The serum used to create the antitoxin had been collected from a horse named Jim, who had contracted 
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tetanus. Signed by President Roosevelt in June 1906, the Food and Drug Act prohibited, amongst other 
things, the interstate promotion of “adulterated” drugs, where the “standard of strength, quality or 
purity” of the active ingredients were either clearly declared on the label or listed in the United States 
Pharmacopoeia or the National Formulary.29 By the 1930s, many groups were campaigning for the 
F.D.A. to have stronger regulatory authority, as a number of radioactive beverages, worthless cures for 
diabetes and tuberculosis and a brand of mascara which caused blindness had been granted approval 
under the 1906 law. After struggling to get passed in Congress for five years, the Food, Drug and 
Cosmetics Act (FD&C Act) was signed into law in 1938, due to the public backlash over the 1937 Elixir 
Sulfanilamide disaster, in which over 100 people died due to an untested solvent.30 This new law 
mandated a pre-market review of the safety of all new drugs, as well as limiting the indications that a 
drug could be marketed for. The Durham-Humphrey Amendment of 1951 designated some drugs as 
“prescription-only,” and this act also allowed for post-marketing recalls of ineffective drugs by the 
F.D.A..30 
 
The Kefauver-Harris Amendment to the FD&C Act in 1962 symbolized a revolution in the regulatory 
authority of the F.D.A., as all new drug applications would not only have to demonstrate safety, but they 
would now have to show “substantial evidence” of the drugs’ activity in order to gain F.D.A. approval.31 
This amendment was brought about by the thalidomide tragedy in Europe in 1959, where thousands of 
children were born with birth defects after their mothers were given thalidomide as an anti-nausea 
medication (Figure 1.8).32 The United States was for the most part spared the tragedy as Dr Frances 
Oldham Kelsey of the F.D.A. refused to authorize the sale of thalidomide until data suggesting severe 
side effects with long term use was explained.33 Marking the start of the modern F.D.A. approval 
process, these reforms resulted in an increased amount of time needed before a drug could be brought 
to market. The AIDS epidemic has however raised concerns over the length of time required for drug 
approval, and in the mid- and late 1980s, the F.D.A. issued new rules aimed to expedite the approval of 
certain drugs for life threatening diseases and expanded the access of patients with limited treatment 
options to drugs which have passed Phase I clinical trials.34-35 In the face of the current Ebola epidemic, 
the F.D.A. has waived the pre-clinical testing requirement for GlaxoSmithKline’s Ebola vaccine,36 and 
ZMapp, an experimental combination treatment from Mapp Biopharmaceutical and LeafBio , has been 
given to a small number of patients under the Expanded Access programme, despite not undergoing 















Figure 1.8. Structure of S- and R-thalidomide. The S-enantiomer is teratogenic, while the R-enantiomer is 
a sedative. 
 
1.1.3. The Process of Drug Discovery: An Expensive Undertaking.  
 
“The more original a discovery, the more obvious it seems afterwards.” 
Arthur Koestler 
The process of bringing a new drug to the shelf of a local pharmacy is a long, arduous, and expensive 
process. The Boston Consulting Group has estimated the average cost as $1 billion over 15 years38-39 
with both numbers fluctuating based on the disease being targeted, the nature of the drug being 
developed, and the type of clinical trials that the drug has to pass before being granted regulatory 
approval by bodies such as the F.D.A..38 With only 5 out of 5,000 compounds that enter the preclinical 
phase surviving the rigours of testing to enter the human trials phase, and only one of these ultimately 
receiving approval, it is an enormous investment in terms of time, money and effort.40 Often referred to 
as a “pipeline”, the process by which a drug is brought to market has a number of distinct stages (Figure 
1.9), each of which requires the complex interaction of the members of the multidisciplinary teams 
responsible for that drug.38,41   
 
Figure 1.9. The drug discovery “pipeline”. 
The Discovery and Basic Research stage is the initial stage, where new molecules are identified which 
have the potential to interact with biological systems, and these identified molecules are subjected to 
biological screening and pharmacological testing to explore the therapeutic potential of these 


















toxicology and safety in the Preclinical Testing phase. Dose formulation and stability is also carried out in 
the preclinical testing period. At this point, an application is made to the relevant regulatory authority to 
use the identified compound in human testing, and should approval be granted, the compound 
progresses to Phase I Clinical Trials. Absorption, distribution metabolism and excretion (ADME) patterns, 
tolerance and pharmacological effects are determined at this stage, often on a group of 20-80 healthy 
human volunteers. Phase II Clinical trials determine effectiveness in treating the targeted disease or 
medical condition in 100-300 patients, as well as any short term risks. Phase III Clinical Trials, which 
involve between 1,000 and 3,000 patients, determines the clinical benefit, if any, of the compound, and 
any adverse reactions which might occur. Process Development and Quality Control aims to establish 
the capacity of a company to produce the compound in large quantities in stable, uniform batches which 
meet the overall quality requirements. Prior to application for approval to market the new drug, 
Bioavailability Studies make use of healthy volunteers to establish that the product which is to be 
marketed is equivalent to the formulation used in the trials. Finally, Phase IV is carried out post-
marketing in order to determine concealed adverse effects and the long term morbidity and mortality 
profile of the drug.38 
 
While the clinical trials stages of drug development contribute the most towards the overall cost of the 
development of new drugs – most sources estimate this proportion as 40% of the total development 
cost38 - the second largest contribution comes from the initial discovery and basic research stage. This 
stage includes chemical synthesis and biological testing of thousands of compounds in order to identify 
hits, which are then further optimized into lead compounds and possibly new drug molecules.40,42 
Traditional medicines and medicinal practices have formed the basis of the majority of early 
medicines,1,43-44 with the subsequent clinical, pharmacological and chemical studies carried out many 
years, in some cases centuries, after these treatments were introduced.1,45 Prime examples of this 
process are the well known compounds morphine, heroin, digitoxin, atropine, scopolamine, and quinine 









































Figure 1.10. Structures of (clockwise from left) morphine, heroin, atropine, quinine, digitoxin and 
scopolamine. 
The ancient Sumerians and ancient Greeks used extracts of the opium poppy (Papaver somniferum) 
medicinally, and the addictive effects of opium were documented by the Arabs, but morphine, one of 
the alkaloids present in the opium extracts, was not isolated until 1803, and heroin (diacetylmorphine) 
was not synthesized from crude morphine for another 70 years.1,46 Foxglove (Digitalis purpurea) has 
been used in Europe since the 10th century, but the compound responsible for the enhanced cardiac 
conduction observed was not identified as digitoxin until the 1700s.46 Atropine and scopolamine, found 
in plants such as deadly nightshade (Atropa belladonna) and mandrake (Mandragora officinarum), have 
been used for thousands of years as an anesthetic or a sleeping agent, with ancient physicians such as 
Theophrastus and Dioscorides describing the use of these plants for these and other purposes.47  
Atropine was only prepared in pure form in 1833 by the German pharmacist Heinrich Mein,48 and 
scopolamine was only isolated in 1880 by Albert Ladenburg.46 The bark of several Cinchona tree species 
had been used for centuries by the Quechua peoples in South America for the treatment of malaria, 
indigestion, fever, mouth and throat diseases,49 but formal use of the bark to treat malaria only began in 
the mid-1800’s with the worldwide cultivation of this plant by the British and the Dutch,46 and F.D.A. 
approval for quinine in the fight against malaria was only officially granted in 2005.50 
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As the majority of the knowledge of the medicinal properties of plants comes as a result of trial and 
error by man over thousands of years,51-52 it is unsurprising that natural products, especially those of a 
plant-based origin, have been vitally important sources of potential drug leads,2,45,53-55 and still 
contribute greatly to the development of new drugs. A recent study of all drugs approved between 1980 
and 2010 showed that almost 40% of these compounds are either natural products, or derived from 
natural products, and over 48% of the drugs approved in this time period for cancer treatment were 
either natural products or natural product derivatives.56 The history of using natural products as a 
template for new drugs goes back to the late 19th century, with the development of acetylsalicylic acid, 
or aspirin, from salicylic acid. Plants such as the white willow (Salix alba) and meadowsweet (Filipendula 
ulmaria) (Figure 1.11) are rich in salicylate compounds, and portions of these plants have been used for 
thousands of years. The first specific reference to the use of these plants as painkillers and anti-
inflammatories is found in the Ebers Papyrus, and references to these plants are found in the works of 
Hippocrates (5th century B.C.E.) and Dioscorides, and additional references can be found in Pliny the 
Elder’s Naturalis Historia (77-79 CE) as well as in Celsus’ De Medicina (ca. 30 C.E), and by the time Galen 
wrote his Opera Omnia in the second century CE, willow bark was commonly used throughout the 
Roman and Arab worlds.57 Willow extract became recognized in the mid-18th century as a cure for fever, 
pain and inflammation when Edward Stone, an English chaplain, sent a letter to the Royal Society, 
relating the ability of this extract to cure a disease known then as ague, but known today to be the 
symptoms of malaria.58 The common treatment for the ague was Peruvian bark, which was notoriously 
expensive, and once the cheaper willow extract was shown to have almost identical effects as the 
Peruvian bark, it became a popular substitute for Peruvian bark.57 However, unlike the Peruvian bark 
which contained quinine, the willow extract relieved the symptoms of malaria rather than curing it.  
 
Figure 1.11. The natural sources of salicylic acids - White willow (Salix alba, left)59 and European 
meadowsweet (Filipendula ulmaria, right).60 
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With the advent of the discipline of organic chemistry in the 19th century, many European scientists 
attempted to isolate, purify and identify the active compounds in the medicines used at that time, and 
the willow extract was not excluded from this scrutiny. In 1828, Joseph Buchner obtain reasonably pure 
salicin crystals, with Henri Leroux identifying a more productive extraction procedure for salicin from 
willow bark the following year.57 A more potent acid form of the willow extract was obtained by Raffaele 
Piria in 1838, which he named salicylic acid. Work was also being carried out on extracts from the 
meadowsweet plant, and in 1834 Johan Pagenstecher isolated what he thought was a new pain-
reducing substance. Karl Jacob Löwig, a German chemist working on identifying the meadowsweet 
extract in the early 1840’s, discovered that it was the same salicylic acid as was identified by Piria in 
1838.57 The use of salicylate medicines, including salicin, salicylic acid and sodium salicylate (Figure 
1.12), grew exponentially through the middle decades of the 19th century, as did the understanding of 
what these medications did – i.e. the reduction of fever, pain and inflammation. However, the side 
effects of these salicylate compounds seriously limited their value, and much research was carried out to 











Figure 1.12. 2D structures of salicin (left) and salicylic acid (right). 
Felix Hoffman, a member of the pharmaceutical group at Bayer, began work on a substitute for salicylic 
acid which did not have the same side effects, and based on work published by other scientists, he 
identified acetylsalicylic acid (Figure 1.13) as a potential replacement. Acetylsalicylic acid had first been 
prepared in 1853 by the French chemist Charles Frederic Gerhardt as a reaction of acetyl chloride and 
sodium salicylate, but as it was merely one of a number of reactions carried out for his paper on 
anhydrides, he did not investigate it any further.61 Von Gilm obtained analytically pure acetylsalicylic 
acid in 1859 from a reaction of salicylic acid and acetyl chloride,62 and Schröder, Prinzhorn and Kraut, by 
repeating both sets of reactions in 1869, concluded that the reactions of Gerhardt and Von Gilm yielded 
the same compound, and they were the first to correctly connect the acetyl group to the phenolic 








Figure 1.13. 2D structure of acetylsalicylic acid. 
In 1897, Hoffman identified a superior method of synthesizing acetylsalicylic acid by heating salicylic acid 
with acetic anhydride at reflux,57,64 and the initial pharmacological testing results were promising, with 
none of the side effects of salicylic acid reported. Clinical trials for acetylsalicylic acid were delayed, in 
part due to the success of another of Hoffman’s compounds, diacetylmorphine or heroin, but by 1899 
Aspirin was being marketed (Figure 1.14) around the world by Bayer.57 Aspirin’s popularity as a painkiller 
declined with the release of paracetamol (acetaminophen) in 1956 and ibuprofen in 1969, but clinical 
trials and other studies from the 1960s to the 1980’s showed that aspirin is an effective anti-clotting 
agent, and sales of aspirin recovered due to this new-found use preventing heart-attacks and strokes.57  
 
 




1.1.4. Designer Drugs: The Rise of Targeted Therapeutics. 
“I'm extremely disappointed. I send you out for exciting, new designer drugs, and you come back with 
tomato sauce.” 
Dr Gregory House, House, M.D. 
As very little can be done to alter the structure of a drug once it has entered clinical trials, a huge 
amount of research goes into finding the optimal structure of a drug prior to this stage. Prior to the 
introduction of computer-aided drug design four decades ago, “Drug Discovery” involved identification 
of a compound or natural product, often based on traditional medicines. In the early part of the 20th 
century, bacterial infections of one form or another were responsible for a large percentage of deaths, 
and extensive studies were carried out in order to understand the microorganisms responsible. The 
discovery and isolation of penicillin from the Penicillium notatum fungus by Alexander Fleming in 192966 
jump-started the search for new antibiotics from microorganisms as well as from natural products and 
other sources.67-68 While the “Golden Age of Antibiotics” is waning, a large number of important 
antibiotic compounds were identified during this period, including vancomycin, erythromycin, 
nocardicin, imipenem and aztreonam (Figure 1.15). Research into new antibiotics has not completely 
been abandoned – the development of drug-resistant microorganisms continues to fuel this area of 
research, and there are presently nine β-lactam antibiotic compounds either in clinical trials or 






















































































Figure 1.15. 2D structures of (clockwise from left) aztreonam, vancomycin, erythromycin, nocardicin, and 
imipenem. 
During this “Golden Age”, many pharmaceutical companies commenced natural product discovery 
(NPD) projects, focusing not only on the development of antibacterial and antifungal agents, but also on 
infectious diseases and anti-cancer drugs. Paclitaxel, (Taxol® - Figure 1.16), the most widely used breast 
cancer drug, was isolated in 1962 from the bark of the Pacific yew (Taxus brevifolia) collected by the 
United States Department of Agriculture as part of the plant screening program carried out by the 
National Cancer Institute70 and doxorubicin (Adriamycin®), which is used to treat acute leukemia, lung 
cancer, thyroid cancer, soft tissue and bone sarcomas as well as both Hodgkin’s and non-Hodgkin’s 
lymphomas, was isolated from a microbe found in a soil sample outside a castle in Italy in the 
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1950’s.45,71-72 Drugs targeting microbial infections, hypercholesteremia and tissue rejection in organ 
transplantation were also developed during this period.73-74 The introduction of automated high 
throughput screening (HTS) during the 1990’s and early 2000’s resulted in countless pharmaceutical 
companies decommissioning their NPD programs,75-76 as biological testing and combinatorial testing 
were being touted as a better approach to creating drug-like compounds for HTS1, which would produce 
lead topics by sheer weight of numbers.77-78 Traditional extract-based screening was thought to result in 
the constant rediscovery of previously isolated compounds, and many believed that both total synthesis 
and derivatization were required for the structural complexity of many natural products, both of which 













Figure 1.16. Pacific yew (Taxus brevifolia),79 source of the cancer drug Taxol®. 
HTS relies on combinatorial chemistry to produce large libraries containing thousands to millions of 
compounds, which are subjected to chemical, pharmacological or genetic tests using robotics and very 
sensitive detectors, in a “top-down” approach. In this “top-down” approach (Figure 1.17), complete 
molecules are tested for activity against a wide variety of targets, in the hope that one of the many 
compounds tested will show some form of activity against a target. HTS was intended to rapidly identify 
active compounds, known as “hits”, and these present the starting points for drug design. Hit 
compounds would then be derivatized and limited optimization carried out to yield potential drug-like 
compounds or “leads”. These leads, after further, more extensive optimization, would enter preclinical 
trials as possible drug candidates.80-82 HTS was to deliver a greater number of lead compounds faster 
than traditional drug discovery techniques could, and without the intellectual property hassles often 
involved with natural products,45,83-86 and, not unexpectedly, natural product research was allocated a 





However, combinatorial chemistry failed to deliver on its early promises, with only one compound, 
sorafendib, a completely synthetic kinase inhibitor (Figure 1.18), approved for use in renal carcinoma by 
the F.D.A. in 2005, despite almost 30 years of research.1,87 The usefulness of many large libraries 
generated by combinatorial chemistry was called in to question by the mid-1990’s78,88-89 with Lipinski 
quoted as saying “The combinatorial libraries in the early years were so flawed that if you took the 
libraries across Pharma from 1992 to 1997 and stored them in dumpsters you would have improved 
productivity.”90 Part of the reason for the inability of combinatorial chemistry to identify lead 
compounds from amongst the millions of compounds subjected to HTS is intrinsic to the way that HTS is 
carried out.81,91 In order to identify a small molecule which inhibits a protein, the entire library of 
compounds is analyzed using, for example, a protein binding assay; however, as protein binding does 
not necessarily indicate inhibition, the hits from the initial screen are subjected to a secondary 
functional screen to determine whether inhibition occurs. An alternate method would be to carry out 
functional screening initially to identify biological activity, followed by extensive characterization of the 
identified hits.92   
Figure 1.17. The “Top-down” approach to drug design. Many compounds are tested to identify hits, 



















Figure 1.18. 2D structure of sorafendib, the only compound developed through combinatorial chemistry 
to receive F.D.A. approval for use in renal carcinoma. 
After the initial hype surrounding combinatorial chemistry had died down, synthetic chemists realized 
that the combinatorial libraries, which contained huge numbers of compounds, lacked the inherent 
complexity of natural products.87 The fact that natural products and the compounds in the 
combinatorial libraries essentially occupied different chemical space was proposed to be another reason 
that HTS had been unable to identify lead compounds.45,93-96 Some groups and companies have 
therefore  begun to focus on “Diversity Oriented Synthesis” (DOS),97-99 where chemists focus on the 
synthesis of compounds which are similar to naturally-occurring compounds – “mimics” – or on 
compounds which have similar topology to natural products. As more emphasis in recent years has been 
placed on the quality of combinatorial libraries as well as the diversity of the libraries, natural products, 
which are well characterized in lists of “privileged structures” - molecular frameworks which are capable 
of providing useful ligands for more than one type of receptor or enzyme target by astute structural 
modifications100 - have become ideal templates for new combinatorial libraries.45,95,101-108 A number of 
these compounds have been and currently are being tested in a wide variety of biological screens to 
determine possible activity, and some of these compounds are in various stages of clinical testing, and 
have received approval for use.87 The antibiotic linezolid – sold under the name Zyvox® (Figure 1.19) was 
developed by chemists at Pharmacea (now part of Pfizer) starting from work carried out at DuPont 
Pharmaceutical on the mechanism of action and antibiotic activity of this novel oxazolidinine class of 
compounds.87,109-113 Derivatives of artemisinin, an anti-malaria drug isolated from the sweet wormwood 
(Artemisia annua) plant, are in development in Europe,2,71 and a synthetic trioxolane based on 
artemisinin is being tested in combination with another synthetic bisquinoline compound, piperaquine, 
as an anti-malarial agent.114 There are at present three semi-synthetic erythromycin derivatives in 
clinical development as antibiotics– cethromycin (ABT, Restanza®), EP-420 (Enanta Pharmaceuticals) and 
BAL-19403 (Basilea),1,53 and the synthetic derivatives of tubocaurarine, a muscle relaxant isolated from 
the Amazonian Chondrodendron tomentosun plant, are now preferred over tubucaurarine due to its 












Figure 1.19. 2D structure of the novel oxazolidinine antibiotic Zyvox® (linezolid). 
The chemical optimization of lead compounds into potential drug-like compounds has, however, led to 
some spectacular failures. Partially attributed to the reduced productivity of the pharmaceutical 
industry, an answer to the high failure rate was sought, and “Lipinski’s Rule of Five” was proposed as a 
guide to identify good lead compounds.115-117 While the rule describes properties important for 
pharmacokinetics in the human body, it does not predict whether a compound will be pharmacologically 
active. Characteristics identified as imperative to a promising compound include the maximum 
molecular weight of a compound (less than 500 Da), the total number of hydrogen bond donors and 
acceptors (5 and ten respectively) and an octanol-water partition coefficient (cLogP) not greater than 5. 
The weight limit of 500 Da came about with the realization of the connection between high molecular 
weight and poor solubility. Optimization of potent lead compounds with high molecular weight often 
results in compounds with even greater masses, and an associated reduction in solubility and poor 
pharmacokinetic properties.77,117 Attempts to improve predictions of “druglikeness” have resulted in 
extensions to this rule, such as the range for number of atoms (between 20 and 70), number of 
rotatable bonds (10 or less) and a polar surface area no greater than 140 Å2. As with any rule, there are 
a number of exceptions – for example the 500 Da weight limit has been a matter of debate as a number 
of drugs, especially the naturally derived antibiotics, far exceed this. It has also been found that the 
polar surface area and the number of rotatable bonds are more important criteria in the identification of 







1.1.5. The Bottom-Up Approach: Tackling the Problem from a Different Angle. 
“Bottom-up thinkers try to start from experience and move from experience to understanding. They don't 
start with certain general principles they think beforehand are likely to be true; they just hope to find out 
what reality is like.”  
John Polkinghorne 
 
An alternative to the “top-down” approach of HTS to drug design is the “bottom-up” or “knowledge-
based” method, where the target of a compound, be it an active site in an enzyme, an area on the 
surface of a protein or a specific receptor protein, is used as a base for the design of a target compound. 
Techniques such as fragment-based drug design (FBDD), computational design and rational synthesis 
integrate existing structural or biochemical data of the target so that the compound which is designed or 
engineered has the best chance of showing the desired activity.119-121 An important distinction between 
FBDD and HTS is that the interaction of the fragments is predisposed towards a specific target, be it a 
protein receptor site, the active site of an enzyme or a patch on the surface of a protein which is 
functionally important.92 This concept was introduced in the early 20th century by John Newport Langley 
and Paul Ehrlich.122-123 Based on his observations of the responses to certain dyes, Ehrlich proposed the 
idea that different receptors exist in microorganisms, parasites and cancer cells,124 and Langley, together 
with his collaborators, put forward the idea that receptors could be activated or inhibited by the binding 
of a ligand to a receptor in 1905,125 with Joseph Clark using both of these theories as the basis for his 
study of drug action on cells in the 1930s.126 
 
As previously stated, the ability of a screen to identify lead compounds is still relatively poor.77,127 One of 
the problems alluded to lies in the nature of the hits identified by HTS. With the molecular weight of 
successful drugs in the World Drug index averaging in the low 300 Da,128 identification of a hit 
compound with a similar mass from a “drug-like” corporate library, would, after optimization, result in a 
lead compound approaching 400 Da, and this compound would show significantly poorer 
pharmacokinetic properties due to this weight increase.117 As a solution, a number of research groups 
have proposed a “fragment-based” approach, where low molecular weight compounds (under 200 Da) 
target subpockets within the active site.115,129-134 Rather than trying to fit a prebuilt molecule into a 
target, as is the case with library screening through HTS, FBDD attempts to find the best fitting molecule 
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for a particular target by identifying building blocks that fit correctly, and then assembling these pieces 
into a complete molecule (Figure 1.20).  
 
Figure 1.20. (a) Library screening vs. (b) fragment based drug design. Library screening attempts to fit a 
prebuilt molecule into a target, while FBDD identifies fragments which can be assembled into a complete 
molecule.92 
 
Initially proposed by Hol and co-workers in 1990135 and again by Fesik and co-workers at Abbot 
Laboratories in 1994,130 FBDD has become a well-known and widely applied strategy for the 
identification of novel hits in both industrial and academic settings,136 with one F.D.A.-approved drug, 
vemurafenib (Zelboraf® - Figure 1.21), originating from this fragment screening and optimization 

















These fragments are defined as low molecular weight organic molecules which are lipophillic and highly 
soluble, and which typically bind to the target protein with low affinity (Figure 1.22).115 A “Rule of 
Three,” analogous to “Lipinski’s Rule of Five,” was proposed by Congreve and co-workers to define these 
fragments.115,139 The “Rule of Three” states that fragments should have a molecular weight under 
300 Da, no more than three hydrogen bond donors or acceptors and a cLogP value of less than 3. 
Additional filters such as the maximum number of rotatable bonds (3) and a polar surface area of 60 Å2 
have also been indicated to aid in the identification of more desirable fragments. Of these widely 
accepted guidelines, the most flexible is the rule related to molecular weight, as fragments over 300 Da 
have been used to identify hits for a range of targets, including peroxisome proliferator-activated 
receptors (PPARs), phosphodiesterase type 4 (PDE-4) and the protein encoded by the mutant B-Raf-
V600E (BRAFV600E) gene.140-143 While these fragments have limited functionality and therefore weaker 
affinity, the hit fragments can either be optimized individually, or the fragments can be connected, 







































































Figure 1.22. A molecular fragment library containing (a) simple carbocyclic and heterocyclic fragments 
and (b) simple drug scaffolds.77 
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Optimization of fragment hits into lead compounds follows one of two paths (Figure 1.23) – 
“Fragment-growing” and “Fragment-linking.”40 Fragment-growing is the stepwise addition of 
substituents or functional groups to a core fragment in order to maximize the interactions with the 
binding site, while fragment-linking approach involves the covalent linking of two or more fragments 
which are independently bound to the binding site with suitable linkers.115,145 Fragment-growing, the 
more common approach, conserves the initial binding mode of the initial fragment, and allows 
researchers to monitor the subtle changes in the binding mode that occur with each step in the 
optimization process.136 Recent studies using fragment growing as the optimization strategy include the 
identification of Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1),146 matrix 
metalloproteins (MMPs),147 phosphatidylinosito-3 kinase (PI3Ks) inhibitors148 and acetylcholine-binding 
protein (AChBP).149 Cheng et al. identified 2-aminoquinoline as an initial fragment hit from a library of 
4,000 fragments screened against BACE1, and optimization using fragment growing improved the 
activity of the fragment by 106 fold146 and a 50-fold improvement was obtained after a single fragment 
growing optimization step was carried on a fragment identified as a hit for AChBP.149  
 
 
Figure 1.23. (a) Fragment growing and (b) fragment linking strategies for drug design.40 
While less common than the fragment-growing methodology, the fragment-linking approach has been 
used by a number of groups to obtain potent compounds from initial fragment hits.150-158 Fesik and co-
workers130 were the first to successfully demonstrate the applicability of fragment-linking, and Barker et 
al.157 have established that linking two low affinity fragments can create a compound with 1,000 fold 
higher affinity than either fragment. In another study, Petros et al.156 identified a B-cell lymphoma 2 
(Bcl-2) inhibitor that was 1,000 fold more selective for Bcl-2 over B-cell lymphoma-extra large (Bcl-XL). 





themselves into one compound, has been described by Lewis et al.,159 Hu et al.160 and Suzuki et al.161 
Lewis et al. demonstrated the acetylcholinesterase-mediated linkage of azides and alkynes into high 
potency inhibitors,159 Hu et al. the self assembly of thio acids and sulfonyl azides in Bcl-XL into a “small 
molecule protein-protein interaction inhibitor” (SMPPII)160 and Suzuki et al. described the formation of 
histone deacetylase inhibitors from an in situ reaction of hydroxamic-containing alkynes and azide 
fragments.161 The fragment-growing approach is more popular as it allows more freedom for 
multidimensional optimization as opposed to fragment-linking, which depends on being able to link 
adjacent fragments without altering the binding modes.115 A study by Hung et al.150 in 2009 compared 
the two optimization methods by applying them to the same target protein – pantothenate synthetase 
from Mycobacterium tuberculosis (Figure 1.24). The fragments used were identified through biophysical 
techniques, and included an indole fragment for the growing approach, and an indole and a benzofuran 
fragment for the linking approach. After optimization was complete, the strategies resulted in similar 
structures with similar potencies, indicating that, at least in this case, there was no significant difference 
between the two strategies.115,150  
 
 
Figure 1.24. Comparison of (a) fragment-growing and (b) fragment-linking techniques for the synthesis 





While the list of benefits of FBDD over HTS is long and cannot be adequately covered here, the 
advantages that FBDD has over traditional HTS can be delineated into three main groups:  
 The chemical diversity space is covered more completely with FBDD than with HTS, as smaller 
FBDD libraries can probe the chemical space more effectively and can generate the same 
amount of information as HTS.115-116,162-164  
  FBDD achieves higher hit rates than HTS, a fact which has been ascribed to the ability of 
fragments to bind to multiple sub-sites of a target as opposed to the larger, more functionalized 
molecules which show significantly more steric hindrance and electrostatic conflicts with the 
binding site.115,162,165  
 Lead compounds optimized from FBDD hits show higher binding efficiency per atom than those 
from HTS hits.115  
FBDD does however have one major shortcoming – the affinity of the fragments used are often outside 
of normal detection limits, and therefore cannot routinely identified using standard bioassays.77 While 
there has been some work on the sensitivity of bioassays, many researchers have used existing 
biophysical techniques such as X-ray crystallography and NMR spectroscopy to screen these low-affinity 
compounds.77,129-130,151 As “traditional” FBDD is not compatible with biochemical screening methods, 
FBDD has been expanded to include scaffold-based drug design (SBDD), where reoccurring chemical 
motifs from marketed drugs are used as templates for drugs.140,166 These scaffolds contain more 
functional groups than the fragments, and as such are able to provide a more substantial starting point 
for optimization. One of the key differences between FBDD and SBDD lies in the molecular weight limit 
imposed. In FBDD, the weight limit is around 200 Da per fragment; the limit for SBDD is 350 Da, with an 
average weight of 250 Da. This weight limit adjustment results in a bigger scaffold library (20,000 
compounds as opposed to the 2,000 fragments used in FBDD), but these scaffolds are often able to bind 
to proteins at affinities which can be detected with biochemical assays.115 While the rate of false 
positives is high due to high compound concentration and low binding affinities, compounds are only 
selected as hits when activity is shown against multiple members of the same protein families.  
 
Another difference between FBDD and SBDD is that only scaffolds with binding modes which will 
tolerate small substitutions are optimized further, leading to more accurate Structure-Activity 
Relationship (SAR) analyses and more efficient further optimization.115 While not often included in FBDD 
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or SBDD, fragments of natural products have also been used in drug design. Waldman and co-workers 
combined commercially available natural product fragments and some which were synthesized in a 
study which combined the chemical space-covering ability and binding ability of fragments with the 
chemistry and geometry of natural products.167 Whilst some of the 193 natural product fragments 
(NPFs) tested resemble known chemotypes, some were novel scaffolds which showed good binding 
ability. By merging the techniques of FBDD and natural products, the authors were able to identify 
compounds which are biologically accessible and could potentially be the basis of novel, synthetic drug-
like molecules which are also biologically optimized, in much the same way as food scientists at the 
Reese corporation were able to merge peanut butter and chocolate into peanut-butter cups, supposedly 




1.2. The Machines Are Taking Over: The Role of Computers in Drug Design. 
“I'm not afraid of computers taking over the world. They're just sitting there. I can hit them with a 
two-by-four.”  
Thom Yorke  
One of the challenges facing drug designers is the vast amount of data generated from techniques such 
as FBDD and SBDD, as well as data generated from biophysical, biostructural and biochemical 
approaches. Playing an important role in the integration of data from various sources, computational 
methods are becoming increasingly more important in many drug discovery processes, with computer 
modeling and simulations estimated to account for 20% of pharmaceutical R&D expenditure by 
2016.40,42 Computational drug design is involved in all stages of drug design (Figure 1.25), from target 
identification to fragment library generation to hit identification and lead optimization and even into the 
clinical trials phase. While a powerful tool in its own right, it has proven to be most useful when used in 
combination with experimental data.115 These in silico methods are cost effective, fast and can be 











Figure 1.25. Application of computational methods to drug design. 
The steps involved in in silico drug design mirror those found in in vitro drug design. A virtual library is 
designed and screened by another virtual approach, such as molecular docking, and prioritized 
fragments can then be virtually grown, linked or a combination of both into a virtual lead compound.115 
As with all computational techniques regardless of the field of application, the adage “Garbage in, 
Garbage out” applies, and it is notoriously difficult to obtain a high quality, potent final compound 
without having a high quality fragment library. While a number of approaches have been developed to 
aid in the compilation of fragment libraries, the simplest and most commonly used technique to design a 
fragment library is the filtration of commercially available chemicals. A number of computational tools, 
such as the descriptor calculator plugins from ChemAxon,168 the Chemistry Development kit (CDK),169-170 
the sdfilter utility from MOE171 and QikProp from Schrödinger,172 can be used to filter libraries of drug-
sized or lead-like compounds based on molecular properties including molecular weight, logP, number 
of rotatable bonds, number of H-bond acceptors or donors, and the polar surface area. With no fixed 
rules for filtering compounds, other filters such as molecular diversity, inclusion of common motifs and 
removal of chemically reactive elements have also been implemented.115 
 
While the “Rule of Three” is often applied to guide the formation of a fragment library, as in the case in 
vitro, exceptions abound and different groups use different filters depending on the situation at hand. 
Fragment libraries have also been designed based on the computational retrosynthesis of compounds 
found on the World Drug Index. RECAP173 (Retrosynthetic Combinatorial Analysis Procedure), designed 
by Lewell et al. was applied to 35,000 compounds on this list, and a number of biologically recognized 





























fragments and privileged scaffolds were identified. In 2006 Kolb and Caflish developed DAIM174 
(Decomposition And Identification of Molecules), a program which follows similar rules to RECAP to 
automatically break apart the compounds in small molecular libraries in order to generate fragments, 
and Degen et al. detailed an enhanced procedure for molecule decomposition using BRICS175 (Breaking 
of Retrosynthetically Interesting Chemical Structures). This approach makes use of novel, more 
elaborate fragmentation rules and also maintains promising motifs through the fragmentation process. 
Comprehending the importance of in silico fragmentation in generating fragment libraries, many 
commercially available programs, such as CoLibri from BiosolveIT,176 the sdfrag utility in MOE,171 Chomp 
from OpenEye177 and the rule-based molecular fragmenting utility from Schrödinger172 are capable of 
carrying out fragmentation operations on small molecule libraries.115 
 
Once a suitable fragment library has been compiled, the next step in the virtual drug design process is 
virtual screening (VS) of the fragments against a drug target, such as an enzyme or a protein receptor 
(Structure-based VS), so as to identify those fragments which are most likely to bind to the target.178-180 
Structure-based VS (SBVS) involves the “docking” of a fragment into a target site of a protein or enzyme, 
and a subsequent application of a scoring function to estimate the probability of the fragment binding to 
the target site.181-182 The majority of these docking programs use hierarchical scoring schemes, where a 
simple shape-based scoring function applied to the entire library eliminates fragments which are 
sterically unsuited to the binding site, followed by progressively more intense scoring functions on the 
surviving fragments to yield, hopefully, a manageable list of compounds with good binding affinity 
scores.183-184 The binding affinity of a fragment is predicted by combining a number of different energetic 
contributions, such as electrostatic interactions, van der Waals interactions and hydrogen bonding 
interactions, however the contributions of entropy to the free energy of binding are difficult to estimate 
and are a source of large uncertainty in the values.92  
 
The initial fragment positioning methods, which in fact predate the experimental techniques,185-191 were 
mostly force field-based methods and relied on protein-ligand interactions from molecular mechanics 
models to predict fragment positions. However, as computational drug design has improved and 
evolved, the positioning methods have made use of the more sophisticated force fields available. 
Examples which make use of these modern force fields include 3D-RISM, which generates the most 
likely binding mode for a given ligand and makes use of the 3D reference interaction site model 
solvation theory,192 and FTMap,193 which generates a consensus site and uses a Fourier transform 
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correlation approach and the analytical continuum electrostatic (ACE) model to deal with solvation 
issues.  
 
Computational screening methods such as molecular docking can be applied to a wide variety of targets 
if high quality structural data is available, and in the absence of experimental structures, 3D or 
homology models can be used. While already a proven technique in drug discovery when coupled with 
experimental validation,194 molecular docking is believed to yield unreliable results due to promiscuous 
binding modes of the fragments, and the inability of a scoring function to separate native and irrelevant 
binding poses,195-196 as most of the docking programs and scoring methods are developed and optimized 
for more drug-like compounds with properties significantly different to those of fragments.115,145 A 
number of studies have been carried out to explore the performance of docking methods and scoring 
functions as virtual screens for fragment libraries, and these studies show that, as for docking in general, 
solvation is important but computationally expensive to carry out; that protein flexibility plays a role and 
that the accuracy of docking results is poorer for weakly-binding ligands.197-198 However, a number of 
studies have shown that the results from fragment docking are similar to those obtained for the docking 
of drug-like compounds in terms of enrichment.115,145  
 
Following the identification of hit fragment, the objective in drug discovery is then to design inhibitors 
using fragment-growing, fragment-linking or fragment-scaffold merging techniques, in much the same 
way as carried out in vitro (Figure 1.26). Although the theoretical basis for fragment connection was 
proposed in 1981,199 computational connecting methods such as CAVEAT,200 HOOK,201 and CONCERTS202 
emerged in the mid 1990s shortly after the first fragment positioning programs were released. While 
fragment-based design is conceptually simple, it proves to be a challenging problem in practice,203-204 as 
most de novo methods do not take into account the routes required for the synthesis of a compound, 
and can often identify a highly potent but synthetically unavailable compound. Modern programs 
attempt to solve this problem by limiting the combinatorial predicament when connecting fragments. 
The CONFIRM205 approach, for example, makes use of a database of bridge molecules derived from 
existing compounds, and by retaining the information about the connecting atom types for the bridges, 
increases the possibility of creating a molecule which can be synthesized, while ReCore206 uses recap 
synthesis rules to link or grow fragments into lead compounds. Common de novo design programs 
include BREED,207 GANDI,208 AlleGrow,209 BROOD,210 GROWMOL211 and FOG.212 BREED, developed by 
Vertex Pharmaceuticals, has been used to create new inhibitors of cyclin-dependent kinase 2 (CDK2), 
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P38 mitogen-activated protein kinase and HIV protease,207 and Ligbuilder, a program combining both 
fragment growing and linking functionalities, has been used to design two potent Cyclophilin A inhibitors 
from an acylurea seed fragment.213  
 
 Figure 1.26. (a) Fragment-growing, (b) fragment-linking and (c) fragment-scaffold merging techniques. 
An interesting case of a novel drug discovery method and computational fragment-based drug design 
was presented by Li et al. in 2011214 when they used the MLSD (Multiple Ligand Simultaneous Docking) 
program215 to simultaneously dock privileged scaffolds into hotspot regions of a cancer target, the 
transcription factor STAT3. In this study, the top fragments were selected for in silico linking, using 
different bridges such as amines, amides, ethers and olefins, and 15 virtual compounds were created. 
These 15 compounds were then used in a similarity search against the Drugbank216 where celecoxib, a 
COX-2 inhibitor, was identified as a novel STAT3 inhibitor. Synthesis of a celecoxib derivative and one of 
the in silico linked hits confirmed this method as these compounds showed good potency against STAT3 
in vitro. In silico drug development can also significantly reduce the time required to develop a drug, as 
demonstrated by Becker and co-workers, who used computational drug design and development to 
create a 5-hydroxytryptamine receptor (5-HT1A) agonist for the treatment of anxiety and depression. The 






than 6 months of optimization and the synthesis of only 31 compounds, whereas without computational 
input, this process takes anywhere from 5 to 10 years.217  
While SBVS has proven to be an important design route for new drugs, the downside to this approach is 
that high-quality protein structure data is required, either from X-ray crystallography of the protein, or 
from other biophysical techniques. As getting this high-quality data is challenging at the best of times, 
there are a number of target proteins where the structure of the active site is not definitively known. 
Ligand-based VS (LBVS) occurs when a pharmacophore, a “conceptual description of the molecular 
features necessary for the interaction of a ligand to a target molecule,” is used as the benchmark against 
which the fragments are judged.218-219 A good pharmacophore model takes into account the common 
chemical motifs, and is able to explain how structurally diverse compounds are able to interact with a 
common receptor or active site.220-224 It highlights the important structural elements required for activity 
(Figure 1.27) and can be used to identify novel compounds which bind to the same receptor.225-228 
Pharmacophore modeling has become an established screening technique,229 and has been used to 
identify a human dihydro-orotate dehydrogenase (DHODH) inhibitor,230 and a potent and selective 
neuronal nitric oxide synthase (nNOS) inhibitor.231 
 
Figure 1.27. The pharmacophore model and resultant lead compound for inhibition of aldose 
reductase 2.232 
Despite the fact that many lead compounds have been identified through either SBVS or LBVS, perhaps 
the most ideal situation arises when both approaches are used in tandem. When SBVS is used, the hit 
compounds or fragments should, by definition, be able to bind to the conformation of the protein, and 
when LBVS is used, the results will, as expected, show chemical similarity.145 During the development of 
a histamine H1 inhibitor, Leurs et al.233 used structure-based docking techniques together with specific 
information obtained from known ligands to identify fragment hits with high binding affinities, including 
one with the highest affinity for a G protein-coupled receptor yet identified through SBVS.217,234  
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As with all things, there are drawbacks to computational fragment-based screening. Perhaps the most 
serious are the relatively low prediction accuracy and the rapid accumulation of errors in the 
calculations. In general, experimental FBDD methods have greater accuracy than computational 
methods, and this difference has been ascribed to imperfect energy functions used to assess the ligand-
protein interactions, as well as problems in sampling the conformational space completely.115 
Computational methods which are fast are less accurate as they tend to make approximations during 
conformer searching, as well as during the calculations of energetic terms during the simulations, and 
the more accurate methods, which carry out more complete conformational searches and include 
protein flexibility, are much slower. A commonly adopted strategy to overcome these issues is to use a 
“layered” approach, where large libraries are screened with a fast method, and the resulting smaller 
collection of compounds is then further screened with a slower, more accurate method. While 
computer-based methods such as docking or molecular dynamics can be carried out on a homology 
model of a protein, the errors from this computationally-derived structure, added to the screening 
errors, can significantly lower the dependability of the hits identified through virtual screening. In spite 
of these disadvantages, the virtual screening of fragments can result in lead identification, although the 
most effective use of computational methods is in conjunction with experimental methods to both 
validate and guide the following computational steps. By focusing on small molecules which bind to a 
specific location, FBDD integrates relevant molecular information into the design of selective inhibitors 
with high affinities, and while this process appears slow, including this detailed interaction information 
into a drug design process is thought to facilitate the discovery of higher affinity binders that work 
through a known mechanism. The integration of experimental techniques with computational methods 










1.2.1. Making Predictions: Modern Techniques for Modern Problems.  
“Trying to predict the future is like trying to drive down a country road at night with no lights while 
looking out the back window.” 
Peter Drucker 
The art of prediction plays a fundamental role in the pharmaceutical industry, be it a biologist 
attempting to predict the effect of target inhibition on cell behavior, a doctor worried about the side 
effects of a drug, or a manager trying to predict future returns on an investment.235 Prediction in drug 
design relies on the knowledge of the three-dimensional (3D) structure of a specific macromolecule, 
such as a protein or enzyme, as the function of a macromolecule is as dependent on the 3D structure of 
the macromolecule as it is on the string of components which make up its primary structure. These 3D 
structures are vitally important to medicinal chemists striving to design compounds which inhibit these 
macromolecules, and many computational methods and techniques, such as molecular docking, de novo 
design, molecular dynamics and free energy calculations are available which aid in the design of novel 
inhibitors. As there are a number of programs and packages available, each with their own unique 
attributes, a review of all of these programs is impractical, and as such, the brief review of 
computational methods which follows will focus on the Schrödinger suite of software so as to better 
understand the results obtained during the design process.  
 
Molecular docking uses known 3D coordinates of the site of interest to orient a ligand into a favored 
conformation within that site, and uses an empirical scoring function to predict the activity of a ligand 
based on the interactions between the ligand and the binding site. Modern structural drug design owes 
its beginning to the “Lock and Key” model for enzymes (Figure 1.28), proposed by Nobel laureate Dr Emil 
Fischer in 1894.236 This model, which describes how the active site of an enzyme is complementary to 
the structure of the native substrate, is still an important part of the molecular docking algorithms used 




Figure 1.28. A schematic diagram of “Lock and Key” model for enzymes, where the active site is 
complementary to the structure of the native ligand. 
The “Lock and Key” model is used to describe the binding process, which takes into account the solution 
structures of the ligand and the receptor separately as well as involving the conformations of the 
complex. While docking algorithms can be simplified by considering the receptor and ligands as rigid 
molecules, which has lead to the successful prediction and reproduction of experimentally-determined 
structures of complexes,237-240 a rigid model is not suited to the majority of receptors and ligands, and 
the structural flexibility of both the receptor and ligand needs to be taken into account during the 
docking process.241 With the increase in computing power and resources, more refined docking 
algorithms and methods have been developed which also take into account advances in our 
understanding of flexible molecular recognition with regards to the receptor and ligand. In particular, 
the Induced-Fit binding model, which suggests that an enzyme will attempt to assume a different 
conformation upon ligand binding in order to maximize the interactions between the protein and the 
ligand (Figure 1.29).242  
 
Figure 1.29. A schematic diagram of the Induced-Fit model for the binding of a ligand into an active site. 
Released in 1982, DOCK made use of rigid spheres as representations of the atoms in the receptor and 
ligands, and removed all internal degrees of freedom.240 This first docking software portrayed the 
receptor as a collection of spheres in pockets and grooves within the binding site rather than depicting 
the individual receptor atoms. The 1986 release of DOCK introduced an algorithm which accounted for 
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the flexibility of the ligand by splitting the ligand into fragments, and then docking those fragments into 
the binding site, with the flexibility of the ligand incorporated into the connections between the 
fragments upon reassembly.243  
 
While the developers of DOCK were tackling the problem of ligand flexibility, other software developers 
were attacking the problem from the other side by working on creating grid files which contained both 
chemical and physical information about the receptor. These grid files pre-calculate information which is 
reused for each ligand, and so increase the efficiency of the docking methods. The program GRID 
pre-calculated the potential energy of receptor-ligand interactions with various functional groups185 and 
DOCKER made use of the grid files to extend the Van der Waals radii of the receptor atoms.244 Including 
approximations to directly calculate the protein-ligand interactions by combining the Van der Waals, 
Coulombic and hydrogen bonding contributions greatly improved these grids, and thus set the standard 
for the use of automated grid file in future docking programs.245-246  
 
 
1.2.2. The First Step: Docking and Pose Evaluation.   
“Science is fun. Science is curiosity. We all have natural curiosity. Science is a process of investigating. It's 
posing questions and coming up with a method. It's delving in.” 
Sally Ride 
Modern docking procedures generally involve four main steps – the creation of a receptor grid, 
generation of ligand conformations, docking of these conformations, and finally assigning a score to the 
docked ligand poses (Figure 1.30), although the specifics of each depend on the software used as well as 
docking method. The majority of docking software packages make use of receptor grid files containing 
structural and chemical information about the receptor, as well as including potential interactions with 
the ligand, and these grid files contains the coordinates and charges of the receptor atoms within a 
distinct binding area. The protein-ligand interaction energies are usually pre-computed and included in a 
table contained within the grid file, along with the location and dimensions of the binding site, obtained 
either through prior knowledge of the protein structure or through the use of binding site prediction 
software.247-250 This pre-calculation of data saves a large amount of computational time, especially when 
virtual screens containing millions of compounds are performed, as the energy calculations are not 
performed for every docking procedure. This grid can also be altered depending on the final goal of the 
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docking procedure – a small grid is used when trying to reproduce a crystal structure conformation, 
while a larger grid is used for the screening of new inhibitors as the binding mode and size of the new 
ligand might vary significantly.251 
 
Figure 1.30. The steps in modern docking processes.   
The flexibility of the receptor is taken into consideration by a number of methods, with the first method 
making the atoms of the receptor “soft” by reducing the Van der Waals repulsion of overlapping 
atoms252 and this method is still used today.253-254 Explicit protein flexibility was put into practice a few 
years later by exploring the flexibility of the rotatable bonds on the protein side chains.255-257 Different 
receptor structures are created by identifying rotatable bonds and systematically sampling the torsions 
of those bonds. Simple methods consider only the rotation of polar hydrogen atoms on receptor side 
chains, while more complex methods can include all possible rotatable bonds of specified side chains.  
 
The most complex algorithms however, involve the simultaneous optimization of the ligand and the 
active site during the docking process,258-260 such as the Induced Fit Docking (IFD) protocol employed by 
the Schrödinger program suite.172 Under this protocol, ligands are docked into a receptor structure with 
a soft van der Waals potential, and the protein is relaxed iteratively until the structure of the protein is 
constant.253 Molecular dynamics can also be used to sample the conformations of proteins, and 
structures from these simulations can be used in ensemble-based docking methods, such as the relaxed 
complex scheme.261-264 These ensemble-based schemes deal with the flexibility of the protein as a 
whole, either with or without a ligand present, while only localized protein flexibility is addressed with 
the rotation of side chains.251  
 
As ligands are significantly simpler than receptors, ligand conformation generators are employed more 
widely than the methods utilizing flexible receptors, and this is particularly the case when the binding 
mode of a ligand is unknown. Docking programs create a variety of different ligand conformations using 
a number of processes; however in most cases the bond distances are not varied. Docking protocols 










docked, and then the fragments reassembled into the complete ligand again.243 Recent docking methods 
include the use of energy optimization techniques, where the docked structure is minimized in order to 
maximize protein-ligand interactions265-266 while the most common approaches involve the use of 
genetic algorithms to generate possible ligand conformations.  
 
Initially proposed by Judson et al.,267 and used by programs such as DARWIN,268 GOLD269 and 
AutoDock270 amongst others,271-273 genetic algorithms use evolutionary ideas to find solution to search 
and optimization problems, such as determining the best binding mode for a ligand in an active site. 
With a genetic algorithm approach, a range of ligand conformations are generated and docked into the 
receptor site, before the coordinates and torsions of the lowest energy structures are used to generate 
a new pool of structures.251 This process is repeated for a specified number of generations in order to 
determine the lowest energy binding modes for each ligand, with “mutations” randomly added to create 
new torsion and/or coordinate values, which ensures the diversity of the ligand conformations. As 
genetic algorithm methods are stochastic in nature, different ligand poses are generated through the 
use of random numbers to vary the internal torsions, rotations and translations of the rotatable bonds, 
and the results from docking programs, such as Schrödinger’s LigPrep program172, will differ from one 
run to another regardless of the input ligand structure.274 AutoDock275 and other similar stochastic 
programs perform energy minimization calculations on the structures, followed by an evaluation of the 
Metropolis criterion276 using Monte Carlo277 methods in order to determine which ligand conformations 
will give rise to the next generation of ligands.278 
 
On the other hand, deterministic docking programs, such as CHARMM279 use a systematic approach – 
molecular dynamics and energy minimization - which leads to identical results if the same calculation is 
carried out on the same processor repeatedly, but even these results can vary depending on the 
coordinates of the input ligands, especially for conformer generation algorithms that use structure 
minimization methods.280 The downside to these deterministic methods is that they often get stuck in an 
energy “rut” – the energy barrier is too large for the algorithm to overcome, and the ligand is trapped in 
an energy minimum. As this prevents all the conformations from being sampled accurately, some 
molecular dynamics algorithms have implemented the use of biasing potentials in order to lower these 





Glide, the docking program from Schrödinger,285 is unique in the fact that the docking process employed 
is a combination of both deterministic and stochastic methods. An exhaustive search of torsion angle 
space generates ligand conformations, followed by a quick initial screening of all the generated poses. 
Promising poses are then minimized within the active site using the standard molecular mechanics 
“Optimized Potentials for Liquid Simulations - all atoms“ (OPLS-aa) force field, which is combined with a 
distance-dependant dielectric model.286 A post-minimization Monte Carlo procedure applied to the 
internal dihedral angles of between three and six of the best poses allows for the optimization of the 
structure within the binding site by sampling the local torsional minima present present.251  
 
 
1.2.3. Scoring Functions: The Maths Behind It All.  
“Today's scientists have substituted mathematics for experiments, and they wander off through equation 
after equation, and eventually build a structure which has no relation to reality.” 
Nikola Tesla 
Regardless of how good a docking algorithm is, if it cannot predict the binding affinity of the ligand 
poses then those poses are worthless. While more sophisticated calculations, such as free energy 
perturbation287 or thermodynamic integration288 exist, molecular docking programs use a simplified 
equation or set of equations – a “scoring function” – to approximate a binding score. These scoring 
functions allow for the calculations of large numbers of protein-ligand binding affinities quickly and 
efficiently, as would be the case in a HTVS of millions of potential drug candidates. Each docking 
program uses a slightly different scoring function, one matched to the docking algorithm used, however, 
in general, scoring functions can be separated into one of three categories – Force-field based, 
Knowledge-based or Empirical.289 
The most computationally expensive scoring functions, force-field-based scoring functions are designed 
on first-principles, and correspond to non-bonded interactions, such as electrostatic and van der Waals 
interactions. The electrostatic interactions are predicted using a Coulombic interaction term, which is 
based on the distance and the charge between two atoms, with the distance assigned a cut-off point to 
reduce the computational requirements. The van der Waals contribution are described by a 
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Lennard-Jones potential function290 (Equation 1), where ε is the depth of a potential well, σ the finite 
distance where particle-particle potential is zero, r the distance between particles and rm the distance 
where the potential is at a minimum. This equation is designed to approximate both the repulsive and 
attractive non-polar interactions present. Several force-field based programs, including GOLD,291 
AutoDock270 and DOCK292 include functional forms of other energy terms in their scoring functions to 
account for the contributions of hydrogen bonding, entropy and solvation energies.251  
                                                 = 4 −  =  −  2                                       (1) 
The frequencies of specific atom-atom interactions in known protein-ligand complexes form the basis of 
knowledge-based scoring functions. In this approach, the interactions of experimental protein-ligand 
structures are analyzed for distance and frequency, and the more often that a particular interaction 
occurs, the more favorable that interaction is considered. The contact populations are converted into a 
scoring function, where the attractive interactions are favoured over the repulsive reactions. 
Knowledge-based scoring functions, including DrugScore,293 PMF score,294 and SMoG,295 are simple, fast 
and computationally inexpensive, and are usually limited by the set of protein-ligand structures chosen 
as the test set, but they can be expanded to include specific interactions, such as π-stacking and 
interactions with phosphorus, sulfur, halogens or metal atoms.251  
 
Empirical scoring functions, such as those found in FlexX,296 LUDI,187and ChemScore,297 are also simple 
and cheap from a computational infrastructure point of view. These equations can be separated into 
discrete energy terms, such as solvation free energies, hydrogen bonding, ionic interactions, entropic 
contributions, and non-polar interactions, but they do not reflect classical non-bonded interaction 
functional.251  In the case of the ChemScore equation (Equation 2), the constants, C, are determined 
from a set of test complexes, the first two summation terms cover all hydrophobic and hydrogen-
bonding interactions for all the atom-atom pairs and the final summation term covers any and all 
pairwise contacts between metal atoms in the receptor and the ligand atoms. The functions f, g and h 
are distance (r) and/or angle (α) dependant functions with the subscripts lr and lm denoting ligand-
receptor or ligand-metal distances or angles. The final term, CrotbHrotb, accounts for the inflexibility of 
ligand bonds by applying an entropic penalty to the frozen bonds, which are defined as a rotatable bond 




based on the premise of fitting data from receptor-ligand complexes with known binding affinities, and, 
while quick to evaluate, the accuracy of these functions is dependent on the set of complexes used to 
determine the coefficients used in the equations. If the test set has problems, for example not 
containing enough or a wide enough variety of complexes, the accuracy of the scoring function is 
negatively affected when a complex not in the test set is included.251  
        ∆ =  + ∑ ( ) + ∑ (∆ )ℎ(∆ ) + ∑ ( ) +              (2) 
The two scoring functions present in Glide – Standard-Precision (SP)285 and Extra-Precision (XP)298 – 
make use of empirical methods which are based on the ChemScore function (Equation 2 above), 
however each of these Glide functions makes use of an expanded equation. The SP function (Equation 3) 
expands the summations found in the ChemScore function into more specific categories in order to 
improve the enrichment of results, especially those associated with the docking of diverse ligands.299 
∆ =  ∑ ( ) +  , ∑ (∆ )ℎ(∆ ) +  , ∑ (∆ )ℎ(∆ ) 
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In Equation 3, the first term, which accounts for lipophillic or hydrophobic interactions is unchanged 
from the original ChemScore equation, but the single hydrogen bonding term is expanded into three 
individually weighted terms. This takes into account the different hydrogen-bonding interactions and 
their different contributions to the docking score, as hydrogen bonds between two neutral functional 
groups have been shown to be the most favourable, while interactions between two charged species as 
the least favourable. The interaction of charged ligand functional groups with receptor metal ions is 
described by the fifth term, with the sixth term taking the entropic cost of restricting the motion of the 
ligand into account. Favourable interaction energies of polar groups without hydrogen bonding 
capabilities in hydrophobic regions is covered by the seventh term, and terms eight and nine account for 
Coulombic and Van der Waals interactions respectively, with the final term accounting for solvation 
effects by explicitly docking water molecules into the binding site. Often neglected in docking scoring 
functions as they are usually computationally expensive, the solvation terms describe the solvated polar 
and charged groups on both the ligand and the receptor and are estimated by the explicit water 




The SP portion of Glide is well suited to the initial screening of large numbers of ligands in a relatively 
short period of time, while the XP scoring function is better suited to the calculation of more accurate 
docked poses and the corresponding binding affinities. SP is “softer”, and allows for some flaws in the 
docked pose, whereas poses which violate known physical chemistry properties, such as loss of entropy, 
protein or ligand strain and desolvation effects, are heavily penalized by XP. There is a downside to the 
increase in accuracy of XP however – XP calculations are more expensive resource-wise, and are thus 
better suited to smaller numbers of compounds. The scoring function used to calculate Glide XP scores 
(Equation 4)298 is similar in structure to the scoring function used by SP. It contains energy contributions 
from Coulombic and Van der Waals interactions (Ecoul + EvdW respectively), and also includes the 
favourable contributions due to binding interactions (Ebind) as well as the unfavourable contributions 
(Epenalty)251.  
                                        =   + +  +                                          (4) 
The Ebind term can be further divided into individual interactions (Equation 5). Ehe accounts for the 
favourable interaction energy of a lipophillic group on a ligand being surrounded by hydrophobic regions 
rather than the water molecules initially situated in that region, as well as for accounting for the 
reduction in the unfavourable interactions between said lipophillic group and the bulk water molecules 
upon binding. The Ehb,nm term approximates the increased significance of hydrogen bonding between 
neutral groups of the ligand and receptor, something identified through both experimental and 
theoretical analyses of pharmaceutical drugs and their targets. Ehb,cc accounts for the contributions of 
charged-charged hydrogen bond motifs, EPI the favourable pi-cation and π-π stacking interactions, with 
the final terms dealing with the placement of halogen atoms into a hydrophobic area of the receptor 
and the application of a correction term in order to improve the binding affinity of smaller molecules 
which are unable to form the same number of interactions with the protein as a larger ligand.251  
                               =  +  , + , + +  , + ,                                       (5) 
The Epenalty term is also separated into individual contributors (Equation 6), with Edesolv calculated in a 
similar manner as the desolvation term found in the SP scoring function, however the XP scoring 
function is more rigorous and weighted differently as it utilizes increased sampling techniques when 
docking the water molecules, and the calculation efficiency is improved as the energies are pre-
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calculated when the receptor grid is generated.251 While it does not comprise a significant portion of the 
overall binding energy, the Els term penalizes those docked conformations with close internal contacts, 
and in doing so takes into consideration the internal strain present in these high-energy structures.251  
                                                           =  +                                                                       (6) 
While docking programs are designed to assess the ability of a ligand to bind to a specific receptor 
conformation, there are a number of restrictions that must be considered. Algorithms and scoring 
functions are intended to be relatively accurate within a timeframe which would allow for the screening 
of millions of compounds, and as such the results should not be the sole method for determining the 
binding of a ligand to a receptor. The poses generated from any of the docking algorithms are static, and 
do not take into account the dynamics involved in protein-ligand interactions. Other theoretical 
methods, such as molecular dynamics, and more sophisticated free energy calculations, such as a 
Molecular Mechanical/Generalized Born Surface Area (MM/GBSA) approach, should follow the initial 
docking calculations, as these more accurately represent the complex. A recent review by Plewczynski et 
al.300 highlights this point, as they found little consistency between the results of a number of docking 
algorithms, and more importantly, no correlation between the docking scores and in vitro binding 

















1.2.4.  The Final Hurdle: The Role Of Post Processing in Computational Drug Design.  
“A computer lets you make more mistakes faster than any other invention in human history, with the 
possible exceptions of handguns and tequila.”  
Mitch Ratcliffe 
 
An important goal in drug design is the reliable estimation of the free energies of protein-ligand binding. 
Since the inception of computational free energy calculations, a number of approaches have been 
proposed, each with their own benefits and drawbacks.301-303 These approaches range from fast but 
relatively inaccurate methods based on rough physical estimates to resource-intensive methods based 
on less harsh approximations of real physics.303 Ideally these free energies would be calculated directly 
(Figure 1.31), however, the vast majority of the energy contributions in these calculations would arise 
from interactions between solvent molecules, and these changes are often an order of magnitude larger 
than the binding energies.  
 
 
Figure 1.31. Ideal method for the calculation of free energy, using the “Lock and Key” model for 
simplicity. 
As direct calculation of binding energies is not possible, it is necessary to divide up the calculations into 
smaller, more manageable pieces. One method of division is the MM/GBSA approach, where the free 
energy of binding is calculated from the differences between the free energies of the ligand, the protein 
and the complex in solution, and this method is the fastest force-field based method currently 
available.303-305 This process is founded on the idea that a combination of molecular mechanics (MM) 
energies, polar and non-polar solvation terms and an entropy term can describe the free energy of 
binding of a ligand to a receptor.303-305 The free energy for each component is converted into a gas phase 
MM energy term (ΔEMM), a solvation term (ΔGsolv) and an entropy term (T·ΔS) (Equation 7).306  
 
                                                   ∆ =  ∆ MM + ∆ solv − ∙ ∆                                                                       (7) 




EMM can be deconstructed into ΔEbat (the sum of bond, angle and torsion terms in the force field), a Van 
der Waals term (ΔEvdW) and a Coulombic term (ΔEcoul), while ΔGsolv can be broken into individual polar 
(ΔGsolv,p) and non-polar (ΔGsolv,np) components while ΔGsolv,np is computed as a linear function of the 
solvent-accessible surface area (SASA). ΔGsolv,p is usually calculated by solving the Generalized-Born 
equation (Equation 8) where ε0 is the permittivity of free space, ε the dielectric constant, qi the 
electrostatic charge on particle i, rij the distance between particles i and j and ai the effective Born 
radius. 303 The entropy term T·ΔS is, in most cases, ignored for calculations involving congeneric series or 
relative free binding energies, as the calculation of this term can be a major source of errors306-308 
however some research groups still support its use in free energy calculations.309 
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As with most computational methods, the accuracy of the results of the MM/GBSA calculations depend 
on how good the underlying algorithm or model is. Schrödinger’s Prime310-311 makes use of an energy 
model known as VSGB 2.0,312 and in this energy model, the determination of the MM energies is based 
on the OPLS protein force fields, and are enhanced by a number of physics-based corrections, including 
terms for the more accurate treatment of hydrogen bond interactions and π-stacking.286,303,312-313 The 
implicit solvent model derives from a variable surface Generalized Born approach, wherein the variable 
dielectric value for each residue is fitted to a substantial set of loop and side-chain predictions, and the 
non-polar solvation free energy (ΔGsolv,np) is calculated from a parametrized hydrophobic term.303  While 
a number of different approaches have been used to calculate binding affinities between ligands and 
proteins, several studies have shown that the Generalized Born method compares satisfactorily with the 
more computationally expensive Poisson-Boltzmann approach (MM/PBSA), which uses the significantly 
more complex Poisson-Boltzmann equation (Equation 9).306-308 Other studies have also supported the 
use of the Generalized Born approach, as the energies calculated after protein-ligand complex 
minimizations in implicit solvent gave correlations to the experimental data which were similar to those 





       
A recent study by Greenidge et al.303 found a significant correlation (R2 = 0.63) between the 
experimental data (Kd or Ki values) and the calculated MM/GBSA energies for a range of structurally 
diverse crystal structures. The results, which made use of a variable internal dielectric constant, showed 
that the MM/GBSA approach yields results which are comparable, at least in principle, among different 
targets, and they propose that this approach is likely to be more reliable for individual series. Their study 
also highlighted a number of limitations of the MM-GBSA method used – they found that the inclusion 
of crystallographic water molecules (water molecules within 3.5 Å of the ligand) results in lowered 
predictive accuracy, while the inclusion of ligand strain improves the overall accuracy of the calculations.  
 
Ultimately, all of the main scoring functions and schemes, with different degrees of complexity in their 
calculations, face the same problems – how to deal with complexes containing ligand-metal ion 
interactions or water-bridged interactions, how to take into account the energetics of water 
displacement, entropy and highly strained ligands. The developers and users of the scoring schemes, be 
they MM/GBSA-based,304-305 classic scoring function-based293,315 or based on free energy 
perturbations,301 need to take responsibility for understanding the biological target, the nature of the 
ligands, as well as the components comprising the scoring scheme used, as knowing the limits of a 











1.2.5. Finding the Diamonds In The Rough: Linking Theory and Practice through NMR 
Analysis of Molecular Flexibility In Solution (NAMFIS).  
“Death is forever. But so are diamonds.” 
Ian Fleming, Diamonds Are Forever.  
The role of computers in drug design does not stop once a potential drug has been identified or 
designed and sent through the various scoring functions available. Computer analysis can be used to 
predict pharmacokinetec properties such as ADME-Tox (Absorption, Distribution, Metabolism Excretion 
and Toxicity) qualities through Quantitative Structure-Activity Relationship (QSAR) or Quantitative 
Structure-Property Relationship (QSPR) calculations and other chemometric applications. Computational 
analysis can also aid in the identification of conformers of a flexible molecule in a solution. As the vast 
majority of drugs are flexible molecules which modulate the activity of proteins by binding to them in a 
single conformation – the “bioactive” conformation- the protein is required to pay a penalty, 
fundamentally an entropic one, for converting the conformation of a molecule in solution into the 
bound conformation.316-317 In order to avoid this penalty, the scientists designing a drug molecule will 
often use the protein-bound conformation if it is available through techniques such as X-ray 
crystallography in order to modify the structure of the molecule in order to “lock” the molecule into a 
favourable conformation prior to binding.  
 
Unfortunately, determining the X-ray structure of every drug bound to every important protein is not 
possible. In some cases, the bioactive conformation is very close to one of the several conformations 
present in solution, and as such it is important that a list exists of all the conformations present for a 
flexible molecule in solution.316-317 There does not, however, have to be a correlation between the 
bioactive conformation and the population of that conformation in solution - as long as the bioactive 
conformation is part of the conformational equilibrium, the protein will be able to select that 
conformation, even if the bioactive conformation is 2-5% of the conformations in solution. The 
challenge, then, is the determination of the population frequencies of the conformations possible for a 
flexible molecule in solution, or the Boltzmann population distribution. This is more difficult than 
appears at first glance, as the relative free energies control the populations of equilibrating 
conformations in solution. There is an exponential relationship between the free energy and the 
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equilibrium constant (Equation 10), and as such, a small change in free energy (ΔG) results in a large 
change in the equilibrium constant (K). For example, for a molecule with only two conformations 
present in solution, with a 1.8 kcal/mol difference between the conformations, the lower energy 
conformation is present at approximately 97%, and if the energy difference is increased to 3 kcal/mol, 
the higher energy conformation is all but non-existent.316-317 In “real-life” cases involving highly flexible 
molecules, many more conformations are present, with very small energy differences between them, 
and a “dominant” conformation may only be present at ~20%.   
 ∆ =  −                                                                                 (10) 
While NMR spectroscopy is useful for determining chiral center configuration, determination of the 
population distribution using this technique is problematic. Almost all drugs are small molecules, under 
500 Da in weight, and these molecules all tend to have a number of rotatable bonds. With three possible 
comformations present for each bond - two gauche and one anti conformations (Figure 1.32) - a 
molecule with 10 rotatable bonds could have 60,000 possible conformations.316-317 While some will be 
excluded due to steric clashes, a large number of these conformations will be present in solution. 
Reduction of the temperature at which an experiment is carried out at could remove some of the 
conformations, however unfeasibly low temperatures would be needed in order to account for the small 
energy differences present. NMR spectroscopy operates on a time scale in the order of tens of 
milliseconds, however the interconversion between conformations is significantly faster, and as such the 

















Figure 1.32. Gauche (left and center) and anti-Gauche (right) conformations.  
As the structure determined through NMR spectroscopy is an average, the proton-proton coupling 
constant (3JH-H), which relates to the conformation through the Karplus Equation (Equation 11) and the 
resultant dihedral angles (φ?),318-319 and the interproton distances determined through NOESY (Nuclear 
Overhauser Effect SpectroscopY) experiments are also averages.320-325 A single structure based on this 
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average data is therefore intrinsically incorrect. Another drawback is the detection limit of NMR 
spectroscopy - conformations present at about 2% are not detectable, even if these conformations are 
the bioactive conformations.   
                                                 ( ) = + +                                                            (11) 
However not all is lost. With the advancement in computational methods over the years, it is now 
possible to combine the average data from the NMR experiments with a set of computationally derived 
conformations and obtain the Boltzmann population distribution present in the solution. Named NMR 
Analysis of Molecular Flexibility In Solution, or NAMFIS, this method calculates the coupling constants 
and distances for each of the conformations generated during the conformer search, and then varies the 
mole fractions of these conformations until the calculated coupling constants and distances match those 
determined experimentally.316-317 While several combinations of conformations would satisfy the NMR 
data, NAMFIS decides which of the possible combinations is ideal based on a sum of square distances 
(SSD) metric.326 
 
 NAMFIS is able to identify individual conformations from average NMR data, and it reduces the many 
thousands of conformational possibilities into a relatively small number. In each of the cases studied so 
far, between 10 and 20 conformations were selected from the thousands generated during the 
conformational search.316-317 NAMFIS has also been used to elucidate the nature of bioactive 
conformations of a number of important drug molecules through the Boltzmann populations of the 
conformations present. One of the molecules studied using this approach is Taxol® (Paclitaxel) (Figure 
1.33). An important cancer drug, the bioactive conformation of Taxol® in tubulin, as determined by 
electron crystallography, was found to be one of the smaller contributors to the NMR data, as it was 















Figure 1.33. The 2D structure of Taxol® (left) and the 3D structure of Taxol® bound in tubulin (right).327 
NAMFIS has also been recently used to show that dominant structure, as determined using the average 
NMR data, might not even occur amongst the conformations present in solution.328 In this case, the 
solution conformations of a 5-residue peptide, previously understood to form an α-helix in solution was 
shown to not include an α-helix, even as a minor conformation. This study also showed that attempting 
to “lock” a molecule into a specific conformation, as was done with this molecule using a metal atom, 
may not in fact constrain the molecule into that conformation.  
 
NAMFIS is a powerful tool, which allows for a better representation of the NMR data as well as for 
correcting previous assumptions, and it also provides a starting point with which to explore the active 
site of a protein if the bioactive conformation is not known. NAMFIS is also able to overcome the 
common problem encountered in most modern docking procedures, where assigning high or low energy 
status to a theoretical conformation depends on the method used – as the structures satisfy NMR data, 
they are, by definition, low energy so as to exist in solution.316-317 One drawback to the more widespread 
use of NAMFIS is the amount of time and effort required to obtain accurate NOESY data from the NMR 
experiments and to extract the distances from this data. However, the information obtained through the 
use of NAMFIS vastly improved the understanding of the behavior of a molecule both in solution and 
bound in a protein, and it can aid in determining the bioactive conformations of important compounds, 
which in turn could lead to the design and implementation of drugs with better Boltzmann distributions 




1.3. Indian Gold: The Story of Curcumin. 
“Each spice has a special day to it. For turmeric it is Sunday, when light drips fat and butter-colored into 
the bins to be soaked up glowing, when you pray to the nine planets for love and luck.” 
Chitra Banerjee Divakaruni, The Mistress of Spices 
If a book was written about the most important plants used for medicinal purposes across the ages, a 
large chapter of this book would have to be devoted to Curcuma longa (Figure 1.34), the root of which is 
known as turmeric.329 Used for many centuries by practitioners of Indian Ayurvedic medicine as well as 
in Chinese traditional medicine, turmeric was and is still used to treat a wide range of afflictions such as 
jaundice, colic, chest pains and toothaches. Turmeric was also recommended to help with liver and 
stomach issues and menstrual difficulties, and was often used to aid in wound healing,330 to lighten scars 
and as an insect repellant and insecticide.329,331 Mentioned in Marco Polo’s descriptions of his 1280 
journey to China and India, turmeric was initially introduced to European markets by Arab traders in the 
13th century. And while Vasco de Gama introduced spices to the West after his visit to India in the 
15th century, it was only during the British rule of India that turmeric was combined with other spices to 
yield “curry powder” as we now know it.329  
 
Figure 1.34. Botanical view of the turmeric (Curcuma longa) plant.332 
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Or perhaps, more correctly, a large chapter of this book would be devoted to curcumin (Figure 1.35), the 
deceptively simple active ingredient in turmeric.333 Initially isolated in 1815, curcumin is merely one of a 
number of phytochemicals present in tumeric, the others include demethoxycurcumin, 
bisdemethoxycurcumin, triethylcurcumin, tetrahydrocurcumin, curcumenol, curcumol, turmerin, 
turmerones, turmeronols, zingiberene and eugenol.334 Turmeric is estimated to contain between two 
and five percent curcumin naturally, while the amount of curcumin found in commercially available 
preparations is approximately 75%, with the remaining 25% made up of demethoxycurcumin and 
bisdemethoxycurcumin, in ratios of approximately 18% and 7% respectively. These three compounds 
have also been isolated from other members of the Curcuma family, including C. mannga,335 C. 
zedoaria,336 C. xanthorrhiza,337 C. aromatica and C. phaeocaulis338 as well as in Costus speciosus,337 
Etlingera elatior339 and Zingiber cassumunar.340 Whether all three compounds are equally active is still a 
matter of debate. In most systems, curcumin is the most active compound341-342 but there are also 
systems in which bisdemethoxycurcumin is more active336,343 and there are thoughts that a mixture of 
the three compounds is more potent than any of the compounds alone.344-347 A number of other studies 
have also shown the effectiveness of curcumin-free turmeric extracts against benzo[a]pyrene-induced 
tumorigenesis in mice348 and 7,12-dimethylbenz[a]anthracene-mammary tumorigenesis in rats349 







Figure 1.35. 2D structure of curcumin. 
Despite the ongoing debate on whether curcumin or one of the 300 other identified compounds present 
in turmeric are the active agent responsible for the majority of the activity seen for turmeric,331,350 
extensive research over the last 4 decades has shown curcumin to have therapeutic potential against a 
long list of diseases330,333,351 and the mechanism by which turmeric (or curcumin) could accelerate wound 
healing has been described in detail.345,352-359 Curcumin demonstrates remarkable activity against 
inflammatory disorders360-363, including pancreatitis,364-366 gastritis,367-368 colitis,369-371 inflammatory bowel 
disease,372 arthritis,373-376 allergy377-378 and fever,379-380 activity against various autoimmune disorders 
such as multiple sclerosis,381-382 diabetes,383-391 scleroderma392 and psoriasis393 and also exhibits 
antioxidant,331,394-395 anti septic, antimicrobial,396-399 and anticarcinogenic400 properties.  
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By inhibiting platelet aggregation, inflammatory responses, fibrinogen synthesis and the oxidation of 
low-density lipoproteins (LDLs), as well as by lowering LDL levels and elevating high-density lipoprotein 
(HDL) levels, curcumin is able to protect against thromboses and myocardial infarctions,329,331,401-410 and 
numerous studies have shown activity against various types of cancer,331,351,411 including 
neuroblastoma,412-413 squamous cell carcinoma,414-415 breast carcinoma,416-421 lung cancer,422-423 
pancreatic carcinoma,424 hepatoblastoma,425-426 leukemia,427-433 non-Hodgkins lymphoma,434-435 multiple 
myeloma,436 basal cell carcinoma437 and melanoma.438-440 And as if the list of properties was not 
extensive enough, curcumin has been linked to the reduction of amyloid-induced inflammation, a 
characteristic of Alzheimers disease,119,441-446 and also shows chemosensitization, chemotherapeutic and 
radiosensitization activities.411,447-450  
 
Since the first reported use of curcumin to treat a human disease published in 1937,451 the observations 
from 67 clinical trials have been published and another 33 are ongoing.351,452 Used either alone or in 
combination with other agents, such as gemcitabine, piperine, quercetin, soy isoflavones, docetaxel, 
sulfasalazine, prednisone, mesalamine, lactoferrin, pantoprazole and N-acetylcysteine, the clinical trials 
completed so far have shown curcumin to be beneficial as a treatment against a variety of human 
diseases, including cancers, skin disorders and cardiac disorders and curcumin has also shown protection 
against chronic arsenic exposure, alcohol intoxication and hepatic conditions.452 The trials have also 
established the safety, non-toxicity and tolerability of large amounts of curcumin by patients suffering 
from a range of diseases, with doses of 8 g per day showing no negative side effects in these trials.452  
Current ongoing studies include evaluation of curcumin against cancer, arthritis and other inflammatory 
conditions, neurological conditions, diabetes and irritable bowel syndrome.452 For some trials, curcumin 
is being administered alone, as nanoparticles, capsules, tablets, powders or solutions, while others 










1.3.1. The Pleotropic Nature of Curcumin: A Simple Explanation. 
“Happy is he who can trace effects to their causes.” 
Virgil 
In an effort to understand the highly pleotropic activity of curcumin, a good place to start is by 
attempting to understand the possible ways in which curcumin could interact with a protein. 
Structurally, curcumin has two hydrophobic phenol rings connected by a flexible carbon chain, and the 
key to curcumin's ability to bind to many different targets lies within the flexibility of this molecule. 
Molecular docking studies have shown that curcumin can adopt a wide variety of conformations in order 
to maximize the interaction with the surrounding protein411 – the phenyl rings are able to participate in 
pi-pi van der Waals interactions with aromatic amino-acid side chains such as phenylalanine, 
tryptophan, histidine and tyrosine, while the carbonyl and phenolic functional groups are able to form 
hydrogen bonds to amino acids such as aspartate, asparagine, glutamate, serine, threonine and glycine. 
Curcumin is also able to bind to the minor groove of DNA, as it forms hydrogen bonds with AT-rich 
regions.453-454 Furthermore, as a β-diketone, curcumin undergoes keto-enol tautomerism (Figure 1.36), 
and the enol form dominates both in solution and in the solid state.455-456 This provides the curcumin 
molecule with additional modes of interaction with the protein as the enol enables the molecule to both 
accept and donate hydrogen bonds as well allowing the molecule to chelate the metal cations which are 
commonly found in the active sites of target proteins.457 An additional benefit to this keto-enol 
tautomerization is in the molecule's ability to undergo nucleophillic attack as a Michael acceptor, and as 
such curcumin is known to bind covalently to the sulfhydrils of cysteine as well as to the selenium in 
selenocysteine.458-459 In this manner, a wide range of possible protein interactions involving hydrophobic 















Figure 1.36. Keto-enol tautomerisation of curcumin. 
While the list of diseases and disorders against which curcumin has shown activity appears lengthy, the 
answer could be very simple. Most chronic diseases have been shown to be the result of disregulated 
inflammation,460-461 and since turmeric has traditionally been used as an anti-inflammatory agent, many 
diseases would appear to be treated with curcumin. In fact, curcumin could merely be resolving the 
inflammation rather than actually treating the source of the inflammation and therefore the root cause 
of the disease or disorder. Science has also provided evidence that curcumin in particular possesses 
potent anti-inflammatory properties,462-472 although as a potent antioxidant, it is unclear at present 
whether the anti-inflammatory properties of curcumin are due to its antioxidant properties. As most 
well-known and well characterized antioxidant compounds do not show any anti-inflammatory 
properties, it is therefore unlikely that the antioxidant activity of curcumin alone is the reason for its 
remarkable anti-inflammatory properties.329  
 
Another mystery in the activity of curcumin is what the metabolites of curcumin are and their respective 
activities, as mode of administration determines which metabolites are formed. For example, oral 
administration results in the formation of curcumin sulfonate and curcumin gluronide,473 whereas 
systemic or intraperitoneal (i.p.) administration results in the metabolization of curcumin into 
tetrahydrocurcumin (which has been shown to be active in some systems but not in others351,361,474-478), 
hexahydrocurcumin and hexahydrocurcuminol. It has also been suggested that it is the metabolites 
themselves which are responsible for the anti-inflammatory activity observed, rather than curcumin 
itself.479 However, when curcumin was substituted with the individual metabolites – in this case vanillin, 
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ferulic acid and feruloyl methane - none of the metabolites showed any significant activity, even at 
concentrations an order of magnitude greater than that used for curcumin.479 
 
Regardless of the ongoing debate on whether curcumin or its metabolites are active, a large amount of 
research over the last 30 years has been directed towards understanding the effect of curcumin on 
modern molecular targets, such as transcription and growth factors, cytokines, kinases and other 
enzymes. Thanks to advanced molecular tools, it is now known that any given disease is controlled by 
over 500 different genes involved in signaling pathways, however current treatments are often based on 
the up or downregulation of a single target.480  
 
The direct interactions of curcumin with some of these targets, the mode of interaction and the 
biological consequences of these interactions are as varied as the disorders traditionally treated with 
curcumin. Various inflammatory molecules such as tumor necrosis factor-α (TNF-α),481 myeloid 
differentiation protein (MD-2),482 cyclooxygenase-1 (COX-1) and COX-2483-484 and human a1-acid 
glycoprotein485 have all been identified as direct targets of curcumin, as have a number of protein 
kinases, including protein kinase C (PKC),486 phosphorylase kinase,487 viral sarcoma (v-Src),488 glycogen 
synthase kinase (GSK-3β)489 and ErbB2 (HER2/neu).490 Protein reductases such as thioredoxin reductase 
(TrxR)459 and aldose reductase (ALR2)491-493 are direct targets of curcumin, as are histone 
acetyltransferase and deacetylase,458,494 glyoxalase 1,495-496 lipoxygenase,497-498 xanthine oxidase,499-500 
lysozyme,501-502 matrix metalloproteinases,503 DNA methyltransferase 1 and polymerase-λ,504-505 
ribonuclease A,506 human immunodeficiency virus type 1 (HIV1) integrase and protease507-508 and 
sarco-(endo)-plasmic reticulum Ca2+ ATPase.509-510 Furthermore, curcumin has also been found to 
interact directly with a number of carrier proteins such as immunoglobulin,511 human serum albumin,512-
519 fibrinogen,516 β-lactoglobulin520-521 and caseins,522-523 as well as with cell survival proteins,524 prion 
proteins,525 DNA and RNA,454 metal ions such as Ca(II), Cu(II), Fe(II), Zn(III), Mn(II), and Pb(III),457,512,526-529 





1.3.2. There’s Always a Downside: The Trouble with Curcumin. 
 “People are always looking for the single magic bullet that will totally change everything. There is no 
single magic bullet.” 
Temple Grandin 
 
While curcumin appears to be a “magic bullet” for many diseases, and while a number of clinical trials 
are underway, it has not yet been approved as a therapeutic agent for any disease. The major reason for 
the lack of approval is the poor relative bioavailability of curcumin in the body. Despite an established 
maximum safe dose of 12 g per day,537-539 curcumin is poorly absorbed and rapidly metabolized, leading 
to low serum levels, limited tissue distribution, and a short half-life. Studies have shown that curcumin is 
poorly absorbed by mice and rats when delivered orally,539-542 while the serum levels of curcumin were 
higher when the dose was delivered through i.p. or intravenous (i.v.) methods.543-544 Human clinical trials 
show similar trends, suggesting that mode of administration used is important in determining achievable 
serum levels.545 The pharmacokinetics of curcumin in tissues also depends on route of administration – 
the distribution of curcumin in body tissues when administered orally is different from the distribution 
observed for i.p. administration. In a study using a mouse model, i.p. administration resulted in 
curcumin being detected at appreciable amounts in the intestine, spleen, liver and kidneys, with only a 
trace amount detected in brain tissue,543 a finding supported by a second study using [14C]-labelled 
curcumin where the disappearance of radioactivity associated with the labeled curcumin molecule was 
monitored. Again, target organs were identified to be the liver, intestines and the kidneys, with 
radioactivity also detected in the lungs, muscles, heart and brain, but at much lower levels.546 In 
contrast, only the stomach, small intestine and cecum show traces of curcumin after oral 
administration.541 Interestingly, in a study using tritium-labeled curcumin, the percentage of curcumin 
absorbed remained constant at between 60% and 66%, regardless of the dose, indicating that, in rats, 
there is a dose-dependent limitation to bioavailability, and that administration of additional curcumin 
does not result in greater absorbtion.542 
 
As previously stated, curcumin undergoes a range of metabolism in the body, depending on the mode of 
administration, and as such, many studies have evaluated the pathways through which curcumin is 
metabolized. The first biodistribution study by Wahlstrom and Blennow reported that uptake of 
curcumin from the gut was poor,540 and the liver was identified later as the major site of metabolism 
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when ingested,547-548 with a further study identifying the major metabolites as glucuronides of 
tetrahydrocurcumin and hexahydrocurcumin, along with the minor metabolites dihydroferulic acid and 
ferulic acid.549 Pan et al. subjected plasma samples to hydrolysis with glucuronidase, and the results 
showed that 99% of the curcumin present in the plasma was present as the glucuronide conjugate.543 
This study also revealed that glucuronide conjugates of dihydrocurcumin and tetrahydrocurcumin, along 
with curcumin-glucuronide and unconjugated tetrahydrocurcumin, are the major in vivo metabolites of 
curcumin, findings supported by Ireson et al.473 and Asai and Miyazawa.550 Curcumin was shown to 
undergo reduction, most likely through alcohol dehydrogenase, followed by conjugation to curcumin 
sulfate or curcumin glucuronide in the gastrointestinal tract by Hoehle and co-workers,551 which 
identified this route as having important implications for the pharmacokinetic fate of curcumin in vivo, 
however, neither the glucuronide nor the sulfate derivatives show the same level of biological activity as 
curcumin.473,552 
 
Due to the poor bioavailability of curcumin and the related metabolism problems, several strategies 
have been explored and employed in attempts to improve the bioavailability of curcumin. The main 
focus points include metabolic pathway blocking by other agents, conjugation and structural 
modifications made to the curcumin molecule itself.553 By far the most common strategy for increasing 
the bioavailability of curcumin is the concomitant use of agents which are able to block the metabolic 
pathways of curcumin. Piperine is a known hepatic and intestinal glucuronidation inhibitor, and a study 
using healthy human volunteers showed that the bioavailability of 2 g of curcumin was increased 2000% 
simply by the administration of 20 mg of piperine.539 Other approaches which have shown promise 
include the use of nanoparticles,554 liposomes,555-558 phospholipid complexes559 and micelles.331,450 For 
example, curcumin nanoparticles prepared by Cheng et al. resulted in significantly higher plasma 
concentration, and the residence time in mice brain was 6-fold higher than that of regular curcumin,560 
and polylactic-co-glycolic acid-encapsulated curcumin exhibited two-fold greater serum concentrations 
in animals.561 Cyclodextrin has also been used to improve the delivery and bioavailability of curcumin, 
and studies show that the cellular uptake and half-life in cancer cells is increased as compared to that of 
free curcumin.562  
 
There are a number of side effects related to the pleiotropy of the curcumin that need to be addressed 
as the development of more bioavailable formulations of curcumin continues. Curcumin has been 
shown to interact with and inhibit the activity of drug-metabolising enzymes, such as glutathione 
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s-transferase and cytochrome p450 both in vitro and in some animal models,343,563-564 and this raises the 
risk of accumulation of drugs such as acetaminophen, morphine and digoxin in the systems of people 
who are taking curcumin alongside these drugs. Curcumin has also been shown to induce DNA damage 
in cells, and increased curcumin levels in the cells could result in the induction of DNA alterations which 
are common in carcinogenesis.565 As a metal cation chelator, curcumin has been linked to the induction 
of anemia in mice566 and as both a pro-oxidant and an antioxidant in cancer cells, concern has been 
raised about the positive and negative implications due to the dual role of reactive oxygen species for 
cancer.567-568 Other side effects related to large doses of curcumin include headaches, nausea and 
diarrhea,553 and in a one study intractable abdominal pain was reported as a side effect affecting 5 of 17 
patients with advanced pancreatic cancer.569 
 
The third strategy employed in the fight to improve the bioavailability of curcumin is the structural 
modification of the curcumin molecule. Modifications have ranged from simple substituent substitution, 
to almost complete redesigning of the curcumin molecule.351 For example, the phenolic hydroxyl groups 
can be synthesized by the demethylation of the methoxy groups360 and can be alkylated, acylated, 
glycosylated and amino acylated.570-572 The linker chain can also be acylated using an arylidene group or 
alkylated.572 Many of these derivatives have shown enhanced bioavailability and increased activity 
against a range of diseases, for instance a mono-carbonyl analogue of curcumin, B63, showed greater 
antiproliferative activity against colon cancer cells than curcumin did, and a dose of only 50 mg/kg of 
B63 was required to achieve results obtained for a 100 mg/kg dose of curcumin.573 
Hydrazinobenzolycurcumin has been shown to induce A549 cell autophagy,574 and 
bis-dehydroxycurcumin shows the ability to induce autophagy in human colon cancer cells whilst leaving 
normal cells untouched.575 A fluoro-curcumin derivative designed and synthesized by Padhye et al. has 
demonstrated the ability to significantly decrease the level of PGE2 by inhibiting COX-2 activity,483 and 
the curcumin analogue B06 was reported to exhibit enhanced anti-inflammatory activity through the 
inhibition of c-Jun N-terminal kinase/NF-κB activation as compared to curcumin.576 5-Chlorocurcumin 
shows free radical scavenging properties,577 and a semicarbazole derivative of curcumin has shown 
efficient antiproliferative and antioxidant properties.578 Curcumin analogues have also been shown to 
inhibit angiogenesis450,579 and to bind directly to proteasomes,580 matrix metalloproteinases,503 DNA 





1.4. A World of Pain: The Role of Cyclooxygenase in How We Feel Pain. 
 “Life is pain, Highness. Anyone who says differently is selling something.” 
The Man in Black, The Princess Bride 
If what studies have told us are true, and that most diseases are caused by disregulated 
inflammation,460-461,581 then perhaps a good way to treat a number of diseases would be to treat the 
inflammation rather than to treat the symptoms of the inflammation. In order to do this, it is vital that 
the mechanism and biochemical pathways of pain are well understood so that we might understand 
how these mechanisms and pathways can be blocked. As the great Chinese general, strategist and 
philosopher Sun Tzu said in The Art of War, “The supreme art of war is to subdue the enemy without 
fighting.”582  
 
Nociception, from the Latin “noci” meaning to hurt, is the process by which a painful stimulus is relayed 
from the site of stimulation to the central nervous system.583 There are four main steps in this process, 
namely stimulation, reception, transmission and pain center reception. Stimuli can be either mechanical, 
such as pressure, puncturing or cutting, or chemical, such as a burn. Normal perception of stimuli, such 
as a light touch or temperature, involves the use of somatic receptors, but when a stimulus causes pain, 
specific nociceptors are activated first. Nociceptors are lightly or non-myelinated and conduct signals 
slower than the myelinated somatic neurons, and these receptors sense pain through free nerve 
endings, while the somatic neurons have specialized endings. Like somatic cells, nociceptor neurons 
travel in peripheral sensory nerves and their cell bodies lie in the dorsal root ganglia of peripheral nerves 
just inside the spine. Nocicepter neurons have been identified in skin, muscle and joint tissues and in 
some internal organs, although the situation in the organs is more complex.584-587 Two classes of 
nociceptors have been identified, namely the thinly myelinated, faster conducting Aδ fibres and the 
non-myelinated slower C fibers.588 Aδ fibers can be further split into mechanosensitive receptors which 
respond to mechanical stimuli such as pressure and touch, and mechanothermal receptors which 




The initial sharp pain felt immediately after stimulation results from a signal being conducted by the Aδ 
receptors (Figure 1.37), and the prolonged dull ache which follows is conducted along the C fibers. Once 
a signal is received, it is transmitted into the spinal cord through the dorsal roots where synapses on 
neurons in the dorsal horn are made. These secondary neurons then transmit the signal through the 
spinothalamic tract to the thalamus through the medulla, where it is relayed to various areas of the 
somatosensory cortex.583,590-591 Signals are then sent to the motor nerves via the motor cortex and the 
spinal cord, causing muscle contractions which remove the body part from the source of stimulation. 
Signals are also transmitted to the midbrain from the somatosensory cortex and the hypothalamus 
which synapse on the ascending pathways to inhibit additional ascending signals.592  
 





1.4.1. Pain Management: What Really Happens.  
“And no, I do not have a pain-management problem, I have a pain problem.” 
Dr Gregory House, House, M.D. 
Pain management after an injury can be accomplished by interrupting the flow of impulses from the site 
of injury to the brain. Pain can be blocked at the injury site, along the nerve itself, and finally at the 
synapses in the spine and in the brain (Figure 1.38). Local anesthetics work by inhibiting the voltage-
gated sodium channels in the neuron cell membrane, which effectively prevents signals from being 
conducted to the brain.594 With local anesthetics, a state-dependent blockade arises, as these drugs bind 
more rapidly to activated sodium channels in neurons that are rapidly firing. Opiate-based painkillers 
attach to opioid receptors found in the brain and spinal cord.595 Activation of these receptors leads to 
closing of the voltage sensitive calcium channels, reduction in the production of cyclic adenosine 
monophosphate (cAMP) and stimulation of potassium efflux. This results in a reduction of neuronal cell 
excitability and nerve impulse transmission, along with inhibition of neurotransmitter release.595  
 
Figure 1.38. Sites of action of the various classes of painkillers.596 
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The action of anti-inflammatory drugs at the site of injury is slightly more complicated than that of local 
anesthetics and opiate-based drugs. In order to understand their action, the processes which 
accompany an injury need to be understood, as does the role of the various substances released. Once 
the stimulus is removed and tissue damage has occurred, the injured cells and the infiltrating immune 
cells, such as neutrophils, monocytes, lymphocytes and macrophages,597-598 release multiple chemical 
mediators into the area around the damaged tissue, creating an “inflammatory soup” which contains 
prostaglandins, histamines, cytokines, chemokines, nerve growth factors, bradykinins, purines, amines, 
ions and many others.599-600 Because the peripheral terminals of nociceptors contain receptors for many 
of these proinflammatory molecules, the activation threshold of the voltage-gated sodium channels, for 
example Nav1.8 or 1.9, and the transient receptor potential cation channel subtype V1 (TRPV1) is 
lowered. Normally responsible for detection of negative stimuli and transduction into electrical energy, 
reduction of the activation threshold results in increased sensitivity of the nociceptor terminals to 
additional pain stimulation.599,601-602 Termed “peripheral sensitization”, this enhanced sensitivity to 
stimuli contributes to inflammatory pain hypersensitivity or hyperalgesia.603 This pain hypersentitivity 
serves to protect the damaged tissues from further damage as additional mechanical stress from 
physical activity is discouraged. A second mechanism, termed “central sensitization” also contributes to 
hyperalgesia.604 Tissue injury not only results in the creation of the inflammatory soup, rather, it also 
stimulates the release of neurotransmitters such as glutamate and substance P from the central 
terminals of nociceptors,599 and increases the production of proinflammatory cytokines such as 
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the spinal cord. As a result of this, the 
dorsal horn neurons are disinhibited and excited, causing abnormal responses to signals originating in 









1.4.2. Taking Responsibility: The Family of Molecules to Blame. 
 “The man who passes the sentence should swing the sword. If you would take a man's life, you owe it to 
him to look into his eyes and hear his final words. And if you cannot bear to do that, then perhaps the 
man does not deserve to die.” 
 George R.R. Martin, A Game of Thrones 
 
Despite there being a number of important substances involved in pain and inflammation, by far the 
most important are the family of compounds known as the prostaglandins. A group of lipid mediators 
produced and released in response to a number of stimuli, prostaglandins include such compounds as 
prostaglandin D2 (PGD2), PGE2, PGF2α, PGI2 and thromboxane A2 (TxA2) (Figure 1.39).606 The 
prostaglandins and TXA2, collectively termed prostanoids, are formed via three sequential enzymatic 
reactions, beginning with the release of arachidonic acid (AA) from membrane phospholipids by 
phospholipase A2. Arachidonic acid is then converted into prostanoids, leukotrienes or 
epoxyeicosatrienoic acids by one of three enzymes – cyclooxyygenase (COX) enzymes form the 





















Figure 1.39. 2D structures of (clockwise from left) PGE2, PGD2, TxA2, PGI2, and PGF2α. 
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The synthesis of all prostanoids starts in the same place– with the release of AA from the membrane. 
The AA is then rapidly oxidized by the cyclooxygenase function of the COX enzymes into the relatively 
unstable PGG2, which is then sequentially reduced to PGH2 by the peroxidase activity of the same COX 
enzyme.599,607-608 PGH2 is then converted into the different prostanoids by their respective terminal 
isomerases and synthases – PGE synthase (PGES) for PGE2, and PGIS, PGDS, PGFS and TxAS respectively 














Figure 1.40. An example of prostaglandin synthesis: the formation of PGE2 from arachidonic acid.609 
 Prostaglandins activate seven rhodopsin-like transmembrane G protein-coupled receptors (GPCRs), 
with the prostanoid receptor subfamily comprising 8 members: E prostanoid receptors 1 through 4 
(EP1-4), PGD receptors (DP1), PGF receptors (FP), PGI receptors (IP) and TX receptors (TP).610 These 
receptors couple to a range of intracellular signaling pathways which mediate the cell function effects of 
receptor activation. EP2, EP4, DP1 and IP receptors cause an increase in intracellular cAMP by activating 
adenylyl cyclase, and EP1 and FP result in the formation of inositol triphosphate and the mobilization of 
intracellular free calcium as they activate the phosphatidylinositol metabolism pathway.597  
 
Of all of the PGs, of most interest in the study of inflammation is PGE2 as all the clinical manifestations of 
inflammation arise due to its cellular effects.597-598,611 The redness and edema characteristic of 
inflammation result from increased blood flow to the inflamed blood tissue through PGE2-mediated 
vasodilation and increased microvascular permeability and the pain associated with inflammation is due 
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to the interaction of PGE2 on the peripheral sensory neurons and at central sites in the spinal cord and 
brain.611-612 The role of PGE2 in promoting the activation of TH17 cells has also recently been 
identified.613-614 Members of the CD4+ helper T cell family, these cells are characterized by the 
production of interleukin-17 (IL-17) and represent a set of potent proinflammatory mediators which 
recruit neutrophils and monocytes to the site of inflammation. If the inflammatory response is thought 
of as a finely tuned orchestra with the interconnected processes involving multiple cell types and 
inflammatory mediators as musicians, then PGE2 can be thought of as the conductor, as it plays a critical 
role in the directing and controlling of many facets of the inflammatory response.607  
 
 
1.4.3. A Fork In the Road: Steroidal and Non-Steroidal Painkillers. 
“Why are there never any good side effects? Just once I'd like to see a drug commercial that says, May 
cause extreme awesomeness.” 
Unknown 
 
It is here then, at the crossroads to all the prostanoids, where anti-inflammatory drugs act. 
Anti-inflammatory drugs fall in to one of two classes, namely steroidal anti-inflammatory drugs and non-
steroidal anti-inflammatory drugs. Steroid anti-inflammatory drugs, such as prednisone, prednisolone, 
methylprednisolone, dexamethasone and hydrocortisone (Figure 1.41), are synthetic 
glucocorticosteroids or glucocorticoids, based on the naturally occurring hydrocortisol. These 
compounds bind to the glucocorticoid receptor, found in almost every cell, which in turn up-regulates 
the expression of various anti-inflammatory proteins in the nucleus of the cell, and also down-regulates 
the expression of pro-inflammatory proteins in the cytosol.615 Regardless of the cause of the 
inflammation, glucocorticoids exert potent anti-inflammatory effects on a number of cell types, 
including macrophanges, T cells, mast cells, neutrophils, eosinophils, endothelial cells and epithelial 
cells,616 but the primary mechanism of action is the up-regulation of lipocortin-1 synthesis. Lipocortin-1 
suppresses phospholipase A2, the enzyme responsible for the release of AA into the system, and also 
inhibits a number of leukocyte events related to inflammation.617-618 As the release of AA is inhibited, the 
production of PGE2 is essentially halted, and the major cause of inflammation is removed. 
Glucocorticoids have also been shown to interact with COX directly, further reducing the production of 
PGE2.616,619 Side effects due to glucocorticoid use include immunosuppression and immunodeficiency, 
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hyperglycemia, gastric ulcers, osteoporosis, weight gain, adrenal insufficiency, muscle breakdown, 
glaucoma, cataracts, hypercortisolemia, and euphoria or psychosis associated with the excitatory effect 











































Figure 1.41. 2D structures of (clockwise from left) prednisone, prednisolone, dexamethasone , 
hydrocortisone and methylprednisolone 
To combat the side effects of steroids, non-steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen, naproxen, sulindac, phenylbutazone, diclophenac, indomethacin and the salicylates such as 
acetylsalicylate (Aspirin®) (Figure 1.42) have been developed over the last century, and these 
compounds interrupt the synthesis of PGE2 by interacting with COX as competitive active site inhibitors 
and preventing the conversion of AA into PGG2.597 Despite existing as a homodimer, only one COX 
partner is used at a time for substrate binding, and the formation of prostanoids can be shut down by 
the binding of an NSAID to one of the monomers of the COX dimer597,621 - the other monomer plays what 
68 
 
appears to be an allosteric role, and the peroxidase activity of COX is not affected by NSAIDs.622 While 
not as serious as the risks associated with steroid anti-inflammatory use, a wide variety of side effects 
related to the use of NSAIDs have been identified, including an increased risk of myocardial infarctions 
and strokes,623 nausea, vomiting, diarrhea and gastric ulcers,624 salt and fluid retention, hypertension, 




























Figure 1.42. 2D structures of (clockwise from left) ibuprofen, naproxen, phenylbutazone  indomethacin,  
diclophenac, and sulindac. 
To find a safe and effective anti-inflammatory is still a challenge for modern medicine. Existing as two 
distinct isoforms referred to as COX-1 and COX-2, the COX enzyme has been the focus of much research 
over the last 4 decades as the clinical effectiveness of structurally different NSAIDs points to the 
importance of prostanoids as mediators in the promotion of pain, inflammation and fever.622 COX-1 is 
the dominant isoform and the major source of prostanoids required by the body for “housekeeping” 
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functions such as homeostasis, renal blood flow maintenance and gastric epithelial cytoprotection.627 
COX-2 is the main source of prostanoids in inflammation and in proliferative diseases such as cancers,627 
and is not expressed, or is expressed at very low levels under basal conditions. Although both isoforms 
contribute to prostanoid synthesis and release during inflammation,597 COX-2 is up-regulated by 
proinflammatory stimuli, growth factors and hormones,628 and it is this inducibility that has provided the 
rationale for the development of NSAIDs which are selective for COX-2 over COX-1, known as coxibs,629 
along with the hypothesis that inhibition of COX-1 explains the adverse gastrointestinal side effects such 
as bleeding ulcers associated with NSAID use.630  
 
With the discovery of the mechanism of action of NSAIDs in the 1970’s came the idea that there were 
alternate forms of COX present,622,631 but the cloning and isolation of a second form of COX was only 
reported in 1991.632 Interestingly, without confirmed knowledge of this second form of COX, a 
compound had been developed by the DuPont company a year earlier which showed anti-inflammatory 
properties without the ulcerogenic effects of the traditional NSAIDs.633 This compound, DuP-697, along 
with NS-398634, became the building block for COX-2 selective compounds (Figure 1.43), including 





















Figure 1.43. 2D structures of (left to right) the COX-2 selective compounds celecoxib, rofecoxib and     
valdecoxib. 
Once the pieces of the puzzle had been put together, the question was then posed: “What then, in the 
structure of the two forms of COX, accounts for the difference in the activity of these compounds?” 
COX-1 and COX-2 are membrane-bound isoenzymes found in the endoplasmic reticulum (ER), and are 
genetically independent proteins where the genes for these enzymes show completely different 
properties and are located on different chromosomes – the COX-1 gene is located on chromosome 9, 
COX-2 is encoded by a gene on chromosome 1.635-636 The DNA sequences of these two genes are very 
similar, with a sequence identity of approximately 60%, leading to a highly conserved overall 
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structure.637-639 After post-translational modification, cleavage of the signal peptide and insertion into 
the ER, the molecular weight of the mature glycosylated COX enzymes differ by 5 kDa, with COX-1 
having a molecular weight of 67 kDa and COX-2 a weight of 72 kDa.637 This weight difference is due to 
the presence of a truncated signal peptide, and the insertion of an 18 amino acid sequence which act as 




1.4.4. Inherent Selectivity: Small Differences Equal Large Changes. 
“Life's a journey and there's no predicting the outcome. The only thing you can control are your choices, 
and they'll define who you are.” 
Richard Castle, Castle 
 
The key to COX-2 selectivity lies in the ca. 40% of the amino acid sequence which is different. Included 
amongst the differences are three simple amino acid substitutions which cause the active site of COX-2 
to be larger than that of COX-1. The active site is a long hydrophobic channel containing areas of high 
electron density, with only two polar amino acid residues - arginine (Arg120 – ovine COX-1 numbering 
system) and glutaminic acid (Glu524) - present.639-640 The larger active site found in COX-2 is due to the 
substitutions of valine 523 (Val523), Arg513 and Val434 for isoleucine 523 (Ile523), histidine 513 
(His513) and Ile434 respectively in COX-1.631 The valine residue at position 523 in COX-2 is less bulky 
than the isoleucine in COX-1, which causes a slight structural modification of the protein. This 
substitution allows access into an additional hydrophilic side pocket which is not accessible in COX-1, 
and it is this pocket which is important for COX-2 selectivity (Figure 1.44).631 Substitution of Ile434 with 
Val434 results in the movement of the side chain of phenylalanine 518 (Phe518) within the protein 
which is able to increase the volume of the active site further. Access to this side pocket allows for 
interactions of inhibitors with Arg513, interactions which are thought to be crucial for the success of 
diaryl heterocycle inhibitors such as the coxibs. Another result of the different amino acid sequence of 
COX-2 is in the altered position of the side chain of leucine 384 (Leu384) at the top of the receptor 
channel. In COX-1, it is directed into the active site, while in COX-2 it is oriented away from the active 




Figure 1.44. Schematic overview of how the structural differences between the COX isoforms allow for 
selective inhibition of COX-2.642 
Celecoxib, marketed as Celebrex® (Figure 1.45), the first coxib brought to market in December 1998 by 
Pfizer, was built upon the scaffolds of DuP-697, a tricyclic inhibitor, and NS-398, a methanesulfonanilide-
based inhibitor.633-634 Based on these and other similar compounds, the team at Searle Research and 
Development established that two aromatic rings situated on adjacent positions on a central ring was 
vital for COX-2 inhibitory activity, and that these phenyl rings could be substituted in order to fine-tune 
the activity of the compounds.643 Extensive Structure Activity Relationship (SAR) analyses concluded that 
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a p-sulfamoylphenyl or a p-(methylsulfonyl)phenyl group attached to position 1 of a 1,5-diaryl pyrazole 
ring showed a higher COX-2 selectivity than the corresponding p-methoxyphenyl group. SAR analysis 
also showed that N-methylation or N,N-dimethylation of the sulfonamide moiety significantly reduced 
the COX-2 activity of the compounds. A degree of flexibility with regards to substitutions at the 
3-position of the pyrazole ring was noted by the research team, with trifluoromethyl and difluoromethyl 
substituents shown to be more active in terms of potency and selectivity.643 Finally, substitutions to the 
phenyl ring at position 5 greatly affected the potency and selectivity of compounds in vitro. 
Substitutions to the 2- or 4-positions provided greater potency than 3-substituted analogues, however 
with sensitivity noted with regard to steric hinderance at the 4-position, smaller substituents proved to 
be more effective than larger ones.643 The high lipophilicity of the active site also partially restricted the 
types of substitutions possible as the coxibs need to be non-polar in order to interact with the active 
site.641 Celecoxib is approximately 20 times more selective for COX-2 over COX-1644, and is currently the 
only COX-2 selective NSAID still holding F.D.A. approval for osteoarthritis, rheumatoid arthritis, 
ankylosing spondilitis, and juvenile rheumatoid arthritis in patients 2 years and older, with sales totaling 










Figure 1.45. 2D structure of celecoxib, currently the only COX-2 selective compound with F.D.A. approval. 
Rofecoxib (Figure 1.46), the second coxib to be released, holds the dubious honour of being the first 
coxib taken off the market, despite being the only one to show clinical evidence that it did not cause the 
same gastrointestinal side effects as did the traditional NSAIDs.646 Marketed under the name Vioxx®, 
rofecoxib was withdrawn from the market by Merck in September 2004 due to concerns about 
increased risk of heart attacks and strokes. The VIGOR646 (VIOXX GI Outcomes Research) study, which 
compared the efficacy and adverse effect profiles of rofecoxib and naproxen (a non-selective NSAID), 
showed a 4-fold increase in the risk of acute heart attacks in rofecoxib patients when compared to 
naproxen patients over the 12 month span of the study, with the elevated risk beginning in the second 
month of the study. While there was no significant difference in the mortality rates between the two 
groups, and no difference in the rate of heart attacks in patients without high cardiovascular risk, 
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patients at higher risk of heart attack prior to the commencement of the study showed a significant 







Figure 1.46. 2D structure of rofecoxib, the first COX-2 selective compound removed from the market due 
to safety concerns. 
Valdecoxib (Figure 1.47), marketed by G.D. Searle & Company as Bextra® between 2001 and 2005 is 
another coxib removed from the market due to safety concerns. Increased cardiovascular risks were first 
acknowledged by Pfizer in October 2004, and soon after the American Heart Association received a 
report stating that patients taking Valdecoxib were more than twice as likely to suffer a heart attack or 
stroke as those patients taking placebos. Valdecoxib has been shown to have less adverse side effects 
for patients with kidney disease and heart arrhythmia than Vioxx, but the renal risks were elevated 
when compared to celecoxib.647 Parecoxib, the inactive amide ester pro-drug of valdecoxib, is water-
soluble and therefore injectable, and is rapidly converted to valdecoxib by hepatic enzymatic 
hydrolysis.648 The F.D.A. issued a letter of non-approval for parecoxib in 2005, and while no official 
reasons were ever given, speculation suggests that political pressure from the US congress resulted in 
the non-approval of another COX-2 selective drug, as the effects of the Vioxx and Bextra affairs were still 
being felt. Parecoxib is marketed as Dynastat® in the European Union by Pfizer for perioperative pain 















Figure 1.47. 2D structures of valdecoxib(l) and its pro-drug parecoxib (r) which is converted into 
valdecoxib in the liver. 
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Along with parecoxib, etoricoxib (Arcoxia®) is a second-generation coxib (Figure 1.48) without F.D.A. 
approval for use in the United States while having approval for use in other countries. Indications differ 
according to country, but include osteoarthritis, rheumatoid arthritis, psoriatic arthritis and gout. 
Studies show that a single oral dose of etoricoxib provides good quality pain control after surgery, and 
the adverse effects are similar to those for a placebo.649 The F.D.A. has not yet approved etoricoxib, 
saying that Merck must provide extensive additional evidence showing that the drug’s benefits 








Figure 1.48. 2D structure of etoricoxib, a second-generation coxib. 
While still technically a coxib, lumiracoxib (Figure 1.49) differs to the other coxibs listed here in a 
number of ways. Lumiracoxib, sold under the name Prexige® is a diclofenac derivative, making it an 
arylalkanoic acid and the only acidic coxib, whereas the other coxibs are essentially based on celecoxib. 
It has been shown to bind to a different site on the protein, and whilst diclofenac is non-selective, 
lumiracoxib shows the highest COX-2 selectivity of any NSAID.651 Initially receiving approval for 
marketing in all European Union countries in November 2006, it was withdrawn from the Australian and 
New Zealand markets in August 2007, following 8 serious liver adverse events, including 2 liver 
transplants and 2 deaths.652-653 Health Canada followed suit and withdrew Prexige® in October 2007,654 











Figure 1.49. 2D structures of lumiracoxib and its parent molecule diclofenac. 
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To explain the selectivity of celecoxib and the other “traditional” coxibs, it is important to take into 
account interactions which occur between the protein and the inhibitors, and how changing amino acids 
within the protein affects these interactions. Within the hydrophilic pocket, the oxygen atom of the 
sulfonamide or sulfone group interacts with His90, glycine 192 (Gln192) and Arg513, forming hydrogen 
bonds between the coxib and the protein.631 Other hydrogen bonds have been reported between the 
coxibs and tyrosine 355 (Tyr355), as well as with Arg120, serine 530 (Ser530) and Val523.640,656 While 
these static 3D structure studies have proven vital in understanding the mechanism of inhibition, they 
often do not take into account the fact that enzymes are not static, and so do not take into account 
enzyme flexibility and rearrangement of the hydrogen bonds surrounding the entrance to the active site. 
Water molecules present in the active site have also been shown to be important in understanding the 
selectivity of inhibitors, as they participate in dynamic hydrogen bonding with Tyr355, Arg120, Glu523 
and Arg513 at the active site entrance, suggesting that active site hydration is important.631,657 
 
In the course of the search for a compound which maintained the efficacy of NSAIDs while removing the 
side effects, the development of the coxibs was based on the assumption that COX-1 was “good”, and 
that COX-2 was “bad”. However, the supposition that COX-1 and COX-2 have distinct homeostatic and 
pathological functions was proven to be an oversimplification.597,599 A number of studies have now 
shown that COX-2 is required for healthy renal, gastric and cardiovascular functions, and COX-1 has also 
been shown to have a role in inflammation,658-662 with human data showing that during the initial phase 
of an acute inflammation, the PGE2 formed is mostly COX-1-derived, and COX-2 –derived PGE2 occurs 
within several hours.629 The role of COX-2 in the cardiovascular system was underscored by the 
increased risk of cardiovascular side effects such as heart attacks and strokes associated with rofecoxib 
and valdecoxib, which lead to the withdrawal of both of these drugs from the market, and for the 










1.4.5. Where To From Here: The Future Of Coxibs. 
 “The way I see it, every life is a pile of good things and bad things. The good things don’t always soften 
the bad things, but vice versa, the bad things don’t always spoil the good things and make them 
unimportant.”  
The Doctor, Dr Who 
 
While coxibs might not have a future as painkillers, there is still much hope for these compounds. With 
the patent on celecoxib expiring in 2015, much research has gone into the study of other uses for 
celecoxib, including as a cancer treatment,668 as it has been stated that prostaglandin synthesis, and 
therefore COX-2, is important for cancer cell growth.669-672 Recent studies have also shown that 
over-expression of the COX-2 metabolites PGA1 and PGA2 interferes with the tumour apoptosis factor 
p53 in neuroblastomas.673 PGA1 and PGA2, when expressed in high quantities, bind to p53 and effectively 
sequester the protein in the cytosol and prevent it from reaching the nucleus of a cancer cell where it 
would cause apoptosis to occur.674 Coxibs, by inhibiting COX-2, halt tumour growth by restoring the 
function of p53, which allows the neuroblastoma cells to commit suicide through apoptosis. COX-2 
up-regulation has also been linked to the phosphorylation and subsequent activation of the E3 
ubiquiting ligase HDM2 in neuroblastoma cells. This protein mediates p53 ligation and tagged 
destruction though ubiquitination, and in neuroblastoma cells, it is overexpressed. Studies have shown 
that the reduction in the concentration of activated HDM2 in cells by a coxib results in the restoration of 
p53 activity, and subsequent cellular apoptosis, although both the mechanism underpinning the 
hyperactivity of HDM2 in neuroblastoma cells, and the mechanism of how coxibs block the 
phosphorylatin of HDM2 is unknown.674  
 
The possibility that coxibs, not just celecoxib, act as anti-cancer agents solely by inhibiting COX-2 was 
brought into contention by a number of studies where celecoxib was shown to interact with other 
proteins in the cell, and could inhibit malignant cell growth without interacting with COX-2.675 Support 
for this hypothesis has come from other research, where analogues of celecoxib with no COX-2 
selectivity displayed significant anti-cancer activity.676-678 These studies showed that the anti-tumour 
potency of a compound did not depend on whether the compound could inhibit COX-2. Further support 
has come from work carried out by Chuang, et al., where celecoxib was shown to inhibit the growth of 




2. Aims and Objectives 




The aim of this project is to design, synthesize, analyze and test a range of novel COX-2 selective 
inhibitors based on a curcumin and coxib backbone, and simultaneously evaluate the modeling process 
of the drug design. The design phase of this project will begin with establishing an understanding of the 
binding present in both the curcumin and coxib parent molecules through the use of molecular 
modeling techniques in order to ascertain what important ligand-protein interactions are present in 
each of these parent compounds. The information gleaned from this study will then be incorporated 
into the structure of novel compounds in an effort to maximize the binding of these compounds to the 
protein target. The new compounds will then be subjected to computational analysis so as to determine 
whether the compounds interact as desired with the protein. The results obtained from the in silico 
analysis of these compounds will be used to predict which of the novel compounds will be potent 
inhibitors of the COX-2 protein.  
 
The synthesis phase of the project will encompass the complete synthesis of these molecules from basic 
starting materials into the final products. Complete analysis of these compounds will be carried using 
techniques such as NMR spectroscopy, High Resolution Mass Spectrometry and X-ray crystallography, 
and analysis of these compounds will include NAMFIS analysis of representative molecules, to establish 
the solution conformations of the selected molecules. Biological testing of these compounds will be 
carried out using the conversion of 10-acetyl-3,7-dihydroxyphenoxazine (ADHP) into resorufin in order 
to determine which, if any, of these compounds are in fact selective COX-2 inhibitors. These results will 






3. Results and Discussion: Computational Design 
and Analysis of Potential COX-2 Selective 
Compounds  
 
3.1. Exploring the Possibilities: Computational Analysis of Curcumin and Celecoxib 
 “Art matters because it is the one true great connector in a world that seems to be very unconnected, 
and it's important now more than ever to shine a huge light on that connectivity that we have, that we 
often forget.” 
 Josh Groban  
“Drug design is a creative act of the same magnitude as composing, sculpting, or writing. The results can 
touch the lives of millions, but the creator is rarely one scientist and the rewards are distributed 
differently in the arts than in the sciences. The mechanisms of creativity are the same, i.e., incremental 
(plodding from darkness to dawn) or sudden (the “Eureka” effect) realization, but both are poorly 
understood. Creativity remains a human characteristic…There is beauty in the fusion of structure and 
function. As a creative enterprise, drug design is a synthesis of scientific knowledge, experience, 
intuition, and aesthetics. However, unlike the arts, this beauty has limited distribution; the general 
public is severely under-informed about the creative process whereby molecules are designed and 
created. Indeed, like artists, scientists are hard-pressed to enunciate their intuitive insights.” These 
opening paragraphs to Meyer, Swanson and Williams’ 2000 paper on molecular modeling and drug 
design succinctly covers the elation and frustration inherent to modern drug design.680 Inspiration (for 
lack of a better word) for drug design can be found in much the same way as an artist looks for ideas in 
the forms and functions of items, the play of light over a surface, the sounds at dawn or the church bells 
of a city in winter. While not as romantic as the artist’s inspirations, the muse of drug designers is often 
found in the more mundane – the novel compound in a rare sea sponge, or in the ingredients of 
traditional medicines.  
 
With 2012 sales of over-the-counter (OTC) internal analgesics totaling over $3.9 billion in the United 
States alone, and not counting the other forms of analgesics such as rubs and sprays, the painkiller 
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industry is the second largest contributor to the $23 billion OTC market.681 As the search for new 
anti-inflammatory, painkilling compounds without serious side effects is always ongoing, it is often a 
good idea to consult the wealth of knowledge contained in the various traditional medicines from 
around the world. One such compound is curcumin (Figure 3.1), one of the components of turmeric. 
This spice has been used for thousands of years in Indian Ayurvedic and other traditional medicines and 
the extensive list of treatments include numerous entries where the antiseptic, anti-oxidant, 
antimalarial, analgesic and anti-inflammatory properties of turmeric have been exploited.329-331 
Curcumin itself has been shown to have therapeutic potential against a number of diseases and 
disorders,330,333,351 and over 50 clinical trials utilizing curcumin are currently ongoing. However, curcumin 
has a number of drawbacks, including poor bioavailability and as-yet-unknown mechanisms of action, 
which limit its utilization in mainstream medicine, and therefore vast amounts of work have been 








Figure 3.1. 2D structure of curcumin. 
The interactions of curcumin with proteins in the solid state are notoriously difficult to study, as 
curcumin does not withstand X-ray irradiation.497 This protein-mediated decomposition of curcumin has 
prevented the acquisition of definitive answers to the question of how curcumin binds to proteins. 
While technically a diketone, curcumin undergoes keto-enol tautomerization (Figure 3.2), and it is the 
enol form (1) which dominates in solution and the solid state,455-456 although whether the enol or the 
diketone form (2) bind to the protein is unknown at present. One possible explanation for the relative 
proportions of the tautomers is the simultaneous extension of conjugation throughout the molecule and 
the formation of a stabilizing internal hydrogen bond between the enol hydrogen atom and the keto-















Figure 3.2. Keto-enol tautomerization of curcumin. 
Despite this uncertainty, curcumin has been the subject of much study, and one of the plethora of 
molecular targets of curcumin are the cyclooxygenase (COX) enzymes. These enzymes are largely 
responsible for the formation of prostanoids from arachidonic acid, including prostacyclin and 
thromboxane A (Figure 3.3). Prostacyclin is known to be an effective vasodilator and also inhibits 
platelet aggregation, while thromboxane A2, a vasoconstrictor, is important during injury and 
inflammation. At present, two main isoforms of COX are known: COX-1, which is constitutively 
expressed at low levels throughout the body, and the inducible COX-2, the production of which is 













Figure 3.3. An example of prostaglandin synthesis: the formation of PGE2 from arachidonic acid.609 
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Reduction of prostaglandin synthesis is the central mechanism upon which non-steroidal 
anti-inflammatory drugs (NSAIDs) act, and the discovery of COX-2 opened up the development of 
targeted NSAIDs which did not show the gastrointestinal toxicity of the non-selective NSAIDs. This lead 
to the development of COX-2 selective anti-inflammatory compounds including celecoxib (Celebrex®), 
rofecoxib (Vioxx®), etoricoxib (Arcoxia®) and lumiracoxib (Prexige®) (Figure 3.4). While effective as COX-
2 selective inhibitors or “coxibs”, there are a number of severe side effects associated with these 
compounds, including heart attacks and strokes, and these side effects have resulted in a number of 



























Figure 3.4. 2D structures of the coxibs (clockwise from top left) celecoxib, rofecoxib, etoricoxib and 
lumiracoxib. 
As most of the coxibs are essentially celecoxib derivatives, these coxib compounds show remarkable 
structural similarity. All of these molecules contain a central ring with a 1,2-substitution pattern, and, 
apart from lumiracoxib - a diclofenac derivative - two additional phenyl rings. Another feature common 
to the coxibs is a p-sulfuryl group, be it a sulfonamide as seen in celecoxib and valdecoxib or a sulfone as 
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found in rofecoxib and etoricoxib. This p-sulfuryl group is vitally important to the selectivity of coxibs for 
COX-2 over COX-1, as it is this moiety which interacts with the secondary pocket present in COX-2 
(Figure 3.5). This interaction of celecoxib with the secondary pocket is highlighted when the structures 
of celecoxib and arachidonic acid from the X-ray crystal structures of COX-2 (PDB files 3LN1684 and 
3HS6685 respectively) are superimposed (Figure 3.6).  
 
Figure 3.5. Ligand interaction diagram of celecoxib with COX-2 showing the interactions of the 
p-sulfonamide group of celecoxib with the secondary pocket present in COX-2, taken from the PDB file 
3LN1.684 The red line indicates the presence of a π-cation interaction between the ligand and the protein, 
the solid purple lines a presence of an H-bond between the ligand and the backbone of the protein, and 




Figure 3.6. X-ray crystal structures of celecoxib (PDB file 3LN1),684  shown with green carbon atoms, and 
arachidonic acid (PDB file 3HS5),685 shown with blue carbon atoms. 
In order to test the applicability of the docking conditions, the native celecoxib ligand was removed from 
the protein structure, prepared using LigPrep686 and redocked using Glide XP687 into the active site of 
COX-2, which had separately undergone preparation (Epik688) and the active site defined using the 
Receptor Grid Generation application of the Schrödinger Maestro suite.689 The poses generated were 
then compared to the X-ray crystal structure of celecoxib, and the root-mean-square deviation (RMSD) 
calculated between the generated pose and the original PDB coordinates. A final RMSD value of 0.44 Å 
was calculated between the best scoring docking pose generated for celecoxib and the original structure 
(Figure 3.7), validating the docking method used.   
 
Figure 3.7. The generated pose of celecoxib with carbon atoms shown in red overlapping with the pose of 
celecoxib bound to COX-2, shown with green carbon atoms (PDB file 3LN1).684 
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Despite being a COX-2 selective compound, celecoxib is also known to bind to COX-1, and an X-ray 
crystal structure of celecoxib bound to COX-1 (PDB file 3KK6) was obtained in 2010 by Rimon, et al.690 
While the docking procedure used for celecoxib and COX-2 showed good correlation, the same 
procedure was used in order to determine the applicability of this procedure for the docking of 
compounds into COX-1. An RMSD value of 0.57 Å between the docked pose and the crystal structure 
(Figure 3.8) again confirmed the suitability of the docking procedure towards COX-1.  
 
Figure 3.8. The generated pose of celecoxib, carbon atoms shown in red, overlapping with the pose of 
celecoxib bound to COX-1, carbon atoms shown in green (PDB file 3KK6).690 
In an effort to understand the possible binding of curcumin to COX-1 and more importantly to COX-2, 
curcumin was subjected to the same docking process as used for celecoxib. Both 1 and 2 were docked 
into the protein (Table 3.1), as while 1 dominates in solution,455-456 it is possible for 2 to exist in solution 
and interact with the protein rather than the predominant enol. As MM-GBSA scores are considered 
better points for comparison than Glide XP scores,691 the docked poses of celecoxib and the two isomers 
of curcumin were rescored using the Prime689 function of Schrödinger, and these results were used for 
comparison, along with visual inspection of the docking poses. 
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1 Celecoxib -10.650 -84.269 -11.605 -86.676 
2 1 -7.888 -86.566 -10.180 -71.117 
3 2 -7.371 -79.410 -11.361 -70.784 
 
At first glance, 1 shows an improvement in binding to COX-2 and a reduction in the binding to COX-1 as 
compared to celecoxib, while 2 shows a reduction in binding to both proteins. However, on further 
inspection of the docked poses, 1 shows fewer interactions with the protein (Figure 3.9), while 2 
appears to fold in such a manner as to mimic the pose and a few of the interactions found between 
celecoxib and COX-2 (Figure 3.10), while neither of the curcumin tautomers show the presence of π-
cation interactions, as shown in Figure 3.5.   
 
Figure 3.9. Ligand interaction diagram of 1 with COX-2 showing the interactions present between the 




Figure 3.10. Ligand interaction diagram (left) of 2 with COX-2 and the overlap of the generated pose with 
the X-ray crystal structure of celecoxib in COX-2 (right).684 
While the docking results show that curcumin could interact with both COX-1 and COX-2 proteins, a 
glaringly obvious piece of information gleaned from these docking studies is that 1 does not interact 
with the secondary pocket of COX-2 as desired, and based on these results, it is not expected to be 
selective for COX-2 over COX-1. While 2 does appear to occupy the secondary pocket, the amount of 2  
present in solution is essentially zero,692 which hinders the applicability of curcumin to wider use as a 
COX-2 selective compound. Consequently, a COX-2 selective compound based on curcumin would need 
to contain other functional groups and/or structural modifications which would enable the selective 
inhibition of COX-2 through contact with the secondary pocket. Another vital piece of information 
obtained from this study is that the pose of the compound under study is important, and that the 
numbers obtained from the various analyses and calculations cannot be the sole basis for judging the 






3.2. In the Beginning:  Initial Design and Analysis of a Novel COX-2 Selective 
Compound 
 “Everything starts somewhere, though many physicists disagree. But people have always been dimly 
aware of the problem with the start of things. They wonder how the snowplough driver gets to work, or 
how the makers of dictionaries look up the spelling of words.” 
Terry Pratchett, Hogfather 
At this point, the important structural features of the coxibs – the 1,2-disubstituted central ring and the 
p-sulfuryl moiety – were combined with the cinnamaldehyde-type structure of curcumin to form a novel 
class of COX-2 selective compounds (Figure 3.11). The α-β unsaturated section of this molecule is 
reminiscent of curcumin, with the p-sulfuryl phenyl ring and its position on the central phenyl ring 
derived from the coxibs. With an eye on synthetic routes, and the inclusion of heteroatoms in the 
coxibs, an ether bond was used to link the central phenyl ring and the p-sulfuryl phenyl ring, and this 
would also allow for a degree of flexibility within the molecule. The two phenyl rings present in the 
chalcone portion could be easily modified with the use of substituted starting materials, which would in 
turn allow for the “tuning” of the molecule in order to maximize the interactions of the compound with 








Figure 3.11. General structure of a novel class of COX-2 selective compounds identifying the important 
structural features derived from the parent molecules. The blue portion is derived from curcumin, the 
purple portion from the 1,2-disubstituted central ring of coxibs and the red portion the common p-
sulfuryl phenyl ring also from the coxibs. 
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As the coxibs demonstrate a range of sulfuryl and other functional groups, a sulfonate (3) and a 
sulfonamide (4) (Figure 3.12) were docked in the active site of COX-2 to determine whether one group is 
more applicable than the other (Table 3.2). Compounds 3 and 4 were also docked into COX-1, as was the 
case with curcumin, and the data obtained during the docking of celecoxib are included to provide a 
benchmark against which to judge the scores obtained for 3 and 4. While a protonated sulfonic acid 
version could also be docked, these compounds are strong acids and would dissociate almost 
completely in the aqueous conditions found in the body, and as such, docking of the acid would not be 
an accurate representation of the situation in vivo. Inspection of the binding energies reveals that 
compound 4 shows improved binding towards COX-1 but weaker binding towards COX-2 as compared to 







X = OH, NH2
 
Figure 3.12. Generic structures of 3 (X = OH) and 4 (X = NH2). 
 











1 Celecoxib -10.650 -84.296 -11.605 -86.676 
2 3  -12.619 -55.772 -10.572 -74.414 
3 4 -11.378 -72.679 -12.823 -89.915 
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On further examination of the poses, both compounds 3 and 4 interact with the secondary pocket in 
COX-2 as desired and the docking poses overlap well with the X-ray crystal structure of celecoxib in COX-
2 (PDB file 3LN1) (Figures 2.13 and 2.14), although the central ring of these compounds overlaps with 
the 5-phenyl ring of celecoxib, rather than the central pyrazole ring. Both compounds 3 and 4 are 
predicted to interact through hydrogen bonds with amino acid residues Arg499 and Phe504 in COX-2, 
sharing the Phe504 interaction with celecoxib, and 4 is predicted to further interact with Gln178, Leu338 
and Ser339 as well, interactions which are shared with celecoxib. Compound 3 is also predicted to 
interact with Tyr341 through π-π stacking, while this interaction is not identified as likely for 4. 
Interestingly, the only interactions predicted for 4 involve the sulfonamide moiety, while 3, despite 
having fewer proposed interactions between the protein and the sulfonate moiety, shows COX-2 
interactions between both the carbonyl oxygen atom and one of the phenyl ring.  
 
Figure 3.13. Ligand interaction diagram for 3 (left) and the docked pose of 3 (shown in blue) overlaid 





Figure 3.14. Ligand interaction diagram for 4 (left) and the docked pose of 4 (blue) overlaid with the 
structure of celecoxib (carbon atoms shown in green) as found in the X-ray crystal structure of COX-2 
(right).684 
While the ligands are predicted to interact with the same type of residues in COX-1 as COX-2, - leucines 
and serines - the actual residues, as expected, are not the same. Compounds 3 and 4 share a hydrogen-
bond interaction to Ser516 with celecoxib, with the sulfonamide sharing two further hydrogen-bond 
interactions, to Leu352 and Ser353, with celecoxib. Compound 3 shares a π-π stacking interaction to 
tyrosine 341 (Tyr341) with celecoxib (Figure 3.15), while 4 is predicted to make two π-stacking 




Figure 3.15. Ligand interaction diagram of 3 in COX-1 highlighting the interactions formed between 
ligand and protein.  
 
Figure 3.16. Ligand interaction diagram of 4 in COX-1 illustrating the contacts made between the protein 
and the docked ligand.   
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However there is space for improvement – compound 3 does not interact as well with the COX-2 
secondary pocket as celecoxib, and compound 4 does not show interactions with COX-2 which involve 
the rest of the molecule. Compound 3, while showing reduced binding towards COX-1, also shows 
significantly reduced binding towards COX-2. Nonetheless, these results are a positive beginning in the 
drug design process. The compounds interact with the protein as desired, and more importantly interact 
with the desired regions of the protein.  
 
 
3.3. Expanding the Horizon: Design and Analysis of Sulfonate Analogs.  
“Engineering, medicine, business, architecture and painting are concerned not with the necessary but 
with the contingent - not with how things are but with how they might be - in short, with design.” 
Herbert Simon 
 
With these promising results in hand, a range of ligands were designed in an attempt to improve on 
these initial compounds. These modifications include the addition of halogen atoms to both the 
cinnamaldehyde (A ring) and central phenyl (B) rings, as well as the introduction of the methoxy groups 
present in curcumin. Eleven modifications were made to the A ring, with six substitutions made on the B 
ring, to yield a total of 83 additional compounds. These substitutions allowed for the investigation into 
the influence of the nature of the substituent as well as the position of that substituent on the binding 
score and the pose of the compound in question. The inherent size difference between bromo-, chloro- 
and fluoro-substituents would permit determination of the steric restrictions at various positions within 
the docking site of the protein. The inclusion of methoxy substituents provides a means of studying 
steric effects with a different electronic effect than is present in the halogenated compounds. In 
addition, the presence of a fluorine atom in the molecule would also provide a means of 19F labelling, 
which is advantageous for both spectroscopic studies and metabolic evaluation.693 Fluorine, an effective 
isosteric replacement for oxygen, has been shown to be important in enhancing lipid solubility of the 
molecule, which results in enhanced biological mobility in vivo, as well as increasing the thermal and 




These compounds were prepared, docked into both COX-1 and COX-2 proteins and scored according to 
the established protocol. As a large number of compounds were designed and evaluated, only selected 
entries are presented in the tables below, with the complete tables found in the supplementary 
information (SI Tables 1 and 2). In order to simplify the discussion of the various substitution patterns 
and their effects, the substituents on the A ring will be identified using the ortho-/meta-/para- system of 
nomenclature, while substitutions made to the B-ring will be identified using the IUPAC numbering (1-, 














Figure 3.17. Ring identification and substituent placement for analogs of 3 and 4.  
The first series of ligands (SI Table 1) was designed using compound 3 as a foundation. All of the 
modifications made resulted in increases in the binding scores for COX-2, as compared to those 
obtained for 3, with a number of modifications resulting in appreciable reductions in the binding scores 




Table 3.3. Glide XP and Prime scores for selected sulfonates. 










1 - - 3 -12.619 -55.772 -10.572 -74.414 
2 - p-Br 5 -11.436 -92.183 -11.767 -89.066 
3 - p-Cl 6 -11.569 -84.908 -11.223 -85.836 
4 - p-F 7 -12.352 -69.067 -6.414 -81.389 
5 - p-OMe 8 -11.898 -94.200 -9.625 -94.815 
6 - m-Br 9 -11.517 -103.141 -11.667 -79.280 
7 - o-Br 10 -12.570 -93.748 -10.102 -80.341 
8 4-F - 11 -12.664 -84.205 -10.416 -61.886 
9 4-Cl - 12 -8.049 -92.404 11.635 -83.947 
10 5-F - 13 -12.755 -87.521 -11.623 -76.281 
11 5-Cl - 14 -11.374 -100.797 -11.323 -83.647 
12 4-Br - 15 -11.013 -75.885 -10.507 -87.806 
13 5-Br - 16 -11.404 -85.328 -11.141 -87.685 
14 4-F p-F 17 -12.767 -86.607 -11.841 -68.525 
15 4-Cl o-F 18 -12.149 -88.670 -11.321 -76.413 
16 4-Br p-OMe 19 -11.197 -104.087 -10.097 -77.155 
17 5-F p-Cl 20 -12.280 -100.693 -11.121 -83.063 
18 5-Cl p-Br 21 -12.531 -109.956 -12.492 -95.080 
19 5-Br o-Br 22 -11.631 -108.849 -11.943 -95.038 
20 4-F o-Br 23 -11.749 -90.352 -12.126 -91.369 
21 4-Cl o-OMe 24 -11.534 -82.327 -10.353 -102.856 
22 4-Br m-Br 25 -9.959 -72.782 -10.293 -101.179 
23 5-F p-Br 26 -12.007 -66.972 -12.292 -94.105 
24 5-Cl o-Cl 27 -12.009 -95.258 -11.970 -106.313 
25 5-Br p-Cl 28 -12.491 -94.983 -11.607 -102.901 
a “-“ indicates all hydrogen atoms present. 
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Addition of a p-substituent to the A ring resulted in enhanced binding, as compared to the unsubstituted 
sulfonate, to both COX-1 and COX-2 (Table 3.3, entries 2-5), while substitution of a bromine atom at 
either the ortho- or meta-positions (Table 3.3, entries 6 and 7) resulted in significantly enhanced binding 
scores (~40-50 kCal.mol- 1) for COX-2, with much smaller changes (~5 kCal.mol- 1) observed for the 
corresponding COX-1 binding scores. The poses calculated for these compounds mirror the pose 
determined for 3 in COX-2, with the B ring positioned in a very similar location as the 5-phenyl ring of 
celecoxib (Figure 3.18). This orientation within the protein results in the A-ring of each of the 
compounds being located towards the entrance of the active site, allowing for more flexibility, and also 
exposes the halogen and methoxy substituents to the solvent. These six compounds make similar 
contacts to the protein as is seen for 3, namely interactions to Ser516, Arg499 and Tyr341, and also 
made additional contacts with residues Arg106 and Trp373, which account for the increases seen in the 
binding scores. When docked into COX-1, compounds 5-10 show inversion and/or rotation of the poses 
when compared to the pose generated for 3. Despite this rotation and/or inversion, the docked poses 
for these compounds share a number of interactions with 3 – interactions with Ser516, Ile517, Phe518 
and Tyr355 are common, with additional interactions to residues such as Ser530 present for more than 
one compound. These shared interactions partially explain the closeness observed in the COX-1 binding 
scores observed, as these compounds do not make a large number of additional interactions with the 
protein.  
 
Figure 3.18. Overlap of the poses generated for compound 5 with celecoxib and 3, when docked into 
COX-2, showing the close clustering obtained. Celecoxib is shown with green carbon atoms, 3 in blue and 
5 in red.  
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Substitutions on the B ring were also shown to influence the binding scores. Addition of fluorine or 
chlorine atoms at either the 4- or 5-positions of the B ring (Table 3.3, entries 8-11) resulted in 
increasingly positive changes – defined here as a large increase in COX-2 binding and a small increase or 
a decrease in COX-1 binding scores – from fluorine to chlorine while substitution with bromine atoms at 
either of these positions resulted in ligands showing smaller changes in the COX-2 binding energies, with 
similar gains in COX-1 binding scores. (Table 3.3, entries 12 and 13). Rather, these two compounds yield 
binding scores lower than those calculated for their respective fluoro analogues. Inspection of the pose 
for compound 15 shows inversion of the molecule when the pose is compared to that of the parent 
compound 3 (Figure 3.19), and compound 16 shows rotation of the alkyl chain linking the A and B rings 
(Figure 3.20). This is most likely due to the steric bulk of the bromine atoms, as the poses generated for 
compounds 15 and 16 do not show the same degree of clustering as the fluoro- or chloro- analogues, 
and accordingly, slightly different interactions are formed between the ligand and the protein. This 
therefore results in the binding scores not “fitting the pattern” previously established. As was the case 
for the A-ring substitutions, compounds 11-16 also show inversion and /or rotation of the poses 
generated when these compounds were docked into COX-1. Compound 11, which contains a 4-fluoro 
substitution, is one of the few compounds which show a reduction in the COX-1 binding scores (Table 
3.3, entry 8), and evaluation of the docked pose shows both inversion and rotation of the alkyl chain as 
compared to 3, leading to different ligand-protein interactions and subsequent reduction in the binding 
scores. 
  
Figure 3.19. The “inversion” of the pose generated for compound 15, shown in purple, as compared to 




Figure 3.20. The rotation of the alkyl chain in the pose generated for 16, shown in green, as compared to 
the pose generated for the parent sulfonate 3, shown in blue. 
Simultaneous substitutions of the A and B rings were also investigated, again with both positive and 
negative changes observed. A p-fluoro substituent on the A ring combined with a fluorine atom at the 
4-position on the B ring  -“p-fluoro/4-fluoro”-  (compound 17)  resulted in enhancement of COX-2 
binding scores, with a reduction in the COX-1 binding scores (Table 3.3, entry 14), as did an 
o-fluoro/4-chloro combination (18), a p-methoxy/4-bromo combination (19), a p-chloro/5-fluoro 
combination (20), a p-bromo/5-chloro combination (21), and surprisingly an o-bromo/5-bromo 
combination (22) (Table 3.3, entries 15-19). These poses again cluster well, with the only pose which did 
not cluster as well was that obtained for compound 22. The inversion of this pose when judged against 3 
most likely allows for some relief of the steric strain present due to the presence of two bromine atoms, 
while maintaining similar ligand-protein interactions (Figure 3.21). This indicates that the size as well as 
the location of substitutions affects the docking and binding scores. As expected, the COX-1 docked 
poses show inversion and/or rotation as compared to 3, while retaining a number of the ligand-protein 
interactions found for 3. These common interactions again aid in the explanation of the similar binding 




Figure 3.21. Ligand interaction diagram for 22 with COX 2, showing the predicted protein-ligand 
interactions. 
In contrast, a combination of an o-bromo substituted A-ring with a 4-fluoro substituted B-ring 
(compound 23) resulted in a ligand showing enhanced binding for both COX-1 and COX-2 (Table 3.3, 
entry 20), and significantly enhanced COX-1 binding with moderate improvement of the COX-2 binding 
scores was observed for o-methoxy/4-chloro (24), m-bromo/4-bromo (25), p-bromo/5-fluoro (26), 
o-chloro/5-chloro (27), and p-chloro/5-bromo ligands (28) (Table 3.3, entries 21-25). Interestingly, the 
pose generated for compound 26 shows good correlation with that generated for 3 (Figure 3.22), 
however it shows one of the smallest changes in the COX-2 binding scores for all the ligands (Table 3.3, 
entry 23). This illustrates one of the limitations of combinatorial chemistry which can be minimized, if 
not avoided altogether, through the use of computational methods – in this case the poses and the 
binding scores of 3 and 26 are very similar, and these compounds are not expected to yield significantly 
different results in vitro and in vivo, despite 26 containing  both a fluorine and a bromine atom. As such 
there is almost no need to synthesize 26, unless the substitutions are likely to enhance other physical 
properties. Compounds 23-28 all show the expected inversion of the docked pose in COX-1, with 
compound 24 also showing movement of the sulfonate group away from the position occupied by 3 and 




Figure 3.22. Overlap of the poses generated for 26 (shown in pink) and 3 (shown in blue). 
 
 
3.4. Always Have a Backup Plan:  Design and Analysis of Sulfonamide Analogs. 
“Tea and cake or death?” 
Eddie Izzard, Dressed to Kill 
The second set of ligands, designed using 4 as a base, and utilizing the same modifications as for the first 
set of ligands, was also docked into COX-1 and COX-2 (SI Table 2). In contrast to the previous set of 
ligands, no modifications resulted in marked reductions in the binding scores for COX-1, and 




Table 3.4. Glide XP and Prime scores for selected sulfonamides. 










1 - - 4 -11.378 -72.679 -12.823 -89.915 
2 - p-F 29 -11.765 -77.769 -12.821 -101.232 
3 4-F p-F 30 -12.537 -91.703 -13.469 -99.267 
4 5-F p-F 31 -12.998 -86.470 -13.337 -85.901 
5 4-Br p-F 32 -11.058 -101.192 -12.675 -107.264 
6 4-Cl p-F 33 -11.532 -93.335 -13.459 -109.749 
7 5-Br p-F 34 -12.852 -98.743 -13.617 -110.607 
8 5-Cl p-F 35 -12.032 -96.919 -13.553 -103.727 
9 - o-Br 36 -11.581 -97.580 -13.253 -114.414 
10 4-F o-Br 37 -11.438 -98.376 -13.143 -95.641 
11 4-Cl o-Br 38 -11.755 -124.159 -13.120 -121.787 
12 4-Br o-Br 39 -11.440 -120.903 -13.312 -115.491 
13 5-F o-Br 40 -11.708 -104.910 -12.968 -90.213 
14 5-Cl o-Br 41 -11.838 -112.508 -13.387 -118.002 
15 5-Br o-Br 42 -11.927 -112.496 -13.415 -110.871 
a “-“ indicates all hydrogen atoms present. 
Addition of a p-fluoro substituent to the A-ring of 4 results in a very small change in the COX-2 binding 
score (Table 3.4, entry 2), and the poses of compounds 4 and 29 are almost identical (Figure 3.23). There 
is a much larger difference between the COX-1 binding scores for 4 and 29, and inspection of the poses 
showed that the pose for 29 is inverted and the p-fluorophenyl group is rotated in comparison to the 
pose generated for 4 (Figure 3.24). While perhaps not interesting in terms of improvement of the 
binding scores of 4, the very small difference in the COX-2 binding energy between these two poses 
indicates that these compounds will most likely interact in very similar ways in vivo, and the presence of 




Figure 3.23. Overlap of the poses generated for 4 (shown in blue) and 29 (shown in green) when docked 
into COX-2. 
 
Figure 3.24. Overlap of the poses generated for 4 (shown in blue) and 29 (shown in green) when docked 
into COX-1. 
Addition of a second fluorine atom to the B-ring at either the 4- or 5-positions resulted in increases to 
both the COX-2 and COX-1 binding scores (Table 3.4, entries 3 and 4). Examination of the poses for 
compounds 30 and 31 when docked into COX-2 revealed that while these two compounds show very 
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similar poses, the poses are different to those obtained for compounds 4 and 29 (Figure 3.25). In COX-1, 
compounds 29, 30 and 31 overlap very well, with compounds 30 and 31 showing the same inversion and 
rotation of the p-fluorophenyl group as seen for compound 29.  
 
Figure 3.25. Overlap of 4 (shown in blue) and 31 (shown in green) when docked into COX-2. 
Addition of bromo- or chloro- substituents at either position on the B-ring resulted in even larger 
changes to the binding scores for both COX-1 and COX-2 (Table 3.4, entries 5-8), and analysis of the 
poses shows movement of the A ring away from the position occupied by the A ring in 4 (Figure 3.26). 
This movement allows for the formation of a hydrogen bond between the side chain of Ser516 with the 
carbonyl oxygen atom in all four compounds, and, in the case of compound 32, the formation of π-π 
stacking interactions between the A-ring, Arg106 and Tyr341 (Figure 3.27). The poses for compounds 32, 
33, 34 and 35 when docked into COX-1 are all inverted as compared to 4, and this inversion allows for 
interaction of the A-ring with Tyr355 (Figure 3.28), resulting in the observed increases in the COX-1 




Figure 3.26. Overlap of the poses of 4 (shown in blue) and 32 (shown in yellow) when docked into COX-2.  
 





Figure 3.28. Ligand interaction diagram for 35 showing the interactions formed between the ligand and 
COX-1. 
Inclusion of an o-bromo substituent on the A-ring resulted in significant increases to the binding scores 
for both COX-1 and COX-2 (Table 3.4, entries 9-15), with compound 38 showing the highest binding 
scores of -121.787 kcal/mol and -124.159 kcal/mol respectively (Table 3.4, entry 11). The 
phenylsulfonamide portion of the pose generated for this compound overlaps well with the parent 
sulfonamide (Figure 3.29), with the poses differing in the chalcone portion of the molecules. This 
deviation from the pose generated for 4 brings the pose generated for 38 closer into alignment with the 
crystal structure of celecoxib (Figure 3.30), and the additional ligand-protein interactions formed 




Figure 3.29. Overlap of the poses generated for 4 (shown in blue) with compound 38 (shown in purple) 
when docked into COX-2. 
 
Figure 3.30. Overlap of the pose generated for 38 when docked into COX-2 (depicted in light blue) with 
the X-ray crystal structure of celecoxib (depicted in green). 
Compound 40, which includes an o-bromo/5-fluoro combination, shows a large positive change in the 
MM/GBSA scores (Table 3.4, entry 13), and while not having the largest binding energy, the very small 
change in the COX-1 binding scores make this compound interesting. Inspection of the binding pose for 
40 in COX-2 showed inversion of the molecule, again allowing for the formation of additional ligand-
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protein interactions (Figure 3.31). The pose generated for 40 when it is docked into COX-1 shows very 
similar protein-ligand interactions to that obtained for 4 (Figure 3.32), which corresponds to the small 
changes in the binding scores obtained.      
 
Figure 3.31. Overlap of the poses of 4 (shown in blue) with 40 (shown in green) when docked into COX-2. 
 
Figure 3.32. Ligand interaction diagram for 40 showing the interactions between the ligand and COX-1.  
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3.5. A Word to the Wise: Selection of Candidates for Synthesis.  
“Knowledge is knowing that a tomato is a fruit. Wisdom is knowing that a tomato doesn't belong in a 
fruit salad.” 
Miles Kingston 
While these docking scores are good indicators of binding, these in silico results do not take into account 
in vivo conditions and cannot predict the actual selectivity of a compound for one protein isoform over 
another – for example, celecoxib shows a higher docking score for COX-1 over COX-2 (ca. -86 kCal.mol-1 
and -84 kCal.mol-1 respectively), but in vivo it is 10-20 times more selective for COX-2 over COX-1.644 As 
such, docking scores such as these are only indications of binding and must not be taken as absolutes; 
rather they should be used in conjunction with in vitro binding studies in order to determine whether 
the docking scores are accurate representations of what occurs in the proteins. 
Synthesis and testing of all 168 compounds would be ideal, as this would allow for the accurate 
comparison of the in silico docking scores with actual experimental results. However, this is intensely 
time-consuming and prohibitively expensive, both in terms of starting materials needed and the cost 
associated with the biological testing of all of these compounds. As such, a representative selection of 
ligands is needed which would demonstrate both positive and negative changes to the docking scores 
obtained. While synthesis of the twenty-five sulfonate compounds identified in Table 3.3 would allow 
for investigation of the  changes observed in the docking scores, and various combinations thereof, 
synthetic challenges (described in detail in Chapter 4) severely limited the number of compounds which 
could be synthesized and tested. Due to these challenges, a different set of ligands was selected which 




Table 3.5. Glide XP and Prime scores for selected sulfonate compounds for synthesis. 










1 - - 3 -12.619 -55.772 -10.572 -74.414 
2 - p-Br 5 -11.436 -92.183 -11.767 -89.066 
3 - p-Cl 6 -11.569 -84.908 -11.223 -85.836 
4 - p-F 7 -12.352 -69.067 -6.414 -81.389 
5 - p-OMe 8 -11.898 -94.200 -9.625 -94.815 
6 - m-Br 9 -11.517 -103.141 -11.667 -79.280 
7 - m-Cl 43 -11.001 -104.953 -11.120 -86.983 
8 - m-F 44 -12.687 -93.861 -5.040 -77.147 
9 - o-Br 10 -12.57 -93.748 -10.102 -80.341 
10 - o-Cl 45 -12.163 -93.155 -10.709 -89.088 
11 - o-F 46 -12.362 -90.999 -11.556 -78.554 
12 - o-OMe 47 -12.111 -70.669 -10.59 -75.929 
13 4-F - 11 -12.664 -84.205 -10.416 -61.886 
14 4-F p- Br 48 -12.064 -96.677 -12.223 -82.510 
15 4-F p- Cl 49 -11.973 -99.575 -12.093 -81.847 
16 4-F p- F 17 -12.767 -86.607 -11.841 -68.525 
17 4-F p-OMe 50 -12.059 -85.854 -10.797 -71.438 
18 4-F m- Br 51 -11.654 -89.884 -10.684 -92.570 
19 4-F m- Cl 52 -11.993 -88.717 -10.825 -86.733 
20 4-F m- F 53 -12.681 -90.577 -4.324 -82.781 
21 4-F o-Br 23 -11.749 -90.352 -12.126 -91.369 
22 4-F o-Cl 54 -12.646 -90.856 -11.267 -88.617 
23 4-F o- F 55 -12.700 -88.670 -11.441 -87.202 
24 4-F o-OMe 56 -12.394 -72.392 -9.992 -76.870 
25 4-Cl - 12 -8.049 -92.404 11.635 -83.947 
26 4-Cl p-OMe 57 -11.497 -98.497 -9.624 -86.845 
27 4-Cl m- Cl 58 -7.813 -88.302 -9.927 -97.391 
28 4-Cl o- Cl 59 -11.325 -100.695 -11.530 -92.396 
29 4-Cl o- F 18 -12.149 -98.884 -11.321 -76.413 
30 4-Cl o-OMe 24 -11.534 -82.327 -10.353 -102.856 
a“-“ indicates all hydrogen atoms present. 
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As previously stated, the addition of a p-bromo-, chloro- or methoxy-substituent to 3 resulted in 
significantly enhanced binding scores for both COX-1 and COX-2 (Table 3.5, entries 2, 3, and 5), and the 
addition of a m-bromo or an o-bromo atom resulted in a large increase in the binding score obtained for 
COX-2, while the binding score for COX-1 is affected to a much lesser degree (Table 3.5, entries 6 and 9). 
Addition of an m-chloro atom also results in a large change in the binding score for COX-2 (Table 3.5, 
entry 7); however the COX-1 binding score is affected to a greater degree than was observed for the m-
bromo compound. Addition of a p-fluoro or an o-methoxy substituent on the A-ring, while still resulting 
in positive changes in the COX-2 binding scores (Table 3.5, entries 4 and 12), show much smaller changes 
than those observed for any of the other substitutions.  
 
The combination of an A-ring o-methoxy substitution with a B-ring 4-fluoro substitution (compound 56), 
however, results in a molecule with a lower COX-2 binding score than those obtained for other multiple 
substitution patterns (Table 3.5, entry 24). This indicates that, at least in this case, the presence of the 
o-methoxy group influences the binding score more than the fluorine atom does, as the docking scores 
obtained for this compound are similar to those obtained for compound 47 (Table 3.5, entry 12), which 
does not contain a fluorine atom. In contrast to the other o-methoxy containing compounds, the 
o-methoxy/4-chloro combination found in compound 24 shows a large change in the COX-1 binding 
score (Table 3.5, entry 30), and investigation of the binding pose showed an inversion in the binding 
pose as compared to compound 3 (Figure 3.33). This inversion results in different interactions with the 
protein (Figure 3.34) and the corresponding change in the binding score. 
  





Figure 3.34. Ligand interaction diagram of 24 with COX 1. 
Interestingly, the only compounds to show small increases or reductions in the COX-1 scores are 
compounds containing a fluorine atom (Table 3.5, entries 13, 16 and 17), with the lowest COX-1 binding 
score obtained for compound 11 (Table 3.5, entry 13). Another interesting observation is that, while the 
di-fluoro compound 17 shows reduction in the COX-1 binding score (Table 3.5, entry 16), other 
molecules containing two fluorine atoms do not show a similar reduction (Table 3.5, entries 20 and 23), 
rather they show increases in both COX-1 and COX-2 binding scores. The di-fluoro compounds 17, 53 
and 55 cluster well with each other and with the pose generated for 3 when docked into COX-2, but 
show inversion in COX-1. Due to this inversion, π-cation interactions are formed between the A-ring and 
the protein, rather than between the central ring and the protein, as seen for compound 3 (Figure 3.35). 
This example clearly illustrates the fact that while the nature of the substitution is important, the 
position of these substitutions can and do affect the interactions between the ligand and the protein, 
thereby affecting the binding scores calculated for each compound. The selected compounds include 
examples of both positive and negative changes to the COX-1 and COX-2 scores, in a variety of 
combinations, and testing of these thirty compounds will potentially provide a way of linking the results 
from the in silico calculations with observations made in vitro. 




Figure 3.35. Ligand interaction diagram of 53 with COX-1. 
 
 
3.6. What We Never Knew We Needed to Know: A Review.  
“The only true wisdom is in knowing you know nothing.” 
Socrates 
Docking of the known COX-2 selective compound celecoxib highlighted important interactions which are 
formed between the ligand molecule and amino acid residues within the active site of the protein. The 
binding scores calculated for celecoxib when docked into COX-1 and COX-2 are similar, indicating that 
the binding scores alone cannot accurately describe the ca. 10-fold difference in selectivity observed for 
celecoxib with these protein isoforms, and as such any computational information must be correlated 
with experimental data in order to determine the accuracy of the model used. Molecular docking shows 
that the dominant keto-enol tautomer of curcumin does not interact with the secondary pocket present 
in COX-2, and as such is not expected to be COX-2 selective. The diketone tautomer presents as a 
possible COX-2 selective compound, however this tautomer is almost nonexistent in solution and as 




Based on the poses and interactions predicted for curcumin and celecoxib, two potential COX-2 selective 
compounds were designed using fragments common to celecoxib and other COX-2 selective 
compounds, as well as fragments present in curcumin. Initial docking showed that both compounds 
interact with the secondary pocket as desired, and make a number of connections to the protein which 
are present between celecoxib and COX-2. The docking results also showed that there was room for 
improvement, and therefore a range of modifications were made in order to explore the impact of 
various substitutions on the docking and binding scores, as well as to explore how the positioning of 
these modifications affected the docking poses and the interactions made between the protein and the 
ligand.   
 
In all cases, the modifications resulted in increased MM/GBSA binding scores for COX-2, and in a few 
cases, a reduction in the COX-1 binding scores were noted. In total, 166 compounds were designed 
across the two classes and these compounds show both positive and negative changes to COX-2 and 
COX-1 binding scores. Due to synthetic challenges, thirty benzenesulfonate-based compounds, which 
characterize the changes seen in the full complement of compounds, were selected as candidates for 




4. Results and Discussion: Synthesis of Target 
Benzenesulfonates   
 
4.1. From the Bottom Up: Retrosynthesis and Initial Synthesis.  
 “My mind rebels at stagnation. Give me work, give me problems.” 
Sir Arthur Conan Doyle, The Sign of Four 
 
While computational modeling is a vastly powerful tool in the process of drug design, the true test of the 
success of a designed drug lies in the results obtained through biological testing. Before a drug 
candidate can be subjected to this testing, the in silico molecule must be translated from the computer 
screen to a vial through chemical synthesis. One of the downsides to computational modeling is that a 
compound which shows good prospects on screen might be so synthetically challenging that the 
molecule might never make it to the testing phase, despite the good computational results.     
 
After identification of suitable candidate molecules through computational modeling, retrosynthetic 
analysis identified two possible synthetic routes (Scheme 4.1). Pathway A involves the formation of a 
chalcone from a 2’-hydroxyacetophenone and a suitable benzaldehyde in a base-catalyzed condensation 
reaction, followed by a base-catalyzed ether formation between the phenolic oxygen atom of the 
acetophenone ring and an appropriate benzyl halide. Pathway B involves the same starting components; 
however the order of the reactions is different. In this pathway, the ether bond is created first between 
the phenolic oxygen atom of the 2’-hydroxyacetophenone and a benzyl halide, followed by the base-
catalyzed condensation reaction with the benzaldehyde. The final steps in these pathways are identical – 
addition of a sulfonyl chloride moiety to the benzyl ring, followed by conversion to the desired sulfonic 
acid or sulfonamide. These pathways provide access to a wide range of compounds as a variety of 










































Initial investigations into the formation of the ether bond were carried out using 
2’-hydroxyacetophenone (60) and benzyl bromide (61) (Scheme 4.2), and the use of 1 equivalent of 
anhydrous potassium carbonate in refluxing acetonitrile695-697 was sufficient to effect the conversion to 
62 cleanly and in almost quantitative yields in 24 hours (Table 4.1.).  
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Table 4.1. Optimization of conditions for ether formation.   
Reaction Equivalents K2CO3 Solvent 
Time at reflux 
/Hours 
Yield /% 
1 1 Me2CO696 24 66 
2 1 Me2CO 48 95 
3 2 Me2CO 24 82 
4 1 MeCN 12 54 
5 1 MeCN 24 89 
 
1H NMR spectral analysis of 62698 showed a significant shift in the location of the methylene proton 
peak, from 4.60 ppm (in the spectrum of 61) to 5.23 ppm (Figure 4.1). As this region of the spectrum is 
clear of other signals, the course of reactions could easily be followed by observing the relative integrals 
of these two signals. Slow evaporation of the solvent resulted in the formation of a crystalline solid, and 
X-ray spectroscopic analysis of suitable crystals of 62 (CCDC deposit number pending) revealed that the 
two aromatic rings are essentially perpendicular to each other, rather than existing as a planar molecule 
(Figure 4.2). While X-ray analysis of any of the synthesized compounds is interesting, this aspect is not of 
great importance to the overall project, and as such the X-ray data is presented merely for the sake of 





Figure 4.1. 1H NMR spectrum of 62 showing the shift in the location of the methylene signals on 
formation of the ether bond. 
 
Figure 4.2. An ORTEP view of 62 showing the perpendicular arrangement of the phenyl rings. 





Test reactions were also carried out to determine optimum conditions for the condensation reactions 
between 60 and 4-bromobenzaldehyde (63) (Scheme 4.3). For this reaction, the optimum conditions for 
the formation of chalcone 64699 were determined to be 2 equivalents of KOH dissolved in absolute 
ethanol, with the reaction stirred at room temperature for 18 hours (Table 4.2), a modification of the 
procedure used by Zhang and Wang.700 










Table 4.2. Optimization of conditions for chalcone formation. 
Entry Equivalents KOH Time /Hours Yield /% 
1 2 2 22 
2 2 6 45 
3 2 12 76 
4 2 18 95 
 
The appearance of two one-proton doublets with J-values greater than 15 Hz in the 1H NMR spectrum 
(Figure 4.3), along with the corresponding disappearance of the aldehyde proton (~10 ppm) and the  
methyl protons (~2.5 ppm) confirmed the formation of a trans double bond701 between the 




Figure 4.3. 1H NMR spectrum of 64 highlighting the signals corresponding to the double bond protons. 
Routes for the conversion of a sulfonyl chloride moiety to a sulfonamide (Scheme 4.4) were also 
explored using p-toluene sulfonyl chloride (65) as the analogue molecule. The sulfonyl chloride could be 
easily converted to the sulfonamide 66702 using THF/aqueous ammonia at 0˚C for 1 h in high yields (over 
80%) following a modification of the procedure used by Corominas and Montaña.703 Proton NMR 
spectral analysis of 66 showed the appearance of a two-proton singlet at 7.36 ppm in the 1H NMR 
spectrum, corresponding to the two amide protons (Figure 4.4). The proton-observed gHSQC 1H-{15N} 
spectrum of 66 shows a signal at 7.36 ppm, indicating that the protons responsible for this signal are 
definitely connected to a nitrogen atom, which indicates that the conversion of the sulfonyl chloride into 
a sulfonamide was successful.  






















4.2. Assembling the Puzzle: Attempts towards the Synthesis of the Final Compounds. 
“Murder mysteries are puzzles that are fun to resolve.” 
Kathy Reichs  
With these procedures in hand, attention was focused on the complete synthesis of the 
benzenesulfonates along Pathway A. Initially five 2’-hydroxyacetophenones and five benzaldehydes 
were used to synthesize 24 chalcones (Scheme 4.5) in good to excellent yields (Table 4.3).  
















1D gHSQC 1H-{15N} spectrum 
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Table 4.3. Yields for formation of various chalcones. 
Entry R1 R2 Compound Yield /% 
1 H (60) H (67) 68704 86 
2  4-Br (63) 69699 93 
3  4-Cl (70) 71699 92 
4  4-F (72) 73705 73 
5  2-Cl (74) 75706 78 
6 4-F (76) 67 77707 72 
7  63 78 69 
8  70 79708 66 
9  72 80 87 
10  74 81709 79 
11 4-Cl (82) 67 83 80 
12  63 84710 67 
13  70 85 84 
14  72 86 82 
15 5-Cl (87) 67 88699 67 
16  63 89711 81 
17  70 90699 74 
18  72 91712 79 
19  74 92699 69 
20 5-Br (93) 67 94711 68 
21  63 95713 68 
22  70 96712 61 
23  72 97712 81 
24  74 98714 65 
Reaction conditions: acetophenone (1 mmol), benzaldehyde (1 mmol), KOH (2 mmol), EtOH, rt, 18 h. 
 
During the course of these reactions, crystals were observed during cleanup procedures, and as such, 
the growth of X-ray-quality crystals was attempted. Suitable crystals were obtained for compound 73, 
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and X-ray crystallographic analysis of this compound (CCDC deposit number pending) showed that, while 
maintaining the electron delocalization throughout, the molecule is not flat as expected, rather the 
benzaldehyde-derived phenyl ring is twisted away from the horizontal by 28.8˚ (Figure 4.5). As with 
compound 62, X-ray crystallographic studies do not play a large role in the overall project and the data 
obtained for 73 is presented for the sake of interest (See SI for complete structural description). 
 
Figure 4.5. An ORTEP view of 73 showing the out-of plane rotation of the benzaldehyde-derived phenyl 
ring Displacement of the non-hydrogen atoms are shown at the 50% probability level.  
While the KOH/Abs EtOH conditions were well suited to the unsubstituted 67 and the halo-substituted 
benzaldehydes 63, 70, 72 and 74, p-anisaldehyde (99) and o-anisaldehyde (100), both methoxy-
substituted benzaldehydes, coupled poorly using these conditions, with yields ranging from 27-41%. 
Further investigations identified NaH/THF/0˚C/4 h715 as conditions more suited to these benzaldehydes, 
and the methoxy-substituted chalcones were obtained in good to very good yields (Table 4.4). 
Interestingly, these conditions were not suited to the halo-benzaldehydes, as reactions using these 
conditions resulted in the isolation of the insoluble Na-salt of the acetophenone, with the benzaldehyde 




Table 4.4. Yields for the formation of methoxy-substituted chalcones.  
Entry R1 R2 Chalcone Yield /% 
1 60 4-OMe (99) 101699 83 
2  2-OMe (100) 102716 79 
3 76 99 103717 81 
4  100 104 87 
5 82 99 105710 91 
6  100 106 92 
7 87 99 107699 88 
8  100 108718 81 
9 93 99 109714 94 
10  100 110 95 
Reaction conditions: acetophenone (1 mmol), benzaldehyde (1 mmol), NaH (2 mmol), dry THF, 0˚C, 4 h. 
Addition of the benzyl group to the phenolic oxygen did not proceed as planned, despite reports of high 
yields in the literature.719 Deprotonation of the phenolic oxygen results in preferential intramolecular 
condensation yielding a flavanone rather than the desired intermolecular ether formation (Scheme 
4.6).720 This was confirmed by the appearance of three one-proton signals in the 1H NMR spectrum, 
corresponding to the three aliphatic protons present in the flavanone (Figure 4.6). The two protons of 
the methylene group are non-equivalent, as seen in the spectrum as evidenced by the splitting pattern, 
which shows both vicinal and germinal coupling.   













Figure 4.6. A portion of the 1H NMR spectrum of the flavanone product showing the characteristic 
aliphatic proton signals with both germinal and vicinal coupling.  
 
 
4.3. Changing Directions: Pathway B as an Alternative Route.  
 “I think you end up doing the stuff you were supposed to do at the time you were supposed to do it.” 
Robert Downey Jr. 
At this point, Pathway B (Scheme 4.7) was explored in order to overcome the synthetic problems 
encountered in Pathway A, and reactions using the established procedures for the ether reaction and 





















60 61 62 99
111
 
As these benzylated chalcones could now be synthesized easily, addition of the sulfonyl chloride moiety 
to form 62a (Scheme 4.8) was attempted with chlorosulfonic acid as described by Talley, et al,722 in the 
synthesis of valdecoxib, and Silva, et al.723 Yields of this reaction were disappointing, with a 30% mass 
recovery obtained after workup, and following NMR analysis of the disappointingly complex mixture it 
was determined that, while the sulfonyl chloride was attached to the molecule, it was located at the 
4-position of the acetophenone ring (62b), rather than on the benzyl ring as desired, a result which 
cannot be explained in terms of the relative directing effects of the substituents on the two aromatic 
rings. 




















As Pathway B appeared more appropriate for the synthesis of these compounds, alternate compounds 
were sought which could be manipulated to yield the final compounds with substitutions at the correct 
positions. Likely candidates were identified in 4-(bromomethyl)benzenesulfonyl chloride 112 and the 
significantly more expensive 4-(bromomethyl)benzenesulfonamide 113160 (Figure 4.7), as a replacement 








Figure 4.7. 2D structures of 4-(bromomethyl)benzenesulfonyl chloride 112 and 
4-(bromomethyl)benzenesulfonamide 113. 
However, initial reactions between the 2’-hydroxyacetophenones and 112 yielded a tosylated 
acetophenone compound, rather than the desired ether (Scheme 4.9). As 112 is a tosyl chloride 
derivative, this reaction was not unexpected, and it was therefore determined that the sulfonyl chloride 
needed to be protected in order to form the ether bond between the bromide and the hydroxyl group. 
A search of the literature yielded large amounts of information on the use of sulfonyl chlorides as 























Rather than focus on one protecting group for both sulfonate and sulfonamide compounds, both 
nitrogen- and oxygen-based protecting groups were tested in order to simplify the synthetic route. A 
protocol for the conversion of the sulfonyl chloride to a sulfonamide using aqueous ammonia had 
previously been established (Scheme 4.4), and this methodology proved successful with 112, however, 
while easy to synthesize, 113 proved too unstable under the subsequent reaction conditions. As 
attempts to protect the sulfonamide after it had been formed using amine protecting groups such as 
Boc and ethyl chloroformate were unsuccessful, primary and secondary amines were explored as 
alternatives. Initial testing of various amines and alcohols were carried out using a variety of conditions, 
with 65 selected as a simple test compound. This evaluation consisted of both protection703,725-727 and 
deprotection728-731  steps in order to identify those groups which could be easily added and removed 
without affecting the remainder of the molecule (Table 4.5).  






















1 Diethylamine725 -N(Et)2 114732 90b 0h 
2 Diisopropylamine725 -N(iPr)2 115733 5b,c - 
3 Dibenzylamine725 -NBz2 116734 8b,c - 
4 Acetamide725 -NHC(=O)CH3 117 15b,d - 
5 Succinamide725 -NSucc 118735 25b,d - 
6 Phthalamide725 -NPhth 119725 86b 81i 
7 Ethanol726 -OEt 120736 90e 93f,j 
8 tButanol726 -OtBu - 0e,f - 
9 iPropanol726 -OiPr - 0e,f - 
10 Phenol727 -OPh 121737 75g 0h 
11 p-Nitrophenol727 -OPhNO2 122 86c,g 0h 
a 1H NMR yield b65, amine, KOH (1.1 eq), MeCN, rt, 2 h cnot characterized duncharacterized products (NMR) e65, 
KOH (1.1 eq), alcohol, rt, 2 h fpotassium salt isolated g65, KOH (1.1 eq), alcohol, THF/H2O (20:1), 0 ˚C, 2 h. 
hmultiple 
deprotection methods attempted. ihydrazine hydrate (80%), reflux, 30min jKOH (1 eq), EtOH/H2O (1:2) reflux, 1h.  
Based on these test reactions, phthalamide was selected as a suitable amine protecting group, and 
ethanol as the acid protecting group. The ethoxy group could be cleaved using a base726  and the 
phthalamide group could be easily cleaved under Gabriel-type conditions by heating with hydrazine 
hydrate to reflux. 728-729 Protection of 112 proceeded smoothly, yielding the corresponding protected 











Figure 4.8. 2D structures of 123 and 124 
 
Table 4.6. Yields for the formation of protected (bromomethyl)tosylates. 
Entry Compound Yield/% 
1 123 88a 
2 124 84b 
a112, KOH (1.1 eq), EtOH, rt, 2 h b112, phthalimide, KOH (1.1 eq), MeCN, 0˚C, 1 h  
Formation of the ether bond between 60 and 123 (Scheme 4.11) initially proved challenging as 123 is 
sparingly soluble in acetonitrile. However, there is sufficient 123 present in solution at any given time to 
allow the reaction to proceed, and to provide very good yields of the ether product after 24 hours. 
Interestingly, the isolated product was not the ether sulfonate with an ethoxy- protecting group as 
expected; rather the potassium salt of 125 was obtained as a precipitate. 
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X = OEt, O- K+
60 123 125
 
As there was no evidence of sulfonate ester formation between two molecules of 123, the hypothesis is 
that 123 is the reactive species, and hydrolysis to the salt follows the reaction with 60. This hypothesis is 
supported by the unsuccessful reactions of the salt form of 112 with 60. Attempts to prevent the 
removal of the ethoxy group were unsuccessful, as when one equivalent of potassium carbonate was 
used, the ether reaction proceeded to ca. 50% and no further, and additional attempts to convert the 
potassium salt back to the ether after hydrolysis were unsuccessful. Organic bases such as DBU and 
DABCO were also tested; however these did not yield as clean a conversion as the potassium 
carbonate/acetonitrile conditions. A test condensation reaction of 125 with benzaldehyde 63 showed 
the presence of the salt did not affect the condensation reaction, and as such, further ether reactions 
made use of the potassium carbonate/acetonitrile conditions as the final products could be isolated 
cleanly and in good yields by filtration (Table 4.7). While fluoro- and chloro-substitutions at the 
4-position of the acetophenone ring were well tolerated (Table 4.7, entries 2 and 3), the 5-substituted 
2’-hydroxyacetophenones 128, 87 and 93 were remarkably unstable under these conditions (Table 4.7, 
entries 4-6), and even use of the mild potassium carbonate/acetone conditions696 resulted in rapid 






Table 4.7. Yields for the formation of various 4-[2-(2-acetylphenyl)ethyl]benzenesulfonates. 
Entry 2’-Hydroxyacetophenone Product Yield /% 
1 H (60) 125 83 
2 4-F (76) 126 79 
3 4-Cl (82) 127 72 
4 5-F (128) 129 15a 
5 5-Cl (87) 130 12a 
6 5-Br (93) 131 9a 
Conditions: 123 (1 mmol), appropriate 2’-hydroxyacetophenone (1mmol), K2CO3 (2 mmol, 2 eq), MeCN, reflux, 24 h. 
aNMR yield, multiple uncharacterized products. 
Compound 124 on the other hand, proved to be too insoluble to be useful. It is remarkably insoluble in 
almost all organic solvents, apart from DMF and DMSO, and even the ether reactions carried out in DMF 
were low yielding. At this point, it was decided that compounds 125-127 would be carried forward into 
the condensation reactions, and the sulfonate converted into the sulfonamide through the sulfonyl 
chloride at a later stage if needed.  
The condensation reactions of 125, 126 and 127 with the various benzaldehydes (Scheme 4.12) to yield 
the thirty compounds identified previously made use of  a modified version of the procedure used for 
synthesis of the chalcones (Table 4.8). Reactions using 125 and 126 (Table 4.8, entries 1-24) proceeded 
cleanly under the conditions employed, with yields for reactions using 126 slightly lower than those 
obtained for compound 125. Reactions with 127 did not proceed as well as hoped under the conditions 
used for 125 and 126, with yields ranging from 25-45% after 24 hours. Extension of the reaction time to 
36 hours resulted in significantly improved yields for these compounds (Table 4.8, entries 25-30). 
Isolation of these compounds was uncomplicated, and only simple recrystallization techniques were 
required in order to obtain samples of high purity. 























Table 4.8. Yields for the formation of target molecules. 
Entry Benzenesulfonate  Benzaldehyde  Product Yield /% 
1 H (125) H (67) 3 73a 
2  4-Br (63) 5 81a 
3  4-Cl (70) 6 76a 
4  4-F (72) 7 72a 
5  4-OMe (99) 8 68a 
6  3-Br (132) 9 73a 
7  3-Cl (133) 43 78a 
8  3-F (134) 44 76a 
9  2-Br (135) 10 66a 
10  2-Cl (74) 45 68a 
11  2-F (136) 46 71a 
12  2-OMe (100) 47 64a 
13 4-F (126) 67 11 68a 
14  63 48 71a 
15  70 49 67a 
16  72 17 70a 
17  99 50 54a 
18  132 51 63a 
19  133 52 64a 
20  134 53 69a 
21  135 23 62a 
22  74 54 67a 
23  136 55 68a 
24  100 56 66a 
25 4-Cl (127) 67 12 69b 
26  99 57 65b 
27  134 58 61b 
28  74 59 60b 
29  136 18 62b 
30  100 24 59b 
asulfonate (1 mmol), benzaldehyde (1 mmol), KOH (2 mmol), EtOH, rt, 24 h bsulfonate (1 eq), benzaldehyde 




4.4. What We Never Knew We Needed to Know: A Review.  
“Review your work. You will find, if you are honest, that 90% of the trouble is traceable to loafing”.  
Ford Frick 
Following identification of potential COX-2 selective compounds through docking and binding studies, 
retrosynthetic analysis afforded two potential synthetic routes involving simple chemistry which would 
allow for the formation of the correct Z-isomer about the double bond. The initial route of synthesis, 
which involved the formation of the double bond through a base-catalysed condensation of an 
acetophenone with a benzaldehyde prior to the formation of the ether bond proved unsuccessful as the 
base-catalyzed intramolecular reaction of the chalcones yielded a flavanone rather than the desired 
benzyl ether. As such, this pathway was abandoned and the alternative pathway identified during the 
retrosynthetic analysis was explored.  
 
Early investigations into this second synthetic pathway, which involved the formation of the ether bond 
prior to the base-catalyzed condensation, yielded the correct benzylated compound in high yields, 
however the addition of the sulfonyl chloride moiety proved unsuccessful, with low yields and addition 
to alternate positions about the molecule observed. At the outset, use of a benzenesulfonyl chloride 
compound in order to circumvent the need for chlorosufonic acid resulted in the formation of a tosyl 
derivative, rather than the desired ether. Conversion of the sulfonyl chloride into a sulfonate or 
sulfonamide prior to the ether formation yielded “protected” species, however the protected 
sulfonamide proved too insoluble to be of use.  
 
An ethyl sulfonate proved a suitable starting material for the ether formation, with high yields obtained 
for three 4-substituted 2’-hydroxyacetophenones, with the 5-substituted 2’-hydroxyacetophenones 
proving to be too inherently unstable. The ethyl group is removed during this reaction and all attempts 
to prevent this removal were unsuccessful; however the removal of the ethyl group did not affect the 
subsequent condensation reactions. The current understanding of this reaction is that the ethyl-
protected sulfonate species is the reactive species, with the ethyl group removed after ether formation. 
This hypothesis is supported by the lack of intermolecular condensation between two benzenesulfonate 
molecules, as would be expected if the ethyl group is removed prior to ether formation. With suitable 
reactions and conditions identified, the synthesis of the thirty compounds previously identified was 
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carried out, using three 2’-hydroxyacetophenones and twelve benzaldehydes, in moderate to good 
yields. These products were isolated cleanly with only simple recrstallization techniques required to 





















5. Results and Discussion: Analysis and 
Identification of Compounds  
 
5.1. The Truth of the Matter: Structure Elucidation through NMR Spectroscopy.  
 “The world is full of obvious things that no one ever observes.”  
 Sherlock Holmes, Elementary 
In the laboratory, a chemist will base the outcome of a particular reaction or isolation on historical data, 
either from their own findings or on information gleaned from the literature. However, things do not 
always go according to plan, and, because of the capricious nature of chemistry, one cannot always 
assume that literature is correct. In some cases, novel synthetic or isolated compounds are identified, 
and in other cases, incorrect identification of compounds occurs. One such example of incorrect 
literature which has been corrected is found in aquatolide (Figure 5.1), a humulane-derived 





    
Figure 5.1. 2D structure of aquatolide and Asteriscus aquaticus.740     
 
Initially characterized in 1989 by San Feliciano, et al.,741 it was thought, based on 1D and 2D NMR 
analysis, to contain a very rare [2]ladderane substructure (Figure 5.2). However, extensive experimental 
and theoretical quantum-chemical NMR analysis by Lodewyk, et al. in 2012742 showed that this novel 
compound did not contain the [2]ladderane core as previously reported, but rather it contained a 
bicyclo[2.1.1]hexane ring system, which was confirmed through X-ray crystallographic techniques. Other 
compounds which were initially incorrectly identified and have since been revised include asperjinone 
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and (+)-pestazaline B, and confusion still exists around the structure of the simpler 2,3,4,5-tetrahydro-
1,5-benzoxazepine-3-ol.743  In most cases this misidentification is through no conscious fault of the 
authors, rather it is due to ambiguous spectra and, as in the case of aquatolide, a lack of sensitivity in 
the equipment used to carry out the analyses. With the significant improvement in the technology 
behind these instruments, and the resultant increase in sensitivity, it is hoped that errors in the 







Figure 5.2. Initial incorrect structure of aquatolide. 
As characterization of large, novel molecules by NMR spectroscopy can be daunting, it is therefore 
convenient to analyze the building blocks which make up the large molecule separately, and then 
compare this data to the spectra obtained for the larger molecule. The correct identification of these 
precursors is vital in order to avoid the incorrect structural identification of the final products. Analysis 
of the final compounds synthesized previously made use of the NMR characterization of the synthesized 
compounds 62, 125, 126, 127 and the various chalcones, as well as spectra obtained for the 
commercially available starting materials. NMR spectral data for many of the compounds are available in 
the literature, however, there is a wide disparity in the field strengths at which the data have been 
acquired, in the solvents used, as well as the degree of completeness of the characterization. As such, 
each compound in this work has been completely characterized in DMSO-d6, with the use of D2O where 
solubility and stability dictated the use of a different solvent. This approach allowed for the 
identification of the peaks belonging to the moieties remaining in the final compounds based on their 
initial structures and the spectra thereof, and allows for the comparison of chemical shifts between 
different compounds, which may be used for assignment of spectral data of new compounds.704 This 
method can be demonstrated in the NMR analysis of compound 6, as it can be characterized based on 
data obtained from chalcone 71 and from 125 which in turn can be characterized based on information 
obtained from 62 (Scheme 5.1).  
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The 1H NMR spectrum of 62 (Figure 5.3) allowed for the identification of the location of the methylene 
peak (Figure 5.3, peak b), as the relative integral ratios easily identify the signals corresponding to the 
protons of the methyl and methylene groups, both singlets with no 3J coupling. This NMR spectrum also 
establishes the peak pattern for the ortho-substituted acetophenone ring, both in fine structure and in 
the relative shifts. While literature spectra for compound 62 are available,744 the data is reported as 
acquired on a 200 MHz with the compound dissolved in CDCl3, and although the chemical shifts are 





Figure 5.3. 1H NMR spectrum and assignment of 62. 
As is often the case with this type of substitution, the fine structure arising from the ABCD spin system 
present in the ortho-substituted acetophenone ring is not resolved and the signals appear in a doublet-
triplet-triplet-doublet pattern. While the order of these coupled partners is revealed by the COSY 
spectrum, the identity of the protons requires the use of a Nuclear Overhauser Enhancement (NOE) 
experiment (Figure 5.4) with selective irradiation of the methylene protons. This selective irradiation 
reveals through-space contacts to the acetophenone ring (Figure 5.4, peak b), from which the identity of 
the other protons of the acetophenone ring can be determined from the 3J COSY correlations. NOE 
interactions are also observed between the methylene protons and the methyl protons (Figure 5.4, peak 
















Figure 5.4. 1D NOE spectrum of 62 with selective irradiation of the methylene protons. 
Comparison of the 13C and the DEPT135 spectra and analysis of the HMBC spectrum allowed for the 
identification and assignment of the quaternary carbons as well as the methyl, methylene and methine 
carbon atoms. HSQC analysis of this compound revealed that the most downfield proton in the 1H 
spectrum, which occupies the 6-position on the acetophenone ring, is not connected to the most 
downfield methine carbon atom in the 13C spectrum; rather the proton occupying the 4-position is 
connected to this carbon.  
 
Following the characterization of 62, the analysis of the 1H spectrum of 125 (Figure 5.5) was relatively 
straightforward. The presence of the p-sulfonate group on the benzyl ring resulted in the simplification 
of the proton spectrum into the classic p-substituted phenyl ring pattern of two doublets (Figure 5.5, 
peaks e and h), corresponding to two protons each, rather than the poorly resolved multiplets seen for 
62. Analysis of the NOESY spectrum (Figure 5.6) allowed for identification of the location of these two 
doublets, as a 3J COSY correlation exists between the methylene protons and the protons on the 
phenylsulfonate ring closer to the methylene, while no interaction is observed between the methylene 













Figure 5.5. 1H NMR spectrum and assignment of compound 125. 
 




























As with 63, analysis and comparison of the 13C, DEPT135 and HMBC spectra obtained for 125 allowed for 
the identification and assignment of the carbon atoms, which showed very close correlation with the 
data obtained for 62, apart from the appearance of a new quaternary carbon and the subsequent loss of 
a methine carbon arising from the sulfonation of the benzyl ring. The data obtained from HSQC analysis 
of this compound corresponds with the data obtained for 62, with the most downfield carbon signal 
connected to the proton at position 4 on the acetophenone ring.  
 
Analysis of 71 also made use of the information collected from the analyses of 62 and 125. As the 
protons present on the acetophenone ring had previously been identified, they could easily be 
distinguished in the 1H spectrum for 71 (Figure 5.7). Evidence for the presence of a trans double bond in 
the molecule was found in the existence of two one-proton doublets in the 1H spectrum (Figure 5.7, 
peaks d and f), with trans-bond characteristic J values of ca. 16 Hz.701 The NMR spectral data are 
reported in literature,699 however, as was the compound 62,  no signal assignments have been made 
precluding a spectral comparison. As the benzaldehyde portion of the chalcone was derived from p-
chlorobenzaldehyde, the proton signals for this ring appeared as two two-proton doublets, with the 
peaks differentiated through the presence (or lack) of NOESY correlations to the adjacent methine 
proton (Figure 5.8, peaks b and c). A COSY correlation, observed as a mixed-phase signal in the NOE 
spectrum (Figure 5.8, peak a), confirms the location of the signal corresponding to the two protons 




Figure 5.7. 1H NMR spectrum and assignment for chalcone 71. 
 


















Once the analyses of these compounds were complete, the analysis of the spectra obtained for 6 was 
relatively uncomplicated, as all of the peaks had previously been identified in at least one prior 
spectrum. The 1H NMR spectrum of 6 (Figure 5.9) shows the presence of a methylene peak (Figure 5.9, 
peak a) as well as the presence of the trans double bond protons (Figure 5.9, peaks d and f), indicating 
that both of these moieties are present in the molecule. The NOESY spectrum (Figure 5.10) again 
showed connections between the methylene proton and the acetophenone ring (highlighted in green), 
between the methylene protons and the sulfonate ring (red), as seen in the spectrum of 125, and 
between the methine proton of the double bond and the protons at the 2-position of the chlorophenyl 
ring (purple), as is seen in the spectrum of 69.   
 
 





















Figure 5.10. 2D NOE spectrum of 6, showing connections between the various components. 
 
5.2.  Separate but Still Together: Diffusion-Ordered Spectroscopy as a 
Chromatography Technique.  
“Research is formalized curiosity. It is poking and prying with a purpose.” 
Zora Neale Hurston 
While monitoring the course of the reactions by NMR spectroscopy, a broadening of the line width of 
the methylene signal was observed from starting material to product (Figure 5.11). While chemical shifts 
and line widths for protons connected to oxygen, nitrogen and sulfur atoms are markedly affected by 
changes in the solvent, as these protons are particularly sensitive to interactions with the solvent, 
protons connected to carbon atoms are usually less affected, often not at all, and as such the changes 
observed for the methylene protons are notable, if for no other than because they occur. Although 



















upon condensation with a benzaldehyde. This is also indicated by the solvent dependence observed for 
the chemical shift of the methylene protons of compound 6 (Figure 5.12).  
 
Figure 5.11. Overlap of the methylene peaks of 112 (shown in red) and 125 (shown in blue) in DMSO-d6. 
The second peak in the spectrum of 112 is a decomposition product due to the reaction of 112 with the 
water present in the NMR solvent.  
 
Figure 5.12. Overlays of the methylene peak region from the 1H NMR spectra of 6, showing the solvent-
dependance of these peaks. The spectrum shown in blue was run in DMSO-d6, the spectrum shown in 




Based on this observation, a diffusion experiment was carried out on compounds 125 and 6. These 
Diffusion-Ordered Spectroscopy (DOSY) experiments separate the components of a mixture on the basis 
of their diffusion coefficients, and simultaneously allows for measurement of the diffusion coefficient. It 
also provides a measure of the approximate size of the hydrodynamic radius for freely tumbling 
molecules in a solution,745 which in turn can provide a measure of the ability of a ligand molecule to 
enter into the active site of a protein. A compound with a large hydrodynamic ratio, for example, is less 
likely to be able to fit into the spatially-constrained active site within a protein than a compound with a 
small hydrodynamic ratio. As the main channel of the COX active site is relatively long and narrow, with 
restricted access through a small entry site, an elongated molecule with a small solvation sphere, such 
as arachidonic acid, will be able to enter into the active site of the COX enzymes much more easily than 
a large, bulky molecule with a large solvation sphere. 
 
DOSY experiments can, in broad terms, be classified as a unique chromatographic technique, as the 
separation of compounds is based on physical characteristics.746 Unlike standard separation methods, 
however, it does not require sample preparation or method optimization, and does not affect the 
sample or the chemical environment during the analysis. In a DOSY experiment, a series of spin echo 
spectra, each with different pulsed gradient strengths, are recorded, and the decay of the signals 
observed. The reduction of the signals is due to the dephasing-diffusion-rephasing sequences 
employed.747 A 90˚ pulse aligns the magnetic moments of the molecules, and once this is complete, a 
dephasing gradient pulse disperses the magnetization. After a period of time, an 180˚ pulse is applied 





Figure 5.13. Spatial spin encoding and decoding in DOSY experiments.748 
Only those signals corresponding to nuclei which have not moved significantly up or down the tube can 
be refocused, and as diffusion causes some of the molecules to move away, the intensities of the signals 
are reduced (Figure 5.14). The longer and more intense the gradient pulse, the more spatially 
discriminating it is, which corresponds to a weaker signal. Therefore, the duration and intensity of this 
magnetic pulse determines the distance a molecule can diffuse while still yielding a detectable signal.749 
All signals arising from the same molecular species will decay at the same rate, with the signal loss 




Figure 5.14. NMR diffusion spectra of a three-component mixture of water, 2-ethoxyethanol and 
caffeine.750  
The degree of attenuation or spectral intensity (Sx) occurs at a rate proportional to the diffusion 
coefficient (D) of the molecule (Equation 1), where S0 is the intensity at zero gradient (the “normal” 
spectrum) and Zx encodes the different gradient amplitudes used.746   
=             (1)  
There are various formulae used to determine the value of Z in terms of the gyromagnetic ratio (δ), the 
amplitude of the gradient applied (G), as well as one or more time parameters, such as Δ, which is the 
time between two pulse gradients and is related to the echo time, and δ, the width of the gradient 
pulse. The original Tanner-Stejskal method751 (Equation 2) which uses two rectangular gradient pulses, 
holds for simple experiments, and this equation can undergo minor modifications for more complex 
pulse sequences.   




Following data processing, the 1D NMR spectra are transformed into a 2D DOSY spectrum (Figure 5.15), 
which allows for the identification of the number of components present in the solution, as well as 
identifying which signals correspond to each component.  
 
Figure 5.15. 2D DOSY spectrum of the caffeine, 2-ethoxyethanol and water mixture showing the 
separation of the three compounds present.750  
Once this transformation is complete, the diffusion coefficient for each compound in a mixture can be 
determined from the y-axis of the 2D plot. This, combined with the viscosity of the solvent can be used 
to determine the effective molecular size in that solvent, based on the Stokes-Einstein equation 
(Equation 3), where r is the Van der Waals radius in meters, k is the Boltzmann constant, T the 
temperature in Kelvin, and η the viscosity in Pascal seconds.749,752 Comparison of this radius with the 
measured mean Van der Waals radius provides an understanding of the solvation sphere surrounding 
each molecule.  
=       (3)  
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DOSY experiments were carried out on 126 in both DMSO-d6 and D2O, and on compound 6 in D2O. The 
diffusion coefficients were then calculated for each compound using the 2D DOSY spectra (Table 5.1). As 
expected, the diffusion coefficients determined for 126 were different based on the solvent used, with 
the diffusion in DMSO-d6 slower than that noted for D2O.  
Table 5.1. DOSY-derived diffusion coefficients for compounds 126 and 6 at 30˚C. 
Entry Compound Solvent 
Diffusion coefficient, 
/x10-10 M2.s-1 
1 125 DMSO-d6 3.3  
2 125 D2O 6.4  
3 6 D2O 1.5 
 
Diffusion coefficients for the non-deuterated water present in D2O, the water present in DMSO-d6, and 
the DMSO-d5 species present in DMSO-d6 were also calculated (Table 5.2), and these values show good 
correlation with those found in the literature.753  
Table 5.2. DOSY-derived self-diffusion coefficients of solvents.   
Entry Compound Solvent 
Diffusion coefficient 
/x10-9 M2.s-1 
This worka                  Literature753 
1 H2O D2O 2.5 2.6a 
2 H2O DMSO-d6 1.1 - 
3 DMSO-d5 DMSO-d6 0.76 0.73, 0.89b 
aT = 30˚C, bExperiments carried out at 25˚C and 35˚C. 
With the diffusion coefficients for compounds 126 and 6 in hand, the Stokes radius for each molecule 
was calculated using the Stokes-Einstein equation (Equation 3, above) and compared to the Van der 
 Waals radii, as calculated using the volume_calc.py script available in the Schrödinger package172 





Table 5.3. Stokes Radii for compounds 126 and 6. 
Entry Compound Solvent Stokes Radius /Å VDW  radius /Å 
1 125 DMSO-d6 3.72 3.34 
2 125 D2O 4.45 3.34 
3 6 D2O 18.9 3.68 
 
Based on these results, it is immediately apparent that the size of the solvation sphere which forms 
around the molecules is dependent on the solvent used, with a larger solvation sphere forming with the 
use of D2O (Table 5.3, entries 1 and 2). This increase is most likely due to the increased interactions 
between the anionic compound 125 and the more polar water molecules than the interactions possible 
in DMSO. Comparison of the Stokes radii to the calculated Van der Waals radii also shows an increase in 
the “effective” size of the molecule in solution due to the presence of the solvation sphere. This is not 
unexpected, as Van der Waals volumes and radii are calculated as isolated gas-phase molecules without 
the solvent interactions inherent in solutions. The number of solvent molecules present in the solvation 
shell could theoretically be determined from these radii, however these estimates depend on the sixth 
root of the gradient strength calibration, and slight theoretical and experimental errors lead to large 
changes in the number of solvent molecules present.749 As the solvation sphere is constantly fluctuating, 
the number of molecules calculated depends on the timescale of the method used to calculate it – the 
smaller the timescale, the larger the solvent shell. The diffusion timescale is several collisions in the 
order of 100 picoseconds, whereas NMR timescales are milliseconds to seconds-long, and as a result 
signals arising from bound solvent molecules do not arise.749  
 
The large difference between the Stokes radius and the Van der Waals radius for compound 6 (Table 
5.3, entry 3) appears to show a huge five-fold increase in the size of the molecule on solvation. However, 
as the Stokes-Einstein equation makes use of literature values for η, it does not take into account the 
changes in the viscosity of the solution, and as such an inflated value is obtained for the Stokes radius 
for this compound. A more accurate measurement of the Stokes radii for this and other compounds 
requires the determination of the viscosity of the solution used for these DOSY experiments and the 
subsequent use of that value for η, rather than making use of literature values. This is a complex 
undertaking, requiring extensive study into areas such as the concentration-dependence of the viscosity, 
and as such is beyond the scope of this project.  
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5.3. Linking the Abstract with the Concrete: Putting NMR Analysis of Molecular 
Flexibility in Solution (NAMFIS) to Work.  
 “When you're curious, you find lots of interesting things to do.” 
Walt Disney 
As previously stated, NMR Analysis of Molecular Flexibility In Solution, or NAMFIS, combines the 
theoretical with the practical in order to determine the populations of conformations in solution. 
Conformations are randomly generated in silico using software such as Schrödinger’s Macromodel, with 
an applicable force field (MMFF, OPLS-2005, etc) and in either a specific solvent or in the gas phase. 
Once the structures have been energy-minimized and the duplicates eliminated, these conformers are 
then screened using constraints determined from NOE/ROE (Rotating Frame Overhauser Enhancement) 
experiments (Figure 5.16). The internuclear distances are determined by calculating the crosspeak 
volume326,754-761 based on the isolated spin pair approximation (ISPA),762 using an internal calibration 
distance (Equation 4). The result is a set of conformers which provide a best fit for the experimental 
parameters, and represent the most likely solution distribution.  
 
Figure 5.16. Processes in NMR Analysis of Molecular Flexibility In Solution (NAMFIS) analysis.  
=       (4)  
The power of this, and other similar techniques,763-764 lies in the ability of these techniques to identify 
what conformations are present in solution, rather than an averaged structure derived from NMR data. 
Comparison of the conformations identified as present in solution with poses derived from docking 
methodologies reveals the likelihood that a compound could bind into a protein, as compounds with 
similar solution and bound conformations would be more likely to interact with a protein than a 
compound with vastly different solution and bound conformations. Due to the well-resolved, clearly 
assignable 1H NMR spectrum obtained, 6 was selected as a candidate for NAMFIS analysis and the 
conformational search yielded 3630 unique conformations from a total of 86915 conformations, 












These conformations were generated using the GBSA constant dielectric model within an energy 
window of 21.0 kJ/mol (5.02 kcal/mol), and minimization was carried out using full-matrix-Newton-
Raphson (FMNR) minimization (OPLS-2005, H2O) within the same energy window (21 kJ/mol) on a 
comparison of “heavy atoms plus OH and SH”.  
 
NOE spectra were obtained for 6 (Figure 5.17), and analysis of this data allowed for the determination of 
the interproton contacts and distances necessary for NAMFIS analysis of the 3630 conformations 
generated (See SI Table for full input and output files). Application of the experimentally determined 
constraints to the conformer pool identified six conformations which together satisfied the conditions of 
the NAMFIS analysis (Table 5.4).  
 

































NOE distances /Å 
Difference /Å 
Experimental Calculated 
1 H31-H38 2.70 2.69 0.01 
2 H38-H40 3.68 3.67 0.01 
3 H37-H40 3.79 3.82 0.03 
4 H28-H38 4.42 4.42 0.00 
5 H28-H35 2.66 2.64 0.02 
6 H28-H30 3.65 3.65 0.00 
7 H29-H30 3.98 4.03 0.05 
8 H29-H35 2.71 2.73 0.02 
Mixing time 180 ms, calibration distance 2.48 Å. 
Of the six conformations identified, four poses are responsible for >95% of the solution population, and 
one of these conformations accounts for almost 50% of the distribution (Table 5.5). When the top two 
conformers are compared, it is interesting to note that the major differences between these conformers 
are the rotation of the benzyl group and the rotation of the α,β-portion, both of which contribute to the 
RMSD value  of 0.64 Å (Figure 5.18).  
Table 5.5. Population distribution and RMSD values of NAMFIS conformers.  





1 6-602 47.21 1.79 1.76 
2 6-1360 21.59 1.61 1.51 
3 6-2492 15.37 1.39 1.34 
4 6-111 11.42 1.56 1.54 
5 6-2456 2.54 2.17 2.36 





Figure 5.18. Overlay of the top NAMFIS-derived conformers 6-602 (shown in purple) and 6-1360 (shown 
in red). 
While comparison of the top conformers is interesting, superposition of these conformations with the 
docked pose of 6 allows for comparison of the predicted solution conformations with the predicted 
docked conformation. An RMSD value of 1.58 Å is obtained when 6-602 is superimposed onto the 
docked pose of 6 in COX-2 (Figure 5.19), and the overlap of 6-602 onto the predicted COX-1 binding 
position, while not as good with an RMSD of 1.76 Å, is still acceptable (Figure 5.20).  
 
Figure 5.19. Overlay of the pose generated for 6 when docked into COX-2 (shown in blue) with the 




Figure 5.20. Overlay of the pose generated for 6 when docked into COX-1 (shown in green) with the 
NAMFIS-derived conformer 6-602 (shown in purple). 
Superposition of 6-1360 with the docked pose of 6 in COX-2 reveals a moderate RMSD of 1.61 Å  
(Figure 5.21), while overlaying the poses of 6-1360 and 6 in COX-1 yields an RMSD value of 1.51 Å 
(Figure 5.22). Despite not overlapping perfectly, the NAMFIS poses are essentially separated by the 
rotation of a single bond, something which could be easily accomplished in binding to a protein.  
 
Figure 5.21. Overlay of the pose generated for 6 when docked into COX-2 (shown in blue) with the 




Figure 5.22. Overlay of the pose generated for 6 when docked into COX-1 (shown in green) with the 
NAMFIS-derived conformer 6-1360 (shown in red). 
The third most prominent conformer 6-2492 (Table 5.5, entry 3) shows the best RMSD values of 1.39 Å 
and 1.34 Å when compared to the poses for 6 when docked into COX-2 and COX-1 respectively. As this 
conformer accounts for 15% of the population, it is possible for this conformer to successfully bind to 
both COX-2 (Figure 5.23) and COX-1 (Figure 5.24). With all of the top four conformations showing RMSD 
values of less than 2 Å for both COX-1- and COX-2-docked 6, it is likely that any one (or all) of these 
conformations could bind into the proteins in vitro. The definitive binding pose, however, can only be 
determined through co-crystallization of the ligand and the protein and subsequent X-ray 
crystallographic analysis, and even then that pose might not be present at observable levels in the 




Figure 5.23. Overlay of the pose generated for 6 when docked into COX-2 (shown in blue) with the 
NAMFIS-derived conformer 6-2492 (shown in purple). 
 
Figure 5.24. Overlay of the pose generated for 6 when docked into COX-1 (shown in green) with the 






5.4. What We Never Knew We Needed to Know: A Review. 
“Education is learning what you didn’t even know you didn’t know.” 
Daniel J. Boorstin 
As one cannot assume that the product obtained from a reaction is the expected product, complete 
spectroscopic analysis of all synthesized compounds must be carried out in order to definitively 
determine the identity of a compound, no matter how sure one is of the outcome of a reaction. As such, 
complete NMR spectroscopic analysis of the synthesized compounds were carried out as a matter of 
course. While appearing daunting, the NMR spectroscopic analysis of the final benzenesulfonate 
compounds can be simplified through the identification and analysis of simpler compounds which are 
components of the final compound. For example, analysis of the unsubstituted 62 allowed for 
identification of the methylene proton and carbon signals, while analysis of 71 and other chalcones 
made the identification of the α,β-unsaturated portion of the final molecule straightforward.  
 
During the course of analysis, broadening of the line widths of methylene peak in the 1H NMR spectrum 
was observed on formation of the ether bond. This broadening indicates that the solution mobility of 
the molecule has changed upon condensation. Based on this observation, DOSY experiments were 
carried out on 125 and 6 in order to determine the diffusion coefficients and hydrodynamic radii for 
these compounds. The experiments carried out on 125 showed that the size of the hydration sphere is 
dependent on the solvent used, while similar experiments carried out on 6 identified a need to take the 
viscosity of the sample into account when calculating the effective radii of compounds rather than using 
literature values for the solvents used. 
 
NAMFIS analysis of 6 identified six conformers from a pool of 3630 potential conformers as existing in 
solution, with four poses comprising >95% of the solution population. While none of the poses identified 
are exact matches when compared to the pose generated for 6 in either COX-1 or COX-2, all but one 
pose show RMSD values of less than 2 Å, which indicates that any of these five conformers could bind 




6. Results and Discussion: Inhibition Screening and 
Selectivity Determination  
 
6.1. When Worlds Collide: Theory Vs. Experiment.  
 “It doesn't matter how beautiful your theory is, it doesn't matter how smart you are. If it doesn't agree 
with experiment, it's wrong.” 
 Richard P. Feynman 
With the hurdles of synthesis and identification successfully navigated, the final challenge in the design 
of these COX-2 selective compounds to be cleared is the in vitro testing to determine whether these 
compounds are in fact selective for COX-2 as desired. One of the easiest methods of COX screening lies 
in the bifunctionality of the COX enzyme, with the COX component first converting arachidonic acid into 
a hydroperoxy endoperoxide (PGG2), which is then reduced to the alcohol (PGH2) by the peroxidase 
element of the enzyme.765-766 Screening of COX activity can be accomplished due to a side reaction of 
PGG2 with 10-acetyl-3,7-dihydroxyphenoxazine (ADHP) which produces resorufin, a highly-fluorescent 
compound (Scheme 6.1). The fluorescence of resorufin can easily be analyzed using an excitation 
wavelength of 530-540 nm and an emission wavelength of 585-595 nm, both ranges which are easily 
accessible using modern plate readers. The presence of fluorescence in a sample indicates that the 
enzyme is active, whereas the reduction or lack of fluorescence indicates that the enzyme has been 
deactivated by an inhibitor. The amount of fluorescence present also allows for determination of the 






































Screening of the 30 synthesized compounds was carried out using a COX Fluorescent Inhibitor Screening 
Assay Kit (Item 700100) from Cayman Chemicals. As the concentration needed was not known, several 
concentrations of 3 were made and tested against both COX-1 and COX-2 proteins (Table 6.1) so as to 
determine an appropriate concentration for further testing. The reference standards DuP-697 and 
SC-560 (Figure 6.1) were included in the testing so as to provide a benchmark for the relative level of 






Table 6.1. Concentration-dependent inhibition of COX-2 and COX-1. 
Entry Compound Concentration /nM 
Percentage Inhibition /% 
COX-2 COX-1 
1 3 100 35 ± 4 12 ± 3 
2 3 50 22 ± 8 0 
3 3 25 20 ± 6 0 
4 3 10 18 ± 5 0 
5 3 5 14 ± 7 0 
6 3 100,000  36 ± 2 19 ± 3 
7 DuP-697 3,000a >90b -c 
8 SC-560 3,300a -c >90b 















Figure 6.1. 2D structures of DuP-697 (left) and SC-560 (right). 
 
At 100 nM, 3 inhibits both COX-2 and COX-1 (Table 6.1, entry 1) at a promising ratio of ca. 3:1, however 
when the concentration is increased 1000-fold to 100 µM (Table 6.1, entry 6), the value for the 
inhibition of COX-2  essentially remains unchanged while the percentage inhibition for COX-1 increases 
significantly from 12% to 19%. This points to the presence of a slightly different kinetic pathway for 
COX-1 than is seen for COX-2, however complete elucidation of these details is beyond the scope of the 
project. While 3 does show COX-2 inhibition at lower concentrations, the standard deviation values 
which accompany the inhibition scores are greater than that observed at 100 nM, and as such are not as 
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reliable. These in vitro results, however, might not necessarily correspond with the inhibition which 
would be seen in vivo. Lumiracoxib, for example, shows a 500-fold greater selectivity for COX-2 over 
COX-1 in vivo, but in vitro it appears as a relatively weak COX-2 inhibitor (ca. 50%).767  
As an initial result, the selectivity observed for 3 is satisfying, as it shows that this drug design 
methodology does work. While one cannot directly compare the in silico results obtained for one 
protein with the results obtained for another, no matter how closely related, it is heartening to see 
some form of selectivity. With the FDA and other agencies being reluctant to grant approval for COX-2 
selective compounds as painkillers due to the associated risk, other avenues, including as potential 
cancer therapeutics, can be explored,668 as a number of cancers have been linked to COX-2 
up-regulation.669-672 PGA1 and PGA2, both COX-2 metabolites, have been shown to bind to the tumour 
growth factor p53 in neuroblastomas, effectively inactivating the apoptotic process governed by this 
factor.673-674 By inhibiting COX-2, p53 function is restored, and the cancerous cells undergo apoptosis. 
COX-2 inhibition has also been shown to prevent the development of colorectal cancers in mice with 
genetic predisposition towards these cancers due to an APC (Adenomatous polyposis coli) gene 
mutation.768 Therefore, should this and other compounds not prove suitable for the roles for which they 




6.2. An Unexpected Turn of Events: When Experiment and Theory Clash. 
“Testing leads to failure, and failure leads to understanding”. 
Burt Rutan 
 
With these satisfying results in hand, the remaining 29 compounds were tested against COX-2 at 100 nM 
(Table 6.2) following the procedures used previously. Despite the optimistic results obtained for 3, only 
two compounds, 56 and 57 (Table 6.2, entries 24 and 26), show comparable inhibition scores, with four 
others showing slight reduction in the degree of inhibition recorded (Table 6.2, entries 16, 25, 28 and 
29). The remaining 23 compounds show significant reduction in the inhibition scores obtained, with a 
number of the substitutions resulting in the complete elimination of inhibition.   
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1 3 35 ± 4 -12.619 -55.772 
2 5 0 -11.436 -92.183 
3 6 0 -11.569 -84.908 
4 7 0 -12.352 -69.067 
5 8 0 -11.898 -94.200 
6 9 0 -11.517 -103.141 
7 43 0 -11.001 -104.953 
8 44 14 ± 3 -12.687 -93.861 
9 10 8 ± 3 -12.570 -93.748 
10 45 4 ± 2 -12.163 -93.155 
11 46 0 -12.362 -90.999 
12 47 6 ± 2 -12.111 -70.669 
13 11 14 ± 2 -12.664 -84.205 
14 48 0 -12.064 -96.677 
15 49 0 -11.973 -99.575 
16 17 28 ± 6 -12.767 -86.607 
17 50 3 ± 1 -12.059 -85.854 
18 51 5 ± 1 -11.654 -89.884 
19 52 2 ± 1 -11.993 -88.717 
20 53 0 -12.681 -90.577 
21 23 0 -11.749 -90.352 
22 54 0 -12.646 -90.856 
23 55 5 ± 2 -12.700 -88.670 
24 56 42 ± 3 -12.394 -72.392 
25 12 20 ± 2 -8.049 -92.404 
26 57 35 ± 4 -11.497 -98.497 
27 58 16 ± 1 -7.813 -88.302 
28 59 28 ± 5 -11.325 -88.670 
29 18 15 ±3 -12.149 -82.327 
30 24 23 ± 4 -11.534 -98.884 
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Comparison of the degree of inhibition to the Prime binding scores obtained showed no obvious 
correlations, with a number of compounds with very good binding scores yielding very poor inhibition 
values, and conversely, a number of low-scoring compounds showing good inhibition. For example, 
compound 43 received the highest binding score (Table 6.2, entry 7), however it shows no inhibition in 
vitro, while compound 56, which has a comparatively poor score, shows an inhibition value of over 40% 
(Table 6.2, entry 24). This discrepancy highlights one of the major shortcomings of using 
computationally-derived data as the sole basis for lead compound identification – in silico binding and 
docking scores are calculated based on poses generated from a user-restricted portion of the protein 
and does not take into account in vitro conditions present. Comparison of the poses generated for these 
compounds with that generated for 3 does not illuminate a reason for the incongruity either – apart 
from the poses for compounds 12, 58 and 59, which show inversion, the poses overlap very well with 
the pose calculated for 3. In this case, the computational model does not appear to accurately describe 
the mode of inhibition observed, and further studies are required in order to ascertain a link between 
the theoretical and experimental data.   
 
It is possible that interactions between the ligand and the protein occur at sites other than the active 
site, and these compounds are therefore allosteric inhibitors rather than competitive inhibitors,769 as is 
the case of Pfizer’s maraviroc (Selzentry®), an antiretroviral compound which acts as a negative 
allosteric CCR5 modulator.770 Allosteric compounds act by binding to allosteric sites, often resulting in 
conformational changes to the protein, which can either enhance or reduce the activity of the protein 
(Figure 6.2). While COX-2 is a homodimer of two tightly-associated monomers with apparently identical 
primary structures, each monomer has a unique function, with one monomer responsible for the 
conversion of arachidonic acid into PGH2, while the other functions as an allosteric monomer.621,771-774 
Irrefutable proof as to the location of the inhibitor within the protein however would only be gained 
through the X-ray spectroscopic study of a co-crystallized protein-ligand complex, a delicate and pain-




Figure 6.2. Allosteric inhibition of proteins.775 
As a number of the compounds tested show COX-2 inhibition as intended, these compounds were also 
screened against COX-1 in order to determine the potential selectivity. Even with the promising results 
obtained for 3, all of the additional compounds show significant COX-1 inhibition (Table 6.3). As was the 
case with the inhibition scores for COX-2, there does not appear to be a link between either the Glide XP 
docking or the Prime binding scores and the degree of inhibition observed, with low-scoring compounds 
showing good inhibition, and high-scoring compounds yielding inhibition scores much lower than 
expected. This lack of congruency between the computationally-derived docking and binding scores and 
the experimental data again illustrates the need for additional testing and study in order to identify a 
method of prediction which could be applied to additional work on these and other compounds. Again, 
it is possible that these compounds are allosteric rather than competitive inhibitors, as a similar 











1 3 12 ± 3 -10.572 -74.414 
2 5 47 ± 2 -11.767 -89.066 
3 6 35 ± 2 -11.223 -85.836 
4 7 32 ± 1 -6.414 -81.389 
5 8 32 ± 2 -9.625 -94.815 
6 9 23 ± 1 -11.667 -79.280 
7 43 22 ± 2 -11.120 -86.983 
8 44 62 ± 2 -5.040 -77.147 
9 10 62 ± 1 -10.102 -80.341 
10 45 56 ± 1 -10.709 -89.088 
11 46 43 ± 2 -11.556 -78.554 
12 47 32 ± 4 -10.590 -75.929 
13 11 27 ± 5 -10.416 -61.886 
14 48 32 ± 2 -12.223 -82.510 
15 49 24 ± 2 -12.093 -81.847 
16 17 65 ± 7 -11.841 -68.525 
17 50 64 ± 8 -10.797 -71.438 
18 51 58 ± 1 -10.684 -92.570 
19 52 60 ± 1 -10.825 -86.733 
20 53 60 ± 2 -4.324 -82.781 
21 23 45 ± 2 -12.126 -91.369 
22 54 40 ± 3 -11.267 -88.617 
23 55 34 ± 5 -11.441 -87.202 
24 56 80 ± 2 -9.992 -76.870 
25 12 87 ± 2 -11.635 -83.947 
26 57 71 ± 4 -9.624 -86.845 
27 58 71 ± 3 -9.927 -97.391 
28 59 61 ± 4 -11.530 -92.396 
29 18 50 ± 5 -11.321 -76.413 
30 24 58 ± 4 -10.353 -102.856 
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6.3. Gazing into the Crystal Ball: The Future of Isoform-Selective Coxibs.  
“Only you can control your future”.  
Dr Seuss 
While these results do not show the desired results, they do open avenues into the development of a 
non-selective, non-steroidal COX inhibitor, similar in action to the “general” painkillers such as aspirin 
and ibuprofen. With the sales of painkillers totaling almost $4 billion in 2012,681 there is a large market 
for over-the-counter analgesics, and a number of compounds tested show promise as both COX-1 
(Table 6.2, entries 24-30) and COX-2 inhibitors (Table 6.1, entries 24-30). The hypothesis that COX-2 is 
solely responsible for inflammation has been questioned by a number of investigations, and current 
belief is that both isoforms are responsible for pain.779-782 COX-1 is thought to be to blame for the initial 
prostanoid response to tissue injury, whereas COX-2 is responsible for the long-term synthesis of 
prostaglandins,783-786 and as such a dual inhibitor would allow for the reduction of both the immediate 
and sustained pain felt after injury. Non-selective COX inhibitors could also be used as anti-cancer 
agents, as a number of studies have shown that non-selective celecoxib analogues have significant anti-
cancer activities, with the potency of a compound not having any correlation with selectivity.675-678 The 
use of non-selective compounds as cancer therapeutics is not without precedence - ketorolac 
(Figure 6.3), a heterocyclic acetic acid derivative, is a non-selective NSAID which has shown the ability to 
reduce the recurrence of breast cancers when administered perioperatively,787 and the more common 






Figure 6.3. 2D structure of ketorolac. 
Another interesting opportunity arises in the potential development of a COX-1 selective compound. 
Despite not being a major focus in the fight against pain in recent years, increased or over-expression of 
COX-1 is involved in a number of other conditions and diseases, and a targeted COX-1 inhibitor might aid 
in combating these diseases as well as acting as a painkiller. COX-1 is involved in post-surgery pain 
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processing,789 and COX-1 inhibitors, administered spinally either before or after surgery, have allowed 
for the treatment of post-operative pain.790-791 Interestingly, similar administration of COX-2 selective 
compounds showed no effect on prostaglandin synthesis.791 Compounds such as 23 and 50-54 show very 
little, if any, COX-2 inhibition (Table 6.1, entries 17-22) while showing good inhibition of COX-1 
(Table 6.2, entries 17-22), and would be suitable candidates for further exploration and additional 
testing. The use of a COX-1 selective pain-relieving compound is not unprecedented, as Mofezolac®, an 







Figure 6.4. 2D structure of Mofezolac®, a COX-1 selective analgesic. 
As previously stated, the COX enzymes are responsible for more than just pain. Inhibition of COX-1 has 
also been shown to have a cardio-protective effect in low doses, much the same as is observed for low 
doses of aspirin. COX-1-derived prostanoids play a vital part in the hardening of arteries associated with 
atherosclerosis and atherothrombosis. Thromboxanes, responsible for the aggregation of platelets and 
for platelet-vessel interactions, are dependent on platelet COX-1 expression,793-794 and inhibition of COX-
1 would reduce the ability of platelets to aggregate into atherosclerotic plaques. Non-aspirin-based COX-
1 inhibitors, such as the compounds presented above, would also allow for the treatment of 






Another potential role for a COX-1 selective inhibitor is as an anti-cancer drug. COX-1 is overexpressed in 
ovarian cancer, where it promotes the production of angiogenic growth factor,795 and is up-regulated in 
a number of cancers, including human breast796 and prostate cancers,797 and in murine lung 
tumorigenesis models,798 as well as in  squamous cell carcinoma and human cervix adenocarcinoma.799  
Finally, microglia-localized COX-1 plays a vital role in neuroinflammation, a key stage in the development 
of a number of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, 
HIV-associated dementia, and is a contributor to the effects of brain injury due to trauma, ischemic 
stroke or epilepsy. Both pharmacological inhibition and genetic negation of COX-1 activity reduces the 
inflammatory response, and also reduces neuronal loss.800 This indicates that a NSAID which shows 
greater selectivity for COX-1 over COX-2 is more likely to reduce the neuroinflammation observed in 
these disorders,800 and a COX-1 selective compound, such as those examined here, could provide a new 
therapeutic approach to neurodegenerative disorders where neuroinflammation is a large component.  
 
One aspect which has not been addressed during the analysis of these compounds is the 
time-dependent nature of COX inhibitors. These analyses were carried out using the incubation times 
recommended by the manufacturer, however as altering these times can significantly alter the values 
obtained, determination of the optimal incubation times for each compound tested would be ideal. It is 
possible that a compound which shows poor inhibition under these conditions might prove to be a good 
inhibitor with an adjusted incubation period. Prescreening optimization is economically unviable with 
the number of compounds tested, but the importance of determining the correct timing for these 






6.4. What We Never Knew We Needed to Know: A Review. 
“Get your facts first. Then you can distort them as you please.” 
Mark Twain 
While the search for a novel COX-2 selective inhibitor is perhaps not as clear-cut as hoped, these results 
demonstrate the ability of these compounds to inhibit the COX enzymes, and in the case of 3, to 
selectively inhibit COX-2 three times more effectively than COX-1 (ca. 3:1) at 100 nM. This unsubstituted 
3 shows potential as a COX-2 selective compound, while a number of the compounds show promise as 
COX-1 selective compounds, including 23 and 50-54, with inhibition scores of over 40%. In addition to 
these isoform-selective compounds, several compounds show potential as non-selective NSAIDs, such as 
12 and 56-58. As there does not appear to be a correlation with either the Glide XP binding scores or the 
Prime docking scores obtained for these compounds, further analysis, both in silico and in vitro, is 
required to determine whether the inhibition observed arises due to interaction of the compounds with 
the COX active site, or whether allosteric inhibition is responsible for the activity observed.  
 
Should these compounds not prove suitable as either COX-1 or COX-2 selective analgesic compounds, 
there are a number of external opportunities where these compounds might prove useful. 
Overexpression of COX-2 has been linked to increased cell growth and a number of cancers,668-672 such 
as neuroblastomas,673 and inhibition of COX-2 allows for the restoration of tumour apoptosis factor p53 
activity and subsequent cell death through apoptosis.674 Coxibs have also been shown to act as 
anti-cancer agents even when the malignant cells do not contain COX-2,675,679 and this is also true for 
non-selective compounds as well.676-678  COX-1 selective compounds are not limited to analgesic uses – a 
number of cancers show up-regulation of this protein,796-799 and COX-1-derived prostaglandins have 
been identified in several neuroinflammatory diseases and disorders.800 Whether these compounds will 
prove to be suitable drug candidates will depend on the results of additional extensive testing and 







“Enjoy the journey of life and not just the endgame.” 
Benedict Cumberbatch 
The search for effective non-steroidal anti-inflammatory compounds without serious side effects is an 
ongoing one, and with the failure of High-Throughput Screening (HTS) in providing new drug-like 
compounds, many researchers are returning to the world of natural products and their derivatives in 
order to identify new lead compounds. One compound which has been the focus of much investigation 
is curcumin, the diferuloyl methane compound found in turmeric. This compound was chosen as a 
model for compounds which would selectively target the inducible form of cyclooxygenase (COX), the 
enzyme responsible for the first step in the conversion of arachidonic acid into the various 
prostaglandins and thromboxanes in the inflammatory process. An in silico investigation into the binding 
of curcumin and celecoxib, a known COX-2 selective analgesic compound, was conducted and important 
ligand-protein interactions were identified which would need to be mimicked by a novel COX-2 selective 
compound. However, as the docking and binding scores for celecoxib when docked into COX-2 are 
similar to the results obtained on docking into COX-1, computational results cannot be the sole criterion 
used when identifying a potential lead compound, as literature reports celecoxib showing 10-20-fold 
selectivity for COX-2 over COX-1 in vivo.  
 
Based on these results, two potential COX-2 selective compounds were designed using moieties found in 
curcumin as well as moieties common to celecoxib and other known COX-2 selective compounds. Initial 
docking results showed that both compounds interact with the secondary pocket present in COX-2 as 
desired, and a number of ligand-protein interactions are made that mimic those seen between celecoxib 
and COX-2, while also identifying the potential for improvement, both in docking and binding scores as 
well as with interactions between the protein and the ligands. Therefore, a range of modifications were 
made to these two parent compounds in order to explore the impact of the various substitutions on the 
docking and binding scores and on the protein-ligand interactions. In all cases, the modifications 
resulted in an increase in the COX-2 binding scores when the scores were compared to that calculated 
for the parent compound, and in a few cases, reductions in the COX-1 binding scores were observed. 
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Thirty of the 166 compounds designed were selected for synthesis and biological screening as these 
compounds exemplified the range of changes observed in the full complement of compounds.  
 
Retrosynthetic analysis identified two potential routes involving simple chemistry, which would allow for 
the formation of the correct Z-isomer about the double bond. The initial synthetic route, which involved 
the formation of the double bond through a base-catalysed condensation of an acetophenone with a 
benzaldehyde prior to the formation of the ether bond proved unsuccessful as the base-catalyzed 
intramolecular reaction of the chalcones yielded a flavanone rather than the desired benzyl ether, and 
as such this pathway was abandoned in favour of the alternate pathway. Early investigations into this 
second synthetic pathway, which involved the formation of the ether bond prior to the base-catalyzed 
condensation, yielded the correct benzylated compound in high yields, however the addition of the 
sulfonyl chloride moiety proved unsuccessful, with low yields and addition to other positions within the 
molecule observed. At the outset, use of a benzenesulfonyl chloride compound in order to circumvent 
the need for chlorosufonic acid resulted in the formation of a tosyl derivative, rather than the desired 
ether. Conversion of the sulfonyl chloride into a sulfonate or sulfonamide prior to the ether formation 
yielded “protected” species, however the protected sulfonamide proved too insoluble to be of use.  
 
High yields were obtained when an ethyl-protected benzenesulfonate was combined with three 
4-substituted 2’-hydroxyacetophenone, however, the corresponding 5-substituted 
2’-hydroxyacetophenone proved too unstable and rapid decomposition was observed even with the use 
of milder reaction conditions. Removal of the ethyl protecting group occurs during the ether formation 
reaction; nevertheless this does not affect the subsequent condensation. The current understanding of 
this reaction is that the ethyl-protected sulfonate species is the reactive species, with the ethyl group 
removed after ether formation. This hypothesis is supported by the lack of intermolecular addition 
between two benzenesulfonate molecules, as would be expected if the ethyl group is removed prior to 
ether formation. With suitable reactions and conditions identified, the synthesis of the thirty 
compounds previously identified was perfomed, using three 2’-hydroxyacetophenones and twelve 
benzaldehydes, in moderate to good yields. These products were isolated cleanly with only simple 




Complete spectroscopic analysis of all synthesized compounds was carried out in order to definitively 
determine the identity of all the compounds. While appearing daunting, the NMR spectroscopic analysis 
of the final benzenesulfonate compounds was simplified through the identification and analysis of 
simpler compounds which are components of the final compound. During the course of analysis, 
broadening of the line widths of methylene peak in the 1H NMR spectrum was observed on formation of 
the ether bond, indicating a change in the solution mobility of the compound. DOSY experiments were 
carried out on two compounds, and the diffusion coefficients and hydrodynamic radii were determined 
for both compounds. The size of the hydration sphere was shown to be solvent-dependent, and a need 
for the determination of the viscosity of the solution used for the DOSY experiments was identified, as 
effective radius calculations make use of literature viscosity values, rather than taking into account the 
viscosity of the solution under investigation.   
 
In order to identify the conformations present in solution, NMR Analysis of Molecular Flexibility In 
Solution (NAMFIS) made use of NOE correlations to identify six conformers as existing in solution, from a 
pool of 3630 potential conformations. Of these six conformers, four poses comprise >95% of the 
solution population, with one pose comprising almost 50%. While none of the poses are exact matches 
when compared to the pose generated for 6 in either COX-1 or COX-2, all but one pose show RMSD 
values of less than 2 Å, which indicates that any of these five conformers could bind into the proteins. 
 
Initial inhibition screening results of the unsubstituted parent benzenesulfonate compound appeared to 
show three-fold selectivity of COX-2 over COX-1 at 100 nM. Testing of the substituted compounds 
revealed that these compounds are not COX-2 selective as desired, rather a number show promise as 
COX-1 selective compounds, with inhibition scores of over 40%, and several other compounds show 
potential as non-selective COX inhibitors. There appears to be no correlation between the inhibition 
results and either the Glide XP docking scores or the Prime binding scores, and as such, additional 
computational analysis as well as experimental testing is required to identify a correlation between the 
theoretical results and the experimental data. It is possible that these compounds could behave 
differently in vivo than is observed in vitro, as is the case for lumiracoxib, and it is also possible that the 
mode of inhibition is allosteric in nature, rather than the competitive inhibition model used here. Should 
these compounds not prove suitable as analgesic compounds, a number of alternative uses exist for 
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COX-isoform selective and non-selective compounds, ranging from cancer treatments to the reduction 























8. Future Work 
“End? No, the journey doesn't end here. Death is just another path, one that we all must take. The grey 
rain-curtain of this world rolls back, and all turns to silver glass, and then you see it.” 
Gandalf, Lord of the Rings. 
Research of any kind, especially in science, often yields more questions than answers, and the research 
presented here is no exception. As such, there is significant scope for future work based on the results 
obtained during this project. Questions which have arisen include the suitability of the current 
computational model in describing the binding observed in vitro, as the results obtained during the in 
silico calculations do not appear to correlate with those obtained during the inhibition study. Additional 
work, with regards to both computational and experimental aspects, is therefore required to gain more 
understanding into the binding of these compounds to the proteins. Once a suitable model has been 
identified, work on an additional series of compounds, which make use of an imine rather than a 
carbonyl moiety (Figure 8.1) can be carried out, as the presence of a primary imine would allow for the 
formation of an additional hydrogen bond to the protein. Imine-containing compounds have also shown 
promise as antiplasmodial drugs during the liver stage of malaria,801 and as vasorelaxants and platelet-









Figure 8.1. Imine-based analogs.  
With reference to the challenges met during the synthesis of the benzenesulfonamide compounds, 
protection of the amine could be accomplished using a propanamide group (Figure 8.2), as is seen in the 
commercially-available pro-drug parecoxib. This propanamide group of parecoxib is cleaved in vivo by 
hepatic enzyme hydrolysis,648 yielding the active sulfonamide drug valdecoxib. Synthesis of the 
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propanamide-protected compound 136 could be achieved through the reaction of propanamide 137 
and tosyl chloride 113 under similar conditions as those used for the formation of the 
phthalamide-protected 125, or through the protection of the sulfonamide 113 with propanoyl chloride 
138 (Scheme 8.1).  



















One of the advantages to using programs such as NAMFIS is that the conformation and population 
results can be verified though comparison of the experiment NMR spectra with spectra based on the 
individual conformations. Programs such as Gaussian are able to compute theoretical 1H and 13C NMR 
peaks based on the conformations  identified by NAMFIS, and, if the NAMFIS calculations are correct, 
the experimental and theoretical spectra should correlate well. Calculation of the predicted NMR 
spectra for 6 using the conformations identified through NAMFIS analysis, and comparison of these 
predicted spectra with the experimentally-derived spectra would allow for the confirmation of the 
NAMFIS results.  
 
As previously stated, COX inhibitors often show time-dependant inhibition, and as such, an investigation 
into the time-dependent nature of the compounds is needed. This, along with additional concentration-
dependent testing, could identify potential COX-isoform selective compounds which do not appear as 
valid leads under the current testing conditions. As in vitro testing results do not always correlate with 
the results seen in in vivo testing, cell-based assaying of the compounds would allow for a more 
complete picture of the selectivity and potency of these compounds, while ADME and toxicity 
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calculations would aid in the identification of leads, and screening of these compounds against other 






















9. Methods and Materials 
 
9.1. General Information. 
1H, 13C, 15N and 19F NMR spectra were recorded on either a Bruker Avance III 500 or Bruker Avance III 
400 spectrometer at frequencies of 500 MHz/400 MHz (1H), 125 MHz/100 MHz (13C), 51 MHz (15N) and 
376 MHz (19F) using one of a 5 mm BBOZ probe 19F-31P-109Ag-{1H}, 5 mm BBIZ probe 1H-{31P-109Ag}, 
or a 5 mm TBIZ probe 1H-{31P}-{31P-103Rh}. All proton and carbon chemical shifts are quoted in ppm 
and are relative to the relevant solvent signal (e.g. DMSO-d6: 1H, 2.50 ppm, 13C, 39.50 ppm; D2O: 1H, 
4.72 ppm; CDCl3: 1H, 7.26 ppm, 13C, 77.00 ppm). Proton-proton coupling constants are reported in Hertz. 
All experiments were conducted at 30 °C unless specified otherwise. High-resolution Mass Spectrometry 
was carried out on a Waters Acquity UPLC + LCT Premier TOF-MS, with either electrospray (ES) or 
atmospheric pressure chemical ionization (AP) acquisition modes in either + or - mode. Single crystal X-
ray diffraction data was collected on either a Bruker Apex II Duo diffractometer fitted with IµS 
microsources (Cu and Mo) and Quasar mirror opticts, or on a Bruker Smart Apex II diffractometer with a 
Mo fine focus sealed tube source. Crystals were mounted in Paratone® oil on either a 100 micron or 200 
micron MiTeGEN cryoloop. Multiscan absorption corrections were used, amd all unit cell data and full 
sets of intensities were collected at 100(1) K using a Mo radiation source. Melting points were recorded 
on a Stuart SMP3 melting point apparatus, and are uncorrected.  
 
1H diffusion (DOSY) experiments were performed using a high-resolution 5 mm BBOZ probe 
19F-31P-109Ag-{1H}, with a gradient calibration of 5.35 G/mm. Diffusion time and gradient pulse length 
calibrations were adjusted for 90-95 % signal attenuation between gradient strengths 5 % and 95 % 
(2.7 G/cm and 50.8 G/cm) using the ledbpgp2s1d pulse program, with diffusion times in the range of 
150 - 250 ms and gradient pulse lengths between 1200 and 1500 µs. Diffusion measurements were 
conducted at a regulated sample temperature of 30 ˚C using the ledbpgp2s 
(longitudinal-eddy-current-delay-bipolar-gradient-pulse-2-spoil-graidents) pulse program808 with 16 
linearly spaced steps between the starting and final gradient levels.  NOE spectra were acquired using a 
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standard gradient NOE pulse program (noesygpph). Data were processed with the diffusion software of 
Topspin 2.1pl6.  
Molecular docking and binding studies were carried out using Schrödinger Small-Molecule Drug 
Discovery Suite, Version 2014-2, on a desktop computer with an Intel™ Core™2 Quad 2.5 GHz processor 
with 8GB RAM on a Windows®7 (64-bit) platform. Protein crystal structures (3LN1 and 3KK6) were 
downloaded from the RSC Protein Database website (http://www.rcsb.org/pdb/home/home.do) and 
prepared using the “Protein Preparation Wizard” within the Schrödinger Maestro suite, prior to the 
creation of the receptor grid from the coordinates of the bound ligand. All compounds were prepared 
using the “LigPrep” application prior to docking with Glide XP using default settings. The poses were 
then rescored using Prime to generate MM/GBSA scores, with protein flexibility set at 4.0 Å. The 
conformational search for NAMFIS analysis was carried out using Macromodel, with either MMFF or 
OPLS-2005 used as the forcefield, and in either chloroform or water. The GBSA constant dielectric model 
was applied within an energy window of 21.0 kJ/mol (5.02 kcal/mol). Minimization of the four sets of 
conformations into final conformer pool of 3630 structures was performed with 
full-matrix-Newton-Raphson (FMNR) minimization (OPLS-2005, H2O) within the same energy window 
(21 kJ/mol) on a comparison of “heavy atoms plus OH and SH”. NAMFIS comparisons were carried out 
using NAMFIS 2.5.0 on a 64-bit CentOS (5.8) Linux platform via a series of Python 2 scripts.   
 
All chemicals were purchased from Sigma-Aldrich or Merck and used without further purification. The 
COX Fluorescent Inhibitor Screening Assay (Cayman Chemical, item 700100) was purchased from 
BIOCOM Biotech and used as directed, with compounds dissolved in distilled water. Fluoresence was 
recorded using a Perkin Elmer EnSpire 2300 Multimode Reader with irradiation at 535 nm and emission 









9.2. Synthesis and Analysis. 
 
1-[2-(benzyloxy)phenyl]ethanone (62)698    
To a suspension of K2CO3 (0.691 g, 5 mmol) in MeCN (30 ml) was added 2’-hydroxyacetophenone 60 
(0.681 g, 5 mmol) and benzyl bromide 61 (0.885 g, 5 mmol), and the solution was heated to reflux for 24 
h.695-697 The solution was cooled, filtered and the solvent removed in vacuo to yield a clear, pale yellow 
solid (1.011 g, 89%). 1H NMR (DMSO-d6): δ 2.51 (s; 3 H; CH3), 5.24 (s; 2 H; CH2), 7.03 (td; J = 7.48, 0.92; 1 
H; CH-CH-Cq-Cq=O), 7.26 (dd; J = 8.40, 0.64; 1 H; CH-Cq-O), 7.33-7.37 (m; 1 H; CH-CH-CH-Cq-CH2), 
7.40-7.43 (m; 2 H; CH-CH-Cq-CH2), 7.50-7.54 (m; 3 H; CH-Cq-CH2 and CH-CH-Cq-O), 7.60 (dd; J = 7.68, 1.84; 
1 H; CH-Cq-Cq=O). 13C NMR (DMSO-d6): δ 31.64 (s; 3 H; CH3), 69.99 (s; 2 H; CH2), 120.55 (d; 1 C; CH-CH-Cq-
Cq=O), 113.59 (d; 1 C; CH-Cq-O), 127.95 (d; 1 C; CH-CH-CH-Cq-CH2), 128.45 (d; 2 C; CH-CH-Cq-CH2), 127.78 
(d; 2 C; CH-Cq-CH2), 128.25 (s; 1 C; Cq-Cq=O), 129.47 (d; 1 C; CH-Cq-Cq=O), 133.59 (d; 1 C; CH-CH-Cq-O), 
136.45 (s; 1 C; Cq-CH2), 157.39 (s; 1 C; Cq-O), 198.80 (s; 1 C; Cq=O). HRMS: Calculated mass for C15H14O2Na 
249.0891; mass found 249.0895. M.P 40-41 ˚C (Lit809 41-42 ˚C). 
 
4-methylbenzenesulfonamide (66)702   
 To a solution of THF (10 ml) and aqueous ammonia (5 ml) on ice was added sulfonyl chloride 65 (0.192 g 
1 mmol), and the reaction was stirred on ice for 2 h. EtOAc (10 ml) and H2O (5 ml) were added, and the 
resultant layers were separated. 703 The organic layer was dried with Na2SO4 and the solvent removed in 
vacuo without heat to yield a white solid (0.144 g, 84%). 1H NMR (DMSO-d6): δ 2.38 (s, 3 H, CH3); 7.25 
(br.s, 2 H, NH2); 7.36 (d, J = 8.2, 2 H, 2x CH-Cq-S); 7.71 (d, J = 8.2, 2x CH-Cq-CH2). 13C NMR (DMSO-d6): δ 
21.36 (q, 1 C, CH3); 126.08 (d, 2 C, 2x CH-Cq-CH2); 129.74 (d, 2 C, 2x CH-Cq-S); 141.92 (s, 1 C, Cq-CH2); 
142.29 (d, 1 C, Cq-S). 15N NMR (DMSO-d6): δ 95.4. HRMS: Calculated mass for C7H9O2NS 171.0354 mass 
found 170.0273 for C7H8O2NS (M-1). M.P 134-136 ˚C (Lit810 135-137 ˚C).  
 
General Procedure for Chalcone Synthesis: Method A.700    
The appropriate 2’-hydroxyacetophenone (1 mmol) and the appropriate benzaldehyde (1 mmol) were 
added to a stirred solution of KOH (0.112 g, 2 mmol) in abs EtOH (10 ml), and stirred at room 
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temperature for 18 h. Acidification of the yellow solution with HCl (conc) yielded a yellow precipitate 
which was removed by filtration and allowed to air dry.  
 
Method B.715   
To a stirred suspension of NaH (0.048 g, 2 mmol) in dry THF (16 ml) under N2 at 0˚C was added a solution 
of the appropriate 2’-hydroxyacetophenone (1 mmol) in dry THF (2ml), followed by a solution of the 
appropriate benzaldehyde (1 mmol) in dry THF (2 ml). The resulting pale yellow suspension was stirred 
at 0˚C for 4 h. H2O (10ml) was added to quench the reaction, and the resultant yellow solution was 
extracted with 3x 20 ml portions of CHCl3. The organic layers were combined and dried with Na2SO4, and 
the solvent was removed in vacuo, yielding a yellow solid.  
 
 (2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one (68)704    
Method A, 2’-hydroxyacetophenone 60 (0.136 g, 1 mmol) and benzaldehyde 67 (0.106 g, 1 mmol) 
afforded 68 as a yellow solid (0.193 g, 86%). 1H NMR (DMSO-d6): δ 7.01 (d, J = 8.3, 1 H, CH-Cq-O); 7.02 (t, 
J = 7.1, CH-CH-Cq-Cq); 7.48-7.49 (m, 3 H, 2x CH-CH-Cq-CH and CH-CH-CH-Cq-CH=CH); 7.57 (td, J = 7.7, 1.4, 
CH-CH-Cq-O); 7.84 (d, J = 15.5, 1 H, CH-CH-Cq=O); 7.83-7.92 (m, 2 H, 2x CH-Cq-CH=CH); 8.03 (d, J = 15.5, 
CH-Cq=O); 8.26 (d, J = 8.3, CH-Cq-Cq); 12.45 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 117.66 (d, 1 C, CH-Cq-
O); 119.12 (d, 1 C, CH-CH-Cq-Cq); 120.76 s, 1 C, Cq-Cq=O); 121.81 (d, 1 C, CH-Cq=O); 128.90 (d, 2 C, 2x 
CH-Cq-CH=CH or 2x CH-CH-Cq-CH=CH); 129.08 (d, 2 C, 2x CH-Cq-CH=CH or 2x CH-CH-Cq-CH=CH); 130.81 
(d, 1 C, CH-Cq-Cq or CH-CH-CH-CH-CH); 130.89 (d, 1 C, CH-Cq-Cq or CH-CH-CH-CH-CH); 134.39 (s, 1 C, Cq-
CH=CH); 136.24 (d, 1 C, CH-CH-Cq-O); 144.69 (CH=CH-Cq=O); 161.73 (s, 1 C, Cq-O); 193.56 (s, 1 C, Cq=O). 
HRMS: Calculated mass for C15H12O2 224.0837; mass found 225.0914 for C15H13O2 (M+1). M.P 89-90 ˚C 
(Lit811 90-91 ˚C). 
 
 (2E)-3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (69)699  
Method A; 2’-hydroxyacetophenone 60 (0.138 g, 1 mmol) and benzaldehyde 63 (0.185 g, 1 mmol) 
afforded 69 as a yellow solid (0.282 g, 93%). 1H NMR (DMSO-d6): δ 7.00 (d, J = 8.4, 1 H, CH-Cq-O); 7.01 (t, 
J = 7.1, 1 H, CH-CH-Cq-Cq); 7.57 (td, J = 7.8, 1.5, 1 H, CH-CH-Cq-O); 7.68 (d, J = 8.4, 2 H, 2x CH-Cq-Br); 7.80 
(d, J = 15.5, 1 H, CH=CH-Cq=O); 7.88 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Br); 8.24 (d, J = 8.2, 1 H, CH-Cq-Cq); 12.39 
(br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 117.67 (d, 1 C, CH-Cq-O); 119.14 (d, 1 C, CH-CH-Cq-Cq); 120.75 (s, 
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1 C, Cq-Cq=O); 122.67 (d, 1 C, CH-Cq=O); 124.30 (s, 1 C, Cq-Br); 130.86 (d, 1 C, CH-Cq-Cq); 130.95 (d, 2 C, 
2x CH-CH-Cq-Br); 131.89 (d, 2 C, 2x CH-Cq-Br); 133.71 (Cq-CH=CH-Cq=O); 136.34 (d, 1 C, CH-CH-Cq-O); 
143.34 (d, 1 C, CH=CH-Cq=O); 161.72 (s, 1 C, Cq-O); 193.45 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C15H11O2Br 301.9942; mass found 300.9866 for C15H10O2Br (M-1). M.P 137-139 ˚C (Lit699 138-139 ˚C). 
  
 (2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (71)699  
 Method A; 2’-hydroxyacetophenone 60 (0.133 g, 1 mmol) and benzaldehyde 70 (0.146 g, 1 mmol) 
afforded 71 as a yellow solid (0.238 g, 92%). 1H NMR (DMSO-d6): δ 6.99 – 7.02 (m, 2 H, CH-Cq-OH and 
CH-CH-Cq-Cq=O); 7.53 (d, J = 8.5, 2 H, 2 x CH-Cq-Cl); 7.55 – 7.58 (m, J = 7.7, 1 H, CH-CH-Cq-OH); 7.81 (d, 
J = 15.6, 1 H, CH=CH-Cq); 7.94 (d, J = 8.5, 2 H, 2 x CH-Cq-CH=CH); 8.04 (d, J = 15.6, 1 H, O=Cq-CH=CH); 8.24 
(dd, J = 8.3, 1.6, 1 H, CH-Cq-Cq=O); 12.43 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 117.67 (d, 1 C, CH-Cq-OH); 
119.11 (d, 1 C, CH-CH-Cq-Cq=O); 120.70 (s, 1 C, Cq-C=O); 122.54 (d, 1 C, CH=CH-Cq=O); 128.93 (d, 2 C, 2 x 
CH-Cq-Cl); 130.74 (d, 2 C, 2 x CH-Cq-CH=CH); 130.85 (d, 1 C, CH-Cq-Cq=O); 133.37 (s, 1 C, Cq-CH=CH-Cq=O); 
135.40 (s, 1 C, Cq-Cl); 136.32 (d, 1 C, CH-CH-Cq-OH); 143.15 (d, 1 C, CH=CH-Cq=O); 161.78 (s, 1 C, Cq-OH); 
193.43 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H11O2Cl 258.0447; mass found 257.0361 for 
C15H10O2Cl (M-1). M.P 147-148 ˚C (Lit699 148-150 ˚C). 
 
 
 (2E)-3-(4-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (73)705   
 Method A; 2’-hydroxyacetophenone 60 (0.132  g, 1 mmol) and benzaldehyde 72 (0.124 g, 1 mmol) 
afforded 73 as a yellow solid (0.179 g, 73%). 1H NMR (DMSO-d6): δ 6.99 (d, J = 7.8, 1 H, CH-Cq-O); 
7.08-7.13 (m, 1 H, CH-CH-Cq-Cq=O); 7.29 (t, J = 8.9, 1 H, 1 of 2 CH-Cq-F); 7.31 (t, J = 8.8, 1 H, 1 of 2 
CH-Cq-F); 7.53-7.58 (m, 1 H, CH-Cq-Cq=O); 7.59-7.63 (m, 2 H, 1 of 2 CH-CH-Cq-F and CH-CH-Cq-O); 7.83 (d, 
J = 14.9, 1 H, CH=CH-Cq=O); 7.96-8.04 (m, 2 H, CH-Cq=O and 1 of 2 CH-CH-Cq-F); 12.49 (br.s, 1 H, OH). 13C 
NMR (DMSO-d6): δ 115.30 (dd, 2J19F-13C = 21.6, 1 C, 1 of 2 CH-Cq-F); 115.93 (dd, 2J19F-13C = 20.8, 1 C, 1 of 2 
CH-Cq-F); 117.95 (d, 1 C, CH-CH-Cq-Cq=O); 118.83 (d, 1 C, CH-Cq-O); 120.57 (s, 1 C, Cq-Cq=O); 120.88 (s, 1 
C, Cq-CH=CH-Cq=O); 121.46 (d, 1 C, CH-Cq=O); 128.84 (dd, 3J19F-13C = 8.4, 1 C, 1 of 2 CH-CH-Cq-F); 131.44 
(dd, 3J19F-13C = 6.9, 1 C, 1of 2 CH-CH-Cq-F); 136.16 (d, 1 C, CH-CH-Cq-O); 143.21 (d, 1 C, CH=CH-Cq=O); 
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160.94 (s, 1 C, Cq-O); 163.38 (d, 1J19F-13C = 248.7, 1 C, Cq-F); 193.40 (s, 1 C, Cq=O). HRMS: Calculated mass 
for C15H11O2F 242.0743; mass found 241.0667 for C15H10O2F (M-1). M.P 114-115 ˚C (Lit705 115-117 ˚C). 
 
 (2E)-3-(2-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (75)706   
Method A; 2’-hydroxyacetophenone 60 (0.135 g, 1 mmol) and benzaldehyde 74 (0.147 g, 1 mmol) 
afforded 75 as a yellow solid (0.201 g, 78%). 1H NMR (DMSO-d6): δ 7.01 (t, J = 7.2, 1 H, CH-CH-Cq-Cq); 
7.02 (d, J = 8.1, 1 H, CH-Cq-O); 7.44-7.52 (m, 2 H, CH-Cq-Cl and CH-CH-Cq-Cq-Cl); 7.57 (t, J = 7.6, 1 H, 
CH-CH-Cq-O); 7.58 (d, J = 7.6, 1 H, CH-CH-Cq-Cl); 8.05 (d, J = 15.5, 1 H, CH=CH-Cq=O); 8.12 (d, J = 15.6, 1 H, 
CH-Cq=O); 8.21 (m, 2 H, CH-Cq-Cq-Cl and CH-Cq-Cq=O); 12.20 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 117.71 
(d, 1 C, CH-Cq-O); 119.10 (d, 1 C, CH-CH-Cq-Cq); 121.04 (s,1 C, Cq-Cq=O); 124.99 (d, 1 C, CH-Cq=O); 127.67 
(d, 1 C, CH-Cq-Cl or CH-CH-Cq-Cq-Cl); 128.88 (d, 1 C, CH-Cq-Cq-Cl); 130.02 (d, 1 C, CH-CH-Cq-Cl); 130.88 (d, 
1 C, CH-Cq-Cq=O); 132.04 (s, 1 C, Cq-Cq-Cl); 132.16 (d, 1 C, CH-Cq-Cl or CH-CH-Cq-Cq-Cl); 136.29 (d, 1 C, CH-
CH-Cq-O); 161.50 (s, 1 C, Cq-O), 193.02 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H11O2Cl 258.0447; 
mass found 257.0367 for C15H10O2Cl (M-1). M.P 101-103 ˚C (Lit812 102 ˚C). 
 
 (2E)-1-(4-fluoro-2-hydroxyphenyl)-3-phenylprop-2-en-1-one (77)707   
Method A; 2’-hydroxyacetophenone 76 (0.155 g, 1 mmol) and benzaldehyde 67 (0.105 g, 1 mmol) 
afforded 77 as a yellow solid (0.174 g, 72%). 1H NMR (DMSO-d6): δ 6.86 (d, J = 9.5, 1 H, CH-Cq-O) 6.88 (td, 
J = 7.4, 4.8, 1 H, CH-CH-Cq-F); 7.46-7.50 (m, 3 H, 2x CH-CH-Cq-CH=CH and CH-CH-CH-CH-CH); 7.85 (d, J = 
15.5, 1 H, CH=CH-Cq=O); 7.90-7.93 (m, 2 H, 2x CH-Cq-CH=CH); 8.03 (d, J = 15.5, 1 H, CH-Cq=O); 8.38 (dd, J 
= 9.6, 7.0, 1 H, CH-Cq-Cq); 12.98 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 107.04 (dd, 2J19F-13C = 21.7, 1 C, 
CH-Cq-O); 109.61 (dd, 2J19F-13C = 26.5, 1 C, CH-CH-Cq-F); 117.97 (s, 1 C, Cq-Cq=O); 121.76 (s, 1 C, 
Cq-CH=CH-Cq=O); 126.60 (d, 2 C, 2x CH-Cq-CH=CH or CH-CH-Cq-CH=CH); 128.51 (d, 1 C, CH-Cq=O); 128.91 
 (d, 2 C, 2x CH-Cq-CH=CH or CH-CH-Cq-CH=CH); 130.99 (d, 1 C, CH-CH-CH-CH-CH); 133.74 (dd, 
3J19F-13C = 11.6, 1 C, CH-Cq-Cq=O);  164.29 (d, 3J19F-13C = 13.8, 1 C, Cq-O); 167.89 (d, 1J19F-13C = 253.6, 1 C, 
Cq-F); 192.50 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H11O2F 242.0743; mass found 241.0654 for 





 (2E)-3-(4-bromophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one (78)  
Method A; 2’-hydroxyacetophenone 76 (0.154 g, 1 mmol) and benzaldehyde 63 (0.187 g, 1 mmol) 
afforded 78 as a yellow solid (0.215 g, 69%). 1H NMR (DMSO-d6): δ 6.88 (m, 2 H, 2x CH-Cq-F); 7.68 (d, J = 
8.4, 2 H, 2x CH-Cq-Br); 7.80 (d, J = 15.6, 1 H, CH=CH-Cq=O); 7.87 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Br); 8.03 (d, J 
= 15.5, CH-Cq=O); 8.36 (d, J = 8.1, 1 H, CH-Cq-Cq); 12.85 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 104.25 (dd, 
2J19F-13C = 23.4, 1 C, CH-Cq-O); 106.87 (dd, 2J19F-13C = 24.6, 1 C, CH-CH-Cq-F); 118.09 (s, 1 C, Cq-Cq=O); 
122.67 (d, 1 C, CH-Cq=O); 124.35 (s, 1 C, Cq-CH=CH-Cq=O); 130.95 (d, 2 C, 2x CH-CH-Cq-Br); 131.88 (d, 2 C, 
2x CH-Cq-Br); 133.67 (s, 1 C, Cq-CH=CH-Cq=O); 133.77 (dd, 3J19F-13C = 12.3, 1 C, CH-Cq-Cq); 143.31 (d, 1 C, 
CH=CH-Cq=O); 164.38 (s, 1 C, Cq-O); 167.78 (d, 1J19F-13C = 253.6, 1 C, Cq-F); 192.22 (s, 1 C, Cq=O). HRMS: 
Calculated mass for C15H10O2BrF 319.9848; mass found 318.9770 for C15H9O2BrF (M-1). M.P 108-110 ˚C.  
 
 (2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one (79)708  
Method A; 2’-hydroxyacetophenone 76 (0.155 g, 1 mmol) and benzaldehyde 70 (0.144 g, 1 mmol) 
afforded 79 as a yellow solid (0.177 g, 66%). 1H NMR (DMSO-d6): δ 6.85 (m, 2 H, 2x CH-Cq-F); 7.59 (d, J = 
8.5, 2 H, 2x CH-Cq-Cl); 7.83 (d, J = 15.6, 1 H, CH=CH-Cq=O); 7.96 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Cl); 8.04 (d, J 
= 15.5, 1 H, CH-Cq=O); 8.39 (d, J = 7.8, 1 H, CH-Cq-Cq); 12.95 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 104.47 
(dd, 2J19F-13C = 26.1, 1 C, CH-Cq-O); 107.07 (dd, 2J19F-13C = 22.7, 1 C, CH-CH-Cq-F); 128.55 (s, 1 C, Cq-Cq=O); 
128.99 (d,2 C, 2x CH-Cq-Cl); 130.82 (d, 2 C, 2x CH-CH-Cq-Cl); 133.33 (s, 1 C, Cq-CH=CH-Cq=O); 133.79 (dd, 
3J19F-13C = 11.6, 1 C, CH-Cq-Cq); 135.50 (s, 1 C, Cq-Cl); 143.42 (d, 1 C, CH=CH-Cq=O); 164.40 (s, 1 C, Cq-O); 
192.35 (s, 1 C, Cq=O); Cq-F not observed. HRMS: Calculated mass for C15H10O2ClF 276.0353; mass found 
275.0265 for C15H9O2ClF (M-1). M.P 182-184 ˚C (Lit708 184-186 ˚C). 
 
 (2E)-1-(4-fluoro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (80)   
Method A; 2’-hydroxyacetophenone 76 (0.156 g, 1 mmol) and benzaldehyde 72 (0.122 g, 1mmol) 
afforded 80 as a yellow solid (0.227 g, 87%). 1H NMR (DMSO-d6): δ 6.95 (td, J = 4.3, 2.5, 1 H, 
Cq-Cq-CH-CH-Cq-F); 7.02 (dd, J = 10.3, 2.4, 1 H, CH-Cq-O); 7.25-7.34 (m, 2 H, 2x CH-CH-Cq-CH=CH); 
7.59-7.63 (m, 1 H, 1 of 2 CH-Cq-CH=CH); 7.81 (d, J = 15.5, 1 H, CH=CH-Cq=O); 7.87 (dd, J = 6.8, 8.7, 1 H, 
CH-Cq-Cq=O); 7.97 (dd, J = 5.9, 8.9, 1 H, 1 of 2 CH-Cq-CH=CH); 8.01 (d, J = 15.9, 1 H, CH-Cq=O); 12.99 (br.s, 
1 H, OH). 13C NMR (DMSO-d6): δ 104.72 (dd, 2J19F-13C = 23.6, 1 C, CH-Cq-O); 109.66 (dd, 2J19F-13C = 25.4, 1 C, 
Cq- Cq-CH-CH-Cq-F); 115.36 (dd, 2J19F-13C = 21.7, 1 C, 1 of 2 CH-CH-Cq-CH=CH); 115.93 (dd, 2J19F-13C = 21.7, 1 
of 2 CH-CH-Cq-CH=CH); 117.86 (s, 1 C, Cq-Cq=O); 122.30 (d, 1 C, CH-Cq=O); 128.94 (dd, 3J19F-13C = 7.9, 1 C, 1 
of 2 CH-Cq-CH=CH); 129.13 (dd, 3J19F-13C = 11.6, 1 C, CH-Cq-Cq=O); 131.38 (dd, 3J19F-13C = 8.9, 1 C, 1 of 2 
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CH-Cq-CH=CH); 134.73 (s, 1 C, Cq-CH=CH-Cq=O); 142.99 (d, 1 C, CH=CH-Cq=O); 162.05 (d, 1J19F-13C = 244.8, 
1 C, Cq-CH-Cq-F or CH-Cq-CH-CH-Cq-F); 162.66 (s, 1 C, Cq-O); 164.02 (d, 1J19F-13C = 257.6, Cq-CH-Cq-F or 
CH-Cq-CH-CH-Cq-F); 190.13 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H10O2F2 260.0649; mass found 
259.0570 for C15H9O2F2 (M-1). M.P 110-112 ˚C. 
 
 (2E)-1-(4-chloro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (81)709  
Method A; 2’-hydroxyacetophenone 76 (0.154 g, 1 mmol) and benzaldehyde 74 (0.146 g, 1 mmol) 
afforded 81 as a yellow solid (0.224 g, 79%). 1H NMR (DMSO-d6): δ 7.01 (d, J = 8.3, 1 H, CH-CH-Cq-Cl); 
7.08 (s, 1 C, CH-Cq-O); 7.40-7.50 (m, 3 H, CH-CH-CH-CH-CH and 2x CH-Cq-CH=CH); 7.80 (d, J = 15.8, 1 H, 
CH=CH-Cq=O); 7.84-7.90 (m, 2 H, 2x CH-CH-Cq-CH=CH); 7.98 (d, J = 15.5, 1 H, CH-Cq=O); 8.19 (d, J = 8.5, 1 
H, CH-Cq-Cq=O); 12.43 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 117.90 (d, 1 C, CH-Cq-O); 119.59 (d, 1 C, 
CH-CH-Cq-Cl); 121.90 (d, 1 C, CH-Cq=O); 122.75 (s, 1 C, Cq-Cq=O); 128.52 (d, 2 C, 2x CH-Cq-CH=CH); 128.91 
(d, 2 C, 2x CH-CH-Cq-CH=CH); 130.86 (d, 1 C, CH-CH-CH-CH-CH); 132.44 (CH-Cq-Cq=O); 134.46 (s, 1 C, 
Cq-CH=CH-Cq=O); 138.41 (s, 1 C, Cq-Cl); 140.33 (d, 1 C, CH=CH-Cq=O); 161.50 (s, 1 C, Cq-O); 190.59 (s, 1 C, 
Cq=O). HRMS: Calculated mass for C15H11O2Cl 258.0447; mass found 257.0365 for C15H10O2Cl (M-1). M.P 
113-114 ˚C. 
 
 (2E)-3-(4-bromophenyl)-1-(4-chloro-2-hydroxyphenyl)prop-2-en-1-one (83)  
Method A; 2’-hydroxyacetophenone 82 (0.171 g, 1 mmol) and benzaldehyde 67 (0.103 g, 1 mmol) 
afforded 83 as a yellow solid (0.207 g, 80%). 1H NMR (DMSO-d6): δ 7.03 (dd, J = 8.6, 2.0, 1 H, 
CH-CH-Cq-Cl); 7.10 (d, J = 2.0, 1 H, CH-Cq-O); 7.66 (d, J = 8.5, 2 H, 2x CH-Cq-Br); 7.77 (d, J = 15.6, 1 H, 
CH=CH-Cq=O); 7.83 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Br); 7.99 (d, J = 15.5, 1 H, CH-Cq=O); 8.19 (d, J = 8.6, 1 H, 
CH-Cq-Cq=O); 12.52 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 117.36 (d, 1 C, CH-Cq-O); 119.25 (d, 1 C, 
CH-CH-Cq-Cl); 120.39 (s, 1 C, Cq-Cq=O); 123.10 (d, 1 C, CH-Cq=O); 124.34 (s, 1 C, Cq-Br); 130.84 (d, 2 C, 2x 
CH-CH-Cq-Br); 131.08 (d, 2 C, 2x CH-Cq-Br); 132.39 (d, 1 C, CH-Cq-Cq=O); 133.66 (s, 1 C, Cq-CH=CH-Cq=O); 
139.98 (s, 1 C, Cq-Cl); 143.28 (d, 1 C, CH=CH-Cq=O); 162.13 (s, 1 C, Cq-O); 192.95 (s, 1 C, Cq=O). HRMS: 
Calculated mass for C15H10O2BrCl 335.9552; mass found 334.9478 for C15H9O2BrCl (M-1). M.P 109-111 ˚C.  
 
(2E)-1-(4-chloro-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one (84)710  
Method A; 2’-hydroxyacetophenone 82 (0.170 g, 1 mmol) and benzaldehyde 63 (0.188 g, 1 mmol) 
afforded 84 as a yellow solid (0.226 g, 67%). 1H NMR (DMSO-d6): δ 7.06 (dd, J = 8.5, 2.1, 1 H, 
CH-CH-Cq-Cq=O); 7.10 (d, J = 2.0, 1 H, Cq-CH-Cq-Cl); 7.53 (d, J = 8.5, 2 H, 2x CH-Cq-Cl); 7.80 (d, J = 15.8, 1 H, 
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CH=CH-Cq=O); 7.93 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Cl); 8.21 (d, J = 8.7, 1 H, CH-Cq-Cq=O); 12.48 (br.s, 1 H, 
OH). 13C NMR (DMSO-d6): δ 117.32 (d, 1 C, CH-Cq-O); 119.37 (d, 1 C, CH-CH-Cq-Cq=O); 120.23 (s, 1 C, 
Cq-Cq=O); 122.88 (d, 1 C, CH-Cq=O); 128.95 (d, 2 C, 2x CH-Cq-Cl); 130.41 (d, 2 C, 2x CH-CH-Cq-Cl); 132.41 
(d, 1 C, CH-Cq-Cq=O); 133.31 (s, 1 C, Cq-CH=CH-Cq=O); 135.49 (s, 1 C, CH-Cq-CH-CH-Cq-Cl); 140.05 (s, 1 C, 
Cq-CH-Cq-Cl); 143.36 (d, 1 C, CH=CH-Cq=O); 162.08 (s, 1 C, Cq-O); 192.46 (s, 1 C, Cq=O). HRMS: Calculated 
mass for C15H10O2Cl2 292.0057; mass found 290.9986 for C15H9O2Cl2 (M-1). M.P 149-150 ˚C (Lit710  
150-151 ˚C). 
 
 (2E)-1-(4-chloro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (85)  
Method A; 2’-hydroxyacetophenone 82 (0.172 g, 1 mmol) and benzaldehyde 70 (0.144 g, 1 mmol) 
afforded 85 as a yellow solid (0.252 g, 84%). 1H NMR (DMSO-d6): δ7.04 (dd, J = 8.6, 2.0, 1 H, 
CH-CH-Cq-Cl); 7.10 (d, J = 2.0, 1 H, CH-Cq-O); 7.30 (t, J = 8.8, 2 H, 2x CH-Cq-F); 7.80 (d, J = 15.5, 1 H, 
CH=CH-Cq=O); 7.96 (d, J = 15.6, 1 H, CH-Cq=O); 7.96 (dd, J = 5.7, 8.6, 2 H, 2x CH-CH-Cq-F); 8.20 (d, J = 8.6, 
1 H, CH-Cq=Cq=O); 12.57 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 115.93 (dd, 2J19F-13C = 22.0, 2 C, 2x 
CH-Cq-F); 117.29 (d, 1 C, CH-Cq-O); 119.32 (d, 1 C, CH-CH-Cq-Cl); 120.20 (s, 1 C, Cq-Cq=O); 121.95 (d, 1 C, 
CH-Cq=O); 131.01 (s, Cq-CH=CH-Cq=O); 131.48 (dd, 3J19F-13C = 8.7, 2 C, 2x CH-CH-Cq-F); 132.34 (d, 1 C, 
CH-Cq-Cq=O); 139.96 (s, 1 C, Cq-Cl); 143.63 (d, 1 C, CH=CH-Cq=O); 162.06 (s, 1 C, Cq-O); 163.58 (d, 
1J19F-13C = 249.6, 1 C, Cq-F); 192.47 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H10O2ClF 276.0353; mass 
found 275.0266 for C15H9O2ClF (M-1). M.P 119-121 ˚C. 
 
 
(2E)-1-(4-chloro-2-hydroxyphenyl)-3-(2-chlorophenyl)prop-2-en-1-one (86)  
Method A; 2’-hydroxyacetophenone 82 (0.170 g, 1 mmol) and benzaldehyde 72 (0.125 g, 1 mmol) 
afforded 86 as a yellow solid (0.229 g, 82%). 1H NMR (DMSO-d6): δ 7.06 (dd, J = 8.5, 1.9, 1 H, 
Cq-CH-CH-Cq-Cl); 7.12 (d, J = 1.8, 1 H, CH-Cq-O); 7.43-7.53 (m, 2 H, CH-CH-CH-Cq-Cl and CH-CH-Cq-Cq-Cl); 
7.58 (d, J = 7.6, 1 H, CH-CH-CH-Cq-Cl); 7.98 (d, J = 15.5, 1 H, CH-Cq=O); 8.09 (d, J = 15.6, 1 H, 
CH=CH-Cq=O); 8.15-8.19 (m, 2 H, CH-Cq-Cq=O and CH-Cq-Cq-Cl); 12.28 (br.s, 1 H, OH). 13C NMR (DMSO-d6): 
δ 117.30 (d, 1 C, CH-Cq-O); 119.44 (d, 1 C, CH-CH-Cq-Cl); 120.55 (s, 1 C, Cq-Cq=O); 125.22 (d, 1 C, 
CH-Cq=O); 127.26 (d, 1 C, CH-CH-CH-Cq-Cl or CH-CH-CH-Cq-Cl); 128.64 (d, 1 C, CH-Cq-Cq=O or CH-Cq-Cq-Cl); 
130.04 (d, 1 C, CH-CH-CH-Cq-Cl); 131.96 (s, 1 C, Cq-Cq-Cl); 132.24 (d, 1 C, CH-CH-CH-Cq-Cl or 
CH-CH-CH-Cq-Cl); 132.45 (d, 1 C, CH-Cq-Cq=O or CH-Cq-Cq-Cl); 134.46 (s, 1 C, Cq-Cq-Cl); 138.90 (d, 1 C, 
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CH=CH-Cq=O); 140.04 (s, 1 C, Cq-CH-Cq-Cl); 161.75 (s, 1 C, Cq-O); 192.01 (S, 1 C, Cq=O). HRMS: Calculated 
mass for C15H10O2Cl2 292.0057; mass found 290.9979 for C15H9O2Cl2 (M-1). M.P 114-115 ˚C.  
 
 (2E)-1-(5-chloro-2-hydroxyphenyl)-3-phenylprop-2-en-1-one (88)699  
Method A; 2’-hydroxyacetophenone 87 (0.171 g, 1 mmol) and benzaldehyde 67 (0.106 g, 1 mmol) 
afforded 88 as a yellow solid (0.175 g, 67%). 1H NMR (DMSO-d6): δ 7.04 (d, J = 8.8, 1 H, CH-Cq-OH); 
7.47-7.49 (m, 3 H, 2x CH-Cq-CH=CH and CH-CH-CH-CH-CH); 7.58 (dd, J = 8.9, 2.6, 1 H, CH-CH-Cq-Cl); 7.82 
(d, J = 15.6, 1 H, CH-CH-Cq=O); 7.90-7.93 (m, 2 H, 2x CH-CH-Cq-CH=CH); 7.99 (d, J = 15.5, 1 H, CH-Cq=O); 
8.18 (d, J = 2.6, 1 H, CH-Cq-Cl); 12.23 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 119.71 (d, 1 C, CH-Cq-OH); 
122.21 (s, 1 C, Cq-Cq=O);  122.31 (d, 1 C, CH-Cq=O); 128.95 (d, 2 C, 2x  CH-Cq-CH=CH); 129.32 (d, 2 C, 2x 
CH-CH-Cq-CH=CH); 129.73 (s, 1 C, Cq-CH-Cq); 131.13 (d, 1 C, CH-CH-CH-CH-CH); 134.28 (s, 1 C, 
Cq-CH=CH-Cq=O); 135.47 (d, 1 C, CH-CH-Cq-Cl); 145.32 (d, 1 C, CH=CH-Cq=O); 159.38 (s, 1 C, Cq-O); 192.39 
(s, 1 C, Cq=O). HRMS: Calculated mass for C15H11O2Cl 258.0447; mass found 257.0368 for C15H10O2Cl 
(M-1). M.P 98-100 ˚C (Lit699 99-101 ˚C). 
 
(2E)-3-(4-bromophenyl)-1-(5-chloro-2-hydroxyphenyl)prop-2-en-1-one (89)711 
Method A; 2’-hydroxyacetophenone 87 (0.170 g, 1 mmol) and benzaldehyde 63 (0.189 g, 1 mmol) 
afforded 89 as a yellow solid (0.228 g, 81%). 1H NMR (DMSO-d6): δ 7.04 (d, J = 8.8, 1 H, CH-Cq-O); 7.58 
(dd, J = 8.9, 2.6, 1 H, CH-CH-Cq-Cl); 7.68 (d, J = 8.4, 2 H, 2x CH-Cq-Br); 7.79 (d, J = 15.5, 1 H, CH=CH-Cq=O); 
7.88 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Br); 8.02 (d, J = 15.6, 1 H, CH-Cq=O); 8.23 (d, J = 2.6, 1 H, CH-Cq-Cq); 
12.20 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 119.55 (d, 1 C, CH-Cq-O); 122.20 (s, 1 C, Cq-Cl or Cq-Cq=O); 
122.31 (s, 1,C, Cq-Cl or Cq-Cq=O); 122.94 (d, 1 C, CH-Cq=O); 124.20 (s, 1 C, Cq-Br); 129.62 (d, 1 C, 
Cq-CH-Cq-Cq); 131.06 (d, 2 C, 2x CH-CH-Cq-Br); 131.89 (d, 2 C, 2x CH-Cq-Br); 133.16 (s, 1 C, 
Cq-CH-CH-Cq-Br); 135.47 (d, 1 C, CH-CH-Cq-Cl); 143.75 (d, 1 C, CH=CH-Cq=O); 159.80 (s, 1 C, Cq-O); 195.60 
(s, 1 C, Cq=O). HRMS: Calculated mass for C15H10O2BrCl 335.9552; mass found 334.9474 for C15H9O2BrCl 
(M-1). M.P 177-178 ˚C (Lit711 178-179 ˚C). 
 
 (2E)-1-(5-chloro-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one (90)699 
Method A; 2’-hydroxyacetophenone 87 (0.172 g, 1 mmol) and benzaldehyde 70 (0.149 g, 1 mmol) 
afforded 90 as a yellow solid (0.119 g, 74%).1H NMR (DMSO-d6): δ 7.04 (d, J = 8.9, 1 H, CH-Cq-OH); 7.54 
(d, J = 8.3, 2 H, 2x CH-Cq-Cl); 7.58 (dd, J = 8.9, 2.5, 1 H, CH-CH-Cq-Cl); 7.81 (d, J = 15.6, 1 H, CH-CH-Cq=O); 
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7.96 (d, J = 8.5, 2 H, 2x Cq-CH-CH-Cq-Cl); 8.01 (d, J = 15.6, 1 H, CH-Cq=O); 8.24 (d, J = 2.3, 1 H, Cq-CH-Cq-Cl); 
12.21 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 119.67 (d, 1 C, CH-Cq-O); 121.22 (s, 1 C, Cq-CH-Cq-Cl); 122.92 (d, 
1 C, CH-Cq=O); 128.97 (d, 2 C, 2x CH-CH-Cq-Cl); 129.66 (d, 1 C, Cq-CH-Cq-Cl); 130.14 s, 1 C, Cq-Cq=O); 
130.93 (d, 2 C, 2x CH-CH-Cq-Cl); 133.35 (s, 1 C, Cq-CH=CH-Cq=O); 135.48 (d, 1 C, CH-CH-Cq-OH); 135.55 
(Cq-CH-CH-Cq-Cl); 143.69 (d, 1 C, CH=CH-Cq=O); 159.81 (s, 1 C, Cq-O); 192.31 (s, 1 C, Cq=O). HRMS: 
Calculated mass for C15H10O2Cl2 292.0057; mass found 290.9980 for C15H9O2Cl2 (M-1). M.P 185-178 ˚C 
(Lit699 186-189 ˚C). 
  
 
 (2E)-1-(5-chloro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (91)712   
Method A; 2’-hydroxyacetophenone 87 (0.171 g, 1 mmol) and benzaldehyde 72 (0.122 g, 1 mmol) 
afforded 91 as a yellow solid (0.219 g, 79%). NMR (DMSO-d6): δ 7.05 (d, J = 8.9, 1 H, CH-Cq-O); 7.30 (t, J = 
8.8, 2 H, 2x CH-Cq-F); 7.55 (dd, J = 8.9, 7.6, 1 H, CH-CH-Cq-Cl); 7.81 (d, J = 15.5, 1 H, CH=CH-Cq=O); 7.94 (d, 
J = 15.6, 1 H, CH-Cq=O); 7.99 (dd, J = 5.7, 8.6, 2 H, 2x CH-CH-Cq-F); 8.21 (d, J = 2.6, 1 H, CH-Cq-Cq=O); 12.24 
(br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 115.92 (dd, 2J19F-13C = 21.7, 2 C, 2x CH-Cq-F); 119.62 (d, 1 C, 
CH-Cq-O); 122.06 (d, 1 C, CH-Cq=O); 122.49 (s, 1 C, Cq-Cl or Cq-Cq=O); 122.82 (s, 1 C, Cq-Cl or Cq-Cq=O); 
129.59 (d, 1 C, CH-Cq-Cq=O); 131.05 (s, 1 C, Cq-CH=CH-Cq=O); 131.62 (dd, 3J19F-13C = 8.7, 2 C, 2x 
CH-CH-Cq-F); 135.31 (d, 1 C, CH-CH-Cq-Cl); 143.89 (d, 1 C, CH=CH-Cq=O); 159.83 (s, 1 C, Cq-O); 163.62 (d, 
1J19F-13C = 249.4, 1 C, Cq-F); 192.25 (s, 1 C, Cq=O). Calculated mass for C15H10O2ClF 276.0353; mass found 
275.0264 for C15H9O2ClF (M-1). M.P 179-180 ˚C (Lit711 181-182 ˚C). 
 
 (2E)-1-(5-chloro-2-hydroxyphenyl)-3-(2-chlorophenyl)prop-2-en-1-one (92)699   
Method A; 2’-hydroxyacetophenone 87 (0.170 g, 1 mmol) and benzaldehyde 74 (0.148 g, 1 mmol) 
afforded 92 as a yellow solid (0.208 g, 69%). 1H NMR (DMSO-d6): δ 7.05 (d, J = 8.9, 1 H, CH-Cq-O); 
7.43-7.53 (m, 2 H, CH- Cq -Cq-Cl and CH-CH-Cq-Cq-Cl); 7.56 (m, 2 H, CH-CH-CH-Cq-Cl and CH-CH-Cq-O); 8.01 
(d, J = 15.5, 1 H, CH-Cq=O); 8.09 (d, J = 15.2, 1 CH=CH-Cq=O); 8.19 (d, J = 2.6, 1 H, Cq-CH-Cq-Cl); 8.21 (dd, J 
= 7.5, 1.8, 1 H, CH-CH-CH-Cq-Cl); 12.01 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 119.62 (d, 1 C, CH-Cq-O); 
122.77 (s, 1 C, Cq-CH-Cq-Cl or Cq-Cq=O); 122.95 (s, 1 C, Cq-CH-Cq-Cl or Cq-Cq=O); 125.20 (d, 1 C, CH-Cq=O); 
127.66 (d, 1 C, CH-Cq-Cq-Cl or CH-CH-CH-Cq-Cl); 128.77 (d, 1 C, CH-CH-CH-Cq-Cl); 130.04 (d, 1 C, 
CH-CH-CH-Cq-Cl); 131.93 (s, 1 C, Cq-Cq-Cl); 132.32 (d, 1 C, CH-Cq-Cq-Cl or CH-CH-CH-Cq-Cl); 134.52 (s, 1 C, 
Cq-Cq-Cl); 135.44 (d, 1 C, CH-CH-Cq-O); 139.18 (d, 1 C, CH=CH-Cq=O); 159.51 (s, 1 C, Cq-O); 191.87 (s, 1 C, 
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Cq=O). HRMS: Calculated mass for C15H10O2Cl2 292.0057; mass found 290.9981 for C15H9O2Cl2 (M-1). M.P 
100-102 ˚C (Lit699 101-103 ˚C). 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-phenylprop-2-en-1-one (94)711  
Method A; 2’-hydroxyacetophenone 93 (0.216 g, 1 mmol) and benzaldehyde 67 (0.104 g, 1 mmol) 
afforded 94 as a yellow solid (0.207 g, 68%). 1H NMR (DMSO-d6): δ 6.99 (d, J = 8.8, 1 H, CH-Cq-O); 
7.42-7.51 (m, 3 H, 2x CH-Cq-CH=CH and CH-CH-CH-CH-CH); 7.69 (dd, J = 8.7, 2.5, 1 H, CH-CH-Cq-Br); 7.82 
(d, J = 15.6, 1 H, CH=CH-Cq=O); 7.90-7.93 (m, 2 H, 2x CH-CH-Cq-CH=CH); .99 (d, J = 15.5, 1 H, CH-Cq=O); 
8.33 (d, J = 2.5, 1 H, Cq-CH-Cq-Br); 12.25 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 110.36 (s, 1 C, Cq-Br); 120.00 
(d, 1 C, CH-Cq-O); 122.26 (d, 1 C, CH-Cq=O); 123.19 (s, 1 C, Cq-Cq=O); 128.87 (d, 2 C, 2x CH-Cq-CH=CH); 
129.23 (d, 2 C, 2x CH-CH-Cq-CH=CH); 131.04 (d, 1 C, CH-CH-CH-CH-CH); 132.47 (d, 1 C, Cq-CH-Cq-Br); 
134.35 (s, 1 C, Cq-CH=CH-Cq=O); 138.13 (d, 1 C, CH-CH-Cq-O); 145.21 (d, 1 C, CH=CH-Cq=O); 160.12 (s, 1 C, 
Cq-O); 192.32 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H11O2Br 301.9942; mass found 300.9865 for 
C15H10O2Br (M-1). M.P 95-97 ˚C (Lit711 94-96 ˚C). 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-(4-bromophenyl)prop-2-en-1-one (95)713 
Method A; 2’-hydroxyacetophenone 93 (0.217 g, 1 mmol) and benzaldehyde 63 (0.189 g, 1 mmol) 
afforded 95 as a yellow solid (0.265 g, 68%). 1H NMR (DMSO-d6): δ 6.98 (d, J =8.8, 1 H, CH-Cq-OH); 7.68 
(d, J = 8.5, 2 H, 2x CH-Cq-Br); 7.68 (dd, J = 8.8, 2.5, 1 H, CH-CH-Cq-O); 7.79 (d, J = 14.8, 1 H, CH=CH-Cq=O); 
7.89 (d, J = 8.4, 2 H, 2x CH-CH-Cq-Br); 8.01 (d, J = 15.7, 1 H, CH-Cq=O); 12.23 (s, 1 H, OH). 13C NMR 
(DMSO-d6): δ 110.32 (s, 1 C, Cq-CH-Cq-Br); 120.02 (s, 1 C, CH-Cq-O); 122.94 (s, 1 C, CH-Cq=O); 123.08 (s, 1 
C, Cq-Cq=O); 124.56 (s, 1 C, Cq-CH-CH-Cq-Br); 131.08 (d, 2 C, 2x CH-CH-Cq-Br); 131.87 (d, 2 C, 2x CH-Cq-Br); 
132.50 (d, 1 C, Cq-CH-Cq-Br); 133.64 (s, 1 C, Cq-CH=CH-Cq=O); 138.24 (d, 1 C, CH-CH-Cq-Br); 143.75 (d, 1 C, 
CH=CH-Cq=O); 160.17 (s, 1 C, Cq-O); 192.20 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H10O2Br2 
379.9047; mass found 378.8981 for C15H9O2Br2 (M-1). M.P 179-181 ˚C (Lit711 180-182 ˚C). 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one (96)712 
Method A; 2’-hydroxyacetophenone 93 (0.214 g, 1 mmol) and benzaldehyde 70 (0.145 g, 1 mmol) 
afforded 96 as a yellow solid (0.209 g, 61%). 1H NMR (DMSO-d6): δ 6.99 (d, J = 8.8, 1 H, CH-Cq-O); 7.54 (d, 
J = 8.5. 2 H, 2x CH-Cq-Cl); 7.69 (dd, J = 8.7, 2.3, 1 H, CH-CH-Cq-Br); 7.80 (d, J = 15.6, 1 H, CH=CH-Cq=O); 
7.96 (d, J = 8.5, 2 H, 2x CH-CH-Cq-Cl); 8.00 (d, J = 15.5, 1 H, CH-Cq=O); 8.33 (d, J = 2.3, 1 H, Cq-CH-Cq-Cl); 
12.22 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 110.33 (s, 1 C, Cq-Br); 120.02 (d, 1 C, CH-Cq-O); 122.96 (d, 1 C, 
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CH-Cq=O); 123.12 (s, 1 C, Cq-Cq=O); 128.94 (d, 2 C, 2x CH-Cq-Cl); 130.89 (d, 2 C, 2x CH-CH-Cq-Cl); 132.50 
(d, 1 C, Cq-CH-Cq-Br); 133.37 (s, 1 C, Cq-CH=CH-Cq=O); 143.66 (d, 1 C, CH=CH-Cq=O); 160.16 (s, 1 C, Cq-O); 
192.27 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H10O2BrCl 335.9552; mass found 334.9475 for 
C15H9O2BrCl (M-1). M.P 178-179 ˚C (Lit711 179-180 ˚C). 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (97)712  
 Method A; 2’-hydroxyacetophenone 93 (0.216 g, 1 mmol) and benzaldehyde 72 (0.125 g, 1 mmol) 
afforded 97 as a yellow solid (0.263 g, 81%). 1H NMR (DMSO-d6): δ 6.99 (d, J = 8.8, 1 H, CH-Cq-O); 7.30 (t, 
J = 8.9, 2 H, 2x CH-Cq-F); 7.66 (dd, J = 8.8, 2.4, 1 H, CH-CH-Cq-Br); 7.80 (d, J = 15.5, 1 H, CH=CH-Cq=O); 7.93 
(d, J = 15.5, 1 H, CH-Cq=O); 7.99 (dd, J = 6.5, 8.6, 2 H, 2x CH-CH-Cq-F); 8.31 (d, J = 2.3, 1 H, CH-Cq-Cq=O); 
12.28 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 110.26 (s, 1 C, Cq-Br); 115.90 (dd, 2J19F-13C = 21.7, 2 C, 2x 
CH-Cq-F); 120.00 (d, 1 C, CH-Cq-O); 122.04 (d, 1 C, CH-Cq=O); 123.08 (s, 1 C, Cq-Cq=O); 131.03 (s, 1 C, 
Cq-CH=CH-Cq=O); 131.63 (dd, 3J19F-13C = 8.1, 2 C,  2x CH-CH-Cq-F); 132.44 (d, 1 C, CH-Cq-Cq=O); 138.10 (d, 1 
C, CH-CH-Cq-Br); 143.10 (d, 1 C, CH=CH-Cq=O); 160.19 (s, 1 C, Cq-O); 163.61 (d, 1J19F-13C = 249.4, 1 C, Cq-F); 
192.19 (s, 1 C, Cq=O). HRMS: Calculated mass for C15H10O2BrF 319.9848; mass found 318.9774 for 
C15H9O2BrF (M-1). M.P 160-162 ˚C (Lit711 162-164 ˚C). 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-(2-chlorophenyl)prop-2-en-1-one (98)714   
 Method A; 2’-hydroxyacetophenone 93 (0.215 g, 1 mmol) and benzaldehyde 74 (0.146 g, 1 mmol) 
afforded 98 as a yellow solid (0.224 g, 65%). 1H NMR (DMSO-d6): δ 6.99 (d, J = 7.9, 1 H, CH-Cq-O); 
7.45-7.49 (m, 2 H, CH-Cq-Cl and CH-CH-CH-Cq-Cl); 7.58 (dd, J = 7.7, 1.4, 1 H, CH-CH-Cq-Cl); 7.66 (d, J = 8.7, 
1 H, CH-CH-Cq-Br); 8.00 (d, J = 15.8, 1 H, CH-Cq=O); 8.08 (d, J = 15.6, 1 H, CH=CH-Cq=O); 8.19 (d, J = 7.4, 1 
H, CH-Cq-Cq-Cl); 8.25 (s, 1 H, Cq-CH-Cq-Br); 11.92 (br.s, 1 H, OH). 13C NMR (DMSO-d6): δ 113.38 (s, 1 C, 
Cq-Br); 120.66 (d, 1 C, CH-Cq-O); 122.08 (s, 1 C, Cq-Cq=O); 125.65 (d, 1 C, CH-Cq=O); 127.64 (d, 1 C, 
CH-Cq-Cl or CH-CH-CH-Cq-Cl); 128.72 (d, 1 C, CH-Cq-Cq-Cl); 130.38 (d, 1 C,  CH-Cq-Cl or CH-CH-CH-Cq-Cl); 
132.02 (d, 1 C, CH-CH-Cq-Cl); 132.52 (d, 1 C, Cq-CH-Cq-Br); 134.46 (s, 1 C, Cq-Cq-Cl); 135.59 (s, 1 C, Cq-Cl); 
137.98 (CH-CH-Cq-Br); 138.53 (d, 1 C, CH=CH-Cq=O); 159.97 (s, 1 C, Cq-O); 189.95 (s, 1 C, Cq=O). HRMS: 
Calculated mass for C15H10O2BrCl 335.9552; mass found 334.9480 for C15H9O2BrCl (M-1). M.P 97-99 ˚C  
 
 (2E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (101)699  
Method B; 2’-hydroxyacetophenone 60 (0.133 g, 1 mmol) and benzaldehyde 99 (0.136 g, 1 mmol) 
afforded 101 as a yellow solid (0.210 g, 83%). 1H NMR (DMSO-d6): δ 3.84 (s, 3 H, CH3); 6.99 (d. J = 8.5, 1 
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H, CH-Cq-OH); 7.00 (td, J = 8.5, 0.9, 1 H, CH-CH-Cq-Cq);  7.04 (d, J = 8.8, 2 H, 2x CH-Cq-O-CH3 ); 7.56 (td, J = 
7.7, 1.4, 1 H, CH-CH-Cq-OH) 7.84 (d, J = 15.4, 1 H, CH=CH-Cq=O); 7.87 (d, J = 7.9, 2 H, 2x CH-CH-Cq-O-CH3); 
7.91 (d, J = 15.2, 1 H, CH-Cq=O); 8.26 (dd, J = 8.1, 1.1, 1 H, CH-Cq-Cq); 12.69 (s, 1 H, OH). 13C NMR 
(DMSO-d6): δ 55.41 (q, 1 C, CH3); 114.46 (d, 2 C, 2x CH-Cq-O-CH3); 117.66 (d, 1 C, CH-Cq-OH); 118.86 (d, 1 
C, CH-Cq=O); 119.01 (CH-CH-Cq-Cq); 120.56 (s, 1 C, Cq-Cq=O); 127.06 (s, 1 C, Cq-CH=CH-Cq=O); 130.68 (d 1 
C, CH-Cq-Cq); 131.18 (d, 2 C, 2x CH-CH-Cq-O-CH3); 136.12 (d, 1 C, CH-CH-Cq-OH); 145.01 (d, 1 C, 
CH=CH-Cq=O); 161.69 (s, 1 C, Cq-OH or Cq-O-CH3); 161.96 (s, 1 C, Cq-OH or Cq-O-CH3); 193.54 (s, 1 S, 
Cq=O). HRMS: Calculated mass for C16H14O3 254.0942; mass found 255.1017 for C16H15O3 (M+1). M.P 
94-95 ˚C (Lit813 95-96 ˚C). 
 
 (2E)-1-(2-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (102)716  
Method B; 2’-hydroxyacetophenone 60 (0.131 g, 1 mmol) and benzaldehyde 100 (0.135 g, 1 mmol) 
afforded 102 as a yellow solid (0.198 g, 79%).  1H NMR (DMSO-d6): δ 3.91 (s, 1 H, CH3); 6.99 (d, J = 8.3, 1 
H, CH-Cq-OH); 7.00 (t,  J = 7.1, 1 H, CH-CH-Cq-Cq=O); 7.05 (d, J = 7.6, 1 H, CH-CH-Cq-CH=CH); 7.13 (t, J = 
8.3, 1 H, CH-Cq-O-CH3); 7.48 (td, J = 7.8. 1.4, 1  H, CH-CH-Cq-O-CH3); 7.56 (td, J = 7.7, 1.3, 1 H, 
CH-CH-Cq-OH); 7.98 (d, J = 15.5, 1 H, CH-Cq=O); 7.99 (dd, J = 8.8, 1.2, 1 H, CH-Cq-Cq-O-CH3); 8.16 (d, J = 
15.8, 1 H, CH=CH-Cq=O); 12.51 (s, 1 C, OH). 13C NMR (DMSO-d6): δ 55.78 (q, 1 C, CH3); 111.86 (d, 1 C, 
CH-Cq-O-CH3); 117.66 (d, 1 C, CH-Cq-OH); 119.11 (d, 1 C, CH-CH-Cq-Cq=O); 120.78 (s, 1 C, Cq-Cq-O-CH3); 
121.42 (d, 1 C, CH-Cq=O); 122.67 (s, 1 C, Cq-Cq=O); 128.74 (d, 1 C, CH-Cq-Cq-O-CH3); 130.64 (d, 1,C, 
CH-Cq-Cq=O); 132.72 (d, 1 C, CH-CH-Cq-O-CH3); 136.15 (d, 1 C, CH-CH-Cq-OH); 139.23 (d, 1 C, 
CH=CH-Cq=O); 158.41 (s, 1 C, Cq-O-CH3); 161.77 (s, 1 C, Cq-OH); 193.67 (s, 1 C, Cq=O). Method B, 79%. 
HRMS: Calculated mass for C16H14O3 254.0942; mass found 255.1012 for C16H15O3 (M+1). M.P 109-111 ˚C 
(Lit814 111-112 ˚C). 
 
 (2E)-1-(4-fluoro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (103)717 
Method B; 2’-hydroxyacetophenone 76 (0.155 g, 1 mmol) and benzaldehyde 99 (0.134 g, 1 mmol) 
afforded 103 as a yellow solid (0.221 g, 81%). 1H NMR (DMSO-d6): δ 3.84 (s, 3 H, CH3); 6.84 (d, J = 9.8, 
1 H, Cq-CH-Cq-F); 6.85 (td, J = 9.5, 2.5, 1 H, CH-CH-Cq-F); 7.04 (d, J = 8.7, 2 H, 2x CH-Cq-O-CH3); 7.84 (d, 
J = 15.4, 1 H, CH-Cq=O); 7.88 (d, J = 15.2, 1 H, CH=CH-Cq=O); 7.89 (d, J = 8.8, 2 H, 2x CH-CH-Cq-O-CH3); 
8.39 (dd, J = 8.3, 6.8, 1 H, CH-CH-Cq-F); 13.16 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 55.54 (q, 1 C, CH3); 
104.26 (dd, 2J19F-13C = 24.0, 1 C, Cq-CH-Cq-F); 106.96 (dd, 2J19F-13C = 23.2, 1 C, CH-CH-Cq-F); 114.51 (d, 2 C, 
2x CH-Cq-O-CH3); 117.82 (s, 1 C, Cq-Cq=O); 118.75 (d, 1 C, CH-Cq=O); 127.04 (s, 1 C, Cq-CH=CH-Cq=O); 
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131.34 (d, 2 C, 2x CH-CH-Cq-O-CH3); 145.33 (d, 1 C, CH=CH-Cq=O); 133.63 (dd, 3J19F-13C = 10.7, 1 C, 
CH-Cq-Cq=O); 161.81 (s, 1 C, Cq-O-CH3); 164.72 (s, 1 C, Cq-OH); 166.73 (d, 1J19F-13C = 253.3, 1 C, Cq-F); 
192.52 (s, 1 C, Cq=O). HRMS: Calculated mass for C16H13O3F 272.0848; mass found 271.0767 for C16H12O3F 
(M-1). M.P 109-111 ˚C (Lit707  111-112 ˚C). 
 
 (2E)-1-(4-fluoro-2-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (104)  
Method B; 2’-hydroxyacetophenone 76 (0.156 g, 1 mmol) and benzaldehyde 100 (0.135, 1 mmol) 
afforded 104 as a yellow solid (0.239 g, 87%). 1H NMR (DMSO-d6): δ 3.91 (s, 3 H, CH3); 6.85 (d, J = 9.6, 1 
H, Cq-CH-Cq-F); 6.88 (td, J = 6.9, 2.5, 1 H, CH-CH-Cq-F); 7.05 (t, J = 7.5, 1 H, CH-CH-CH-Cq-O-CH3); 7.14 (t, J 
= 8.4, 1 H, CH-Cq-O-CH3); 7.48 (td, J = 7.8, 1.4, CH-CH-Cq-O-CH3); 7.96 (d, J = 15.6, 1 H, CH-Cq=O); 7.99 (dd, 
J = 7.7, 1.3, 1 H, CH-Cq-Cq-O-CH3); 8.16 (d, J = 15.6, 1 H, CH=CH-Cq=O); 8.33 (dd, J = 6.7, 9.4, 1 H, 
CH-Cq-Cq=O); 12.99 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 55.75 (q, 1 C, CH3); 104.20 (dd, 2J19F-13C = 22.5, 1 
C, CH-Cq-OH); 106.88 (dd, 2J19F-13C =  22.4, 1 C, CH-CH-Cq-F); 111.88 (d, 1 C, CH-Cq-O-CH3); 118.04 (s, 1 C, 
Cq-Cq=O); 120.72 (d, 1 C, CH-CH-Cq-Cq-O-CH3); 121.25 (d, 1 C, CH-Cq=O); 122.63 (s, 1 C, Cq-Cq-O-CH3); 
128.71 (d, 1 C, CH-Cq-Cq-O-CH3); 132.83 (d, 1 C, CH-CH-Cq-O-CH3); 133.56 (dd, 3J19F-13C = 12.2, 1 C, 
CH-Cq-Cq=O); 139.38 (d, 1 C, CH=CH-Cq=O); 158.49 (s, 1 C, Cq-O-CH3); 164.13 (d, 1J19F-13C = 235.8, 1 C, 
Cq-F); 164.38 (S, 1 C, Cq-OH); 192.53 (s, 1 C, Cq=O). HRMS: Calculated mass for C16H13O3F 272.0848; mass 
found 271.0765 mass for C16H12O3F (M-1). M.P. 99-101 ˚C.  
 
 (2E)-1-(4-chloro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (105)710 
Method B; 2’-hydroxyacetophenone 82 (0.170 g, 1 mmol) and benzaldehyde 99 (0.136 g, 1 mmol) 
afforded 105 as a yellow solid (0.264 g, 91%). 1H NMR (DMSO-d6): δ 3.83 (s, 3 H, CH3); 7.00-7.06 (m, 3 H, 
2x CH-Cq-O-CH3 and CH-CH-Cq-Cl); 7.08 (d, 1 H, CH-Cq-OH); 7.81-7.83 (m, CH=CH-Cq=O and CH-Cq=O); 
7.86 (d, J = 8.82 H, CH-Cq-CH=CH); 8.24 (d, J = 8.8, 1 H, CH-Cq-Cq=O); 12.81 (br.s, 1 H, OH). 13C NMR 
(DMSO-d6): δ 55.39 (q, 1 C, CH3); 114.46 (d, 2 C, 2x CH-Cq-O-CH3); 117.35 (d, 1 C, CH-Cq-OH); 119.13 (d, 1 
C, CH-CH-Cq-CH or CH-Cq=O); 119.20 (d, 1 C, CH-CH-Cq-CH or CH-Cq=O); 120.00 (s, 1 C, Cq-Cq=O); 126.99 
(s, 1 C, Cq-CH=CH-Cq=O); 131.21 (d, 2 C, 2x CH-Cq-CH=CH); 132.26 (d, 1 C, CH-Cq-Cq=O); 139.87 (s, 1 C, 
Cq-Cl); 145.26 (d, 1 C, CH=CH-Cq=O); 161.77 (s, 1 C, Cq-O-CH3); 162.49 (s, 1 C, Cq-OH); 192.50 (s, 1 C, 
Cq=O). HRMS: Calculated mass for C16H13O3Cl 288.0553; mass found 287.0468 for C16H12O3Cl (M-1). M.P. 





 (2E)-1-(4-chloro-2-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (106)  
Method B; 2’-hydroxyacetophenone 82 (0.171 g, 1 mmol) and benzaldehyde 100 (0.134g, 1 mmol) 
afforded 106 as a yellow solid (0.266 g, 92%). 1H NMR (DMSO-d6): δ 3.90 (s, 3 H, CH3); 7.02-7.06 (m, 2 H, 
CH-CH-Cq-Cq=O and CH-CH-Cq-CH=CH); 7.09 (d, J = 2.0, 1 H, CH-Cq-OH); 7.13 (d, J = 8.3, 1 H, CH-Cq-O-CH3); 
7.47 (t, J = 8.5, 1 H, CH-CH-Cq-O-CH3); 7.92 (d,  15.7, CH-Cq=O); 7.96 (dd, J = 7.7, 1.2, 1 H, CH-Cq-CH=CH); 
8.13 (d, J = 15.8, 1 H, CH=CH-Cq=O); 8.17 (d, J = 8.7, 1 H, CH-Cq-Cq=O); 12.52 (br.s, 1 H, OH). 13C NMR 
(DMSO-d6): δ 55.79 (q, 1 C, CH3); 111.91 (d, 1 C, CH-Cq-O-CH3); 117.37 (d, 1 C, CH-Cq-OH); 119.37 (d, 1 C, 
CH-CH-Cq-Cl or CH-CH-Cq-Cq-O-CH3); 120.33 (s, 1 C, Cq-Cq=O); 120.73 (d, 1 C, CH-CH-Cq-Cl or 
CH-CH-Cq-Cq-O-CH3); 121.77 (d, 1 C, CH-Cq=O); 122.73 (s, 1 C, Cq-Cq-O-CH3); 128.72 (d, 1 C, CH-Cq-CH=CH); 
132.28 (CH-Cq-Cq=O); 132.84 (d, 1 C, CH-Cq-CH=CH); 139.45 (s, 1 C, Cq-Cl); 139.90 (d, 1 C, CH=CH-Cq=O); 
158.47 (s, 1 C, Cq-O-CH3); 162.18 (s, 1 C, Cq-OH); 192.37 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C16H13O3Cl 288.0553; mass found 287.0474 for C16H12O3Cl (M-1). M.P. 121-123 ˚C. 
 
 
 (2E)-1-(5-chloro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (107)699 
Method B; 2’-hydroxyacetophenone 87 (0.172 g, 1 mmol) and benzaldehyde 99 (0.135 g, 1 mmol) 
afforded 107 as a yellow solid (0.256 g, 88%). 1H NMR (DMSO-d6): δ 3.84 (s, 3 H, CH3); 7.02 (d, J = 8.7, 1 
H, CH-Cq-OH); 7.03 (d, J = 8.7, 2 H, 2x CH-Cq-O-CH3); 7.56 (dd, J = 8.7, 2.5, 1 H, CH-CH-Cq-Cl); 7.82 (d, J = 
15.7, 1 H, CH-Cq=O); 7.90 (d, J = 15.0, 1 H, CH=CH-Cq=O); 7.91 (d, J = 8.7, 2 H, 2x CH-CH-Cq-O-CH3); 8.27 
(d, J = 2.6, 1 H, Cq-CH-Cq-Cl); 12.50 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 55.41 (q, 1 C, CH3); 114.44 (d, 2 C, 
2x CH-Cq-O-CH3); 119.16 (d, 1 C, CH-Cq-OH); 119.62 (d, 1 C, CH-Cq=O); 122.22 (s, 1 C, Cq-Cl or Cq-Cq=O); 
122.81 (s, 1 C, Cq-Cl or Cq-Cq=O); 127.02 (s, 1 C, Cq-CH=CH-Cq=O); 129.53 (d, 1 C, Cq-CH-Cq-Cl); 131.42 (d, 2 
C, 2x CH-CH-Cq-O-CH3); 135.33 (s, 1 C, CH-CH-Cq-Cl); 145.68 (d, 1 C, CH=CH-Cq=O); 160.09 (s, 1 C, Cq-OH); 
161.84 (s, 1 C, Cq-O-CH3); 192.44 (s, 1 C, Cq=O). HRMS: Calculated mass for C16H13O3Cl 288.0553; mass 
found 287.0473 for C16H12O3Cl (M-1) M.P.87-88 ˚C (Lit699 88-90 ˚C). 
 
 (2E)-1-(5-chloro-2-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (108)718 
Method B; 2’-hydroxyacetophenone 87 (0.173 g, 1 mmol) and benzaldehyde 100 (0.134 g, 1 mmol) 
afforded 108 as a yellow solid (0.236 g, 81%). 1H NMR (DMSO-d6): δ 3.90 (s, 3 H, CH3); 7.03 (d, J = 9.0, 1 
H, CH-Cq-OH); 7.05 (t, J = 8.5, 1 H, CH-CH-CH-Cq-O-CH3); 7.13 (d, J = 8.4, 1 H, CH-Cq-O-CH3); 7.48 (td, J = 
7.8, 1.5, 1 H, CH-CH-Cq-O-CH3); 7.56 (dd, J = 8.8, 2.6, 1 H, CH-CH-Cq-Cl); 7.93 (d, J = 15.5, 1 H, CH-Cq=O); 
8.03 (dd, J = 7.7, 1.2, 1 H, CH-Cq-Cq-O-CH3); 8.15 (d, J = 15.7, 1 H, CH=CH-Cq=O); 8.18 (d, J = 2.6, 1 H, 
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Cq-CH-Cq-Cl); 12.25 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 55.76 (q, 1 C, CH3); 111.86 (CH-Cq-O-CH3); 119.59 
(d, 1 C, CH-Cq-OH); 120.66 (d, 1 C, CH-CH-CH-Cq-O); 121.77 (d, 1 C, CH-Cq=O); 122.61 (s, 1 C, Cq-Cl or 
Cq-Cq=O); 122.66 (Cq-Cq-O-CH3); 122.83 (s, 1 C, Cq-Cl or Cq-Cq=O); 128.52 (d, 1 C, CH-Cq-Cq-O-CH3); 129.50 
(d, 1 C, Cq-CH-Cq-Cl); 132.88 (d, 1 C, CH-CH-Cq-O-CH3); 135.22 (d, 1 C, CH-CH-Cq-Cl); 139.46 
(CH=CH-Cq=O); 158.39 (Cq-O-CH3); 159.70 (Cq-OH); 192.37 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C16H13O3Cl 288.0553; mass found 287.0472 for C16H12O3Cl (M-1). M.P. 115-117 ˚C. 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (109)714  
Method B; 2’-hydroxyacetophenone 93 (0.215 g, 1 mmol) and benzaldehyde 99 (0.135 g, 1 mmol) 
afforded 109 as a yellow solid (0.314 g, 94%). 1H NMR (DMSO-d6): δ 3.84 (s, 3 H, CH3); 6.97 (d, J = 8.8, 1 
H, CH-Cq-OH); 7.04 (d, J = 8.7, 2 H, 2x CH-Cq-O-CH3); 7.68 (dd, J = 8.8, 2.3, 1 H, CH-CH-Cq-Br); 7.81 (d, J = 
15.4, 1 H, CH-Cq=O); 7.88 (d, J = 14.9, 1 H, CH=CH-Cq=O); 7.91 (d, J = 8.6, 2 H, 2x CH-CH-Cq-O-CH3); 8.37 
(d, J = 2.4, 1 H, Cq-CH-Cq-Br); 12.51 (s, 1 H, OH). 13C NMR (DMSO-d6): δ 55.40 (q, 1 C, CH3); 110.22 (s, 1 C, 
Cq-Br); 114.42 (d, 2 C, 2x CH-Cq-O-CH3); 119.19 (d, 1 C, CH-Cq=O); 120.01 (d, 1 H, CH-Cq-OH); 122.85 (s, 1 
C, Cq-Cq=O); 127.01 (s, 1 C, Cq-CH=CH-Cq=O); 131.38 (d, 2 C, 2x CH-CH-Cq-O-CH3); 132.35 (d, 1 C, 
Cq-CH-Cq-Br); 138.08 (d, 1 C, CH-CH-Cq-Br); 145.67 (d, 1 C, CH=CH-Cq=O); 160.44 (s, 1 C, Cq-O-CH3); 161.82 
(s, 1 C, Cq-OH); 192.34 (s, 1 C, Cq=O). HRMS: Calculated mass for C16H13O3Br 332.0048; mass found 
330.9966 for C16H12O3Br (M-1). M.P. 100-103 ˚C (Lit 815 102-104 ˚C). 
 
 (2E)-1-(5-bromo-2-hydroxyphenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (110)   
Method B; 2’-hydroxyacetophenone 93 (0.216 g, 1 mmol) and benzaldehyde 99 (0.134 g, 1 mmol) 
afforded 110 as a yellow solid (0.317 g, 95%). 1H NMR (DMSO-d6): δ 3.90 (s, 3 H, CH3); 6.97 (d, J = 8.8, 1 
H, CH-Cq-OH); 7.05 (t, J = 7.5, CH-CH-CH-Cq-O-CH3); 7.13 (d, J = 8.3, CH-Cq-O-CH3); 7.48 (td, J = 7.8, 1.3; 
CH-CH-Cq-O-CH3); 7.67 (dd, J = 8.8, 2.4, 1 H, CH-CH-Cq-Br); 7.92 (d, J = 15.7, 1 H, CH-Cq=O); 8.03 (dd, J = 
7.7, 1.2, 1 H, CH-Cq-Cq-O-CH3); 8.14 (d, J = 15.6, 1 H, CH=CH-Cq=O); 8.28 (dd, J = 2.2, 1 H, Cq-CH-Cq-Br); 
12.25 (s, 1 H, OH).  13C NMR (DMSO-d6): δ 55.78 (q, 1 C, CH3); 110.29 (s, 1 c, Cq-Br); 111.87 (d, 1 C, 
CH-Cq-O-CH3); 119.99 (d, 1 C, CH-Cq-OH); 120.65 (d, 1 C, CH-CH-CH-Cq-O); 121.83 (d, 1 C, CH-Cq=O); 
122.63 (s, 1 C, Cq-Cq-O-CH3); 123.34 (s, 1 C, Cq-Cq=O); 128.52 (d, 1 C, CH-Cq-Cq-O-CH3); 132.37 (d, 1 C, 
Cq-CH-Cq-Br); 132.88 (d, 1 C, CH-CH-Cq-O-CH3); 137.99 (CH-CH-Cq-Br); 139.44 (d, 1 C, CH=CH-Cq=O); 
158.39 (s, 1 C, Cq-O-CH3); 160.06 (s, 1 C, Cq-OH); 192.32 (s, 1 C, Cq=O). HRMS: Calculated mass for 




4-(bromomethyl)benzenesulfonamide (113)160    
To a solution of THF (10 ml) and aqueous ammonia (5 ml) on ice was added sulfonyl chloride 112 
(0.269 g, 1 mmol), and the reaction stirred on ice for 1 hour.703 EtOAc (10 ml) and H2O (5 ml) were 
added, and the resultant layers were separated. The organic layer was dried with Na2SO4 and the solvent 
removed in vacuo without heat to yield a white solid (0.202 g, 81 %). 1H NMR (DMSO-d6): δ 4.76 (s, 2 H, 
CH2); 7.36 (br.s, 2 H, NH2); 7.62 (d, J = 8.4, 2 H, 2x CH-Cq-S); 7.80 (d, J = 8.3, 2x CH-Cq-CH2). 13C NMR 
(DMSO-d6): δ 33.42 (t, 1 C, CH2); 126.52 (d, 2 C, 2x CH-Cq-CH2); 130.22 (d, 2 C, 2x CH-Cq-S); 142.36 (s, 1 C, 
Cq-CH2); 144.27 (d, 1 C, Cq-S). 15N NMR (DMSO-d6):  δ 95.5. HRMS: Calculated mass for C7H9O2NSBr 
248.9459; mass found 249.9468 for C7H10O2NSBr (M+1). M.P 189-191 ˚C (Lit816 191-192 ˚C). 
 
General procedure for Protection of Sulfonyl Chloride: Method C: (Amine protecting groups) 
KOH (0.610 g, 1.1 mmol) was dissolved in MeCN (25 ml), and then the appropriate amine (1 mmol) was 
added. The solution was stirred at room temperature for 30 mins, before the appropriate sulfonyl 
chloride (1 mmol) was added and the reaction stirred at room temperature for 2 hours.725 The 
precipitate was filtered off and allowed to air dry. An additional portion of material (5-15%) could be 
recovered from the filtrate; however this required labor-intensive separation from unreacted starting 
materials.  
 
Deprotection: The sulfonamide was dissolved in hydrazine hydrate (80%, 25 ml) and the solution was 
heated to reflux for 20 mins.729 The reaction was then removed from heat and allowed to cool to room 
temperature, after which H2O (10 ml) and EtOAc (50 ml) were added. The organic layer was removed, 
dried over MgSO4 and the solvent removed in vacuo without heat.  
 
Method D (Alkyl alcohol protecting groups) 
KOH (0.608 g, 1.1 mmol) was added to the appropriate alcohol (20 ml) and stirred to dissolve. Na2SO4 
was added to remove the water, followed by the appropriate sulfonyl chloride (1 mmol) and the 
reaction was stirred at room temperature for 2 hours.726 The solution was filtered and the solvent 




Deprotection: The sulfonate was added to a solution of KOH (1.122 g, 2 mmol), EtOH (20 ml) and H2O 
(10 ml) and heated to reflux for 1hr.730 The solution was allowed to cool and the resulting ppt filtered off 
and allowed to air dry.    
 
Method E (Phenol protecting groups) 
KOH (0.609 g, 1.1 mmol) was added to THF/H2O (10 ml, 20:1) and allowed to dissolve. Na2SO4 was added 
to remove the water, followed by the appropriate phenol (1 mmol) and sulfonyl chloride 65 (0.191 g, 1 
mmol). The reaction was stirred at 0˚C for 2 hours,727 before warming to room temperature. The 
solution was filtered and the solvent removed in vacuo.  
 
Deprotection: KOH (1.122 g, 2 mmol) was added to abs EtOH (5 ml) and stirred to dissolve, before 
addition to a solution of the appropriate sulfonate in CHCl3 (20 ml). The reaction was heated to reflux for 
2 hours, and allowed to cool.731 H2O (30 ml) and EtOAc (30 ml) was added, and the organic layer 
removed, dried over MgSO4 and removed in vacuo.  
 
  
N,N-diethyl-4-methylbenzenesulfonamide (114)732  
Method C; Diethylamine (0.073 g, 1 mmol) and sulfonyl chloride 65 (0.192 g, 1 mmol) afforded 114 as a 
white solid (0.205 g, 90%). 1H NMR (CDCl3): δ 1.12 (t, J = 7.1, 6 H, 2x CH2-CH3); 2.41 (s, 3 H, Cq-CH3); 3.23 




2-[(4-Methylphenyl)sulfonyl]-1H-isoindole-1,3(2H)-dione (119)725   
Method C; Phthalamide (0.147 g, 1 mmol) and sulfonyl chloride 65 (0.191 g, 1 mmol) afforded 119 as a 
white solid (0.259 g, 86%, deprotection 81%). 1H NMR (DMSO-d6): δ 2.40 (s, 3 H, CH3); 7.48 (d, J = 8.2, 2 
H, 2x CH-Cq-CH3); 7.92 (d, J = 1.5, 4 H, 2x CH-Cq-Cq=O and 2 x CH-CH-Cq-Cq); 7.98 (d, J = 8.5, 2 H, 2x 
CH-Cq-S). M.P. 229-230 ˚C (Lit818 230 ˚C). 
 
Ethyl 4-methylbenzenesulfonate (120)736   
 Method D; Ethanol (20 ml) and sulfonyl chloride 65 (0.192 g, 1 mmol) afforded 120 as an off-white solid 
(0.180 g, 90%, deprotection 93%). 1H NMR (CDCl3): δ 1.29 (t, J = 7.1, 3 H, CH2-CH3); 2.44 (s, 3 H, Cq-CH3); 
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4.10 (q, J = 7.2, 2 H, CH2); 7.34 (d, J = 8.2, 2 H, 2x CH-Cq-CH3); 7.478 (d, J = 8.5, 2 H, 2x CH-Cq-S). M.P. 
31-33 ˚C (Lit819 33-34 ˚C). 
 
Phenyl 4-methylbenzenesulfonate (121)737  
Method E; Phenol (0.094 g, 1 mmol) and sulfonyl chloride 65 (0.193 g, 1 mmol) afforded 121 as a white 
solid (0.186 g, 75%). 1H NMR (DMSO-d6): δ 2.42 (s, 3 H, CH3); 7.02 (d, J = 7.7, 2 H, 2x CH-CH-Cq-O); 7.31 (t, 
J = 7.0, 1 H, CH-CH-CH-Cq-O); 7.38 (t, J = 7.5, 2 H, 2x CH-Cq-O); 7.46 (d, J = 7.7, 2 H, 2x CH-Cq-CH3); 7.73 (d, 
J = 7.9, 2 H, 2x CH-Cq-S). M.P. 93-94 ˚C (Lit820 94-95 ˚C). 
 
4-Nitrophenyl 4-methylbenzenesulfonate (122)  
Method E; 4-nitrophenol (0.139 g, 1 mmol) and sulfonyl chloride 65 (0.194 g, 1 mmol) afforded 122 as a 
white solid (0.251 g, 86%). 1H NMR (CDCl3): δ 2.26 (s, 3 H, CH3); 6.98 (d, J = 9.1, 2 H, 2x CH-Cq-O); 7.15 (d, 
J = 8.1, 2 H, 2x CH-Cq-CH3); 7.52 (d, J = 8.3, 2 H, 2x CH-Cq-S); 7.98 (d, J = 9.1, 2 H, 2x CH-Cq-N=O). 
M.P.99-101˚C. 
 
Ethyl 4(bromomethyl)benzenesulfonate (123)738  
Method D; Ethanol (20 ml) and sulfonyl chloride 112 (0.269 g, 1 mmol) afforded 123 as a pale beige solid 
(0.272 g, 88%). 1H NMR (DMSO-d6): δ 1.21 (t, J = 7.1, 3 H, CH3); 4.12 (q, J = 7.1, 2 H, CH2-CH3); 4.79 (s, 2 H, 
CH2-Br); 7.76 (d, J = 8.4, 2 H, 2x CH-Cq-CH2); 7.89 (d, J = 8.3, 2 H, 2x CH-Cq-S). 13C NMR (DMSO-d6): δ 14.79 
(q, 1 C, CH3); 32.32 (t, 1 C, CH2-Br); 67.79 (t, 1 C, CH2-CH3); 127.89 (d, 2 C, 2x CH-Cq-S); 130.42 (d, 2 C, 2x 
CH-Cq-CH2); 135.18 (s, 1 C, Cq-S); 144.39 (s, 1 C, Cq-CH2). HRMS: Calculated mass for C7H6O3S 248.9221; 
mass found 248.9230. M.P. 39-41˚C  
 
2-{[4-(bromomethyl)phenyl]sulfonyl}-1H-isoindole-1,3(2H)-dione (124)739 
Method C; phthalamide (0.146 g, 1 mmol) and sulfonyl chloride 112 (0.268 g, 1 mmol) afforded 124 as a 
white solid (0.3319 g, 84%). 1H NMR (DMSO-d6): δ 4.48 (s, 2 H, CH2); 7.58 (d, J = 8.4, 2 H, 2x CH-Cq-CH2); 
7.81 (dd, J = 5.6, 3.0, 2 H, 2x CH-Cq-Cq or 2x CH-CH-Cq-Cq); 7.92 (dd, J = 5.6, 3.0, 2 H, 2x CH-Cq-Cq or 2x 
CH-CH-Cq-Cq); 8.19 (d, J = 8.5, 2 H, 2x CH-Cq-S). 13C NMR (DMSO-d6): δ 31.02 (t, 1 C, CH2); 124.67 (d, 2 C, 
2x CH-Cq-Cq or 2x CH-CH-Cq-Cq); 128.96 (d, 2 C, CH-Cq-S); 129.89 (d, 2 C, 2x CH-Cq-CH2); 130.91 (s, 2 C, 2x 
Cq-Cq=O); 135.59 (d, 2 C, 2x CH-Cq-Cq or 2x CH-CH-Cq-Cq); 138.17 (s, 1 C, Cq-S); 144.78 (s, 1 C, Cq-CH2); 
162.83 (s, 2 C, 2x Cq=O). HRMS: Calculated mass for C15H10O4BrNS 378.9514; mass found 378.9509.  M.P. 





General procedure for the Synthesis of Target Compounds– Method F 
Compound 123 (0.309 g, 1 mmol), the appropriate 2’-hydroxyacetophenone (1 mmol) and K2CO3 
(0.275 g, 2 mmol) were added to THF (30 ml) and heated to reflux for 24 hours. The resulting cream 
precipitate was filtered from solution and allowed to air dry.  
 
Method G  
Compound 123 (0.309 g, 1 mmol), appropriate 2’-hydroxyacetophenone (1 mmol) and K2CO3 (0.415 g, 
3 mmol) were added to THF (30 ml) and heated to reflux for 36 hours. The resulting cream precipitate 
was filtered from solution and allowed to air dry.  
 
Potassium 4-[2-(2-acetylphenyl)ethyl]benzenesulfonate (125)  
Method F; sulfonate 123 (0.310 g, 1 mmol) and 2’-hydroxyacetophenone 60 (0.136 g, 1 mmol) afforded 
125 as a pale beige solid (0.285 g, 83%). 1H NMR (DMSO-d6): δ 2.51 (s, 3 H, CH3); 5.24 (s, 2 H, CH2); 7.03 
(ddd, 1 H, J = 7.7, 7.3, 1.0, CH-CH-Cq-Cq=O); 7.24 (d, 1 H, J = 8.2, CH-Cq-O); 7.46 (d, 2 H, J = 8.3, 
2 x CH-Cq-CH2); 7.52 (ddd, 1 H, J = 8.4, 7.3, 1.9, CH-CH-Cq-O); 7.59 (dd, 1 H, J = 7.7, 1.8, CH-Cq-Cq=O); 7.64 
(s, 2 H, J = 8.2, 2 x CH-Cq-S). 13C NMR (DMSO-d6): δ 31.72 (q, 1 C, CH3); 69.73 (t, 1 C, CH2); 113.63 (d, 1 C, 
CH-Cq-O); 120.57 (d, 1 C, CH-CH-Cq-Cq=O); 125.71 (d, 2 C, 2 x CH-Cq-S); 127.15 (d, 2 C, 2 x CH-Cq-CH2); 
128.17 (s, 1 C, Cq-Cq=O); 129.50 (d, 1 C, CH-Cq-Cq=O); 133.65 (d, 1 C, CH-CH-Cq-O); 136.57 (s, 1 C, Cq-CH2 
or Cq-S); 148.04 (s, 1 C, Cq-CH2 or Cq-S); 157.40 (s, 1 C, Cq-O); 198.79 (s, 1 C, Cq=O). HRMS: Calculated 
mass for C15H13O5S 305.0477; mass found 305.0484. Decomposes above 180 ˚C. 
 
Potassium 4-[2-(2-acetyl-5-fluorophenyl)ethyl]benzenesulfonate (126)   
Method F; sulfonate 123 (0.309 g, 1 mmol) and 2’-hydroxyacetophenone 76 (0.154 g, 1 mmol) afforded 
126 as a pale beige solid (0.286 g, 79%). 1H NMR (DMSO-d6): δ 2.48 (s, 3 H, CH3); 5.25 (s, 2 H, CH2); 6.87 
(td, J = 8.4, 2.4, 1 H, CH-CH-Cq-F); 7.17 (dd, J = 11.5, 2.4, 1 H, Cq-CH-Cq); 7.47 (d, J = 8.3, 2 H, 
2 x CH-Cq-CH2); 7.65 (d, J = 8.2, 2 H, 2 x CH-Cq-S); 7.71 (dd, J = 8.7, 7.2, 1 H, CH-Cq-Cq=O). 13C NMR 
(DMSO-d6): δ 31.67 (q, 1 C, CH3); 70.35 (t, 1 C, CH2); 101.56 (dd, 2J19F-13C = 25.9, 1 C, Cq-CH-Cq); 107.53 
(dd, 2J19F-13C = 21.9, 1 C, CH-CH-Cq-F); 124.53 (s, 1 C, Cq-Cq=O); 125.75 (d, 1 C, 2 x CH-Cq-S); 127.37 (d, 1 C, 
2 x CH-Cq-CH2); 132.01 (dd, 3J19F-13C = 11.2, 1 C, CH-Cq-Cq=O); 135.96 (s, 1 C, Cq-CH2); 148.24 (s, 1 C, Cq-S); 
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159.44 (d, 3J19F-13C = 11.1, 1 C, Cq-O-CH2); 165.34 (d, 1J19F-13C = 250.3, 1 C, Cq-F); 197.00 (s, 1 C, Cq=O). 19F 
NMR (DMSO-d6): δ -104.5 (m, 1 F, Cq-F). HRMS: Calculated mass for C15H12O5FS 323.0389; mass found 
323.0385. Decomposes above 195 ˚C. 
 
Potassium 4-[2-(2-acetyl-5-chlorophenyl)ethyl]benzenesulfonate (127)   
Method G; sulfonate 123 (0.311 g, 1 mmol) and 2’-hydroxyacetophenone 82 (0.170 g, 1 mmol) afforded 
127 as a pale beige solid (0.272 g, 72%). 1H NMR (D2O, 40˚C): δ 2.48 (s, 3 H, CH3); 5.27 (s, 2 H, CH2); 7.10 
(dd, J = 8.3, 1.6, 1 H, CH-CH-Cq-Cl); 7.36 (d, J = 1.6, 1 H, Cq-CH-Cq-Cl); 7.46 (d, J = 8.1, 2 H, 2 x CH-Cq-CH2); 
7.57 (d, J = 8.3, 1H, CH-Cq-Cq=O); 7.66 (d, J = 7.9, 2 H, 2 x CH-Cq-S). 13C NMR (DMSO-d6): δ 32.09 (q, 1 C, 
CH3); 65.22 (t, 1 C, CH2); 114.07 (d, 1 C, CH-Cq-O); 120.89 (d, 1 C, CH-CH-Cq-Cl); 126.26 (d, 2 C, 2 x CH-Cq-
S); 127.08 (s, 1 C, Cq-Cq=O); 127.82 (d, 2 C, 2 x CH-Cq-CH2); 131.52 (d, 1 C, CH-Cq-Cq=O); 136.45 (s, 1 C, Cq-
Cl); 138.67 (s, 1 C, Cq-CH2); 146.03 (s, 1 C, Cq-S); 159.08 (s, 1 C, Cq-O); 198.16 (s, 1 C, Cq=O). HRMS: 
Calculated mass for C15H12O5ClS 339.0094; mass found 339.009. Decomposes above 195 ˚C. 
 
General procedure for the Synthesis of the Target Compounds:  Method H: 
The appropriate sulfonate (1 mmol) and the appropriate benzaldehyde (1  mmol) were added to a 
stirred solution of KOH (0.275 g, 2 mmol) in abs EtOH (10 ml), and stirred at room temperature for 24 
hours. The precipitate was filtered from solution and allowed to air dry. The precipitate was 
recrystallized from water, filtered and allowed to air dry.  
 
Method I: 
The appropriate sulfonate (1 mmol) and the appropriate benzaldehyde (1 mmol) were added to a stirred 
solution of KOH (0.414 g, 3 mmol) in abs EtOH (10 ml), and stirred at room temperature for 36 hours. 
The precipitate was filtered from solution and allowed to air dry. The precipitate was then recrystallized 
from water, filtered and allowed to air dry.   
 
Potassium 4-(2-{2-[(2E)-3-phenylprop-2-enoyl]phenoxy}methyl)benzenesulfonate (3)  
Method H; sulfonate 125 (0.344 g, 1 mmol) and benzaldehyde 67 (0.104 g, 1 mmol) afforded 3 as an off-
white solid (0.315 g, 73%). 1H NMR (D2O, 40˚C): δ 5.07 (br.s, 2 H, CH2); 7.09 (t, J = 7.5, 1 H, CH-CH-Cq-Cq); 
7.16 (d J = 8.8, CH-Cq-O); 7.25 (d, J = 16.3, 1 H, CH-Cq=O); 7.31 (d, J = 7.3, 2 H, 2x CH-Cq-CH=CH); 7.35 (t, J 
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= 7.6, 2 H, 2x CH-CH-Cq-CH=CH); 7.39 (d, J = 7.5, 2 H, 2x CH-Cq-CH2); 7.38-7.43 (m, 3 H); 7.41 (d, J = 16.2, 1 
H, CH=CH-Cq=O); 7.50 (d, J = 7.5, 1 H, CH-Cq-Cq=O); 7.55 (t, J = 8.7, 1 H, CH-CH-Cq-O); 7.58 (d, J = 8.2, 2 H, 
2x CH-Cq-S). 13C NMR (DMSO-d6): δ 71.34 (t, 1 C, CH2); 115.14 (d, 1 C, CH-Cq-O); 123.12 (d, 1 C, 
CH-CH-Cq-Cq=O); 127.31 (d, 2 C, 2x CH-Cq-S); 128.28 (d, 1 C, CH-Cq=O); 129.45 (s, 1 C, Cq-Cq=O); 129.66 (d, 
2 C, 2x CH-Cq-CH2); 130.09 (d, 2 C, 2x CH-Cq-CH=CH); 130.74 (d, 2 C, 2x CH-CH-Cq-CH=CH); 131.81 (d, 1 C, 
CH-Cq-Cq=O); 132.83 (d, 1 C, CH-CH-CH-CH-CH); 135.59 (s, 1 C, Cq-CH=CH-Cq=O); 136.01 (d, 1 C, 
CH-CH-Cq-O); 140.69 (s, 1 C, Cq-CH2); 143.43 (s, 1 C, Cq-S); 146.69 (d, 1 C, CH=CH-Cq=O); 158.60 (s, 1 C, 
Cq-O); 197.10 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H17O5S 393.0797; mass found 393.0797. 
Decomposes above 230 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(4-bromophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (5)  
Method H; sulfonate 125 (0.343 g, 1 mmol) and benzaldehyde 63 (0.188 g, 1 mmol) afforded 5 as an off-
white solid (0.414 g, 81%). 1H NMR (D2O, 40˚C): δ 4.86 (br.s, 2 H, CH2); 6.78 (d, J = 7.4, 2 H, 2x 
CH-CH-Cq-Br); 6.90-6.95 (m, 2 H, CH-Cq-O and CH-CH-Cq-Cq); 6.95 (d, J = 16.7, 1 H, CH-Cq=O); 7.09 (d J = 
15.8, 1 H, CH=CH-Cq=O); 7.21 (d J = 7.1, 2 H, 2x CH-Cq-Br); 7.26 (d, J = 7.9, 2 H, CH-Cq-CH2); 7.35 (d, J = 
7.6, 1 H, CH-Cq-Cq=O); 7.39 (t, J = 7.7, CH-CH-Cq-O); 7.57 (d, J = 8.2, 2x CH-Cq-S). 13C NMR (DMSO-d6): δ 
69.85 (t, 1 C, CH2); 113.55 (CH-Cq-O); 121.44 (d, 1 C, CH-CH-Cq-Cq); 124.67 (s, 1 C, Cq-CH=CH-Cq=O or 
Cq-Cq=O); 125.79 (d, 2 C, 2x CH-Cq-S); 126.89 (d, 1 C, CH-Cq=O); 127.36 (s, 1 C, Cq-CH=CH-Cq=O or 
Cq-Cq=O); 128.09 (d, 2 C, 2x CH-Cq-CH2); 129.72 (d, 2 C, 2x CH-CH-Cq-Br); 130.41 (d, 1 C, CH-Cq-Cq=O); 
131.96 (d, 2 C, 2x CH-Cq-Br); 132.99 (s, 1 C, Cq-Br); 134.61 (d, 1 C, CH-CH-Cq-O); 139.10 (s, 1 C, Cq-CH2); 
142.63 (s, 1 C, Cq-S); 143.10 (d, 1 C, CH=CH-Cq=O); 157.21 (s 1 C, Cq-O); 194.26 (s, 1 C, Cq=O). HRMS: 
Calculated mass for C22H16O5BrS 470.9902; mass found 470.9913. Decomposes above 220 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (6)   
Method H; sulfonate 125 (0.346 g, 1 mmol) and benzaldehyde 70 (0.145 g, 1 mmol) afforded 6 as an off-
white solid (0.351 g, 76%). 1H NMR (D2O, 40˚C): δ 4.57 (br.s, 2 H, CH2); 6.62 (d, J = 8.4, 1 H, CH-Cq-O); 
6.63 (t, J = 7.3, 1 H, CH-CH-Cq-Cq=O); 6.69 (d, J = 8.3, 2 H, 2 x CH-Cq-CH=CH); 6.83 (d, J = 15.6, 1 H, 
CH-Cq=O); 6.89 (d, J = 8.3, 2 H, 2 x CH-Cq-Cl); 6.98 (d, J = 15.8, 1 H, CH=CH-Cq=O); 7.05 (d, J = 8.0, 2 H, 2 x 
CH-CH-Cq-S); 7.08 (t, J = 7.7, 1 H, CH-CH-Cq-O); 7.23 (dd, J = 7.5, J = 1.3, 1 H, CH-Cq-Cq); 7.52 (d, J = 8.2, 
2 H, 2 x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 69.56 (t, 1 C, CH2); 113.26 (d, 1 C, CH-Cq-O); 121.00 (d, 1 C, 
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CH-CH-Cq-Cq=O); 125.79 (d, 2 C, 2 x CH-Cq-S); 126.81 (d, 1 C, CH=CH-Cq=O); 127.62 (s, 1 C, Cq-Cq=O); 
127.70 (d, 2 C, 2x CH-CH-Cq-S); 128.92 (d, 2 C, 2 x CH-Cq-Cl); 129.42 (d, 2 C, 2x CH-Cq-CH=CH); 130.41 (d, 
1 C, CH-Cq-Cq=O); 132.65 (s, 1 C, Cq-CH=CH); 133.98 (d, 1 C, CH-CH-Cq-O); 135.82 (s, 1 C, Cq-Cl); 138.86 (s, 
1 C, Cq-S or Cq-CH2); 142.13 (d, 1 C, CH=CH-Cq=O); 142.83 (s, 1 C, Cq-S or Cq-CH2); 157.11 (s, 1 C, Cq-O); 
192.35 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5ClS 427.0407; mass found 427.0412. 
Decomposes above 220 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(4-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (7)  
Method H; sulfonate 125 (0.345 g, 1 mmol) and benzaldehyde 72 (0.123 g, 1 mmol) afforded 7 as an off-
white solid (0.324 g, 72%). 1H NMR (D2O, 40˚C): δ 5.09 (s, 2 H, CH2); 7.05-7.12 (m, 3 H, 2x CH-Cq-F and 
CH-CH-Cq-Cq=O);  7.17 (d, J = 15.8, 1 H, CH-Cq=O); 7.18 (d, J = 8.5. 1 H, CH-Cq-O); 7.26-7.30 (m, 2 H, 2x 
CH-CH-Cq-F); 7.38 (d, J =15.9, 1 H, CH=CH-Cq=O);  7.42 (d, J = 8.2, 2 H, 2x CH-Cq-CH2); 7.53 (dd, J = 7.7, 
1.6, 1 H, CH-Cq-Cq=O); 7.57 (td, J = 7.1, 1.6, 1 H, CH-CH-Cq-O); 7.62 (d, J = 8.1, 2 H, 2x CH-Cq-S). 13C NMR 
(D2O, 40˚C): δ 71.36 (t, 1 C, CH2); 115.12 (d, 1 C, CH-Cq-O); 117.66 (dd, 2J19F-13C = 21.7, 2 C, 2x CH-Cq-F); 
123.07 (d, 1 C, CH-CH-Cq-Cq=O); 127.30 (d, 2 C, 2x CH-Cq-S); 127.95 (d, 1 C, CH-Cq=O); 129.67 (s, 1 C, 
Cq-Cq=O or Cq-CH=CH-Cq=O); 129.72 (d, 2 C, 2x CH-Cq-CH2); 131.82 (d, 1 C, CH-Cq-Cq=O); 131.98 (s, 1 C, 
Cq-Cq=O or Cq-CH=CH-Cq=O); 132.13 (dd, 3J19F-13C = 9.3, 2 C, 2x CH-CH-Cq-F); 136.03 (d, 1 C, CH-CH-Cq-O); 
140.61 (s, 1 C, Cq-CH2); 144.54 (s, 1 C, Cq-S); 145.24 (d, 1 C, CH=CH-Cq=O); 158.65 (s, 1 C, Cq-O) 166.78 (d, 
1J19F-13C = 250.9, 1 C, Cq-F); 196.59 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5FS 411.0702; mass 
found 411.0707. Decomposes above 230 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(4-methoxyphenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (8)  
Method H; sulfonate 125 (0.344 g, 1 mmol) and benzaldehyde 99 (0.137 g, 1 mmol) afforded 8 as an off-
white solid (0.314 g, 68%). 1H NMR (D2O, 40˚C): δ 3.76 (s, 3 H, CH3); 4.98 (s, 2 H, CH2); 6.79 (d, J = 8.4, 2 
H, 2x CH-CH-Cq-O-CH3); 6.98-7.13 (m, 5 H, 2x CH-Cq-O-CH3, CH-Cq=O, CH-Cq-O-CH2 and CH-CH-Cq-Cq=O); 
7.32 (d, J = 15.9, 1 H, CH=CH-Cq=O); 7.36 (d, J = 8.0, 2 H, 2x CH-Cq-CH2); 7.44-7.55 (m, 2 H, 
CH-CH-Cq-O-CH2 and CH-Cq-Cq=O); 7.62 (d, J = 8.2, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 57.01 (q, 1 C, 
CH3); 71.21 (t, 1 C, CH2); 114.90 (d, 1 C, CH-Cq-O-CH2); 116.07 (d, 2 C, 2x CH-CH-Cq-O-CH3); 122.95 (d, 1 C, 
CH-CH-Cq-Cq=O); 125.87 (d, 1 C, CH-Cq=O); 127.29 (d, 2 C, 2x CH-Cq-S); 128.45 (s, 1 C, Cq-Cq=O or 
Cq-CH=CH-Cq=O); 129.31 (s, 1 C, Cq-Cq=O or Cq-CH=CH-Cq=O); 129.68 (d, 2 C, 2x CH-Cq-CH2); 131.82 (d, 
1 C, CH-Cq-Cq=O); 131.99 (d, 2 C, 2x CH-Cq-O-CH3); 135.80 (d, 1 C, CH-CH-Cq-O-CH2); 140.54 (s, 1 C, 
Cq-CH2); 144.61 (s, 1 C, Cq-S); 146.27 (d, 1 C, CH=CH-Cq=O); 158.57 (s, 1 C, Cq-O-CH2); 162.87 (s, 1 C, 
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Cq-O-CH3); 195.98 (s, 1 C, Cq=O). HRMS: Calculated mass for C23H19O6S 423.0902; mass found 423.0916. 
Decomposes above 240 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(3-bromophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (9)  
Method H; sulfonate 125 (0.342 g, 1 mmol) and benzaldehyde 132 (0.186 g, 1 mmol) afforded 9 as an 
off-white solid (0.373 g, 73%).1H NMR (D2O, 40˚C): δ 4.77 (br.s, 2 H, CH2); 6.77 (t,  J = 7.4, 1H, 
CH-CH-Cq-Cq=O); 6.81 (d, J = 8.5, 1 H, CH-Cq-O) 6.95-6.98 (m, 3 H, CH-Cq=O, CH-Cq-CH=CH and CH-Cq-Br); 
7.07 (d, J = 15.7, 1 H, CH=CH-Cq=O) 7.16 (br.s, 1 H, Cq-CH-Cq-Br) 7.19-7.22 (m, 4 H, CH-CH-Cq-O, 2x 
CH-Cq-CH2 and CH-CH-Cq-Br); 7.29 (dd, J = 7.6, 1.5, 1 H, CH-Cq-Cq=O)   7.61 (d, J= 8.3, 2 H, 2 x CH-Cq-S). 13C 
NMR (D2O, 40˚C): δ 70.99 (t, 1 C, CH2); 114.81 (d, 1 C, CH-Cq-O); 122.63 (d, 1C, CH-CH-Cq-Cq); 123.96 (s, 1 
C, Cq-Br); 127.31 (d, 2 C, 2x CH-Cq-S); 128.34 (d, 1 C, CH-Cq=O); 129.01 (d, 2 C, 2x CH-Cq-CH2); 129.16 (d, 1 
C, CH-CH-Cq-Br); 129.41 (s, 1 C, Cq-Cq=O); 131.73 (d, 1 C, CH-Cq-Cq); 132.13 (d, 1 C, CH=CH-Cq-CH-CH or 
CH-CH-Cq-Br) 132.18 (d, 1 C, Cq-CH-Cq-Br); 134.71 (d, 1 C, d, 1 C, CH=CH-Cq-CH-CH or CH-CH-Cq-Br); 
135.47 (d, 1 C, CH-CH-Cq-O); 137.76 (s, 1 C, Cq-CH=CH); 140.36 (s, 1 C, Cq-CH2); 143.39 (s, 1 C, 
CH=CH-Cq=O); 144.64 (s, 1 C, Cq-S); 158.36 (s, 1 C, Cq-O); 194.48 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C22H16O5BrS 470.9902; mass found 470.9902. Decomposes above 210 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(3-chlorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (43) 
 Method H; sulfonate 125 (0.346 g, 1 mmol) and benzaldehyde 133 (0.145 g, 1 mmol) afforded 43 as an 
off-white solid (0.364 g, 78%). 1H NMR (D2O, 40˚C): δ 4.80 (s, 2 H, CH2); 6.79 (t, J = 7.3, 1 H, 
CH-CH-Cq-Cq=O); 6.85 (d, J = 8.3, 1 H, CH-Cq-O); 6.91 (d, J = 7.1, 1 H, CH-Cq-CH-Cq-Cl); 6.99-7.15 (m, 5 H, 
Cq-CH-Cq-Cl, CH-CH-Cq-Cl, CH-CH-Cq-Cl, CH-Cq=O and CH=CH-Cq=O); 7.23 (d, J = 8.1, 2 H, 2x CH-Cq-CH2); 
7.26 (t, J = 7.7, 1 H, CH-CH-Cq-O); 7.33 (d, J = 7.4, 1 H, CH-Cq-Cq=O); 7.61 (d, J = 8.1, 2 H, 2x CH-Cq-S). 13C 
NMR (D2O, 40˚C): δ 70.97 (t, 1 C, CH2); 114.68 (d, 1 C, CH-Cq-O); 122.61 (d, 1 C, CH-CH-Cq-Cq=O); 127.17 
(d, 1 C, Cq-CH-Cq-Cl); 127.27 (d, 2 C, 2x CH-Cq-S); 127.81 (d, 1 C, CH-Cq=O or CH-CH-Cq-CH=CH); 127.83 (d, 
1 C, CH-Cq=O or CH-CH-Cq-CH=CH);  129.05 (d, 2 C, 2x CH-Cq-CH2); 129.33 (s, 1 C, Cq-Cq=O); 131.72 (d, 1 C, 
CH-CH-Cq-Cl); 131.76 (d, 1 C, CH-Cq-Cq=O); 135.49 (d, 1 C, CH-CH-Cq-Cl); 135.55 (s, 1 C, Cq-CH-Cq-Cl or 
Cq-Cl); 137.48 (s, 1 C, Cq-CH-Cq-Cl or Cq-Cl); 140.21 (s, 1 C, Cq-CH2); 143.22 (d, 1 C, CH=CH-Cq=O); 144.83 
(s, 1 C, Cq-S); 158.42 (s, 1 C, Cq-O); 194.30 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5ClS 





Potassium 4-(2-{2-[(2E)-3-(3-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (44) 
 Method H; sulfonate 125 (0.344 g, 1 mmol) and benzaldehyde 134 (0.124 g, 1 mmol) afforded 44 as an 
off-white solid (0.342 g, 76%). 1H NMR (D2O, 40˚C): δ 5.28 (s, 2 H, CH2); 7.22 (t, J = 7.5, 1 H, 
CH-CH-Cq-Cq=O); 7.24-7.38 (m, 4 H, CH-Cq-O, CH-CH-Cq-F, Cq-CH-Cq-F and CH-CH-CH-Cq-F); 7.46 (d, J = 
15.9, 1 H, CH-Cq=O); 7.50-7.59 (m, 4 H, CH=CH-Cq=O, 2x CH-Cq-O and  CH-CH-Cq-F); 7.65 (dd, J =7.7, 1.3, 1 
H, CH-Cq-Cq=O); 7.67-7.72 (m, 3 H, 2x CH-Cq-S and CH-CH-Cq-O). 13C NMR (D2O, 40˚C): δ 71.05 (t, 1 C, 
CH2); 114.94 (d, 1 C, CH-Cq-O); 116.07 (dd, 2J19F-13C =21.1, 1 C, Cq-CH-Cq-F); 119.24 (dd, 2J19F-13C = 21.6, 1 C, 
CH-CH-Cq-F); 122.99 (d, 1 C, CH-CH-Cq-Cq=O); 125.83 (d, 1 C, CH-Cq-CH-Cq-F); 127.13 (d, 2 C, 2x CH-Cq-S); 
129.32 (d, 2 C, 2x CH-Cq-CH2); 129.38 (s, 1 C, Cq-Cq=O); 129.48 (d, 1 C, CH-Cq=O); 131.59 (d, 1 C, 
CH-Cq-Cq=O); 132.51 (dd, 3J19F-13C = 8.1, CH-CH-Cq-F); 135.88 (d, 1 C, CH-CH-Cq-O); 137.83 (d, 3J19F-13C = 7.6, 
1 C, Cq-CH-Cq-F); 140.78 (s, 1 C, Cq-CH2); 144.15 (d, 1 C, CH=CH-Cq=O); 145.17 (s, 1 C, Cq-S); 158.42 (s, 1 C, 
Cq-O); 165.19 (d, 1J19F-13C = 244.7, 1 C, Cq-F); 196.02 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5FS 
411.0702; mass found 411.0706. Decomposes above 230 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(2-bromophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (10)  
Method H; sulfonate 125 (0.346 g, 1 mmol) and benzaldehyde 135 (0.185 g, 1 mmol) afforded 10 as an 
off-white solid (0.337 g, 66%). 1H NMR (D2O, 40˚C): δ 4.87 (br.s, 2 H, CH2); 6.87 (t, J = 7.3, 1 H, 
CH-CH-Cq-Cq); 6.94 (d, J = 8.3, 1 H, CH-Cq-O); 6.99 (d, J = 7.9, 1 H, CH-Cq-Cq-Br); 7.01 (d, J = 15.1, 1 H, 
CH-Cq=O); 7.09 (m, 2 H, Br-Cq-Cq-CH-CH and CH-CH-Cq-Br); 7.29 (d, J = 8.1, 2 H, 2x CH-Cq-CH2); 7.32-7.35 
(m, 2 H, CH-Cq-Br and CH-CH-Cq-O); 7.40 (d, J = 7.7, 1 H, CH-Cq-Cq); 7.61 (d, J = 16.1, 1 H CH=CH-Cq); 7.62 
(d, J = 8.2, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 71.17 (t, 1 C, CH2); 114.61 (d, 1 C, CH-Cq-O); 122.74 (d, 
1 C, CH-CH-Cq-Cq); 122.81 (s, 1 C, Cq-Cq=O); 126.79 (s, 1 C, Cq-Br); 127.28 (d, 2 C, 2x CH-Cq-S); 129.01 (d, 1 
C, CH-Cq-Cq-Br); 129.46 (d, 2 C, 2x CH-Cq-CH2); 129.66 (d, 1 C, CH-CH-Cq-Cq-Br or CH-CH-Cq-Br); 130.38 (d, 
1 C, CH-Cq=O); 133.54 (d, 1 C, CH-CH-Cq-Cq-Br or CH-CH-Cq-Br); 134.22 (d, 1 C, CH-Cq-Br); 134.75 (s, 1 C, 
Cq-Cq-Br); 140.23 (s, 1 C, Cq-CH2); 143.22 (d, 1 C, CH=CH-Cq=O); 144.89 (s, 1 C, Cq-S); 158.62 (s, 1 C, Cq-O); 
194.60 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5BrS 470.9902; mass found 470.9901. 
Decomposes above 220 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(2-chlorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (45)  
Method H; sulfonate 125 (0.346 g, 1 mmol) and benzaldehyde 74 (0.148 g, 1 mmol) afforded 45 as an 
off-white solid (0.317 g, 68%). 1H NMR (D2O, 40˚C): δ 4.91 (s, 2 H, CH2); 6.89 (t, J = 7.4, 1 H, 
CH-CH-Cq-Cq=O); 6.97 (d, J = 8.4, 1 H, CH-Cq-O); 7.03 (d, J = 8.4, 1 H, CH-Cq-Cl); 7.07-7.13 (m, 2 H, CH-Cq=O 
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and CH-CH-Cq-Cq-Cl); 7.19-7.22 (m, 2 H, CH-CH-Cq-Cl and CH-Cq-Cq-Cl); 7.31 (d, J = 8.1, 2 H, 2x CH-Cq-CH2); 
7.37 (t, J = 7.1, 1 H, CH-CH-Cq-O); 7.42 (d, J = 7.7, 1 H, CH-Cq-Cq=O); 7.63 (d, J = 8.2, 2 H, 2x CH-Cq-S); 7.68 
(d, J = 15.8, 1 H, CH=CH-Cq=O). 13C NMR (D2O, 40˚C): δ 71.07 (t, 1 C, CH2); 114.61 (d, 1 C, CH-Cq-O); 
122.71 (d, 1 C ,CH-CH-Cq-Cq=O); 127.24 (d, 2 C, 2x CH-Cq-S); 128.88 (d, 1 C, CH-CH-Cq-Cq=O); 128.96 (s, 1 
C, Cq-Cq=O); 129.03 (d, 1 C, CH-CH-Cq-Cq-Cl); 129.41 (d, 2 C, 2x CH-Cq-CH2); 130.34 (d, 1 C, CH-Cq=O); 
131.40 (d, 1 C, CH-CH-Cq-Cl or CH-Cq-Cq-Cl); 131.82 (d, 1 C, CH-Cq-Cq=O); 133.33 (d, 1 C, CH-CH-Cq-Cl or 
CH-Cq-Cq-Cl); 135.83 (d, 1 C, CH-CH-Cq-O); 135.89 (s, 1 C, Cq-Cl); 140.07 (s, 1 C, Cq-CH2); 140.24 (d, 1 C, 
CH=CH-Cq=O); 145.03 (s, 1 C, Cq-S); 158.61 (s, 1 C, Cq-O); 194.48 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C22H16O5ClS 427.0407; mass found 427.0413. Decomposes above 205 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(2-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (46)  
Method H; sulfonate 125 (0.344 g, 1 mmol) and benzaldehyde 136(0.123 g, 1 mmol) afforded 46 as an 
off-white solid (0.320 g,  71%). 1H NMR (D2O, 40˚C): δ 4.99 (s, 2 H, CH2); 6.91 (t, J = 7.5, 1 H, 
CH-CH-Cq-Cq=O); 6.96 (dd, J = 8.6, 10.6, 1 H, CH-Cq-F); 7.01-7.04 (m, 2 H, CH-Cq-O and CH-CH-Cq-Cq-F); 
7.13 (t, J = 7.6, 1 H, CH-CH-Cq-F); 7.19 (d, J = 16.1, 1 H, CH-Cq=O); 7.26-7.28 (m, 3 H, 2x CH-Cq-CH2 and 
CH-Cq-Cq-F); 7.35 (d, J = 7.6, 1 H,  CH-Cq-Cq=O); 7.37 (d, J = 16.0, 1 H, CH=CH-Cq=O); 7.39 (td, J =7.8, 1.6, 1 
H, CH-CH-Cq-O); 7.45 (d, J = 8.2, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 71.03 (t, 1 C, CH2); 114.83 (d, 1 
C, CH-Cq-O); 117.59 (dd, 2J19F-13C = 22.3, 1 C, CH-Cq-F); 122.93 (d, 1 C, CH-CH-Cq-Cq=O); 123.22 (d, 2J19F-13C = 
10.7, 1 C, Cq-Cq-F); 126.55 (d, 1 C, CH-CH-Cq-Cq-F); 127.12 (d, 2 C, 2x CH-Cq-S); 129.20 (s, 1 C, Cq-Cq=O); 
129.31 (d, 2 C, 2x CH-Cq-CH2); 130.18 (d, 1 C, CH-Cq=O or CH-CH-Cq-F); 130.20 (d, 1 C, CH-Cq=O or 
CH-CH-Cq-F); 131.64 (d, 1 C, CH-Cq-Cq=O); 134.42 (dd, 3J19F-13C = 9.1, 1 C, CH-Cq-Cq-F); 135.92 (d, 1 C, 
CH-CH-Cq-O); 137.75 (d, 1 C, CH=CH-Cq=O); 140.12 (s, 1 C, Cq-CH2); 145.15 (s, 1 C, Cq-S); 158.44 (S, 1 C, 
Cq-O); 162.40 (d, 1J19F-13C = 252.3, 1 C, Cq-F); 195.80 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5FS 
411.0702; mass found 411.0707. Decomposes above 210 ˚C. 
 
Potassium 4-(2-{2-[(2E)-3-(2-methoxyphenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (47)  
Method H; sulfonate 125 (0.345 g, 1 mmol) and benzaldehyde 100 (0.136g, 1 mmol) afforded 47 as an 
off-white solid (0.296 g, 64%). 1H NMR (D2O, 40˚C): δ 3.83 (s, 3 H, CH3); 5.12 (s, 2 H, CH2); 7.07 (t, J = 7.5, 
1 H, CH-CH-Cq-Cq-O-CH3); 7.12 (d, J = 8.0, CH-Cq-O-CH3); 7.19 (t, J =7.5, 1 H, CH-CH-Cq-Cq=O); 7.29 (d, J = 
8.5, CH-Cq-O-CH2); 7.38-7.44 (m, 2 H, CH-Cq=O and CH-Cq-Cq-O-CH3); 7.50-7.55 (m, 3 H, 2x CH-Cq-CH2 and 
CH-CH-Cq-O-CH3); 7.57 (d, J = 7.5, 1 H, CH-Cq-Cq=O); 7.64 (t, J = 7.3, 1 H, CH-CH-Cq-O-CH2); 7.69 (d, J = 8.1, 
2 H, 2x CH-Cq-S); 7.86 (d, J = 16.1, 1 H, CH=CH-Cq=O). 13C NMR (D2O, 40˚C): δ 56.90 (q, 1 C, CH3); 70.86 (t, 
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1 C, CH2); 113.29 (CH-Cq-O-CH3); 114.74 (CH-Cq-O-CH2); 122.55 (d, 1 C, CH-CH-Cq-Cq-O-CH3); 122.85 (d, 
1 C, CH-CH-Cq-Cq=O); 123.87 (s, 1 C, Cq-Cq=O); 127.06 (d, 2 C, 2x CH-Cq-S); 128.34 (d, 1 C, CH-Cq=O); 
129.08 (d, 2 C, 2x CH-Cq-CH2); 129.77 (s, 1 C,  Cq-CH=CH-Cq=O); 129.92 (s, 1 C, CH-Cq-Cq-O-CH3); 131.37 (d, 
1 C, CH-Cq-Cq=O); 134.39 (d, 1 C, CH-CH-Cq-O-CH3); 135.36 (d, 1 C, CH-CH-Cq-O-CH2); 135.56 (d, 1 C, 
CH-CH-Cq-O-CH2); 140.17 (s, 1 C, Cq-CH2); 141.08 (d, 1 C, CH=CH-Cq=O); 145.16 (s, 1 C, Cq-S); 158.06 (s, 1 
C, Cq-O-CH2); 159.68 (s, 1 C, Cq-O-CH3); 196.53 (s, 1 C, Cq=O). HRMS: Calculated mass for C23H19O6S 
423.0902; mass found 423.0913. Decomposes above 225 ˚C. 
 
Potassium 4-({5-fluoro-2-[(2E)-3-phenylprop-2-enoyl]phenoxy}methyl)benzenesulfonate (11) 
Method H; sulfonate 126 (0.362 g, 1 mmol) and benzaldehyde 67 (0.106 g, 1 mmol) afforded 11 as an 
off-white solid (0.387 g, 68%). 1H NMR (D2O, 40˚C): δ 5.44 (s, 2 H, CH2); 7.14 (dd, J = 4.1, 2.2, 1 H, 
CH-Cq-O); 7.35 (dd, J = 11.1, 2.1, 1 H, CH-CH-Cq-F); 7.67-7.69 (m, 5 H, 2x CH-Cq-CH=CH, 2x 
CH-CH-Cq-CH=CH and CH-CH-CH-CH-CH); 7.69 (d, J = 15.5, 1 H, CH-Cq=O); 7.74 (d, J = 8.2, 2 H, 2x 
CH-Cq-S); 7.78 (d, J = 15.8 (1 H, CH=CH-Cq=O); 7.85 (d, J = 8.1, 2 H, 2x CH-Cq-CH2); 7.92 (dd, J = 6.9, 8.6, 1 
H, CH-CH-Cq-F). 13C NMR (D2O, 40˚C): δ 71.44 (t, 1 C, CH2); 102.71 (dd, 2J19F-13C = 25.8, 1 C, CH-CH-Cq-F); 
109.69 (dd, 2J19F-13C = 22.3, 1 C, CH-Cq-O); 125.79 (s, 1 C, Cq-Cq=O); 127.10 (d, 2 C, 2x CH-Cq-S); 127.80 (d, 
1 C, CH-Cq=O); 129.43 (d, 2 C, 2x CH-Cq-CH2); 129.73 (d, 2 C, 2x CH-Cq-CH=CH); 130.63 (d, 2 C, 2x 
CH-CH-Cq-CH=CH); 132.56 (d, 1 C, CH-CH-CH-CH-CH); 133.79 (dd, 3J19F-13C = 11.5, 1 C, CH-CH-Cq-F); 135.31 
(s, 1 C, Cq-CH=CH-Cq=O); 139.14 (s, 1 C, Cq-CH2); 145.49 (d, 1 C, CH=CH-Cq=O); 145.89 (s, 1 C, Cq-S); 160.77 
(s, 1 C, Cq-O); 167.07 (d, 1J19F-13C = 252.1, 1 C, Cq-F); 193.64 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C22H16O5FS 411.0702; mass found 411.0707. Decomposes above 230 ˚C. 
 
Potassium 4-({2-[(2E)-3-(4-bromophenyl)prop-2-enoyl]-5-fluorophenoxy}methyl)benzenesulfonate (48)  
Method H; sulfonate 126 (0.361 g, 1 mmol) and benzaldehyde 63 (0.187 g, 1 mmol) afforded 48 as an 
off-white solid (0.369 g, 71%). 1H NMR (D2O, 40˚C): δ 5.52 (br.s, 2 H, CH2); 7.22 (t, J = 7.5, 1 H, 
F-Cq-CH-CH-Cq); 7.44 (d, J = 10.7, 1 H, F-Cq-CH-Cq); 7.63 (d, J = 8.0, 2 H, 2x CH-Cq-Br); 7.76 (s, 1 H, 
CH-Cq=O); 7.77 (s, 1 H, CH=CH-Cq); 7.83 (d, J = 7.6, 2 H 2x CH-Cq-CH2); 7.91 (d, J = 7.9, 2x CH-Cq-CH=CH); 
7.98 (d, J = 6.8, 2 H, 2x CH-Cq-S); 8.01 (d, J = 8.6, 1 H, CH-Cq-Cq). 13C NMR (D2O, 40˚C): δ 71.43 (t, 1 C, CH2); 
102.56 (dd, 2J19F-13C = 26.4, Cq-CH-Cq-F); 109.45 (dd, 2J19F-13C = 22.5, 1 C, F-Cq-CH-CH); 125.54 (s, 1 C, 
Cq-Cq=O); 125.65 (s, 1 C, Cq-Br); 126.95 (d, 2 C, 2x CH-Cq-S); 128.17 (d, 1 C, CH-Cq=O), 129.22 (d, 2 C, 
206 
 
CH-Cq-CH2); 131.18 (d, 2 C, 2x CH-Cq-Br); 133.32 (d, 2 C, 2x CH-Cq-CH=CH); 133.68 (dd, 3J19F-13C = 10.8, 1 C, 
CH-Cq-Cq); 134.46 (s, 1 C, Cq-CH=CH); 138.66 (s, 1 C, Cq-CH2); 143.46 (d, 1 C, CH=CH-Cq=O); 146,40 (s, 1 C, 
Cq-S); 160.20 (s, 1 C, Cq-O); 166.83 (d, 1J19F-13C = 251.3, 1 C, Cq-F); 192.49 (s, 1 C, Cq=O). HRMS: Calculated 
mass for C22H16O5BrFS 488.9808; mass found 488.9809. Decomposes above 225 ˚C. 
 
Potassium 4-({2-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]-5-fluorophenoxy}methyl)benzenesulfonate (49) 
Method H; sulfonate 126 (0.361 g, 1 mmol) and benzaldehyde 70 (0.145 g, 1 mmol) afforded 49 as an 
off-white solid (0.324 g, 67%). 1H NMR (D2O, 40˚C): δ 5.23 (br.s, 2 H, CH2); 6.94 (td, J = 8.3, 2.1, 1 H, 
CH-CH-Cq-F); 7.13 (dd, J = 11.1, 2.0, 1 H, CH-Cq-O); 7.32 (d, J = 8.2, 2 H, 2x CH-CH-Cq-Cl); 7.41 (d, J = 15.9, 
1 H, CH-Cq=O); 7.49 (d, J = 8.5, 2 H, 2x CH-Cq-Cl); 7.52 (d, J = 15.8, 1 H, CH=CH-Cq=O); 7.59 (d, J = 8.3, 2 H, 
2x CH-Cq-CH2); 7.73-7.77 (m, 3 H, 2x CH-Cq-S and CH-Cq-Cq). 13C NMR (D2O, 40˚C): δ 71.73 (t, 1 C, CH2); 
102.86 (dd, 2J19F-13C = 26.8, 1 C, CH-Cq-O); 109.96 (dd, 2J19F-13C = 20.1, 1 H, CH-CH-Cq-F); 125.40 (s, 1 C, 
Cq-Cq=O); 127.37 (d, 1 C, 2x CH-Cq-S); 128.33 (d, 1 C, CH-Cq=O); 129.89 (d, 2 C, 2x CH-Cq-CH2); 130.70 (d, 2 
C, 2x CH-Cq-Cl); 131.19 d, 2 C, 2x CH-CH-Cq-Cl); 134.17 (s, 1 C, CH-Cq-CH=CH); 134.20 (dd, 3J19F-13C = 11.2, 1 
C, CH-Cq-Cq); 137.60 (s, 1 C, Cq-Cl); 139.60 (s, 1 C, Cq-CH2); 144.22 (d, 1 C, CH=CH-Cq=O); 145.49 (s, 1 C, 
Cq-S); 160.81 (s, 1 C, Cq-O); 168.93 (d, 1J19F-13C = 256.7, 1 C, Cq-F); 193.66 (s, 1 C, Cq=O). HRMS: Calculated 
mass for C22H16O5ClFS 445.0313; mass found 448.0308. Decomposes above 230 ˚C. 
 
Potassium 4-({5-fluoro-2-[(2E)-3-(4-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (17)  
Method H; sulfonate 126 (0.365 g, 1 mmol) and benzaldehyde 72 (0.123 g, 1 mmol) afforded 17 as an 
off-white solid (0.323 g, 70%). 1H NMR (D2O, 40˚C): δ 5.48 (br.s, 2 H, CH2); 7.19 (td, J = 8.5, 2.5, 1 H, 
CH-Cq-F-CH-Cq); 7.40 (dd, J = 11.1, 2.0, 1 H, Cq-CH-Cq-F); 7.48 (t, J = 8.8, 2 H, 2x CH-Cq-F); 7.67 (d, J = 16.2, 
1H, CH-Cq=O); 7.70-7.76 (m, 2 H, 2x CH-Cq-CH=CH); 7.78 (d, J = 16.0, CH=CH-Cq=O);  7.79 (d, J = 8.2, 2 H, 
2x CH-Cq-CH2); 7.92 (d, J = 8.1, 2 H, 2x CH-Cq-S); 7.95 (dd, J = 7.7, 2.6, CH-Cq-Cq). 13C NMR (D2O, 40˚C): δ 
71.52 (t, 1 C, CH2); 102.58 (dd, 2J19F-13C = 24.9, Cq-F-CH-Cq); 109.55 (dd, 2J19F-13C = 22.5, 1 C, CH-CH-Cq-Cq); 
117.51 (dd, 2J19F-13C = 19.9, 2 C, 2x CH-Cq-F); 125.64 (s, 1 C, Cq-Cq=O); 127.03 (d, 2 C, 2x CH-Cq-S); 127.55 
(d, 1 C, CH-Cq=O); 129.37 (d, 2 C, 2x CH-Cq-CH2); 131.72 (dd, 1J19F-13C = 251.7, 2 C, 2x CH-Cq-CH=CH); 
133.74 (dd, 2J19F-13C = 11.7, 1 C, CH-Cq-Cq); 138.86 (s, 1 C, Cq-CH2); 143.87 (d, 1 C, CH=CH-Cq=O); 146.24 (s, 
1 C, Cq-S); 146.33 (s, 1 C, Cq-CH=CH); 160.27 (s, 1 C, Cq-O); 163.49 (d, 1 C, 1J19F-13C = 249.8, CH-CH-Cq-F); 
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168.12 (d, 1J19F-13C = 251.1, 1 C, O-Cq-CH-Cq-F); 192.98 (s, 1 C, Cq=O). HRMS: Calculated mass for 




Method H; sulfonate 126 (0.365 g, 1 mmol) and benzaldehyde 99 (0.136g, 1 mmol) afforded 50 as an 
off-white solid (0.259 g, 54%). 1H NMR (D2O, 40˚C): δ 3.87 (s, 3 H, CH3); 5.16 (s, 2 H, CH2); 6.90 (t, J = 8.4, 
1 H, CH-CH-Cq-F); 6.96 (d, J = 8.6, 2 H, 2x CH-Cq-O-CH3); 7.06 (d, J = 10.7, 1 H, CH-Cq-O-CH2); 7.28 (d, J = 
8.0, 2 H, 2x CH-Cq-CH=CH); 7.29 (d, J = 15.7, 1 H, CH-Cq=O); 7.51 (d, J = 15.7, 1 H, CH=CH-Cq=O); 7.55 (d, 
J = 8.0, 2 H, 2x CH-Cq-CH2); 7.70 (t, J = 7.8, CH-Cq-Cq=O); 7.75 (d, J = 8.1, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 
40˚C): δ 56.99 (q, 1 C, CH3); 71.65 (t, 1 C, CH2); 102.70 (dd, 2J19F-13C = 24.5, 1 C, CH-Cq-O-CH2); 109.83 (dd, 
2J19F-13C = 21.6, 1 C, CH-CH-Cq-F); 116.08 (d, 2 C, 2x CH-Cq-O-CH3); 125.51 (d, 1 C, CH-Cq=O); 125.56 (s, 1 C, 
Cq-Cq=O); 127.30 (d, 2 C, 2x CH-Cq-S); 128.35 (s, 1 C, Cq-CH=CH-Cq=O); 129.82 (d, 2 C, 2x CH-Cq-CH2); 
131.88 (dd, 3J19F-13C =10.1, 2 C, 2x CH-Cq-CH=CH); 134.09 (d, 1 C, CH-Cq-Cq=O); 139.60 (s, 1 C, Cq-CH2); 
145.39 (S, 1 C, Cq-S); 145.80 (d, 1 C, CH=CH-Cq=O); 160.53 (d, 3J19F-13C = 11.0, Cq-O-CH2); 162.87 (s, 1 C, 
Cq-O-CH3); 167.41 (d, 1J19F-13C = 251.0; 1 C, Cq-F); 193.48 (s, 1 C, Cq=O). HRMS: Calculated mass for 
C23H18O6FS 441.0808; mass found 441.0798. Decomposes above 230 ˚C. 
 
Potassium 4-({2-[(2E)-3-(3-bromophenyl)prop-2-enoyl]-5-fluorophenoxy}methyl)benzenesulfonate (51)  
Method H; sulfonate 126 (0.364 g, 1 mmol) and benzaldehyde 132 (0.187 g, 1 mmol) afforded 51 as an 
off-white solid (0.333 g, 63%). 1H NMR (D2O, 40˚C): δ 5.10 (br.s, 2 H, CH2); 6.85 (td, J = 8.3, 2.1, 1 H, 
CH-CH-Cq-F); 6.99 (dd, J = 11.3, 2.1, 1 H , CH-Cq-O); 7.16 (d, J = 7.6, 1 H, CH-CH-CH-Cq-Br); 7.26 (t, J = 7.8, 
1 H, CH-CH-Cq-Br); 7.28 (d, J  = 15.9, 1 H, CH-Cq=O); 7.36 (d, J = 15.8, 1 H, CH=CH-Cq=O); 7.48 (d, J = 8.2, 2 
H, 2x CH-Cq-CH2); 7.53 (s, 1 H, Cq-CH-Cq-Br); 7.54 (d, J = 8.2, 1 H, CH-CH-Cq-Br); 7.63 (dd, J = 8.6, 1.6, 1 H, 
CH-Cq-Cq); 7.69 (d, J = 8.2, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 71.64 (t, 1 C, CH2); 102.80 (dd, 
2J19F-13C =27.1, 1 C, CH-Cq-O); 109.99 (dd, 2J19F-13C = 21.7, 1 C, CH-CH-Cq-F); 124.00 (s, 1 C, Cq-CH-Cq-Br); 
125.48 (s, 1 C, Cq-Cq=O); 127.39 (d, 2 C, 2x CH-Cq-S); 128.42 (d, 1 C, CH-CH-CH-Cq-Br); 129.04 (d, 1 C, 
CH-Cq=O); 129.58 (d, 2 C, 2x CH-Cq-CH2); 132.35 (d, 1 C, CH-Cq-Br or CH-CH-Cq-Br); 132.37 (d, 1 C, 
CH-Cq-Br or CH-CH-Cq-Br); 134.34 (d, 1 C, CH-Cq-Cq); 135.02 (d, 1 C, CH-CH-Cq-Br); 137.76 (s, 1 C, Cq-Br); 
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139.73 (s, 1 C, Cq-CH2); 143.45 (d, 1 C, CH=CH-Cq=O); 145.07 (s, 1 C, Cq-S); 160.64 (s, 1 C, Cq-O); 193.58 (s, 
1 C, Cq=O); Cq-F not observed. HRMS: Calculated mass for C22H16O5BrFS 488.9808; mass found 488.9803. 
Decomposes above 210 ˚C. 
 
Potassium 4-({2-[(2E)-3-(3-chlorophenyl)prop-2-enoyl]-5-fluorophenoxy}methyl)benzenesulfonate (52) 
 Method H; sulfonate 126 (0.361 g, 1 mmol) and benzaldehyde 133 (0.144 g, 1 mmol) afforded 52 as an 
off-white solid (0.310 g, 64%). 1H NMR (D2O, 40˚C): δ 5.21 (br.s, 2 H, CH2); 6.94 (t, J = 7.9, 1 H, 
CH-CH-Cq-F); 7.12 (d, J = 10.5, 1 H, CH-Cq-O); 7.25 (d, J = 7.3, 1 H, CH-Cq-CH=CH); 7.39-7.53 (m, 5 H, 2x 
CH-Cq-Cl, CH-CH-Cq-Cl, ); 7.58 (d, J = 7.3, 2 H, 2x CH-Cq-CH2); 7.73 (dd, J = 7.8, 2.3, 1 H, CH-Cq-Cq); 7.77 (d, 
J = 7.3, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 71.59 (t, 1 C, CH2); 102.65 (dd, 2J19F-13C =26.9, 1 C, 
CH-Cq-O); 109.78 (dd, 2J19F-13C = 20.8, 1 C, CH-Cq-F); 125.41 (s, 1 C, Cq-Cq=O); 127.22 (d, 2 C, 2x CH-Cq-S); 
127.72 (d, 1 C, CH-Cq-CH=CH); 128.92 (d, 1 C, CH-Cq=O); 129.31 (d, 1 C, Cq-CH-Cq-Cl); 129.38 (d, 2 C, 2x 
CH-Cq-CH2); 131.92 (s, 1 C, CH-CH-Cq-Cl or CH-CH-Cq-Cl); 132.15 (s, 1 C, CH-CH-Cq-Cl or CH-CH-Cq-Cl); 
134.11 (dd, 3J19F-13C = 11.4, 1 C, CH-Cq-Cq); 135.52 (s, 1 C, Cq-Cl); 137.40 (s, 1 C, Cq-CH=CH); 139.25 (s, 1 C, 
Cq-CH2); 143.06 (d, 1 C, CH=CH-Cq=O); 145.62 (s, 1 C, Cq-S); 160.52 (d, 3J19F-13C = 11.4, 1 C, Cq-O); 168.66 
(d, 1J19F-13C = 253.6, 1 C, Cq-F); 192.80 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5FClS 445.0313; 
mass found 445.0314. Decomposes above 220 ˚C. 
 
Potassium 4-({5-fluoro-2-[(2E)-3-(3-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (53) 
Method H; sulfonate 126 (0.361 g, 1 mmol) and benzaldehyde 134 (0.125 g, 1 mmol) afforded 53 as an 
off-white solid (0.323 g, 69%). 1H NMR (D2O, 40˚C): δ 5.39 (br.s, 2 C, CH2); 7.10 (td, J = 8.4, 2.3, 1 H, 
CH-CH-Cq-F); 7.30 (dd, J = 11.0, 2.3, 1 H, CH-Cq-O); 7.41 (d, J = 7.4, 1 H, CH-Cq-CH=CH); 7.42 (td, J = 8.5, 
2.2, 1 H, CH-CH-Cq-F); 7.50 (d, J = 9.7, 1 C, Cq-CH-Cq-F); 7.61-7.73 (m, 3 H, CH=CH-Cq=O, CH-Cq=O and 
CH-CH-Cq-F); 7.71 (d, J = 7.9. 2 H, CH-Cq-CH2); 7.82 (d, J = 8.3, 2 H, CH-Cq-S); 7.87 (dd, J = 7.9, 3.1, 
CH-Cq-Cq). 13C NMR (D2O, 40˚C): δ 71.42 (t, 1 C, CH2); 102.75 (dd, 2J19F-13C = 27.8, 1 C, CH-Cq-O); 109.76 
(dd, 2J19F-13C =22.3, 1 C, CH-CH-Cq-Cq); 116.11 (dd, 2J19F-13C =22.4, 1 C, Cq-CH-Cq-F); 118.99 (dd, 2J19F-13C = 
22.1, 1 C, CH-CH-CH-Cq-F); 125.46 (d, 1 C, CH-Cq-CH=CH); 125.65 (2, 1 C, Cq-Cq=O); 127.07 (d, 2 C, 2x 
CH-Cq-S); 129.11 (d, 1 C, CH-Cq=O); 129.26 (d, 2 C, 2x CH-Cq-CH2); 132.45 (dd, 3J19F-13C = 8.2, 1 C, 
CH-CH-CH-Cq-F); 133.89 (dd, 3J19F-13C =12.3, 1 C, CH-Cq-Cq); 137.75 (d, 2J19F-13C = 7.7, 1 C, Cq-CH=CH); 
139.09 (s, 1 C, CH-Cq-CH2); 143.39 (d, 1 C, CH=CH-Cq=O); 145.88 (s, 1 C, Cq-S); 160.34 (d, 3J19F-13C = 11.6, 1 
C, Cq-O); 164.92 (d, 1J19F-13C = 248.9, 1 C, F-Cq-CH-Cq-O); 167.73 (d, 1J19F-13C = 252.3, 1 C, F-Cq-CH-Cq); 
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193.21 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5F2S 429.0608; mass found 429.0602. 
Decomposes above 215 ˚C. 
 
Potassium 4-({2-[(2E)-3-(2-bromophenyl)prop-2-enoyl]-5-fluorophenoxy}methyl)benzenesulfonate (23)  
Method H; sulfonate 126 (0.363 g, 1 mmol) and benzaldehyde 135 (0.189 g, 1 mmol) afforded 23 as an 
off-white solid (0.328 g, 62%). 1H NMR (D2O, 40˚C): δ 5.41 (br.s, 2 H, CH2); 7.13 (t, J = 7.8, 1 H, 
CH-CH-Cq-F); 7.33 (d, J = 10.4, 1 H, CH-Cq-O), 7.48 (d, J = 7.3, 1 H, CH-Cq-Cq-Br); 7.52-7.63 (m, 3 H, 
CH-CH-Cq-Cq-Br, CH-CH-Cq-Br and CH-Cq=O), 7.73 (d, J = 7.8, 2 H, 2x CH-Cq-CH2); 7.87 (d, J = 8.3, 2 H, 2x 
CH-Cq-S); 7.89 (d, J = 7.4, 1 H, CH-Cq-Br); 7.92 (d, J = 7.3, 1 H, CH-Cq-Cq=O); 8.01 (d, J = 16.1, 1 H, 
CH=CH-Cq-Cq-Br). 13C NMR (D2O, 40˚C): δ 71.50 (t, 1 C, CH2); 102.58 (dd, 2J19F-13C = 26.9, 1 C, CH-Cq-O); 
109.70 (dd, 2J19F-13C = 21.8, 1 C, CH-Cq-F); 125.32 (s, 1 C, Cq-Cq=O); 126.32 (s, 1 C, Cq-Cq-Br); 127.07 (d, 2 C, 
2x CH-Cq-S); 128.98 (d, 1 C, CH-Cq-Cq-Br); 129.40 (d, 2 C, CH-Cq-CH2); 129.77 (d, 1 C, CH-Cq=O); 130.27 (d, 
1 C, CH-CH-Cq-Cq-Br or CH-CH-Cq-Br); 133.62 (d, 1 C, CH-CH-Cq-Cq-Br or CH-CH-Cq-Br); 133.99 (dd, 
3J19F-13C = 14.3, 1 C, CH-Cq-Cq); 134.62 (d, 1 C, CH-Cq-Br); 134.76 (s, 1 C, Cq-Br); 138.84 (s, 1 C, Cq-CH2); 
142.36 (d, 1 C, CH=CH-Cq=O); 146.09 (s, 1 C, Cq-S); 160.45 (s, 1 C, Cq-O); 167.27 (d, 1J19F-13C = 251.9, 1 C, 
Cq-F); 192.49 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5BrFS 488.9808; mass found 488.9814. 
Decomposes above 240 ˚C. 
 
Potassium 4-({2-[(2E)-3-(2-chlorophenyl)prop-2-enoyl]-5-fluorophenoxy}methyl)benzenesulfonate (54)   
Method H; sulfonate 126 (0.364 g, 1 mmol) and benzaldehyde 74 (0.145 g, 1 mmol) afforded 54 as an 
off-white solid (0.324 g, 67%). 1H NMR (D2O, 40˚C): δ 5.41 (br.s, 1 H, CH2); 7.13 (t, J = 10.9, 1 H, CH-Cq-F); 
7.33 (d, J = 6.8, 1 H, CH-Cq-O); 7.51 (t, J = 7.8, 1 H, CH-CH-Cq-Cq-Cl); 7.55 (t, J = 7.8, 1 H, CH-CH-Cq-Cl); 
7.61-7.69 (m, 3 H, CH-Cq=O, CH-Cq-Cl and CH=Cq-Cq-Cl); 7.73 (d, J = 8.3; 2 H, 2x CH-Cq-CH2); 7.87 (d, J = 
8.7, 2 H, 2x CH-Cq-S); 7.92 (d, J = 8.3, 1 H, CH-Cq-Cq=O); 8.06 (d, J = 16.1, 1 H , CH=CH-Cq=O). 13C NMR 
(D2O, 40˚C): δ 71.49 (t, 1 C, CH2); 102.59 (dd, 2J19F-13C = 25.8, 1 C, CH-Cq-O); 109.70 (dd, 2J19F-13C = 23.3, 1 
C, CH-Cq-F); 125.31 (s, 1 C, Cq-Cq=O); 127.06 (d, 2 C, 2x CH-Cq-S); 128.81 (d, 1 C, CH-CH-Cq-Cq-Cl or 
CH-CH-Cq-Cl); 129.18 (d, 1 C, CH-CH-Cq-Cq-Cl or CH-CH-Cq-Cl); 129.40 (d, 2 C, 2x CH-Cq-CH2); 130.12 (d, 1 
C, CH-Cq=O); 131.35 (d, 1 C, CH-Cq-Cl); 133.07 (s, 1 C, Cq-Cl); 133.46 (d, 1 C, CH-Cq-Cq-Cl); 133.98 (dd, 
3J19F-13C = 10.4, 1 C, CH-Cq-Cq=O); 135.55 (s, 1 C, Cq-Cq-Cl); 138.85 (2, 1 C, Cq-CH2); 139.66 (d, 1 C, 
CH=CH-Cq=O); 146.05 (s, 1 C, Cq-S); 160.44 (d, 3J19F-13C = 11.9, 1 C, Cq-O); 167.26 (d, 1J19F-13C = 252.1, 1 C, 
Cq-F); 192.54 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5FClS 445.0313; mass found 445.0307. 




Potassium 4-({5-fluoro-2-[(2E)-3-(2-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (55)   
Method H; sulfonate 126 (0.365 g, 1 mmol) and benzaldehyde 136 (0.125 g, 1 mmol) afforded 55 as an 
off-white solid (0.319 g, 68%). 1H NMR (D2O, 40˚C): δ 5.19 (br.s, 2 H, CH2); 6.92 (t, J = 8.3, 1 H, CH-Cq-F); 
7.09 (d, J = 10.6, 1 H, CH-Cq-O); 7.24 (t, J = 9.2, 1 H, CH-Cq-Cq); 7.25-7.33 (m, 2 H, CH-Cq-Cq-F and 
CH-CH-Cq-Cq-F), 7.48 (d, J = 15.8, 1 H, CH-Cq=O); 7.55 (t, J = 7.1, 1 H, CH-CH-CH-Cq-F); 7.56 (d, J = 8.0, 2 H, 
CH-Cq-CH2); 7.65 (d, J = 15.9, 1 H, CH=CH-Cq=O); 7.72 (t, J = 7.6, 1 H, CH-Cq-Cq=O); 7.75 (d, J = 7.7, 2 H, 
CH-Cq-S). 13C NMR (D2O, 40˚C): δ 71.54 (t, 1 C, CH2); 102.61 (dd, 2J19F-13C =25.4, CH-Cq-O); 109.79 (dd, 
2J19F-13C = 22.0, 1 C, CH-Cq-F); 117.50 (dd, 2J19F-13C = 22.1, 1 C, CH-Cq-Cq-CH=CH); 123.13 (d, 2J19F-13C = 11.8, 
1 C, Cq-Cq-F); 125.31 (s, 1 C, Cq-Cq=O); 126.45 (d, 1 C, CH-Cq-Cq-F or CH-CH-Cq-Cq-F);  127.14 (d, 2 C, 2x 
CH-Cq-S); 129.48 (d, 2 C, 2x CH-Cq-CH2); 129.70 (d, 1 C, CH-Cq=O); 129.86 (d, 1 C, CH-Cq-Cq-F or 
CH-CH-Cq-Cq-F); 134.12 (dd, 3J19F-13C = 9.8, 1 C, CH-CH-CH-Cq-F); 134.28 (dd, 3J19F-13C = 8.7, 1 C, 
CH-Cq-Cq=O); 136.71 (s, 1 C, CH=CH-Cq=O); 139.22 (s, 1 C, Cq-CH2); 145.57 (s, 1 C, Cq-S); 160.60 (s, 1 C, 
Cq-O); 162.16 (d, 1J19F-13C = 251.3, Cq-Cq-F); 167.36 (d, 1J19F-13C = 253.4, 1 C, Cq-CH-Cq-F); 192.89 (s, 1 C, 




(56)   
Method H; sulfonate 126 (0.364 g, 1 mmol) and benzaldehyde 100 (0.136 g, 1 mmol) afforded 56 as an 
off-white solid (0.317 g, 66%). 1H NMR (D2O, 40˚C): δ 3.70 (s, 3 H, CH3); 5.11 (s, 2 H, CH2); 6.82 (td, J = 
8.3, 2.2, 1 H, CH-CH-Cq-F); 6.93 (t, J = 7.5, 1 H, CH-CH-Cq-Cq-O-CH3); 6.99 (d, J = 8.6, 1 H, CH-Cq-O-CH3); 
7.01 (dd, J = 11.8, 2.8, 1 H, CH-Cq-O-CH2); 7.29 (dd, J = 7.7, 1.4, 1 H, CH-CH-Cq-O-CH3); 7.34-7.40 (m, 4 H, 
2x CH-Cq-S, CH-Cq-Cq-O-CH3 and CH-Cq=O); 7.51 (d, J = 8.2, 2 H, 2x CH-Cq-CH2); 7.54 (dd, J = 6.9, 8.6, 1 H, 
CH-Cq-Cq=O); 7.72 (d, J = 16.0, 1 H, CH=CH-Cq=O).  13C NMR (D2O, 40˚C): δ 56.72 (d, 1 C, CH3); 71.10 (t, 
1 C, CH2); 102.46 (dd, 2J19F-13C = 27.2, 1 C, CH-Cq-O); 109.31 (dd, 2J19F-13C = 21.6, 1 C, CH-CH-Cq-F); 113.00 
(d, 1 C, CH-Cq-O-CH3); 122.27 (d, 1 C, CH-CH-Cq-CH=CH); 123.56 (s, 1 C, Cq-Cq-O-CH3); 126.11 (s, 1 C, 
Cq-Cq=O); 126.78 (d, 2 C, 2x CH-Cq-S); 127.80 (d, 1 C, CH-Cq=O); 128.68 (d, 2 C, 2x CH-Cq-CH2);  128.79 (d, 
1 C, CH-Cq-Cq-O-CH3); 129.46 (d, 1 C, CH-CH-Cq-O-CH3); 133.27 (dd, 2J19F-13C = 11.9, 1 C, CH-CH-Cq-F); 
138.65 (s, 1 C, Cq-CH2); 139.94 (d, 1 C, CH=CH-Cq=O); 146.18 (s, 1 C, Cq-S); 159.30 (s, 1 C, Cq-O-CH3); 
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159.67 (d, 3J19F-13C =11.1, 1 C, Cq-O-CH2); 166.45 (d, 1J19F-13C = 250.8, 1 C, Cq-F); 193.34 (s, 1 C, Cq=O). 
HRMS: Calculated mass for C23H18O5FS 441.0808; mass found 441.0798.  Decomposes above 220 ˚C. 
 
Potassium 4-({5-chloro-2-[(2E)-3-phenylprop-2-enoyl]phenoxy}methyl)benzenesulfonate (12)  
Method I; sulfonate 127 (0.379 g, 1 mmol) and benzaldehyde 67 (0.106 g, 1 mmol) afforded 12 as an off-
white solid (0.322 g g, 69%). 1H NMR (D2O, 40˚C): δ 5.13 (s, 2 H, CH2); 7.07 (dd, J = 8.2, 1.6, 1 H, 
CH-CH-Cq-Cl); 7.26 (d, J = 1.5, 1 H, Cq-CH-Cq-Cl); 7.33 (d, J = 16.0, 1 H, CH-Cq=O); 7.36-7.74 (m, 7 H, 2x 
CH-Cq-CH2), 2x CH-Cq-CH=CH, 2 X CH-CH-Cq-CH=CH and CH-CH-CH-CH-CH); 7.44 (d, J = 15.7, 1 H, 
CH=CH-Cq=O); 7.51 (d, J = 8.3, 1 H, CH-Cq-Cq=O); 7.54 (d, J = 8.1, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 
71.22 (t, 1 C, CH2); 114.93 (d, 1 C, CH-Cq-O); 122.57 (d, 1 C, CH-CH-Cq-Cl); 126.88 (d, 2 C, 2x CH-Cq-S); 
128.04 (s, 1 C, Cq-Cq=O); 128.79 (d, 1 C, CH-Cq=O); 128.92 (d, 2 C, 2x CH-Cq-CH2); 129.51 (d, 2 C, 2x 
CH-Cq-CH=CH) 130.39 (d, 2 C, 2x CH-CH-Cq-CH=CH); 132.31 (d, 1 C, CH-CH-CH-CH-CH); 135.06 (s, 1 C, 
Cq-CH=CH-Cq=O); 138.71 (s, 1 C, Cq-CH2); 139.45 (s, 1 C, Cq-Cl); 145.42 (d, 1 C, CH=CH-Cq=O); 146.18 (s, 1 
C, Cq-S); 158.67 (s, 1 C, Cq-O); 193.32 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H16O5ClS 427.0407; 




Method I; sulfonate 127 (0.377 g, 1 mmol) and benzaldehyde 99 (0.136 g, 1 mmol) afforded 57 as an off-
white solid (0.323 g, 65%). 1H NMR (D2O, 40˚C): δ 3.69 (s, 3 H, CH3); 4.82 (br.s, 2 H, CH2); 6.67 (d, J = 8.5, 
2 H, 2x CH-Cq-CH=CH); 6.90 (d, J = 8.1, 2 H, 2x CH-Cq-O-CH3); 6.97-7.01 (m, 3 H, 2x CH-Cq-Cl and 
CH-Cq=O), 7.25 (d, J = 15.4, 1 H, CH=CH-Cq=O); 7.31 (d, J = 8.1, 2 H, 2x CH-Cq-CH2); 7.57 (d, J = 8.1, 1 H, 
CH-Cq-Cq=O); 7.67 (d, J = 7.7, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): δ 56.81 (q, 1 C, CH3); 71.46 (t, 1 C, 
CH2); 114.74 (d, 1 C, CH-Cq-O-CH2); 115.7 (d, 2 C, 2x CH-Cq-CH=CH); 122.78 (d, 1 C, CH-CH-Cq-Cl); 125.27 
(d, 1 C, CH-Cq=O); 127.28 (d, 2 C, 2x CH-Cq-S); 127.78 (s, 1 C, Cq-Cq=O or CH=CH-Cq-CH); 128.28 (s, 1 C, 
Cq-Cq=O or CH=CH-Cq-CH); 129.53 (d, 2 C, 2x CH-Cq-CH2); 131.35 (d, 1 C, CH-Cq-O-CH3); 133.43 (d, 1 C, 
CH-Cq-Cq=O); 139.36 (s, 1 C, Cq-CH2); 140.46 (s, 1 C, Cq-Cl); 144.85 (d, 1 C, CH=CH-Cq=O); 145.24 (s, 1 C, 
Cq-S); 161.39 (s, 1 C, Cq-O-CH3); 162.43 (s, 1 C, Cq-O-CH2); 191.53 (s, 1 C, Cq=O). HRMS: Calculated mass 




Potassium 4-({5-chloro-2-[(2E)-3-(3-chlorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (58) 
Method I; sulfonate 127 (0.378 g, 1 mmol) and benzaldehyde 134 (0.124 g, 1 mmol) afforded 58 as an 
off-white solid (0.306 g, 61%). 1H NMR (D2O, 40˚C): 5.10 (s, 2 H, CH2); 7.06 (d, J = 8.3, 1 H, 
Cq-CH-CH-Cq-Cl); 7.17 (s, 1 H, Cq-CH-Cq-CH=CH); 7.24 (s, 1 H, CH-Cq-O); 7.31 (d, J = 15.9, 1 H, CH-Cq=O); 
7.33-7.45 (m, 4 H, CH=CH-Cq=O, CH-CH-CH-Cq-Cl, CH-CH-CH-Cq-Cl and CH-CH-CH-Cq-Cl); 7.48 (d, J = 8.1, 2 
H, 2x CH-Cq-CH2); 7.53 (d, J = 8.3, 1 H, CH-Cq-Cq=O); 7.71 (d, J = 8.1, 2 H, 2x CH-Cq-S). 13C NMR (D2O, 40˚C): 
δ 70.36 (t, 1 C, CH2); 115.15 (d, 1 C, CH-Cq-O); 122.95 (d, 1 C, Cq-CH-CH-Cq-Cl); 127.27 (d, 2 C, 2x CH-Cq-S); 
127.74 (s, 1 C, Cq-Cq=O); 127.92 (d, 1 C, Cq-CH-Cq-CH=CH); 128.86 (d, 1 C, CH-Cq=O); 129.38 (d, 2 C, 2x 
CH-Cq-CH2); 131.70 (d, 1 C, CH-Cq-CH=CH); 132.08 (d, 1 C, CH-CH-Cq-CH=CH or CH-CH-CH-Cq-Cl); 133.09 
(d, 1 C, CH-Cq-Cq=O); 135.61 (s, 1 C, CH-CH-CH-Cq-Cl or O-Cq-CH-Cq-Cl); 137.37 (s, 1 C, CH-CH-CH-Cq-Cl or 
O-Cq-CH-Cq-Cl); 139.42 (s, 1 C, Cq-CH2); 143.59 (d, 1 C, CH=CH-Cq=O); 145.44 (s, 1 C, Cq-S); 159.20 (s, 1 C, 
Cq-O); 193.34 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H15O5Cl2FS 461.0017; mass found 461.0019. 
Decomposes above 210 ˚C. 
 
Potassium 4-({5-chloro-2-[(2E)-3-(2-chlorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (59) 
Method I; sulfonate 127 (0.380 g, 1 mmol) and benzaldehyde 74 (0.147 g, 1 mmol) afforded 59 as an off-
white solid (0.301 g, 60%). 1H NMR (D2O, 40˚C): δ 5.42 (s, 2 H, CH2); 7.38 (d, J = 8.4, 1 H, CH-CH-Cq-Cl); 
7.54-7.58 (m, 3 H, CH-Cq-O, CH-CH-CH-Cq-Cl and CH-CH-Cq-Cq-Cl); 7.59 (d, J =16.0, 1 H, CH-Cq=O); 7.66 
(td, J = 7.4, 1.7, 1 H, CH-CH-CH-Cq-Cl); 7.71 (d, J = 8.4, 1 H, CH-Cq-Cq-Cl); 7.73 (d, J = 8.3, 2 H, 2x 
CH-Cq-CH2); 7.83 (d, J = 8.3, 1 H, CH-CH-Cq-Cq=O); 7.90 (d, J = 8.0, 2 H, 2x CH-Cq-S); 8.06 (d, J = 15.9, 1 H, 
CH=CH-Cq=O). 13C NMR (D2O, 40˚C): δ 71.49 (t, 1 C, CH2); 115.05 (d, 1 C, CH-Cq-O); 122.86 (d, 1 C, 
CH-CH-Cq-Cq=O); 127.08 (d, 2 C, 2x CH-Cq-S); 127.57 (s, 1 C, Cq-Cq=O); 128.89 (d, 1 C, CH-CH-CH-Cq-Cl or 
CH-CH-CH-Cq-Cl); 129.17 (d, 1 C, CH-CH-CH-Cq-Cl or CH-CH-CH-Cq-Cl); 129.30 (d, 2 C, 2x CH-Cq-CH2); 
130.02 (d, 1 C, CH-Cq=O); 131.38 (d, 1 C, CH-Cq-Cq-Cl); 132.93 (d, 1 C, CH-Cq-Cq=O); 133.03 (s, 1 C, 
Cq-Cq-Cl); 133.54 (d, 1 C, CH-CH-CH-Cq-Cl); 135.63 (s, 1 C, Cq-CH=CH-Cq=O); 139.02 (s, 1 C, Cq-CH2); 140.30 
(d, 1 C, CH=CH-Cq=O); 140.54 (s, 1 C, O-Cq-CH-Cq-Cl); 145.84 (s, 1 C, Cq-S); 159.08 (s, 1 C, Cq-O); 193.25 (s, 





Potassium 4-({5-chloro-2-[(2E)-3-(2-fluorophenyl)prop-2-enoyl]phenoxy}methyl)benzenesulfonate (18) 
Method I; sulfonate 127 (0.376 g, 1 mmol) and benzaldehyde 136 (0.123 g, 1 mmol) afforded 18 as an 
off-white solid (0.301 g, 62%). 1H NMR (D2O, 40˚C): δ 5.45 (s, 2 H, CH2); 7.39 (dd, J = 8.3, 2.0, 1 H, 
CH-CH-Cq-Cl); 7.43-7.46 (m, 2 H, CH-Cq-F and CH-CH-CH-Cq-F); 7.49 (t, J = 7.3, 1 H, CH-CH-Cq-F); 7.57 (s, 1 
H, CH-Cq-O); 7.65-7.72 (m, 4 H, 2x CH-Cq-CH2, CH-Cq=O and CH-Cq-Cq-F); 7.81-7.84 (m, 3 H, 2x CH-Cq-S and 
CH-Cq-Cq=O); 7.85 (d, J = 16.3, 1 H, CH=CH-Cq=O). 13C NMR (D2O, 40˚C): δ 71.29 (t, 1 C, CH2); 115.09 (d, 
1 C, CH-Cq-O); 117.50 (dd, 2J19F-13C = 22.6, 1 C, CH-Cq-F); 122.87 (d, 1 C, CH-CH-Cq-Cl); 123.02 (s, 1 C, 
Cq-Cq-F); 126.55 (d, 1 C, CH-Cq-Cq-F or CH-CH-Cq-Cq-F); 127.01 (d, 2 C, 2x CH-Cq-S); 127.89 (s, 1 C, 
Cq-Cq=O); 129.14 (d, 2 C, 2x CH-Cq-CH2); 129.83 (d, 1 C, CH-Cq=O); 130.10 (d, 1 C, CH-Cq-Cq-F or 
CH-CH-Cq-Cq-F); 132.85 (d, 1 C, CH-Cq-Cq=O); 134.41 (dd, 3J19F-13C = 8.9, CH-CH-Cq-F); 137.25 (d, 1 C, 
CH=CH-Cq=O); 139.04 (s, 1 C, Cq-CH2); 140.28 (s, 1 C, Cq-Cl); 145.92 (s, 1 C, Cq-S); 158.89 (s, 1 C, Cq-O); 
163.20 (d, 1J19F-13C = 252.0, Cq-F); 193.78 (s, 1 C, Cq=O). HRMS: Calculated mass for C22H15O5ClFS 




Method I; sulfonate 127 (0.379 g, 1 mmol) and benzaldehyde 100 (0.135 g, 1 mmol) afforded 24 as an 
off-white solid (0.298 g, 60%). 1H NMR (D2O, 40˚C): δ 3.68 (s, 3 H, CH3); 5.09 (s, 2 H, CH2); 6.92 (t, J = 7.4, 
1 H, CH-CH-Cq-CH=CH); 6.97 (d, J = 8.3, 1 H, CH-Cq-O-CH3); 7.04 (d, J = 7.8, 1 H, CH-CH-Cq-Cl); 7.20 (s, 1 H, 
Cq-CH-Cq-Cl); 7.26-7.31 (m, 2 H, CH-Cq=O and CH-CH-Cq-O); 7.32-7.39 (m, 3 H, 2x CH-Cq-CH2 and 
CH-Cq-CH=CH); 7.43 (d, J = 7.9, 1 H, CH-CH-Cq-Cq=O); 7.51 (d, J = 7.6, 2 H, 2x CH-Cq-S); 7.69 (d, J = 16.0, 
1 H, CH=CH-Cq=O). 13C NMR (D2O, 40˚C): δ56.82 (q, 1 C, CH3); 71.16 (t, 1 C, CH2); 113.15 (d, 1 C, 
CH-Cq-O-CH3); 114.97 (d, 1 C, CH-Cq-O-CH2); 122.41 (d, 1 C, CH-CH-Cq-CH=CH); 122.68 (d, 1 C, 
CH-CH-Cq-Cl); 126.90 (d, 2 C, 2x CH-Cq-S); 127.83 (d, 1 C, CH-Cq=O); 128.42 (s, 1 C, Cq-Cq=O); 128.80 (d, 2 
C, 2x CH-Cq-CH2); 129.71 (d, 1 C, CH-CH-Cq-O); 132.49 (d, 1 C, CH-Cq-Cq=O); 134.23 (d, 1 C, CH-Cq-CH=CH); 
138.96 (s, 1 C, Cq-CH2); 139.55 (s, 1 C, Cq-Cl); 140.77 (d, 1 C, CH=CH-Cq=O); 145.88 (s, 1 C, Cq-S); 158.85 (s, 
1 C, Cq-O-CH2); 159.49 (s, 1 C, Cq-O-CH3); 194.26 (s, 1 C, Cq=O). HRMS: Calculated mass for C23H18O6ClS 
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